3.4.21.5 Abetalipoproteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Abnormalities, Multiple http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32003946&form=6&db=m Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Abortion, Habitual http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9672284&form=6&db=m Increased thrombin generation in women with recurrent miscarriage. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Abortion, Habitual http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31599511&form=6&db=m Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Abortion, Spontaneous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4084461&form=6&db=m Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe). diagnostic usage,unassigned 3,0 3.4.21.5 Abortion, Spontaneous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21130429&form=6&db=m Increased thrombin generation measured in the presence of thrombomodulin in women with early pregnancy loss. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Abortion, Spontaneous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25790916&form=6&db=m Platelet function in patients with a history of unexplained recurrent miscarriage who subsequently miscarry again. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Abortion, Spontaneous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31599511&form=6&db=m Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Abruptio Placentae http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12380602&form=6&db=m Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Abruptio Placentae http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17403427&form=6&db=m Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition. causal interaction,unassigned 2,0 3.4.21.5 Abruptio Placentae http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23058370&form=6&db=m Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells. therapeutic application,unassigned 1,0 3.4.21.5 Abruptio Placentae http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27108773&form=6&db=m Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Abruptio Placentae http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32365105&form=6&db=m Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone. causal interaction,unassigned 2,0 3.4.21.5 Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11461851&form=6&db=m Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,4 3.4.21.5 Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19246211&form=6&db=m Complications of modern diagnostic cerebral angiography in an academic medical center. therapeutic application,unassigned 2,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2116681&form=6&db=m Influence of hypercapnia and hypoxia on rabbit platelet aggregation. causal interaction,unassigned 2,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3969318&form=6&db=m Effects of acidosis on fetal and maternal blood coagulation: a fetal lamb model. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12623442&form=6&db=m Capacitative calcium influx and intracellular pH cross-talk in human platelets. causal interaction,unassigned 2,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15920416&form=6&db=m Independent contributions of hypothermia and acidosis to coagulopathy in swine. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17452929&form=6&db=m Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18469643&form=6&db=m Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. unassigned - 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19590336&form=6&db=m Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21502874&form=6&db=m Coagulation Changes to Systemic Acidosis and Bicarbonate Correction in Swine. causal interaction,unassigned 4,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22164935&form=6&db=m [Trauma-induced coagulopathy--mechanisms and state of the art treatment]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23266689&form=6&db=m Acidosis, magnesium and acetylsalicylic acid: effects on thrombin. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24608516&form=6&db=m Coagulopathy induced by acidosis, hypothermia and hypocalcaemia in severe bleeding. therapeutic application,unassigned 1,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25839182&form=6&db=m Mechanistic Modeling of the Effects of Acidosis on Thrombin Generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27789847&form=6&db=m Acidosis induced by carbon dioxide insufflation decreases heparin potency: a risk factor for thrombus formation. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31609256&form=6&db=m Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32635883&form=6&db=m Preconditioning Effect of Remifentanil Versus Fentanyl in Prevalence of Early Graft Dysfunction in Patients After Liver Transplant: A Randomized Clinical Trial. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34306432&form=6&db=m Effects of emergency treatment mode of damage-control orthopedics in pelvic fracture complicated with multiple fractures. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Acidosis, Lactic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3322525&form=6&db=m Use of clinical pathology in evaluation of horses with colic. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2494880&form=6&db=m Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6410533&form=6&db=m The action of thrombin on modified fibrinogen. unassigned - 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10925365&form=6&db=m Thrombin induces apoptosis in human tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18599803&form=6&db=m Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. therapeutic application,unassigned 1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19404540&form=6&db=m A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. therapeutic application,unassigned 1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19707440&form=6&db=m Clinical use of topical thrombin as a surgical hemostat. therapeutic application,unassigned 1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21360607&form=6&db=m Looking at the proteases from a simple perspective. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22282693&form=6&db=m Thrombin use in surgery: an evidence-based review of its clinical use. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27011792&form=6&db=m Sepsis and disseminated intravascular coagulation. therapeutic application,unassigned 1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30640738&form=6&db=m The use of new procoagulants in blunt and penetrating trauma. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30817396&form=6&db=m The use of new procoagulants in blunt and penetrating trauma. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Acromegaly http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31994012&form=6&db=m The haemostatic system in acromegaly: a single-centre case-control study. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7780127&form=6&db=m Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9763350&form=6&db=m Molecular biology and pathophysiology of APC resistance: current insights and clinical implications. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608043&form=6&db=m No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10928463&form=6&db=m A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11012376&form=6&db=m The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. causal interaction,unassigned 4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11102598&form=6&db=m Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11256874&form=6&db=m Effects of hormone replacement on hemostasis in spontaneous menopause. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11897150&form=6&db=m Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC). ongoing research,unassigned 2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11924538&form=6&db=m Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12152677&form=6&db=m Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12353069&form=6&db=m Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12492586&form=6&db=m Acquired resistance to activated protein C in breast cancer patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,2 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12680634&form=6&db=m Screening for thrombophilia: a laboratory perspective. diagnostic usage,unassigned 4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709915&form=6&db=m Hemostasis during normal pregnancy and puerperium. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12877675&form=6&db=m Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14671159&form=6&db=m Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15166917&form=6&db=m Exercise-induced activation of coagulation in subjects with activated protein C resistance. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15199493&form=6&db=m Changes of hemostatic variables during oral contraceptive use. diagnostic usage,unassigned 2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613919&form=6&db=m Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711747&form=6&db=m Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,2 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15886799&form=6&db=m Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16359508&form=6&db=m Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16390236&form=6&db=m A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study. diagnostic usage,unassigned 2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16493484&form=6&db=m Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16532128&form=6&db=m Hematologic risk factors for stroke in Saudi children. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16601829&form=6&db=m Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis. causal interaction,unassigned 4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16645152&form=6&db=m Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16721492&form=6&db=m Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16879211&form=6&db=m The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17179188&form=6&db=m Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. diagnostic usage,unassigned 4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17221323&form=6&db=m Lemierre syndrome variant: Staphylococcus aureus associated with thrombosis of both the right internal jugular vein and the splenic vein after the exploration of a river cave. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461930&form=6&db=m Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549295&form=6&db=m Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17565236&form=6&db=m Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17569674&form=6&db=m Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17666016&form=6&db=m Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17958739&form=6&db=m Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18064321&form=6&db=m APC resistance during the normal menstrual cycle. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18768782&form=6&db=m Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19036061&form=6&db=m Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19350113&form=6&db=m The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20399945&form=6&db=m An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. unassigned - 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21947267&form=6&db=m Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21979881&form=6&db=m Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22265675&form=6&db=m Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway. causal interaction,unassigned 3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23233637&form=6&db=m Thrombotic disease in the myeloproliferative neoplasms. causal interaction,unassigned 1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23410231&form=6&db=m Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23676348&form=6&db=m Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25121606&form=6&db=m Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25260941&form=6&db=m Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26492443&form=6&db=m Factor V Leiden. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27090446&form=6&db=m Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27734187&form=6&db=m The use of direct oral anticoagulants in inherited thrombophilia. causal interaction,unassigned 4,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27956417&form=6&db=m Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28287382&form=6&db=m Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29097362&form=6&db=m Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,1 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29356700&form=6&db=m The effects of transport temperature and time on routine and specialized coagulation assays. diagnostic usage,unassigned 2,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30359453&form=6&db=m The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31444961&form=6&db=m Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31984653&form=6&db=m Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance. unassigned - 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33080636&form=6&db=m Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk. causal interaction,unassigned 1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33249717&form=6&db=m Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a?2GPI and aPS/PT antibodies. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33571724&form=6&db=m Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33784534&form=6&db=m Effect of blood loss during caesarean section on coagulation parameters. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34205545&form=6&db=m Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7583543&form=6&db=m Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7895349&form=6&db=m Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923645&form=6&db=m Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7959365&form=6&db=m Thrombin in arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140759&form=6&db=m [Coronary thrombosis--pathogenic basis of acute coronary syndromes] causal interaction,unassigned 1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8889359&form=6&db=m Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9028306&form=6&db=m A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9261263&form=6&db=m Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9263656&form=6&db=m Antiplatelet and antithrombin therapies in the acute coronary syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9371302&form=6&db=m Treatment of arterial thromboembolic disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626825&form=6&db=m Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9628448&form=6&db=m New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9676792&form=6&db=m Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9777137&form=6&db=m The GUSTO 2b and related studies. Global Use of Strategies to Open Occluded Coronary Arteries. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9778085&form=6&db=m Pathobiology of thrombin in acute coronary syndromes. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9809887&form=6&db=m Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9809894&form=6&db=m Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9878932&form=6&db=m Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9890391&form=6&db=m A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9950667&form=6&db=m Vasoflux, a new anticoagulant with a novel mechanism of action. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10364818&form=6&db=m [Persistent activation and/or reactivation in the subacute phase of unstable angina. Reasons for prolonged antithrombotic treatment] causal interaction,unassigned 3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10505536&form=6&db=m Anticoagulants in acute coronary syndromes. causal interaction,unassigned 1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10520784&form=6&db=m Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10562259&form=6&db=m Clinical outcomes of bivalirudin for ischemic heart disease. therapeutic application,unassigned 4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603518&form=6&db=m Platelet Activation Determined by Flow Cytometry Persists Despite Antithrombotic Therapy in Patients with Unstable Angina and Non-Q-Wave Myocardial Infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629409&form=6&db=m Direct thrombin inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639214&form=6&db=m Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639631&form=6&db=m The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis" causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639635&form=6&db=m Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10640797&form=6&db=m Failure of thrombin generation markers to triage patients presenting with chest pain. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10653827&form=6&db=m Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751791&form=6&db=m Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10767118&form=6&db=m Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10868518&form=6&db=m Antithrombins and the importance of good control. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10947916&form=6&db=m Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10972630&form=6&db=m Use of direct thrombin inhibitors in acute coronary syndrome. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10980906&form=6&db=m Novel inhibitors of factor X for use in cardiovascular diseases. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10997290&form=6&db=m Antithrombotic therapy in acute coronary syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11072276&form=6&db=m New strategies in the management of acute coronary syndromes. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11136505&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11295956&form=6&db=m Antithrombotic therapy in patients with acute coronary syndromes. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11322919&form=6&db=m Systematic Review of Hirudin in Acute Coronary Syndromes and Percutaneous Coronary Intervention. causal interaction,unassigned 3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11686357&form=6&db=m Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11704709&form=6&db=m Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET. unassigned - 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11766066&form=6&db=m Mental stress and physical exercise increase platelet-dependent thrombin generation. causal interaction,unassigned 4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11785993&form=6&db=m Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11830196&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11864920&form=6&db=m Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,1 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11864933&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes: present and future. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11967385&form=6&db=m Acute coronary syndromes: a focus on thrombin. ongoing research,unassigned 2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12020054&form=6&db=m Ximelagatran (AstraZeneca). causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12032397&form=6&db=m High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12064570&form=6&db=m The biology of thrombin in acute coronary syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12127922&form=6&db=m Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12215055&form=6&db=m Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12241752&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12270876&form=6&db=m Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation. causal interaction,unassigned 1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12473984&form=6&db=m Low molecular weight heparins in the treatment of unstable angina. causal interaction,unassigned 4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12598065&form=6&db=m Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12644341&form=6&db=m Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. unassigned - 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12644344&form=6&db=m The evolving role of direct thrombin inhibitors in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12679753&form=6&db=m Anticoagulation in acute cardiac care in patients with chronic kidney disease. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12714831&form=6&db=m Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. causal interaction,unassigned 1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12811010&form=6&db=m Clinical results with direct thrombin inhibitors. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12843003&form=6&db=m Coagulation activation and long-term outcome in acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14564303&form=6&db=m Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14574076&form=6&db=m Clinician update: direct thrombin inhibitors in acute coronary syndromes. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14988229&form=6&db=m Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. causal interaction,unassigned 3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15023292&form=6&db=m Is the use of unfractionated heparin in acute coronary syndrome outmoded? causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15172401&form=6&db=m Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15205585&form=6&db=m Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15253941&form=6&db=m Will oral antithrombin agents replace warfarin? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15282656&form=6&db=m Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15823862&form=6&db=m Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15918828&form=6&db=m Direct thrombin inhibitors: pharmacology and clinical relevance. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16038707&form=6&db=m Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion. causal interaction,unassigned 4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16079449&form=6&db=m A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16088663&form=6&db=m Acute myocardial ischemia and infarction: making the right decisions in antithrombotic and reperfusion therapies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16123917&form=6&db=m Prevention of cardiovascular events after acute coronary syndrome. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16175024&form=6&db=m Update on acute coronary syndromes and ST-elevation myocardial infarction. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16214829&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16219659&form=6&db=m Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients? causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305521&form=6&db=m Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16511607&form=6&db=m Ximelagatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16775505&form=6&db=m Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. causal interaction,unassigned 2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16781360&form=6&db=m A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17223726&form=6&db=m Plasma tissue factor in coronary artery disease: further step to the understanding of the basic mechanisms of coronary artery thrombosis. causal interaction,unassigned 4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17368152&form=6&db=m Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17696566&form=6&db=m Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17917621&form=6&db=m Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17944993&form=6&db=m Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18248357&form=6&db=m Current Update on Glycoprotein IIb-IIIa and Direct Thrombin Inhibition in Percutaneous Coronary Intervention for Non-ST Elevation Acute Coronary Syndromes: Balancing Bleeding Risk and Antiplatelet Efficacy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18315550&form=6&db=m Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18487475&form=6&db=m Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18499566&form=6&db=m Bivalirudin during primary PCI in acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18827868&form=6&db=m Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19090933&form=6&db=m Advances in antiplatelet therapy for ACS and PCI. causal interaction,unassigned 4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19178132&form=6&db=m Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19213062&form=6&db=m Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19539068&form=6&db=m Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19699853&form=6&db=m The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19739103&form=6&db=m Thrombin induces cyclooxygenase-2 expression and prostaglandin E(2) release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. unassigned - 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19804135&form=6&db=m Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20124733&form=6&db=m Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. therapeutic application,unassigned 3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20617417&form=6&db=m Novel anticoagulant therapy: principle and practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21030935&form=6&db=m Antithrombotic treatment in acute coronary syndromes. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21068524&form=6&db=m Emerging oral antiplatelet therapies for acute coronary syndromes. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21241354&form=6&db=m Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21640216&form=6&db=m Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21718239&form=6&db=m Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 inhibition and Thrombin Receptor Antagonists. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21999110&form=6&db=m Safety of bivalirudin in patients with coronary artery disease. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22339254&form=6&db=m In the Bivalirudin Era, are we still Looking for a Potent Antiplatelet Agent? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22459907&form=6&db=m Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22577900&form=6&db=m Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22583760&form=6&db=m Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in High-Risk Patients Undergoing Percutaneous Coronary Intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin Study). causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22705889&form=6&db=m Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22877639&form=6&db=m Direct thrombin inhibitor-bivalirudin functionalized plasma polymerized allylamine coating for improved biocompatibility of vascular devices. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23068568&form=6&db=m Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23160017&form=6&db=m [New oral anticoagulants: recommendations, precautions and perspectives for use]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23470494&form=6&db=m New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23530022&form=6&db=m Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23806863&form=6&db=m [Prehospital treatment with bivalirudin in acute myocardial infarction referred for primary angioplasty. About 152 consecutive patients study.] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23968500&form=6&db=m Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24219045&form=6&db=m The clinical and economic impact of bivalirudin for percutaneous coronary intervention. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24444781&form=6&db=m Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24514756&form=6&db=m Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24650773&form=6&db=m Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25030773&form=6&db=m Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25129064&form=6&db=m Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). ongoing research,unassigned 1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25135288&form=6&db=m Oral antiplatelet therapy in acute coronary syndromes: recent developments. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25262270&form=6&db=m Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25458650&form=6&db=m Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25614282&form=6&db=m Role of oral anticoagulants in patients after an acute coronary syndrome. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25764910&form=6&db=m The Spectrum of Thrombin in Acute Coronary Syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25776457&form=6&db=m Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26025218&form=6&db=m Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26715178&form=6&db=m Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26895973&form=6&db=m Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26927051&form=6&db=m New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor? unassigned - 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26994821&form=6&db=m Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27171403&form=6&db=m Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,2 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27228186&form=6&db=m Novel oral anticoagulants in the management of coronary artery disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27419389&form=6&db=m Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27437658&form=6&db=m Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,3 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27502866&form=6&db=m Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27676253&form=6&db=m Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27765885&form=6&db=m Novel oral anticoagulants for acute coronary syndrome. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27903864&form=6&db=m Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28363222&form=6&db=m Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. causal interaction,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29249166&form=6&db=m Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29421012&form=6&db=m Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30340765&form=6&db=m Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). causal interaction,unassigned 3,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30568593&form=6&db=m TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32761372&form=6&db=m ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32898227&form=6&db=m Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10352499&form=6&db=m [New findings on the physiopathology of acute hemolytic transfusion reactions] ongoing research,unassigned 3,0 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16731303&form=6&db=m Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19050602&form=6&db=m Argatroban for anticoagulation in continuous renal replacement therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20170696&form=6&db=m Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane. unassigned - 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20506163&form=6&db=m Thrombin down-regulates the TGF-beta-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1. causal interaction,unassigned 1,0 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24009280&form=6&db=m Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34303838&form=6&db=m Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury. therapeutic application,unassigned 3,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2221583&form=6&db=m Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8186352&form=6&db=m Antithrombin III deficiency in neonatal respiratory distress syndrome. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8726231&form=6&db=m Thrombin inhibitors reduce intrapulmonary accumulation of fibrinogen and procoagulant activity of bronchoalveolar lavage fluid during acute lung injury induced by pulmonary overdistention in newborn piglets. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817717&form=6&db=m Heparin improves gas exchange during experimental acute lung injury in newborn piglets. therapeutic application,unassigned 3,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12152667&form=6&db=m Coagulation and inflammation in acute lung injury. causal interaction,unassigned 4,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12682445&form=6&db=m Tissue factor-dependent coagulation protease signaling in acute lung injury. causal interaction,unassigned 4,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12699352&form=6&db=m Anticoagulant therapy for acute lung injury or pneumonia. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15087821&form=6&db=m Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16488723&form=6&db=m Crosstalk between thrombosis and inflammation in lung reperfusion injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21858121&form=6&db=m Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. ongoing research,unassigned 1,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24469066&form=6&db=m Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25664391&form=6&db=m Platelet Activation and Aggregation Promote Lung Inflammation and Influenza Virus Pathogenesis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28428256&form=6&db=m Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor. unassigned - 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3941458&form=6&db=m Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat. ongoing research,unassigned 4,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6287488&form=6&db=m Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7306974&form=6&db=m Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11504518&form=6&db=m Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11964083&form=6&db=m Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21799402&form=6&db=m Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26238780&form=6&db=m Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26489727&form=6&db=m Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27609342&form=6&db=m The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31048498&form=6&db=m Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion. causal interaction,unassigned 2,0 3.4.21.5 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27566553&form=6&db=m TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30104289&form=6&db=m Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Adenomyosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33228345&form=6&db=m [Changes of coagulation function in patients with adenomyosis and its clinical significance]. diagnostic usage,unassigned 1,0 3.4.21.5 Adrenocortical Hyperfunction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34509666&form=6&db=m Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=920833&form=6&db=m Stimulation of fibrinogen synthesis by thrombin in rabbits with ancrod-induced afibrinogenemia. unassigned - 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2275170&form=6&db=m [The importance of the enzyme preparation ancistron-N in the diagnosis of disseminated intravascular coagulation] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2477208&form=6&db=m [Defibrination syndrome after snake bites] diagnostic usage,unassigned 3,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6334102&form=6&db=m Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. causal interaction,unassigned 1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6713090&form=6&db=m Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8086775&form=6&db=m Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10150402&form=6&db=m Techniques for evaluating the cause of bleeding in the ICU. Diagnostic clues and keys to interpreting hemostatic tests. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12195697&form=6&db=m Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). causal interaction,unassigned 4,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13746056&form=6&db=m [Congenital afibrinogenemia. II. Studies on thrombin formation and inactivation (silent coagulation)] unassigned - 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16403286&form=6&db=m [Inherited Afibrinogenemia Caused by Compound Heterozygous Mutations in the Beta beta-Chain of Fibrinogen.] diagnostic usage,unassigned 4,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16434491&form=6&db=m A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22123482&form=6&db=m Chronic subdural hematoma in a patient with congenital afibrinogenemia successfully treated with fibrinogen replacement. unassigned - 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23148136&form=6&db=m Treatment of afibrinogenemia in a chihuahua. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23546710&form=6&db=m Thrombin clotting time. diagnostic usage,unassigned 4,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25590527&form=6&db=m Hemostatic and thrombotic issues in cardiac surgery. therapeutic application,unassigned 4,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30345592&form=6&db=m Thromboelastography and thrombin generation assay in inherited afibrinogenemia. diagnostic usage,unassigned 3,0 3.4.21.5 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34455742&form=6&db=m [Analysis of gene mutation spectrum and pharmacokinetics of fibrinogen infusion in 146 cases of congenital fibrinogen disorders]. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15857159&form=6&db=m Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21389321&form=6&db=m Low but sustained coagulation activation ameliorates glucose induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. causal interaction,unassigned 3,0 3.4.21.5 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21955218&form=6&db=m Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28111966&form=6&db=m Procoagulant activity in patients with combined type 2 diabetes and coronary artery disease: No effects of long-term exercise training. diagnostic usage,unassigned 1,0 3.4.21.5 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34043882&form=6&db=m Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes. therapeutic application,unassigned 1,0 3.4.21.5 Alkalosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12623442&form=6&db=m Capacitative calcium influx and intracellular pH cross-talk in human platelets. causal interaction,unassigned 2,0 3.4.21.5 Alkalosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15850610&form=6&db=m Thrombin stimulation of Cl-/HCO3- exchange in human platelets. causal interaction,unassigned 1,0 3.4.21.5 Altitude Sickness http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29614518&form=6&db=m Hypobaric Hypoxia Causes Elevated Thrombin Generation Mediated by FVIII that is Balanced by Decreased Platelet Activation. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.5 Alveolar Bone Loss http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31039763&form=6&db=m Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=645319&form=6&db=m [Changes in the blood clotting system of patients with atherosclerotic and senile dementias] unassigned - 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1491781&form=6&db=m Thrombin accumulation in brains of patients with Alzheimer's disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7704602&form=6&db=m Protease nexin-1, a potent thrombin inhibitor, is reduced around cerebral blood vessels in Alzheimer's disease. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7858160&form=6&db=m Serine proteases and their serpin inhibitors in Alzheimer's disease. causal interaction,unassigned 3,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8333868&form=6&db=m Non-age related differences in thrombin responses by platelets from male patients with advanced Alzheimer's disease. causal interaction,unassigned 1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9141094&form=6&db=m Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease. therapeutic application,unassigned 2,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9204916&form=6&db=m Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10037469&form=6&db=m Mechanism of thrombin clearance by human astrocytoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11121687&form=6&db=m Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12379905&form=6&db=m Role of p38 and p44/42 mitogen-activated protein kinases in microglia. causal interaction,unassigned 4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15165703&form=6&db=m Thrombin, a mediator of neurotoxicity and memory impairment. causal interaction,unassigned 4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201482&form=6&db=m Injured brain endothelial cells release neurotoxic thrombin. unassigned - 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15542598&form=6&db=m Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. diagnostic usage,unassigned 1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15843610&form=6&db=m Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16410745&form=6&db=m Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16627934&form=6&db=m Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. causal interaction,unassigned 4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17254021&form=6&db=m Cyclin D1, cdk4, and Bim are involved in thrombin-induced apoptosis in cultured cortical neurons. unassigned - 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18183616&form=6&db=m Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18841278&form=6&db=m Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20150433&form=6&db=m Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23144146&form=6&db=m Direct thrombin inhibitors' potential efficacy in Alzheimer's disease. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25079808&form=6&db=m Targeting thrombin: an inflammatory neurotoxin in Alzheimer's disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26613657&form=6&db=m The Alzheimer's disease peptide A? promotes thrombin generation through activation of coagulation factor XII. therapeutic application,unassigned 1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27169378&form=6&db=m The Alzheimer's disease peptide ?-amyloid promotes thrombin generation through activation of coagulation factor XII: comment. therapeutic application,unassigned 1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27173418&form=6&db=m The Alzheimer's disease peptide ?-amyloid promotes thrombin generation through activation of coagulation factor XII: reply. therapeutic application,unassigned 1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27458694&form=6&db=m Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27553758&form=6&db=m HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28344073&form=6&db=m Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. causal interaction,unassigned 4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32792902&form=6&db=m Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33294639&form=6&db=m Short-term treatment with dabigatran alters protein expression patterns in a late-stage tau-based Alzheimer's disease mouse model. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33878266&form=6&db=m Femtomolar Detection of Thrombin in Serum and Cerebrospinal Fluid via Direct Electrocatalysis of Oxygen Reduction by the Covalent G4-Hemin-Aptamer Complex. causal interaction,unassigned 1,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34500640&form=6&db=m First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34524687&form=6&db=m Control of hippocampal pKr-2 expression reduces neurotoxic symptoms in 5XFAD mice. causal interaction,unassigned 3,0 3.4.21.5 Amnesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24352712&form=6&db=m Reversal of Trauma-Induced Amnesia in Mice by a Thrombin Receptor Antagonist. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Amnesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29182653&form=6&db=m Recovery from trauma induced amnesia correlates with normalization of thrombin activity in the mouse hippocampus. causal interaction,unassigned 4,0 3.4.21.5 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1904284&form=6&db=m Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6372111&form=6&db=m Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30258666&form=6&db=m A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia. causal interaction,unassigned 3,0 3.4.21.5 Amyotrophic Lateral Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30804878&form=6&db=m Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders. therapeutic application,unassigned 1,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1158526&form=6&db=m Evidence of fibrinogen degradation in rat anaphylaxis. diagnostic usage,unassigned 1,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2232133&form=6&db=m [Anaphylactic shock following topical use of thrombin for irrigation of urinary bladder] diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3988169&form=6&db=m [Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8096685&form=6&db=m Anaphylactic reaction to topical bovine thrombin. unassigned - 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10876222&form=6&db=m Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11918917&form=6&db=m Autologous thrombin for treatment of pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14656362&form=6&db=m Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population. therapeutic application,unassigned 1,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15229401&form=6&db=m [Treatment of postcatheterization femoral false aneurysms] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19870622&form=6&db=m THE COAGULATION OF BLOOD BY SNAKE VENOMS AND ITS PHYSIOLOGIC SIGNIFICANCE. unassigned - 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26003458&form=6&db=m Anaphylactic reaction to bovine thrombin in ultrasound-guided treatment of femoral pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411561&form=6&db=m A Case of Intraoperative Anaphylaxis Caused by Bovine-Derived Thrombin. unassigned - 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1335778&form=6&db=m [The diagnostic difficulties in a case of a hemorrhagic syndrome in an infant] unassigned - 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2959926&form=6&db=m [Coagulopathy and anemia caused by anticonvulsants] unassigned - 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8050212&form=6&db=m Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients. causal interaction,unassigned 4,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11503969&form=6&db=m Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells. diagnostic usage,unassigned 3,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17854302&form=6&db=m Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22398014&form=6&db=m Tissue factor and thrombin in sickle cell anemia. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23640650&form=6&db=m Renal involvement in sepsis: a prospective single-center study of 136 cases. causal interaction,unassigned 3,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23711829&form=6&db=m Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia. unassigned - 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25629417&form=6&db=m Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25811447&form=6&db=m Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload. diagnostic usage,unassigned 2,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26657082&form=6&db=m Acute kidney injury in high-risk cardiac surgery patients: roles of inflammation and coagulation. causal interaction,unassigned 4,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29470097&form=6&db=m A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32576489&form=6&db=m Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33228345&form=6&db=m [Changes of coagulation function in patients with adenomyosis and its clinical significance]. diagnostic usage,unassigned 1,0 3.4.21.5 Anemia, Aplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7833251&form=6&db=m Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Anemia, Refractory http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373191&form=6&db=m The human thrombin receptor gene and the 5q-syndrome. causal interaction,unassigned 4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1390242&form=6&db=m Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1893065&form=6&db=m Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. causal interaction,unassigned 4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2731776&form=6&db=m Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7993800&form=6&db=m Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation. causal interaction,unassigned 4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8191393&form=6&db=m Enhanced thrombin generation in children with sickle cell disease. causal interaction,unassigned 3,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9787186&form=6&db=m Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. ongoing research,unassigned 4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12694167&form=6&db=m Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14693325&form=6&db=m Hypercoagulability in sickle cell disease: a curious paradox. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17607590&form=6&db=m Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18024615&form=6&db=m Hypercoagulability in sickle cell disease: new approaches to an old problem. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22052675&form=6&db=m Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22360627&form=6&db=m Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. causal interaction,unassigned 2,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22398014&form=6&db=m Tissue factor and thrombin in sickle cell anemia. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22535498&form=6&db=m The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23530655&form=6&db=m Thrombin Generation in Children with Sickle Cell Disease: Relationship with Age, Hemolysis, Transcranial Doppler Velocity and Hydroxyurea Treatment. therapeutic application,unassigned 4,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23711829&form=6&db=m Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia. unassigned - 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24119168&form=6&db=m The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24449213&form=6&db=m Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. ongoing research,unassigned 3,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24759144&form=6&db=m Red blood cells and thrombin generation in sickle cell disease. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25596265&form=6&db=m Excess of heme induces tissue factor-dependent activation of coagulation in mice. causal interaction,unassigned 1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27430959&form=6&db=m Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28888622&form=6&db=m The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32576489&form=6&db=m Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33221576&form=6&db=m Thrombin generation in vivo and ex vivo in sickle cell disease patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,2 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2108549&form=6&db=m Transcatheter thrombosis of a leaking saccular aneurysm of the main renal artery with preservation of renal blood flow. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3111693&form=6&db=m Embolization of a subclavian artery aneurysm with steel coils and thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3487958&form=6&db=m Coagulation of aneurysms by direct percutaneous thrombin injection. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8192417&form=6&db=m [Iatrogenic aneurysm of the hepatic artery. Treatment by percutaneous injection of thrombin and selective arterial embolization] therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10490575&form=6&db=m Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10587389&form=6&db=m Thrombin injection versus compression of femoral artery pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10787206&form=6&db=m Percutaneous thrombin injection of splanchnic artery aneurysms: two case reports. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10929536&form=6&db=m [The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,4 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11052874&form=6&db=m Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060373&form=6&db=m Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11090397&form=6&db=m CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair. unassigned - 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11232891&form=6&db=m Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,3 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743570&form=6&db=m Colonic necrosis subsequent to catheter-directed thrombin embolization of the inferior mesenteric artery via the superior mesenteric artery: a complication in the management of a type II endoleak. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11757469&form=6&db=m [Minimally invasive percutaneous contrast-ultrasound guided thrombin occlusion of iatrogenic pseudoaneurysm] causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958321&form=6&db=m Percutaneous thrombin injection of carotid artery pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958322&form=6&db=m Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12170222&form=6&db=m Intraoperative thrombin occlusion of a visceral artery aneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12651253&form=6&db=m Interventional therapy for stenosis and aneurysm in renal graft artery: report of 9 cases. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14686668&form=6&db=m Sonographically guided thrombin injection for the treatment of femoral artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14712380&form=6&db=m Ischemic colitis following translumbar thrombin injection for treatment of endoleak. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753310&form=6&db=m The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14760606&form=6&db=m Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15111871&form=6&db=m Transluminal thrombin injection and exclusion of a paramesenteric abdominal aortic aneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15129344&form=6&db=m Reperfusion of splanchnic artery aneurysm following transcatheter embolization: treatment with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15322573&form=6&db=m EVAR: critical applied aortic morphology relevant to type-II endoleaks following device enhancement in patients with abdominal aortic aneurysms. unassigned - 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15674446&form=6&db=m Ruptured left gastric artery aneurysm successfully treated by thrombin injection: case report and literature review. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15890542&form=6&db=m Transluminal coil embolization of an inferior gluteal artery aneurysm by ultrasound-guided direct puncture of the target vessel. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16010511&form=6&db=m Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16432702&form=6&db=m Percutaneous treatment of a ruptured superior mesenteric artery aneurysm in a child. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16440266&form=6&db=m [Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16765241&form=6&db=m Reducing duplex examinations in patients with iatrogenic pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17445680&form=6&db=m Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17543674&form=6&db=m Treatment of type II endoleak with a transcatheter transcaval approach: results at 1-year follow-up. ongoing research,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17580217&form=6&db=m Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report. ongoing research,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17924731&form=6&db=m Strategies to Reduce the Rate of Type II Endoleaks: Routine Intraoperative Embolization of the Inferior Mesenteric Artery and Thrombin Injection Into the Aneurysm Sac. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,2 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17960643&form=6&db=m Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17966536&form=6&db=m Spontaneous pseudo-aneurysm of the deep femoral artery treated by a covered stent. unassigned - 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18184931&form=6&db=m Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18292393&form=6&db=m Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm. causal interaction,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18299923&form=6&db=m Percutaneous injection therapy for a peripheral pulmonary artery pseudoaneurysm after failed transcatheter coil embolization. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18670384&form=6&db=m A case of gastroduodenal artery aneurysm in a HIV-positive patient treated by combined percutaneous thrombin injection and endovascular coil embolization. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18795234&form=6&db=m Strategies of endoleak management following endoluminal treatment of abdominal aortic aneurysms in 95 patients: how, when and why. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18925399&form=6&db=m The use of thrombin in the radiology department. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18948871&form=6&db=m Transcatheter thrombin embolization of a giant visceral artery aneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19026565&form=6&db=m Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214627&form=6&db=m Percutaneous Cyanoacrylate Glue Injection into the Renal Pseudoaneurysm to Control Intractable Hematuria After Percutaneous Nephrolithotomy. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19449064&form=6&db=m Traumatic Inferior Gluteal Artery Aneurysm Managed with Emergency Transcatheter Thrombin Injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19561825&form=6&db=m Pseudoaneurysm of the radial artery diagnosed by bedside ultrasound. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19625264&form=6&db=m Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737712&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20212423&form=6&db=m Use of FloSeal in the endovascular treatment of voluminous aneurysm of a lower gluteus artery. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20619591&form=6&db=m A ruptured aneurysm after stent graft puncture during computed tomography-guided thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21170532&form=6&db=m Embolization of an Internal Iliac Artery Aneurysm after Image-Guided Direct Puncture. diagnostic usage,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21256835&form=6&db=m The dermatan sulfate-dependent anticoagulant pathway is mostly preserved in aneurysm and in severe atherosclerotic lesions while the heparan sulfate pathway is disrupted. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21890561&form=6&db=m Thrombin injection for the treatment of mycotic gluteal aneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22669095&form=6&db=m Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22727838&form=6&db=m Innominate artery aneurysm with hemoptysis and airway compression in a patient with bovine aortic arch. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22864607&form=6&db=m Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23312838&form=6&db=m Transcaval embolization as an alternative technique for the treatment of type II endoleak after endovascular aortic aneurysm repair. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23348304&form=6&db=m Treatment protocol of traumatic pseudoaneurysm of the superficial temporal artery. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23404313&form=6&db=m Branch ligatures and blood aspiration for post-traumatic superficial temporal artery pseudoaneurysm: surgical technique. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23580114&form=6&db=m Endovascular management of an infected superficial femoral artery pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23592808&form=6&db=m Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23737024&form=6&db=m Saccular Aneurysm of Superior Vena Cava Treated with Percutaneous, Transcatheter Thrombin Injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24199765&form=6&db=m Intraprocedural and postprocedural perigraft arterial sac embolization (PASE) for endoleak treatment. unassigned - 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24365080&form=6&db=m Posttraumatic Lingual Artery Pseudoaneurysm Treated with Ultrasound-Guided Percutaneous Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24654250&form=6&db=m Iliac artery pseudoaneurysm presenting as a paravertebral collection: a potentially fatal mimic. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24661399&form=6&db=m Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25097678&form=6&db=m Endovascular treatment of pseudoaneurysms in pancreatitis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25121631&form=6&db=m Endoscopic ultrasound-guided thrombin injection in a large splenic artery aneurysm: first report in a patient with tropical chronic pancreatitis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25170402&form=6&db=m Percutaneous thrombin embolization of a pancreatico-duodenal artery pseudoaneurysm after failing of the endovascular treatment. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26336421&form=6&db=m Thrombin obliteration of subclavian artery aneurysm with intravascular balloon protection. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26975606&form=6&db=m Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27298673&form=6&db=m Percutaneous Thrombin Injection for Treatment of a Splenic Artery Aneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27366881&form=6&db=m Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28787245&form=6&db=m Laser-assisted transprosthesial coil embolization combined with thrombin injection for treatment of an endoleak type II after endovascular aneurysm repair. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29470097&form=6&db=m A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30042807&form=6&db=m Endovascular management of a rare complication of an aortic coarctation. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30655931&form=6&db=m Percutaneous puncture and embolisation for pancreatitis-related pseudoaneurysm: the feasibility of thrombin injection even in collection of fluid surrounding the pseudoaneurysm. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31032803&form=6&db=m Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31462961&form=6&db=m Radial Artery Pseudoaneurysms Treated by Ultrasound-Guided Differential Compression: An Effective and Simple Method. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31481998&form=6&db=m Endovascular therapy of arteriovenous malformation in a male patient with severe post-coital pelvic pain. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31890070&form=6&db=m Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32018025&form=6&db=m Combined Endovascular Exclusion with Percutaneous Sac Aspiration and Thrombin Injection in the Management of Popliteal Artery Aneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175151&form=6&db=m Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,4 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32258603&form=6&db=m Temporary aneurysm neck balloon occlusion during percutaneous thrombin embolization of a superficial femoral artery pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32580633&form=6&db=m Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice. causal interaction,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32648523&form=6&db=m Endovascular Solution to Endoleak Phenomenon After Open Repair of Abdominal Aortic Aneurysm. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32773931&form=6&db=m Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32892126&form=6&db=m Upper gastrointestinal bleeding due to hepatic artery aneurysm: Case report and literature review. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32978055&form=6&db=m Embolization of a Giant Hepatic Venous Aneurysm by Complementary Use of Coils, Vascular Plug, and Thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33549781&form=6&db=m Prophylactic Aneurysm Embolization during EVAR Is Safe, Improves Sac Regression and Decreases the Incidence of Type II Endoleak. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34522908&form=6&db=m Microsurgical and Endovascular Management of Congenital Iliac Aneurysms in the Neonatal Period: Two Cases and a Literature Review. unassigned - 3.4.21.5 Aneurysm, Dissecting http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11678459&form=6&db=m Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. causal interaction,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2783516&form=6&db=m Embolotherapy of a high-flow false aneurysm by using an occlusion balloon, thrombin, steel coils, and a detachable balloon. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3495980&form=6&db=m Transcatheter occlusion of a profunda femoral artery pseudoaneurysm using thrombin. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9240316&form=6&db=m Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9652465&form=6&db=m Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783797&form=6&db=m Duplex-directed thrombin injection as a method to treat femoral artery pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10405652&form=6&db=m Ultrasound-guided percutaneous thrombin injection for treatment of femoral pseudoaneurysms: technical note. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10441110&form=6&db=m Treatment of an iatrogenic femoral artery pseudoaneurysm with percutaneous duplex-guided injection of thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10470945&form=6&db=m Vascular and interventional case of the day. Pancreatic head pseudoaneurysm treated with percutaneous thrombin injection. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10490575&form=6&db=m Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10511172&form=6&db=m Thrombin injection for the repair of brachial artery pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10587389&form=6&db=m Thrombin injection versus compression of femoral artery pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10644137&form=6&db=m Iatrogenic femoral pseudoaneurysms: thrombin injection after failed US-guided compression. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10664498&form=6&db=m Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10787204&form=6&db=m US-guided percutaneous thrombin injection: a new method of repair of superficial temporal artery pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10796916&form=6&db=m Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10796957&form=6&db=m Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10836833&form=6&db=m Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10840372&form=6&db=m Thrombin injection for treating a subclavian artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10876222&form=6&db=m Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10877422&form=6&db=m Prolonged generalized urticarial reaction after percutaneous thrombin injection for treatment of a femoral artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10915699&form=6&db=m Successful sonographically guided thrombin injection in an infant with a femoral artery pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10928808&form=6&db=m Duplex-guided thrombin injection for iatrogenic femoral artery pseudoaneurysm is effective even in anticoagulated patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10929536&form=6&db=m [The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10986031&form=6&db=m Percutaneous duplex-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10997467&form=6&db=m Treatment of subclavian artery pseudoaneurysm with use of US-guided percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11000159&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11052874&form=6&db=m Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060373&form=6&db=m Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11067794&form=6&db=m Ultrasound-guided thrombin injection for the treatment of postcatheterization pseudoaneurysms. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11086770&form=6&db=m Pseudoaneurysms of the extremity without fracture: treatment with percutaneous ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11128459&form=6&db=m Treatment of femoral artery pseudoaneurysms with percutaneous thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11151655&form=6&db=m [Ultrasound guided percutaneous thrombin injection for treatment of a pseudoaneurysm after inguinal or brachial catheterization; good results in 14 patients] diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11159095&form=6&db=m Sonographically guided percutaneous thrombin injection versus sonographically guided compression for femoral artery pseudoaneurysms. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11232891&form=6&db=m Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,3 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11250982&form=6&db=m Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11261620&form=6&db=m Ultrasound-guided thrombin injection of iatrogenic femoral pseudoaneurysms: a prospective analysis. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11261628&form=6&db=m Ultrasound-guided percutaneous thrombin injection for femoral artery pseudoaneurysms. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11264104&form=6&db=m Sonographically guided percutaneous thrombin injection for treatment of a vein graft pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11274546&form=6&db=m Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11331854&form=6&db=m Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11340145&form=6&db=m Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11380368&form=6&db=m Percutaneous ultrasound-guided thrombin injection for coagulation of post-traumatic pseudoaneurysms. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11387617&form=6&db=m Treatment of femoral artery pseudoaneurysm with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11461851&form=6&db=m Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11517052&form=6&db=m Low-dose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11565042&form=6&db=m Ultrasound-guided thrombin injection is a safe and durable treatment for femoral pseudoaneurysms. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11574979&form=6&db=m Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11585404&form=6&db=m Treatment of femoral artery pseudoaneurysms using percutaneous thrombin injection under ultrasound guidance alone-proceed with caution. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11700498&form=6&db=m Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11748951&form=6&db=m Treatment of postcatheterisation false aneurysms: ultrasound-guided compression vs ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11756136&form=6&db=m Successful percutaneous thrombin injection of a brachial artery pseudoaneurysm in a neonate. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11757469&form=6&db=m [Minimally invasive percutaneous contrast-ultrasound guided thrombin occlusion of iatrogenic pseudoaneurysm] causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11800355&form=6&db=m Percutaneous ultrasound-guided thrombin injection for the treatment of pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11804894&form=6&db=m Percutaneous thrombin injection for treatment of an intrarenal pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877701&form=6&db=m Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11901428&form=6&db=m Human thrombin injection for the percutaneous treatment of iatrogenic pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11907756&form=6&db=m Recurrence of dialysis shunt pseudoaneurysm following percutaneous thrombin embolization. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11907761&form=6&db=m Re: Internal mammary artery pseudoaneurysm complicating central venous line placement: treatment with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11918917&form=6&db=m Autologous thrombin for treatment of pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11926954&form=6&db=m Ultrasound-guided thrombin injection is the treatment of choice for femoral pseudoaneurysms. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958321&form=6&db=m Percutaneous thrombin injection of carotid artery pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958322&form=6&db=m Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958323&form=6&db=m Thrombin injection for pseudoaneurysm occlusion: technical considerations. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958390&form=6&db=m Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11976971&form=6&db=m Ultrasound-guided thrombin injection of iatrogenic pseudoaneurysm at a community hospital. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12003722&form=6&db=m Pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12021713&form=6&db=m Protected carotid stenting: safety and efficacy of the MedNova NeuroShield filter. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12060164&form=6&db=m Lumbar artery pseudoaneurysm following renal biopsy: treatment with ultrasound-guided thrombin injection. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12075599&form=6&db=m Ipsilateral femoral vein compression: a contraindication to thrombin injection of femoral pseudoaneurysms. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12113707&form=6&db=m [Percutaneous thrombin injection for closure of femoral pseudoaneurysms: preliminary experience] therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12153944&form=6&db=m Inferior epigastric artery pseudoaneurysm: ultrasound diagnosis and treatment with percutaneous thrombin. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12196234&form=6&db=m Treatment of iatrogenic femoral artery false aneurysms with ultrasound-guided thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12203934&form=6&db=m Successful treatment of a femoral artery pseudoaneurysm mimicking a deep venous thrombosis following cardiac catheterization. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12225482&form=6&db=m Treatment of femoral pseudoaneurysms. Percutaneous US-guided thrombin injection versus US-guided compression. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12239038&form=6&db=m Pseudoaneurysm of the breast related to 18-gauge core biopsy: successful repair using sonographically guided thrombin injection. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12364872&form=6&db=m Ultrasound-guided percutaneous thrombin injection for treatment of extrarenal pseudoaneurysm after renal transplantation. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12368739&form=6&db=m A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12400828&form=6&db=m Obliteration of femoral artery pseudoaneurysm by thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12455094&form=6&db=m Thrombin injection to treat pseudoaneurysm of internal mammary artery bypass graft: a case report. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12469072&form=6&db=m Duplex-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12510248&form=6&db=m [Non-surgical therapy of iatrogenic false aneurysms] causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12514600&form=6&db=m Thrombin injection for failed stent graft repair of perforated atherosclerotic aortic ulcer. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12541131&form=6&db=m Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12563139&form=6&db=m Femoral pseudoaneurysms: management with percutaneous thrombin injections--success rates and effects on systemic coagulation. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12564089&form=6&db=m [Treatment of pseudoaneurysms with injection of thrombin] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12581058&form=6&db=m Thrombin injection for repair of pseudoaneurysms: a case for caution. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12618721&form=6&db=m Regarding "Bovine thrombin injection for the treatment of iatrogenic arterial pseudoaneurysms: is it too good to be true?". therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12652502&form=6&db=m Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12686007&form=6&db=m Iatrogenic Femoral Artery Pseudoaneurysm. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12695475&form=6&db=m Management of complex, two chamber false aneurysm by thrombin injections. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12704074&form=6&db=m Large iatrogenic pseudoaneurysm of the posterior tibial artery treated with sonographically guided thrombin injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12736923&form=6&db=m Ultrasound-guided thrombin injection of femoral artery pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12764292&form=6&db=m Regarding "A prospective study of ultrasound-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication". ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12777870&form=6&db=m Hepatic artery pseudoaneurysm after liver transplantation: treatment with percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12817037&form=6&db=m Current treatment methods for postcatheterization pseudoaneurysms. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12828884&form=6&db=m [Usefulness of sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12883841&form=6&db=m A prospective study on ultrasound-guided compression therapy or thrombin injection for treatment of iatrogenic false aneurysms in patients receiving full-dose anti-platelet therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12901409&form=6&db=m Percutaneous ultrasonographically guided thrombin injection of iatrogenic pseudoaneurysms in unusual sites. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12902566&form=6&db=m Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12903004&form=6&db=m Treatment of femoral artery pseudoaneurysms using ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12947284&form=6&db=m Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12973063&form=6&db=m Postcatheterization pseudoaneurysms: new developments in the diagnosis and treatment with ultrasound. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14512011&form=6&db=m Ultrasound guided thrombin injection to treat a pseudoaneurysm secondary to chronic pancreatitis. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14512012&form=6&db=m Thrombosis of a proximal aortic false aneurysm following AAA repair by endovascular thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14514815&form=6&db=m Transluminal occlusion of a pseudoaneurysm arising from a thoracic aortic graft patch using catheter delivery of thrombin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14528444&form=6&db=m Treatment of a radial artery pseudoaneurysm with ultrasound-guided percutaneous thrombin injection in a patient with Behçet's syndrome. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14562987&form=6&db=m Ultrasonic-guided percutaneous injection of pancreatic pseudoaneurysm with thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14573423&form=6&db=m Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14686668&form=6&db=m Sonographically guided thrombin injection for the treatment of femoral artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14716660&form=6&db=m Embolization of traumatic pseudoaneurysms after total knee arthroplasty. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14989565&form=6&db=m Percutaneous thrombin injection for pseudoaneurysm repair. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15011988&form=6&db=m Iatrogenic pseudoaneurysms: comparison of treatment modalities, including duplex-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15018170&form=6&db=m Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15053797&form=6&db=m How to perform ultrasound-assisted thrombin injection for closure of iatrogenic femoral pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15116244&form=6&db=m A review of the therapeutic uses of thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15194031&form=6&db=m Occlusion of pseudoaneurysms using human or bovine thrombin using contrast-enhanced ultrasound guidance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15195176&form=6&db=m [Treatment of pseudoaneurysms after vascular interventions] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15229401&form=6&db=m [Treatment of postcatheterization femoral false aneurysms] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15250085&form=6&db=m [Ultrasound-guided intraluminal thrombin injection for false aneurysm: report of one case] therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15278409&form=6&db=m Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm of the gastroduodenal artery. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15297836&form=6&db=m Iatrogenic subclavian artery pseudoaneurysm causing airway compromise: treatment with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15337894&form=6&db=m Occlusion of a giant splenic artery pseudoaneurysm with percutaneous thrombin-collagen injection. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15465248&form=6&db=m Treatment of radial and ulnar artery pseudoaneurysms using percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15482031&form=6&db=m Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15525756&form=6&db=m Percutaneous thrombin injection treatment of a profunda femoris pseudoaneurysm after femoral neck fracture. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15525892&form=6&db=m Occlusion of postcatheterisation femoral pseudoaneurysms with percutaneous thrombin injection under ultrasound guidance. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15615938&form=6&db=m Radial artery pseudoaneurysm: a maneuver to decrease the risk of thrombin therapy. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15716754&form=6&db=m Diagnosis and treatment of iatrogenic femoral artery pseudoaneurysms. diagnostic usage,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719182&form=6&db=m Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15838761&form=6&db=m [Treatment of iatrogenic femoral pseudoaneurysms with thrombin injection--results in 54 patients] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15855136&form=6&db=m Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15864476&form=6&db=m Paravertebral pseudoaneurysm thrombosed after percutaneous thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15934410&form=6&db=m Compression repair versus low-dose thrombin injection for the treatment of iatrogenic femoral pseudoaneurysm: a retrospective case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15999239&form=6&db=m Percutaneous repair of radial artery pseudoaneurysm in a hemodialysis patient using sonographically guided thrombin injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16002512&form=6&db=m Percutaneous treatment of a splenic artery pseudoaneurysm by thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16010502&form=6&db=m Treatment options for traumatic pseudoaneurysms of the paravisceral abdominal aorta. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16010511&form=6&db=m Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16012467&form=6&db=m Translumbar thrombin embolization of an aortic pseudoaneurysm complicating lumbar disk surgery. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16055694&form=6&db=m Postcatheterization pseudoaneurysm: results of US-guided percutaneous thrombin injection in 240 patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16096571&form=6&db=m Posttraumatic pseudoaneurysm of the hepatic artery: treatment with ultrasound-guided percutaneous transhepatic thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16116543&form=6&db=m Endoscopic ultrasound-guided thrombin injection for the treatment of pancreatic pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16360579&form=6&db=m True and false aneurysms of the femoral artery. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16374298&form=6&db=m Percutaneous thrombin injection to treat a post-traumatic hepatic pseudoaneurysm. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16380869&form=6&db=m [Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.] ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16380870&form=6&db=m [Comment to article Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.] therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16400767&form=6&db=m [US-guided percutaneous management of femoral artery pseudoaneurysms by thrombin injection: personal experience and review of the literature] therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16423945&form=6&db=m Development of nonobstructive intraarterial thrombi after injection of thrombin into pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16437508&form=6&db=m Surgery versus non-surgical treatment for femoral pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16440266&form=6&db=m [Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16495597&form=6&db=m Renal artery pseudoaneurysm following renal transplantation and treatment by percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16520183&form=6&db=m Thrombin injection of a pancreaticoduodenal artery pseudoaneurysm after failed attempts at transcatheter embolization. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598390&form=6&db=m Large femoral aneurysm as a late complication after vessel closure device application. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16604412&form=6&db=m CT-guided percutaneous thrombin injection for treatment of an inferior pancreaticoduodenal artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643084&form=6&db=m Percutaneous repair of abdominal aortic pseudoaneurysm by catheter-based delivery of thrombin. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673612&form=6&db=m [Treatment of iatrogenic femoral pseudoaneurysms by ultrasound-guided percutaneous thrombin injection: effectiveness and complications] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16752531&form=6&db=m Ultrasound guided percutaneous thrombin injection for the treatment of post-catheterisation femoral pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16765241&form=6&db=m Reducing duplex examinations in patients with iatrogenic pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16789522&form=6&db=m [Femoral artery pseudoaneurysms: treatment with ultrasound guided thrombin injection in 28 patients] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16845559&form=6&db=m Pseudoaneurysm in the iliac fossa after renal transplantation--treatment with ultrasound-guided thrombin injection. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16895137&form=6&db=m Endovascular repair of a large post-traumatic calf pseudoaneurysm and arteriovenous fistula. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16960880&form=6&db=m Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17031732&form=6&db=m Superior mesenteric artery pseudoaneurysm following pancreaticoduodenectomy: management by endovascular stent-graft placement and transluminal thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17038576&form=6&db=m Endovascular coil embolization for large femoral false aneurysms: two case reports. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17099540&form=6&db=m Cannulated screw for proximal tibial fracture complicated by iatrogenic popliteal pseudoaneurysm: definitive treatment by ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17131209&form=6&db=m Percutaneous ultrasound-guided thrombin injection as first-line treatment of pancreatic pseudoaneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17171306&form=6&db=m Treatment of a splenic artery pseudoaneurysm by endoscopic ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17185690&form=6&db=m Percutaneous thrombin injection of a pulmonary artery pseudoaneurysm refractory to coil embolization. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17265027&form=6&db=m Combined percutaneous thrombin injection and endovascular treatment of gastroduodenal artery pseudoaneurysm (PAGD): case report. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17278317&form=6&db=m Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17404724&form=6&db=m Percutaneous thrombin embolization of a post-traumatic superficial temporal artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437982&form=6&db=m Diagnosis and management of pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17445680&form=6&db=m Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17508246&form=6&db=m Femoral artery thrombosis following percutaneous treatment with thrombin injection of a femoral artery pseudoaneurysm: a case report. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17519848&form=6&db=m Combined endovascular intervention and percutaneous thrombin injection in the treatment of iatrogenic pseudoaneurysm. Case report. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17533544&form=6&db=m Minimally Invasive Repair of a Left Ventricular Pseudoaneurysm After Surgical Patch Reconstruction of an Infarct-Related Free Posterior Wall Rupture: CT-Guided Intervention. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17580217&form=6&db=m Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report. ongoing research,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17690879&form=6&db=m Pseudoaneurysm following vertebral biopsy and treatment with percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17708100&form=6&db=m Occlusion of iatrogenic pseudoaneurysms with percutaneous ultrasound guided thrombin injection. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17875956&form=6&db=m Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17899575&form=6&db=m Pelvic arterial pseudoaneurysm-a rare complication of Cesarean section: diagnosis and novel treatment. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17927002&form=6&db=m Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17943349&form=6&db=m Postpyelolithotomy renal artery pseudoaneurysm management with percutaneous thrombin injection: a case report. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17960643&form=6&db=m Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17968621&form=6&db=m Percutaneous thrombin injection of a femoral artery pseudoaneurysm with simultaneous venous balloon occlusion of a communicating arteriovenous fistula. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18174678&form=6&db=m Percutaneous thrombin embolization of a ruptured peripancreatic pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18192040&form=6&db=m A prospective study on ultrasound-guided percutaneous thrombin injection for treatment of iatrogenic post-catheterisation femoral pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18196334&form=6&db=m Minimally invasive therapy of pseudoaneurysms of the trunk: application of thrombin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18210055&form=6&db=m [Embolotherapy: principles and indications.] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18238924&form=6&db=m Ultrasound-guided thrombin injection of iatrogenic groin pseudoaneurysm: Doppler features and technical tips. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18299924&form=6&db=m Crural artery traumatic injuries: treatment with embolization. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18316364&form=6&db=m Treatment of spontaneous lumbar artery pseudoaneurysm by computed tomography--guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18367371&form=6&db=m Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18388079&form=6&db=m Percutaneous thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms: a case for caution. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18398227&form=6&db=m Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18455971&form=6&db=m Postcatheterization femoral artery pseudoaneurysms: therapeutic options. A case-controlled study. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18471452&form=6&db=m Treatment of post-catheterization femoral artery pseudo-aneurysm with para-aneurysmal saline injection. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18563346&form=6&db=m Ultrasound-guided thrombin injection: an alternative treatment for femoral artery pseudoaneurysm with better efficiency and safety. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18634525&form=6&db=m [Application of the percutaneuos thrombin injection in treatment of iatrogenic femoral pseudoaneurysms] causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18690571&form=6&db=m [Femoral pseudoaneurysms - ultrasound-guided thrombin injection as a method of treatment] therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18700514&form=6&db=m Pathological fracture of the clavicle causing subclavian pseudoaneurysm formation. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18764789&form=6&db=m Successful endovascular treatment of a hemodialysis graft pseudoaneurysm by covered stent and direct percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19085901&form=6&db=m Stent graft exclusion of pseudo-aneurysm arising from PTFE hemodialysis graft after recurrence following ultrasound guided thrombin injection. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19141724&form=6&db=m Medial plantar artery pseudoaneurysm following percutaneous pinning for lisfranc fracture-dislocation. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19180654&form=6&db=m Arterial complications associated with cardiac catheterization in pediatric patients with a previous history of kawasaki disease. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19223384&form=6&db=m Surgical Treatment of an Extrarenal Pseudoaneurysm After Kidney Transplantation. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19231554&form=6&db=m Traumatic pseudoaneurysm of the anterior tibial artery treated with ultrasound-guided thrombin injection in a pediatric patient. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19246211&form=6&db=m Complications of modern diagnostic cerebral angiography in an academic medical center. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19370614&form=6&db=m Treatment for femoral pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19449064&form=6&db=m Traumatic Inferior Gluteal Artery Aneurysm Managed with Emergency Transcatheter Thrombin Injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19534238&form=6&db=m Post-catheterization pseudoaneurysm in a one-year-old child treated by ultrasound-guided human thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19561825&form=6&db=m Pseudoaneurysm of the radial artery diagnosed by bedside ultrasound. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19602496&form=6&db=m Post-sternotomy intercostal artery pseudoaneurysm. Sonographic diagnosis and thrombosis by ultrasound-guided percutaneous thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19660885&form=6&db=m Percutaneous ultrasound-guided thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19702352&form=6&db=m Safety and efficacy of the StarClose vascular closure system using 7-F and 8-F sheath sizes: a consecutive single-center analysis. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737712&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19755331&form=6&db=m The recurrence of iatrogenic femoral artery pseudoaneurysm after occlusion by ultrasound guided percutaneous thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19823708&form=6&db=m [Complex supraclavicular false aneurysm. Case report.] diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19856429&form=6&db=m Treatment of an extracapsular post-renal biopsy pseudoaneurysm with ultrasound-guided thrombin injection. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19906551&form=6&db=m Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19909682&form=6&db=m Thrombin injection to treat a scalp pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19909684&form=6&db=m Iatrogenic venous pseudoaneurysm: case report and review of the literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19918533&form=6&db=m Coil embolization of inferior epigastric artery pseudoaneurysm after percutaneous thrombin injection failure: a case report. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20030287&form=6&db=m [Ultrasound-guided thrombin injection for the treatment of femoral artery pseudoaneurysms--report of three cases] therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20058004&form=6&db=m Transarterial Thrombin Injection Secured with an Embolic Protection Device as a Treatment for a Superior Mesenteric Artery Pseudoaneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20087733&form=6&db=m CT-Guided Thrombin Injection to Control Rapid Expansion of Ascending Aortic False Aneurysm 15 Months After Bentall-Bono Operation. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20162284&form=6&db=m Endovascular Treatment of Complications of Femoral Arterial Access. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20201962&form=6&db=m Pseudoaneurysm in association with a knee endoprothesis operation in an inhibitor-positive haemophilia A patient - treatment with local thrombin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20464675&form=6&db=m Successful treatment of a mycotic pseudoaneurysm of the brachial artery with percutaneous ultrasound-guided thrombin injection and antibiotics. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20589203&form=6&db=m Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20630509&form=6&db=m A visceral pseudoaneurysm: management by EUS-guided thrombin injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20638222&form=6&db=m Complex subclavian artery pseudoaneurysm causing failure of endovascular stent repair with salvage by percutaneous thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20858370&form=6&db=m Nonsurgical Repair of a Pseudoaneurysm in a Cynomolgus Macaque (Macaca fascicularis). therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20858808&form=6&db=m Incidence of infectious complications after an ultrasound-guided intervention. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20955656&form=6&db=m Use of an endovascular stent graft and percutaneous thrombin injection to treat an iatrogenic hepatic artery pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21113371&form=6&db=m Pseudoaneurysm of ulnar artery after endoscopic carpal tunnel release. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21160978&form=6&db=m Post-traumatic hepatic artery pseudoaneurysm treated with endovascular embolization and thrombin injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21283978&form=6&db=m Ultrasound guided thrombin injection of pseudoaneurysm of the radial artery after percutaneous coronary intervention. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21468788&form=6&db=m Endoscopic ultrasound-guided injection therapy for hepatobiliary disease. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21498325&form=6&db=m Minimally invasive application of thrombin in the treatment of pseudoaneurysms following open aortic surgery. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21523646&form=6&db=m Fatal Complication after Thrombin Injection for Post-Catheterization Femoral Pseudoaneurysm. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21621968&form=6&db=m Anastomotic Pseudoaneurysm Formation After Bypass Grafting to Porcelainized Peroneal Artery: Successful Treatment by Percutaneous Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21646232&form=6&db=m The Use of the Starclose Device for Obtaining Femoral Artery Hemostasis. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21732263&form=6&db=m [Treatment of pseudoaneurysms by thrombin injection]. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21826574&form=6&db=m Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21835587&form=6&db=m Endovascular Treatment of a Giant Aorto-Ostial Renal Artery Pseudoaneurysm. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21928195&form=6&db=m Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21944714&form=6&db=m Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21969234&form=6&db=m Percutaneous ultrasound-guided thrombin injection of a post-traumatic pancreatic pseudoaneurysm in a pediatric patient. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22017919&form=6&db=m Ultrasound-guided thrombin injection for the treatment of an iatrogenic hepatic artery pseudoaneurysm: a case report. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22198911&form=6&db=m Ultrasonography-guided percutaneous thrombin injection of postcatheterization pseudoaneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22232329&form=6&db=m Results of a new human recombinant thrombin for the treatment of arterial pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22259171&form=6&db=m [Treatment of pseudoaneurysms by thrombin injection]. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22259172&form=6&db=m [Treatment of pseudoaneurysms by thrombin injection]. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22318072&form=6&db=m Pseudoaneurysm of the inferior epigastric artery: a rare complication of laparoscopic ventral hernia repair. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22411947&form=6&db=m Image-guided Percutaneous Splenic Interventions. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22431105&form=6&db=m Treatment of an iatrogenic femoral artery pseudoaneurysm with concomitant arteriovenous fistula with percutaneous implantation of an amplatzer vascular plug. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22448549&form=6&db=m [Traumatic pseudoaneurysm of the superficial temporal artery]. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22473579&form=6&db=m Splenic artery pseudoaneurysm treated with thrombin injection guided by endoscopic ultrasound. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22479145&form=6&db=m Successful direct thrombin injection of a femoral artery pseudoaneurysm in an anticoagulated patient with a mechanical mitral valve. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22583199&form=6&db=m Successful treatment of a two centimeter breast pseudoaneurysm with thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22644008&form=6&db=m Treatment of arterial pseudoaneurysms with percutaneous ultrasound-guided thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22669095&form=6&db=m Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22685024&form=6&db=m Intercostal artery pseudoaneurysm: a rare complication of transaortic transcatheter aortic valve implantation. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22802774&form=6&db=m Personal experiences in direct ultrasound-guided injection of thrombin into the lumen of pseudoaneurysm as a method of treatment in case of iatrogenic femoral artery damage. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22864607&form=6&db=m Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22865179&form=6&db=m Ultrasound-guided thrombin injection for pseudoaneurysms: a case series at a local hospital. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22891829&form=6&db=m Use of the 8-f angio-seal vascular closure device in large-caliber arteriotomies. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23019996&form=6&db=m Managing coronary artery vein bypass graft stump pseudoaneurysm: a novel approach. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23109771&form=6&db=m Percutaneous Thrombin Injection of Common Carotid Artery Pseudoaneurysm without Cerebral Protection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23161362&form=6&db=m Percutaneous Treatment of Iatrogenic Pseudoaneurysms by Cyanoacrylate-Based Wall-Gluing. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23198251&form=6&db=m Dissecting pseudoaneurysm of the proper hepatic artery repaired by primary anastomosis: a case report. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23204825&form=6&db=m Treatment of Iatrogenic Pseudoaneurysms Using Ultrasound-Guided Thrombin Injection over a 5-Year Period. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23348304&form=6&db=m Treatment protocol of traumatic pseudoaneurysm of the superficial temporal artery. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23580114&form=6&db=m Endovascular management of an infected superficial femoral artery pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23589038&form=6&db=m Post-traumatic pseudoaneurysm of the thyrocervical trunk. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23660876&form=6&db=m Percutaneous thrombin injection in an infant to treat hepatic artery pseudoaneurysm after failed embolization. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23693049&form=6&db=m Percutaneous thrombin injection with a distal embolic protection device for treatment of a common carotid artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23737023&form=6&db=m Deep Pelvic Postprostatectomy Pseudoaneurysm Treated by Transrectal Ultrasound-Guided Thrombin Injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23778887&form=6&db=m Erratum to: Deep Pelvic Postprostatectomy Pseudoaneurysm Treated by Transrectal Ultrasound-Guided Thrombin Injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23833415&form=6&db=m Combined thrombin-collagen injection for the management of an iatrogenic pseudoanuerysm in the popliteal region. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23885937&form=6&db=m Peripheral artery aneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23929421&form=6&db=m Treatment of temporal artery pseudoaneurysms. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24042960&form=6&db=m A Rare Case of Iatrogenic Pseudoaneurysm of the Left Brachiocephalic Vein After Central Venous Catheterization Treated With Thrombin Injection. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24151057&form=6&db=m Ultrasound-guided thrombin injection in the treatment of iatrogenic arterial pseudoaneurysms: Single-center experience. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24322310&form=6&db=m [Ultrasound-guided percutaneous thrombin injection therapy for the treatment of iatrogenic brachial pseudoaneurysms]. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24365080&form=6&db=m Posttraumatic Lingual Artery Pseudoaneurysm Treated with Ultrasound-Guided Percutaneous Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24560862&form=6&db=m Ultrasound-guided percutaneous thrombin injection of iatrogenic upper extremity pseudoaneurysms. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24581101&form=6&db=m A cost effective endovascular approach for management of post-catheterization profunda femoris artery pseudoaneurysm using thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24661399&form=6&db=m Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24692534&form=6&db=m Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24749101&form=6&db=m Femoral pseudoaneurysms requiring surgical treatment. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24849462&form=6&db=m Correction of procedural arterial pseudoaneurysms: established and novel procedures. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24868218&form=6&db=m Percutaneous ultrasound-guided thrombin injection is effective even in infants with external iliac artery pseudoaneurysms. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24951176&form=6&db=m External carotid artery pseudoaneurysm following microvascular free flap reconstruction. The role of endovascular thrombin injection in embolization: a case report and review. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015326&form=6&db=m Percutaneous thrombin injection treatment of a gluteal pseudoaneurysm following radiofrequency ablation of a hip osteoid osteoma in a 6-year-old boy. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25049050&form=6&db=m Ultrasound guided percutaneous thrombin injection in a radial artery pseudoaneurysm following percutaneous coronary intervention. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25170402&form=6&db=m Percutaneous thrombin embolization of a pancreatico-duodenal artery pseudoaneurysm after failing of the endovascular treatment. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25201028&form=6&db=m Cardiologist operated ultrasound guided thrombin injection as a safe and efficacious first line treatment for iatrogenic femoral artery pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25209597&form=6&db=m The Use of ExoSeal Vascular Closure Device for Direct Antegrade Superficial Femoral Artery Puncture Site Hemostasis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25475476&form=6&db=m Expect the unexpected: acute and subacute coronary stent thrombosis following percutaneous thrombin injection for treatment of femoral pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25706367&form=6&db=m Intercostal artery pseudoaneurysm after ultrasound-guided liver biopsy: a case report and review of the literature. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25796189&form=6&db=m Ultrasound-guided thrombin injection of genicular artery pseudoaneurysm. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25797019&form=6&db=m Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26003458&form=6&db=m Anaphylactic reaction to bovine thrombin in ultrasound-guided treatment of femoral pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26179719&form=6&db=m Complications of percutaneous thrombin injection in patients with postcatheterization femoral pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26317260&form=6&db=m Percutaneous thrombin embolisation of an iatrogenic pseudoaneurysm of the subclavian artery with neuroprotection in a critically ill patient. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26421108&form=6&db=m Endoscopic ultrasound guided thrombin injection of angiographically occult pancreatitis associated visceral artery pseudoaneurysms: Case series. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26590924&form=6&db=m Percutaneous thrombin injection under sonographic guidance for exclusion of non-catheterizable post-pancreatitis pseudoaneurysm of the superior mesenteric artery: a minimally invasive and expeditious treatment option. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26728544&form=6&db=m Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26732387&form=6&db=m Pseudoaneurysm after pertrochanteric femur fracture: a case report. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26912762&form=6&db=m A novel approach to the management of carotid blowout syndrome: the use of thrombin in a case of failed covered stenting. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26929774&form=6&db=m Ultrasound-guided thrombin injection for treatment of superficial traumatic pseudoaneurysms and associated expanding hematomas: experience in five patients. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26932800&form=6&db=m A novel approach to the management of carotid blowout syndrome: the use of thrombin in a case of failed covered stenting. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26975606&form=6&db=m Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27013002&form=6&db=m Ultrasound-Guided Thrombin Injection for the Treatment of Femoral Pseudoaneurysm in Pediatric Patients. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27026390&form=6&db=m Ultrasound Guided Compression Versus Ultrasound Guided Thrombin Injection for the Treatment of Post-Catheterization Femoral Pseudoaneurysms: Systematic Review and Meta-Analysis of Comparative Studies. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27066441&form=6&db=m Ultrasound Guided Local Endovascular Coiling of an Iatrogenic Superficial Temporal Artery Pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27141239&form=6&db=m Traumatic axillary artery pseudoaneurysm treated with intravascular balloon occlusion and percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27174354&form=6&db=m Iatrogenic Femoral Pseudoaneurysm and Secondary Ipsilateral Deep Vein Thrombosis: An Indication for Early Surgical Exploration. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27238985&form=6&db=m A Pulsatile Mass in the Right Buttock. ongoing research,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27255797&form=6&db=m Endovascular retrograde recanalization in Asian critical limb ischaemia patients. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27259089&form=6&db=m Procedural outcomes with use of the flash ostial system in aorto-coronary ostial lesions. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27366881&form=6&db=m Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27370682&form=6&db=m Post-procedural pseudoaneurysms: Single-center experience. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27375804&form=6&db=m Successful Treatment of Iatrogenic Subclavian Artery Pseudoaneurysm by Ultrasound-Guided Thrombin Injection. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27407963&form=6&db=m Non Surgical Management of Pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27481496&form=6&db=m Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European Study. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27505324&form=6&db=m Ulnar pseudoaneurysm after transulnar coronary angiogram treated with percutaneous ultrasound-guided thrombin injection. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27531081&form=6&db=m Management of an Iatrogenic Pseudoaneurysm of the Superior Gluteal Artery by Percutaneous Ultrasound-Guided Thrombin Injection: A Case Report. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27935882&form=6&db=m [Puncture treatment of pseudoaneurysms of femoral arteries with the use of human thrombin]. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27936421&form=6&db=m Catheter-directed endovascular application of thrombin: Report of 3 cases and review of the literature. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28045415&form=6&db=m Percutaneous thrombin injection treatment of a femoral artery pseudoaneurysm with simultaneous arterial balloon occlusion: Case report and review of the literature. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28203308&form=6&db=m Successful Post-Pancreatitis Pseudoaneurysm Coagulation by Percutaneous Computed Tomography (CT)-Guided Thrombin Injection. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28394757&form=6&db=m A novel interventional method for treating femoral pseudoaneurysms: results from a monocentric experience. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28407277&form=6&db=m Recurrence of Thrombin-Injected Pseudoaneurysms Under Ultrasound Guidance: A 10-Year Retrospective Analysis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28421908&form=6&db=m Extravasating uterine pseudoaneurysm: A rare cause of postpartum haemorrhage. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28430313&form=6&db=m Successful balloon assisted percutaneous thrombin injection of right subclavian artery pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28466646&form=6&db=m Ultrasound-guided transvaginal thrombin injection of uterine arteries pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28560886&form=6&db=m Ultrasound-Guided Thrombin Injection Is a Safe and Effective Treatment for Femoral Artery Pseudoaneurysm in the Morbidly Obese. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28561908&form=6&db=m Successful treatment of uterine artery pseudoaneurysm with laparoscopic temporary clamping of bilateral uterine arteries, followed by hysteroscopic surgery. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28571227&form=6&db=m Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28578990&form=6&db=m Outcomes of Ultrasound-Guided Thrombin Injection of Nongroin Arterial Pseudoaneurysms. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28602578&form=6&db=m Femoral Arterial Haemostasis Using an Anchored Collagen Plug after Percutaneous EVAR with an Ultra-Low Profile Device: Prospective Audit of an Evolving "Post-Close" Technique. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28613001&form=6&db=m Novel approach to uterine artery pseudoaneurysm embolization for delayed post-partum hemorrhage: Thrombin really necessary? Reply. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28647639&form=6&db=m Flow reduction aided thrombin injection for complex femoral pseudoaneurysms: Case series and review of the literature. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28705337&form=6&db=m [Treatment of post-catheterization pseudoaneurysms by ultrasound-guided thrombin injection: A single-center experience and practical guideline]. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28707761&form=6&db=m Letter to 'Novel approach to uterine artery pseudoaneurysm embolization for delayed post-partum hemorrhage': Thrombin really necessary? therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28856301&form=6&db=m A Pseudoaneurysm of the Deep Palmar Arch After Penetrating Trauma to the Hand: Successful Exclusion by Ultrasound Guided Percutaneous Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28887253&form=6&db=m Comparison of ultrasound-guided thrombin injection of iatrogenic pseudoaneurysms based on neck dimension. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28924291&form=6&db=m Varied percutaneous and endovascular management of large iatrogenic Profunda Femoris artery pseudoaneurysm. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28946810&form=6&db=m Pseudoaneurysm of the superior lateral genicular artery following anterior cruciate ligament repair. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29049794&form=6&db=m A novel approach to treating a post-sternotomy internal mammary artery pseudoaneurysm. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29077886&form=6&db=m Minimally invasive intervention of radial artery pseudoaneurysm using percutaneous thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29158648&form=6&db=m Non-invasive repair of an iatrogenic tibial artery branch pseudoaneurysm after intramedullary nailing. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29457228&form=6&db=m Usefulness of ultrasonography in diagnosis, percutaneous management and follow up of post-traumatic scalp pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29470097&form=6&db=m A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29528838&form=6&db=m A Rare Case of Axillary Artery Pseudoaneurysm Due to Shoulder Dislocation Treated With Percutaneous Thrombin Injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29563376&form=6&db=m Combining Percutaneous Ultrasound-Guided Hematoma Aspiration and Compression Repair to Treat Femoral Artery Pseudoaneurysm after Cardiac Catheterization. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29633298&form=6&db=m Severe allergic reaction: A rare complication of ultrasound-guided injection of thrombin in a femoral pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29778611&form=6&db=m Traumatic Aorto-Cisterna Chlyi Fistula with Treatment of Aortic Pseudoaneurysm with CT-Guided Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29782129&form=6&db=m Successful Treatment of a Common Femoral Arterial Pseudoaneurysm with US-Guided Thrombin Injection: A Case Report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29960794&form=6&db=m Fascial suture technique versus open femoral access for thoracic endovascular aortic repair. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29971689&form=6&db=m Endoscopic ultrasound-guided thrombin injection for management of visceral artery pseudoaneurysm: A novel approach. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30065485&form=6&db=m Thrombin Injection to Treat an Iatrogenic Internal Mammary Artery Pseudoaneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30151500&form=6&db=m Two Rare Cases of Posttraumatic Peripheral Artery Pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30155849&form=6&db=m Percutaneous embolization of post traumatic splenic pseudoaneurysm. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30175945&form=6&db=m Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30321142&form=6&db=m [Treatment of iatrogenic femoral artery pseudoaneurysms]. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30322345&form=6&db=m A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30335915&form=6&db=m Ultrasound-guided thrombin injection in the management of pseudoaneurysm after percutaneous arterial access. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30363619&form=6&db=m Traumatic pseudoaneurysm following ankle trauma. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30374751&form=6&db=m Treatment strategies for bleeding from gastroduodenal artery pseudoaneurysms complicating the course of chronic pancreatitis-A case series of 10 patients. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30375288&form=6&db=m Impact of thrombin injection in femoral artery pseudoaneurysms with AV-fistula. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30459975&form=6&db=m Brachial pseudoaneurysm of the neonate with partial response to thrombin injections and late spontaneous thrombosis and regression during expectant management. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30537784&form=6&db=m Endoscopic ultrasound-guided coil embolization and thrombin injection of a bleeding gastroduodenal artery pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30655931&form=6&db=m Percutaneous puncture and embolisation for pancreatitis-related pseudoaneurysm: the feasibility of thrombin injection even in collection of fluid surrounding the pseudoaneurysm. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30691971&form=6&db=m Interventional treatment of bleeding complications due to percutaneous cannulation for peripheral extracorporeal membrane oxygenation. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30734400&form=6&db=m Pseudoaneurysm after vacuum-assisted breast biopsy treated with percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30739134&form=6&db=m Imaging-guided percutaneous thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30851076&form=6&db=m Percutaneous ultrasound guided thrombin injection for axillary artery pseudoaneurysm following stenting of the arterial duct in two infants: Case report with review of literature. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30898555&form=6&db=m Short-term results with transcatheter aortic valve replacement for treatment of left ventricular assist device patients with symptomatic aortic insufficiency. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30955413&form=6&db=m Traumatic pseudoaneurysm of the ulnar artery treated with ultrasound guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30982331&form=6&db=m Factors associated with pseudoaneurysm development and necessity for reintervention: a single centre study. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31028852&form=6&db=m Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31032465&form=6&db=m EUS-guided thrombin injection of cystic artery pseudoaneurysm leading to Mirizzi's syndrome and hemobilia. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31032803&form=6&db=m Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31165346&form=6&db=m Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31263620&form=6&db=m Treatment of Common Femoral Artery Pseudoaneurysm: A Novel Approach Utilizing a VASCADE Percutaneous Closure Device. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31367094&form=6&db=m Endovascular treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde Angio-Seal deployment. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31404356&form=6&db=m Ultrasound-Guided Thrombin Injection for Iliopsoas Pseudoaneurysm. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31448171&form=6&db=m Percutaneous Thrombin Injection for Treatment of a Hepatic Arterial Pseudoaneurysm after the Placement of a Transjugular Intrahepatic Portosystemic Shunt. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31462961&form=6&db=m Radial Artery Pseudoaneurysms Treated by Ultrasound-Guided Differential Compression: An Effective and Simple Method. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31578127&form=6&db=m Predictors of Groin Access Pseudoaneurysm Complication: A 10-Year Institutional Experience. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31601777&form=6&db=m A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31711638&form=6&db=m Interventional treatment of arterial injury during blind central venous catheterisation in the upper thorax: experience from two centres. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31724605&form=6&db=m Ultrasound-guided percutaneous thrombin for the management of superior mesenteric artery pseudoaneurysm. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31893630&form=6&db=m Safety and Effectiveness of Percutaneous Low-Dose Thrombin Injection for Femoral Puncture Site Pseudoaneurysms in Neurointervention: Single-Center Experience. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31956042&form=6&db=m Percutaneous suture technique with ProGlide to manage vascular access pseudoaneurysm after percutaneous coronary intervention procedure: A case report. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31981367&form=6&db=m Spontaneous external jugular vein pseudoaneurysm treated by thrombin injection: Case report and literature review. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31982077&form=6&db=m Pseudoaneurysm in a patient with haemophilia A: thrombin injection plugs the hole. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31995828&form=6&db=m Endoscopic and percutaneous ultrasound-guided thrombin and glue injection in a pseudoaneurysm of the right hepatic artery. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32003302&form=6&db=m Utility of percutaneous thrombin injection for treating visceral pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32014339&form=6&db=m Comparison of the Efficacy and Safety of Two Dosing Protocols for Ultrasound Guided Thrombin Injection in Patients with Iatrogenic Femoral Pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32107892&form=6&db=m Ultrasound-guided thrombin injections for arterial pseudoaneurysms: a 14-year study conducted at King Khalid University Hospital Vascular Lab. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32118114&form=6&db=m Endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32166262&form=6&db=m Percutaneous Decannulation Instead of Surgical Removal for Weaning After Venoarterial Extracorporeal Membrane Oxygenation-A Crossed Perclose ProGlide Closure Device Technique Using a Hemostasis Valve Y Connector. diagnostic usage,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175151&form=6&db=m Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,4 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32191751&form=6&db=m Endovascular management of femoral access-site and access-related vascular complications following percutaneous coronary interventions (PCI). diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32258603&form=6&db=m Temporary aneurysm neck balloon occlusion during percutaneous thrombin embolization of a superficial femoral artery pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32338189&form=6&db=m Successful Percutaneous Transcatheter Closure of a Common Femoral Artery Pseudoaneurysm With Use of MicroVascular Plug Despite Continued Catheter-Directed Thrombolysis. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32381528&form=6&db=m Iatrogenic thyroid pseudoaneurysm following thyroid nodule radiofrequency ablation. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32411632&form=6&db=m Ultrasound-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms compared with open surgery: first experiences from a single institution. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32452286&form=6&db=m Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32473913&form=6&db=m Distal radial pseudoaneurysm after chronic total occlusion percutaneous coronary intervention resolved by percutaneous thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32504793&form=6&db=m Midterm Results of the Treatment of Penetrating Abdominal Aortic or Iliac Artery Ulcer with the BeGraft Balloon-Expandable Covered Stent-A Single-Center Experience. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32626820&form=6&db=m Response to article on endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32633730&form=6&db=m Response to letter on endoscopic ultrasound-guided thrombin injection a management approach for visceral artery pseudoaneurysm: case series. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32768535&form=6&db=m A Bail Out Solution for an Urgent Situation: Endovascular Exclusion and Embolization of an Infected Femoral Pseudoaneurysm. ongoing research,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32773931&form=6&db=m Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32790484&form=6&db=m Angiography-guided percutaneous thrombin injection for haemostasis of active bleeding complicated by femoral access: a case report. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32875180&form=6&db=m A hybrid approach for vascular control and repair of an expanding iatrogenic femoral artery pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32924996&form=6&db=m Contrast-enhanced ultrasound-guided thrombin injection in the management of iatrogenic pseudoaneurysm (PSA): A case report and review of literatures. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32929773&form=6&db=m Transvaginal ultrasound-guided direct thrombin injection for the treatment of intramyometrial pseudoaneurysm in a young female with uterine hemorrhage after failed uterine artery embolization. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32964466&form=6&db=m Successful treatment of a femoral pseudoaneurysm by ultrasonographically-guided application of a suture-mediated closure device. therapeutic application,unassigned 3,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33011878&form=6&db=m Percutaneous transthoracic embolisation for massive haemoptysis secondary to peripheral pulmonary artery pseudoaneurysms. unassigned - 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33294754&form=6&db=m Salvage of autogenous dialysis access with balloon-assisted thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33576932&form=6&db=m Effective treatment of iatrogenic femoral pseudoaneurysms by combined endovascular balloon inflation and percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33665531&form=6&db=m Post-traumatic pseudoaneurysm of the medial plantar artery with arteriovenous fistula treated by coil embolization of the main feeding artery and percutaneous thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34025835&form=6&db=m Late to early velocity index as a predictor of iatrogenic femoral artery pseudoaneurysm recurrence in patients treated with ultrasound-guided thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34034380&form=6&db=m [Feasibility, efficacy and safety of transbrachial access for interventional therapy on paravalvular leak post surgical valve replacement]. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34276893&form=6&db=m Traumatic Pseudoaneurysm of Anterior Tibial Artery Treated by Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34318149&form=6&db=m Complete percutaneous decannulation from femoral venoarterial extracorporeal membrane oxygenation. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34338651&form=6&db=m Secondary Femoral Access Hemostasis During Transcatheter Aortic Valve Replacement: Impact of Vascular Closure Devices. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34402241&form=6&db=m Percutaneous Thrombin Injection Based on Computational Fluid Dynamics of Femoral Artery Pseudoaneurysms. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34404860&form=6&db=m Choosing a treatment method for post-catheterization pseudoaneurysms guided by the late to early velocity index. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, False http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34448060&form=6&db=m Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula. therapeutic application,unassigned 4,0 3.4.21.5 Aneurysm, Infected http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17453516&form=6&db=m Percutaneous thrombin embolization of a hepatic artery mycotic aneurysm. therapeutic application,unassigned 1,0 3.4.21.5 Aneurysm, Infected http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18925399&form=6&db=m The use of thrombin in the radiology department. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, Infected http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32754376&form=6&db=m Mycotic Aneurysm of the Hepatic Artery: A Case Report and its Management. unassigned - 3.4.21.5 Aneurysm, Ruptured http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18925399&form=6&db=m The use of thrombin in the radiology department. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aneurysm, Ruptured http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20619591&form=6&db=m A ruptured aneurysm after stent graft puncture during computed tomography-guided thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1608202&form=6&db=m [The prognostic significance of changes in the level of natural antibodies to thrombin in stenocardia patients] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712515&form=6&db=m [The effect of plasmasorption on the content of natural antibodies to thrombin and alpha 2-macroglobulin in stenocardia patients] causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2100876&form=6&db=m Functional and antigenic antithrombin III in angina pectoris and acute myocardial infarction patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6233800&form=6&db=m [Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8115978&form=6&db=m Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8788552&form=6&db=m Fibrin generation and digestion in patients with angina pectoris. causal interaction,unassigned 1,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1772997&form=6&db=m Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6197872&form=6&db=m Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6832466&form=6&db=m Platelet release reaction and prostaglandin pathway activation in angina patients during exercise: effect of indobufen. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7900072&form=6&db=m Markers of hemostatic activation in affected coronary arteries during angioplasty. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9076381&form=6&db=m Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10441098&form=6&db=m Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. diagnostic usage,unassigned 3,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16118546&form=6&db=m The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17966595&form=6&db=m [Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18392332&form=6&db=m Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation. diagnostic usage,unassigned 4,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18499566&form=6&db=m Bivalirudin during primary PCI in acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22343680&form=6&db=m Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26771969&form=6&db=m Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet' Response to Clopidogrel in Patients with Stable Angina. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1516190&form=6&db=m Transient intermittent lymphocyte activation is responsible for the instability of angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1541449&form=6&db=m Coronary angioplasty for unstable angina. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1892068&form=6&db=m Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina patients. diagnostic usage,unassigned 4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1894862&form=6&db=m Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2083863&form=6&db=m Heparin and antiaggregating therapy in unstable angina. diagnostic usage,unassigned 2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2119139&form=6&db=m Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7549081&form=6&db=m Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641350&form=6&db=m Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7732975&form=6&db=m Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation. causal interaction,unassigned 4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863966&form=6&db=m Activation of blood coagulation by plaque rupture: mechanisms and prevention. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7886362&form=6&db=m [Unstable angina pectoris: coagulation disorder and its therapy] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111056&form=6&db=m Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris. causal interaction,unassigned 2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8459055&form=6&db=m Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8459056&form=6&db=m Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal? therapeutic application,unassigned 4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8480641&form=6&db=m Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8568564&form=6&db=m Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin. diagnostic usage,unassigned 3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578525&form=6&db=m Advances in antithrombotic therapy: novel agents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8592407&form=6&db=m Antithrombotic effects of hirulog in a rat carotid endarterectomy model. therapeutic application,unassigned 4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8604621&form=6&db=m Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8653867&form=6&db=m Thrombin activity and early outcome in unstable angina pectoris. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8762100&form=6&db=m Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778585&form=6&db=m A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8921778&form=6&db=m Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8925580&form=6&db=m Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8950498&form=6&db=m Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9470321&form=6&db=m Anti-thrombotic and anticoagulant treatment in interventional cardiology. therapeutic application,unassigned 2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9527073&form=6&db=m Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531029&form=6&db=m Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9552495&form=6&db=m Wall passivation for unstable angina. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9576150&form=6&db=m Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9671009&form=6&db=m Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy). therapeutic application,unassigned 3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9701880&form=6&db=m [Clinical presentation of unstable angina may influence the formation of thrombin during spontaneous episodes of ischemia] causal interaction,unassigned 4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819023&form=6&db=m Tissue factor expression by monocytes: regulation and pathophysiological roles. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9842027&form=6&db=m Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9988016&form=6&db=m Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy). therapeutic application,unassigned 3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10329069&form=6&db=m The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10342131&form=6&db=m [Pathophysiology of acute coronary syndromes] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10364817&form=6&db=m [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10413631&form=6&db=m Synthetic direct thrombin inhibitors in unstable angina - more questions than answers. therapeutic application,unassigned 1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10413640&form=6&db=m Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10413853&form=6&db=m [Blood coagulation and fibrinolysis in arteriosclerosis] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10441098&form=6&db=m Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. diagnostic usage,unassigned 3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10468144&form=6&db=m Thrombin inhibitors as anticoagulant agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10577463&form=6&db=m Newer antithrombin agents in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603519&form=6&db=m Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639214&form=6&db=m Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639631&form=6&db=m The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis" causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639635&form=6&db=m Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10728020&form=6&db=m Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10767113&form=6&db=m Lack of Correlation Between Activation of Hemostatic Mechanism and Inflammation in Unstable Angina Pectoris. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10978264&form=6&db=m In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,3 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127437&form=6&db=m Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11257732&form=6&db=m Thrombomodulin--endothelial thrombin receptor in blood of patients with unstable angina pectoris. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11686357&form=6&db=m Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11775622&form=6&db=m Platelet-dependent thrombin generation in patients with unstable angina pectoris. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,1 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11833835&form=6&db=m Bivalirudin: a direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11869846&form=6&db=m Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. therapeutic application,unassigned 4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12769712&form=6&db=m G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783606&form=6&db=m Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12843003&form=6&db=m Coagulation activation and long-term outcome in acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14985171&form=6&db=m Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992034&form=6&db=m Low molecular weight heparin in acute stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17270293&form=6&db=m Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of thrombosis, fibrinolysis and atherosclerotic burden. diagnostic usage,unassigned 3,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18412079&form=6&db=m What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18926355&form=6&db=m The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11460008&form=6&db=m In vitro interaction of C1-inhibitor with thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,1,0 3.4.21.5 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19076541&form=6&db=m Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22272913&form=6&db=m Inflammation and Coagulation in Urticaria and Angioedema. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31281319&form=6&db=m Coagulation and Skin Autoimmunity. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31814604&form=6&db=m Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33725261&form=6&db=m Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22288590&form=6&db=m Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31814604&form=6&db=m Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33725261&form=6&db=m Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Angiomyolipoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719182&form=6&db=m Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Anthrax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18816024&form=6&db=m Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest. ongoing research,unassigned 3,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8865529&form=6&db=m Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. causal interaction,unassigned 4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10990227&form=6&db=m Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11739542&form=6&db=m Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. unassigned - 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14653441&form=6&db=m Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15339683&form=6&db=m Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. causal interaction,unassigned 4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16014540&form=6&db=m Identification of thrombin antibodies in patients with antiphospholipid syndrome. diagnostic usage,unassigned 4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16026408&form=6&db=m Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16113788&form=6&db=m Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16325498&form=6&db=m Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. causal interaction,unassigned 4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17469158&form=6&db=m Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. diagnostic usage,unassigned 3,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17958739&form=6&db=m Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19155517&form=6&db=m Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. causal interaction,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22274722&form=6&db=m Thrombin inhibition profiles in healthy individuals and thrombophilic patients. unassigned - 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22635224&form=6&db=m Thrombin generation in antiphospholipid syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25864630&form=6&db=m Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25895847&form=6&db=m Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. diagnostic usage,unassigned 3,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27429595&form=6&db=m Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27730530&form=6&db=m A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27807637&form=6&db=m Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31527216&form=6&db=m A catastrophic antiphospholipid syndrome complicated with heparin-induced thrombocytopaenia, successfully managed with double filtration plasmapheresis, steroids and a direct thrombin inhibitor. therapeutic application,unassigned 3,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32507383&form=6&db=m Thrombin Generation in a patient with Triple Positive Antiphospholipid Syndrome Treated with Three Different Anticoagulants. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34205545&form=6&db=m Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1523607&form=6&db=m Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1755000&form=6&db=m The transient increase of plasma thrombin-antithrombin III (TAT) complex levels in patients with congenital antithrombin III deficiency during antithrombin III administration is due to extraction of thrombin from fibrin. unassigned - 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7209877&form=6&db=m Thrombin generation and formation of thrombin-antithrombin III complexes in congenital antithrombin III deficiency. therapeutic application,unassigned 1,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7955182&form=6&db=m Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8286739&form=6&db=m Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. causal interaction,unassigned 3,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8470046&form=6&db=m An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. unassigned - 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9288875&form=6&db=m Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21303963&form=6&db=m Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31020242&form=6&db=m A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Aortic Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31890070&form=6&db=m Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Aortic Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32580633&form=6&db=m Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice. causal interaction,unassigned 1,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9046916&form=6&db=m Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping. ongoing research,unassigned 2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10361322&form=6&db=m Vascular surgical society of great britain and ireland: inhibition of systemic fibrinolysis is associated with myocardial injury in patients operated on for ruptured abdominal aortic aneurysm causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10388633&form=6&db=m Ischaemia and reperfusion during open abdominal aortic aneurysm surgery induce extensive thrombin generation and activity. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11090397&form=6&db=m CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair. unassigned - 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12835992&form=6&db=m Successful treatment of a type-II endoleak with percutaneous CT-guided thrombin injection in a patient after endovascular abdominal aortic aneurysm repair. therapeutic application,unassigned 4,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753310&form=6&db=m The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14760606&form=6&db=m Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac. therapeutic application,unassigned 4,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15111871&form=6&db=m Transluminal thrombin injection and exclusion of a paramesenteric abdominal aortic aneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16102614&form=6&db=m Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17484533&form=6&db=m Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17650080&form=6&db=m Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18184931&form=6&db=m Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19625264&form=6&db=m Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19795099&form=6&db=m [Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.] causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20356864&form=6&db=m Markers of proteolysis, fibrinolysis, and coagulation in relation to size and growth rate of abdominal aortic aneurysms. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21975058&form=6&db=m Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22328619&form=6&db=m A case of hybrid repair of ruptured abdominal aortic aneurysm with use of thrombin for acute treatment of type II endoleak. therapeutic application,unassigned 4,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23140799&form=6&db=m Effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis. therapeutic application,unassigned 2,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30350931&form=6&db=m Changes in circulating markers of coagulation and fibrinolysis after EVAR. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30655925&form=6&db=m Percutaneous direct thrombin injection with hydrodissection to manage type II endoleak after endovascular abdominal aortic aneurysm repair. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Aortic Aneurysm, Thoracic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32580633&form=6&db=m Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice. causal interaction,unassigned 1,0 3.4.21.5 Aortic Coarctation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29481306&form=6&db=m Platelet-derived microparticles promote endothelial cell proliferation in hypertension via miR-142-3p. causal interaction,unassigned 3,0 3.4.21.5 Aortic Coarctation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30042807&form=6&db=m Endovascular management of a rare complication of an aortic coarctation. therapeutic application,unassigned 2,0 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20732681&form=6&db=m Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. unassigned - 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21057695&form=6&db=m Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties. unassigned - 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21519234&form=6&db=m Activated factor XI and tissue factor in aortic stenosis: links with thrombin generation. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,2,0 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21561895&form=6&db=m Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21890868&form=6&db=m Ambivalent effect of aortic stenosis on von Willebrand factor and thrombin generation. Is transvalvular gradient the guilty party? unassigned - 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25169013&form=6&db=m Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis. causal interaction,unassigned 1,0 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27010400&form=6&db=m Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,2 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29768939&form=6&db=m Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,3 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31185469&form=6&db=m Oral Anticoagulation Therapy and Progression of Calcific Aortic Valve Stenosis: Factor Xa versus Factor IIa Inhibition? causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32000579&form=6&db=m Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Appendicitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12953424&form=6&db=m [The role of thyroid and thymic hormones in regulation of fibrinolytic and pro-coagulant activity of leukocytes in patients with acute destructive appendicitis] diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Arenaviridae Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8384497&form=6&db=m Haemostatic derangements associated with arenavirus infection in the guinea-pig: radioimmunoassay of fibrinopeptide A to assess thrombin action in infected animals. unassigned - 3.4.21.5 Arrhythmias, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12379580&form=6&db=m Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes: implications for ischemic sodium loading. causal interaction,unassigned 4,0 3.4.21.5 Arrhythmias, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28302320&form=6&db=m Platelet reactivity and mean platelet volume as risk markers of thrombogenesis in atrial fibrillation. unassigned - 3.4.21.5 Arrhythmias, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7881702&form=6&db=m Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with ASA in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8241093&form=6&db=m Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10229740&form=6&db=m Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608016&form=6&db=m Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 3.4.21.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14694767&form=6&db=m Thrombin-antithrombin complex and the prothrombin fragment in arterial and venous blood of patients with peripheral arterial disease. causal interaction,unassigned 4,0 3.4.21.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21614411&form=6&db=m Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,1 3.4.21.5 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5269283&form=6&db=m [The thrombin generation test and heparin overloading in normal subjects and patients with arteriosclerosis] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5436060&form=6&db=m [Effect of alimentary lipemia on thrombin generation in the plasma of healthy persons and in arteriosclerosis] diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6283297&form=6&db=m [Pathogenesis of arteriosclerosis. Thrombin, factor XIII and fibronectin as regulators of fibroblast proliferation, endothelial cells and smooth muscle cells] causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7994808&form=6&db=m Fibrin formation and degradation in patients with arteriosclerotic disease. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16087677&form=6&db=m Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds. causal interaction,unassigned 2,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11438279&form=6&db=m Femoral pseudoaneurysm thrombinjection. diagnostic usage,unassigned 1,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16895137&form=6&db=m Endovascular repair of a large post-traumatic calf pseudoaneurysm and arteriovenous fistula. therapeutic application,unassigned 4,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17968621&form=6&db=m Percutaneous thrombin injection of a femoral artery pseudoaneurysm with simultaneous venous balloon occlusion of a communicating arteriovenous fistula. therapeutic application,unassigned 4,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20162284&form=6&db=m Endovascular Treatment of Complications of Femoral Arterial Access. therapeutic application,unassigned 4,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26728544&form=6&db=m Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis. therapeutic application,unassigned 1,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30335915&form=6&db=m Ultrasound-guided thrombin injection in the management of pseudoaneurysm after percutaneous arterial access. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,4 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31711638&form=6&db=m Interventional treatment of arterial injury during blind central venous catheterisation in the upper thorax: experience from two centres. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33665531&form=6&db=m Post-traumatic pseudoaneurysm of the medial plantar artery with arteriovenous fistula treated by coil embolization of the main feeding artery and percutaneous thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34448060&form=6&db=m Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula. therapeutic application,unassigned 4,0 3.4.21.5 Arteriovenous Malformations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783357&form=6&db=m Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Arteriovenous Malformations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21975060&form=6&db=m Nonsurgical treatment of scalp arteriovenous malformation using a combination of ultrasound-guided thrombin injection and transarterial coil embolization. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8040300&form=6&db=m Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11005778&form=6&db=m Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11238564&form=6&db=m Amelioration of collagen-induced arthritis by thrombin inhibition. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11945154&form=6&db=m Leech thrombin inhibitors. therapeutic application,unassigned 1,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16078333&form=6&db=m Prothrombin gene expression in articular cartilage with a putative role in cartilage degeneration secondary to joint immobility. causal interaction,unassigned 3,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17761350&form=6&db=m Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23237573&form=6&db=m Autoantibody-mediated arthritis in the absence of C3 and activating Fc? receptors: C5 is activated by the coagulation cascade. unassigned - 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385683&form=6&db=m Thrombin promotes matrix metalloproteinase-13 expression through the PKC? c-Src/EGFR/PI3K/Akt/AP-1 signaling pathway in human chondrocytes. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11238564&form=6&db=m Amelioration of collagen-induced arthritis by thrombin inhibition. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19445983&form=6&db=m Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3126818&form=6&db=m Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7554443&form=6&db=m Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8311562&form=6&db=m Thrombin in inflammation and healing: relevance to rheumatoid arthritis. therapeutic application,unassigned 1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8735810&form=6&db=m Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8877916&form=6&db=m Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976643&form=6&db=m Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9524076&form=6&db=m A hirudin-sensitive, growth-related proteinase from human fibroblasts. diagnostic usage,unassigned 3,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9640132&form=6&db=m Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10733483&form=6&db=m Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11128663&form=6&db=m Thrombin stimulates cell proliferation in human fibroblast-like synoviocytes in nuclear factor-kappaB activation and protein kinase C mediated pathway. ongoing research,unassigned 4,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12176812&form=6&db=m Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15229942&form=6&db=m Relationship between cathepsin B and thrombin in rheumatoid arthritis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18590834&form=6&db=m Osteopontin is dispensable for protection against high load systemic fungal infection. ongoing research,unassigned 2,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18787303&form=6&db=m Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19445983&form=6&db=m Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20593110&form=6&db=m Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22658376&form=6&db=m Thrombin generation in rheumatoid arthritis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22959919&form=6&db=m Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis. causal interaction,unassigned 4,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26001728&form=6&db=m Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis. therapeutic application,unassigned 1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26188585&form=6&db=m Alterations of the thrombin generation profile in rheumatoid arthritis. unassigned - 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26397418&form=6&db=m Nanostructured bioluminescent sensor for rapidly detecting thrombin. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27262798&form=6&db=m Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30105021&form=6&db=m The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review. therapeutic application,unassigned 3,0 3.4.21.5 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31209709&form=6&db=m Assessment of hemostatic disturbances in women with established rheumatoid arthritis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Arthus Reaction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1534318&form=6&db=m Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1913263&form=6&db=m Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,1 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7626288&form=6&db=m alpha-Thrombin increases cytosolic calcium and induces human airway smooth muscle cell proliferation. causal interaction,unassigned 4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10384063&form=6&db=m Thrombin in the airways of asthmatic patients. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10409227&form=6&db=m alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors. therapeutic application,unassigned 1,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14531295&form=6&db=m [Coagulation activity in the airways of asthmatic patients] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14630620&form=6&db=m Increased thrombin activity after allergen challenge: a potential link to airway remodeling? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16282712&form=6&db=m Effect of thrombin on permeability of human epithelial cell monolayers. causal interaction,unassigned 3,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17934112&form=6&db=m Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18385289&form=6&db=m Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation. causal interaction,unassigned 1,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18789772&form=6&db=m Role of the coagulation system in allergic inflammation in the upper airways. causal interaction,unassigned 3,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19487837&form=6&db=m [Potential mechanisms of airway remodeling initiated by activated thrombin in asthma] causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20150920&form=6&db=m A functional polymorphism (-603A --> G) in the tissue factor gene promoter is associated with adult-onset asthma. causal interaction,unassigned 4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23964923&form=6&db=m Dose-dependent differential effects of thrombin in allergic bronchial asthma. ongoing research,unassigned 3,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25519468&form=6&db=m Role of the extracellular signal-regulated kinase 1/2 signaling pathway in the process of thrombin-promoting airway remodeling in ovalbumin-allergic rats. causal interaction,unassigned 4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26120939&form=6&db=m The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26320153&form=6&db=m Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26369819&form=6&db=m Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales. causal interaction,unassigned 4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26714414&form=6&db=m Prothrombotic state in patients with severe and prednisolone-dependent asthma. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27019085&form=6&db=m Asthma is associated with enhanced thrombin formation and impaired fibrinolysis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28429138&form=6&db=m Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF?, in Peripheral Blood. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28887505&form=6&db=m Impaired fibrinolysis and lower levels of plasma ?2-macroglobulin are associated with an increased risk of severe asthma exacerbations. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30262412&form=6&db=m Thrombin lag time is increased in children with mild asthma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31863766&form=6&db=m Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32542982&form=6&db=m Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein. causal interaction,unassigned 4,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2546047&form=6&db=m Thrombin and trypsin act at the same site to stimulate phosphoinositide hydrolysis and calcium mobilization. ongoing research,unassigned 2,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7650024&form=6&db=m G12 requirement for thrombin-stimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells. ongoing research,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8396137&form=6&db=m A requirement for Ras protein function in thrombin-stimulated mitogenesis in astrocytoma cells. therapeutic application,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8713057&form=6&db=m Thrombin receptors modulate insulin-stimulated phosphatidylinositol 3,4,5-trisphosphate accumulation in 1321N1 astrocytoma cells. ongoing research,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8930892&form=6&db=m Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells. ongoing research,unassigned 2,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9247313&form=6&db=m The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain. therapeutic application,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9359863&form=6&db=m Thrombin produces phosphorylation of cytosolic phospholipase A2 by a mitogen-activated protein kinase kinase-independent mechanism in the human astrocytoma cell line 1321N1. ongoing research,unassigned 4,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9553056&form=6&db=m Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10037469&form=6&db=m Mechanism of thrombin clearance by human astrocytoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10480888&form=6&db=m A rho exchange factor mediates thrombin and Galpha(12)-induced cytoskeletal responses. therapeutic application,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10664248&form=6&db=m The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12684505&form=6&db=m Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes. ongoing research,unassigned 4,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15447683&form=6&db=m Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2. ongoing research,unassigned 2,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16051696&form=6&db=m Subnanomolar concentrations of thrombin enhance the volume-sensitive efflux of taurine from human 1321N1 astrocytoma cells. ongoing research,unassigned 2,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16805424&form=6&db=m Regulated release of nucleotides and UDP sugars from astrocytoma cells. therapeutic application,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18478545&form=6&db=m Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced morphological changes in 1321N1 human astrocytoma cells. therapeutic application,unassigned 1,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18687805&form=6&db=m Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61. unassigned - 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19699703&form=6&db=m Quantification of extracellular UDP-galactose. ongoing research,unassigned 3,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22687694&form=6&db=m Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30649824&form=6&db=m Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=41337&form=6&db=m The isoelectric point of thrombin and its behaviour compared to prothrombin at some solid surfaces. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=308066&form=6&db=m Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1320300&form=6&db=m Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1328304&form=6&db=m Thrombin receptor expression in normal and atherosclerotic human arteries. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1381849&form=6&db=m Heparin cofactor II deficiency in the elderly: comparison with antithrombin III. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1560563&form=6&db=m The effect of thrombin on low-density lipoprotein permeability and uptake by an arterial endothelial smooth muscle cell bilayer. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1988465&form=6&db=m An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2822287&form=6&db=m Alterations of vascular reactivity in atherosclerosis. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3087655&form=6&db=m Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3164315&form=6&db=m Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3680531&form=6&db=m Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4039471&form=6&db=m Release of plasminogen activator from isolated perfused dog heart. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4661652&form=6&db=m Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6297517&form=6&db=m Comparative beneficial effects on platelet functions and atherosclerosis of dietary linoleic and gamma-linolenic acids in the rabbit. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6309278&form=6&db=m Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641321&form=6&db=m Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7762612&form=6&db=m Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7806495&form=6&db=m Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863969&form=6&db=m Role of thrombosis in atherosclerosis and its complications. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863981&form=6&db=m Role of the thrombin receptor in restenosis and atherosclerosis. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923681&form=6&db=m Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8158841&form=6&db=m [Regulation of the endothelial function by thrombomodulin and/or thrombin receptor] causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8163952&form=6&db=m A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8226804&form=6&db=m Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells. ongoing research,unassigned 2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8305417&form=6&db=m Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. causal interaction,unassigned 1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8552614&form=6&db=m Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8653841&form=6&db=m Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807710&form=6&db=m Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134645&form=6&db=m Thrombin generation markers and coronary heart disease risk factors in a Polish population sample. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9168786&form=6&db=m Vascular thrombin receptor regulation in hypertensive rats. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186620&form=6&db=m Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: role of thrombin in atherosclerosis and restenosis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9207626&form=6&db=m Platelet-dependent thrombin generation in patients with hyperlipidemia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9403612&form=6&db=m Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9409313&form=6&db=m Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9427704&form=6&db=m Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9484989&form=6&db=m Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493599&form=6&db=m Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9695019&form=6&db=m Thrombin. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9743227&form=6&db=m Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819023&form=6&db=m Tissue factor expression by monocytes: regulation and pathophysiological roles. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10066865&form=6&db=m Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats. ongoing research,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10385784&form=6&db=m Potential non-glycoprotein IIb/IIIa effects of abciximab. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10397693&form=6&db=m Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10441098&form=6&db=m Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. diagnostic usage,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10544927&form=6&db=m Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11168298&form=6&db=m Impaired platelet prostacyclin receptor activity: a monozygotic twin study discordant for spinal cord injury. causal interaction,unassigned 2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11240387&form=6&db=m Thrombin as a regulator of inflammation and reparative processes in tissues. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11323017&form=6&db=m Suppressing thrombin generation is compatible with the development of atherosclerosis in mice. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11336112&form=6&db=m A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11701462&form=6&db=m Thrombin induces interleukin-6 expression through the cAMP response element in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11701463&form=6&db=m cAMP response element-binding protein mediates thrombin-induced proliferation of vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11727307&form=6&db=m Thrombin receptor antagonists as novel therapeutic targets. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11841339&form=6&db=m The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11855916&form=6&db=m The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12176958&form=6&db=m Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12676802&form=6&db=m Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. ongoing research,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12774450&form=6&db=m Thrombin contraction of vascular smooth muscle: implications for vasospasm. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12921859&form=6&db=m Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14529396&form=6&db=m Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14529894&form=6&db=m Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14569394&form=6&db=m [Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?] causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14734047&form=6&db=m Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14744972&form=6&db=m High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017006&form=6&db=m Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15063481&form=6&db=m Mechanisms of sex steroids. Future developments. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15101518&form=6&db=m Pharmacologic agents in stroke prevention, acute stroke therapy, and interventional procedures. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102593&form=6&db=m American Heart Association scientific sessions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15175791&form=6&db=m New nonlipid effects of statins and their clinical relevance in cardiovascular disease. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15286460&form=6&db=m Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15317289&form=6&db=m Potent non-peptide thrombin receptor antagonists. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15574198&form=6&db=m Blood coagulation and the risk of atherothrombosis: a complex relationship. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15684708&form=6&db=m Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15716125&form=6&db=m Induction of synthesis of a large heparan sulfate proteoglycan, perlecan, by thrombin in cultured human coronary smooth muscle cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15725689&form=6&db=m Role of thrombogenic factors in the development of atherosclerosis. causal interaction,unassigned 1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15951827&form=6&db=m Thrombin-induced glucose transport via Src-p38 MAPK pathway in vascular smooth muscle cells. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15984896&form=6&db=m Place of drug therapy in the treatment of carotid stenosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16434491&form=6&db=m A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16504676&form=6&db=m Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16601225&form=6&db=m Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16678686&form=6&db=m Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757126&form=6&db=m Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461731&form=6&db=m Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17489367&form=6&db=m Anti-hypertensive effect of the Dongchunghacho, Isaria sinclairii, in the spontaneously hypertensive rats. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549254&form=6&db=m Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18000795&form=6&db=m Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18385289&form=6&db=m Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation. causal interaction,unassigned 1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18405171&form=6&db=m Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18571697&form=6&db=m Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18633427&form=6&db=m Association of aortic valve sclerosis with thrombin generation in hypertensive patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18971786&form=6&db=m Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150392&form=6&db=m Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19217621&form=6&db=m Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228706&form=6&db=m Is thrombin a key player in the 'coagulation-atherogenesis' maze? causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19628787&form=6&db=m Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19687358&form=6&db=m Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19747479&form=6&db=m Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19906551&form=6&db=m Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19943541&form=6&db=m [Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20412272&form=6&db=m Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21042684&form=6&db=m Relationship between thrombin generation and carotid intima-media thickness. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21052830&form=6&db=m Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21107326&form=6&db=m Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21606930&form=6&db=m Non-conventional hemostatic risk factors for coronary heart disease in individuals with spinal cord injury. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21700444&form=6&db=m Bi-cell surface plasmon resonance detection of aptamer mediated thrombin capture in serum. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21728962&form=6&db=m Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21787749&form=6&db=m Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-?B signaling pathway activation in vascular endothelial cells. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21840881&form=6&db=m Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22161772&form=6&db=m Human cytomegalovirus infection and atherothrombosis. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22398011&form=6&db=m Tissue factor-driven thrombin generation and inflammation in atherosclerosis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22488213&form=6&db=m Transcriptional regulation of platelet-derived growth factor-B chain by thrombin in endothelial cells: involvement of Egr-1 and CREB-binding protein. causal interaction,unassigned 1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22534729&form=6&db=m In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22618708&form=6&db=m Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism. causal interaction,unassigned 1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22837011&form=6&db=m The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in Apolipoprotein E-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22940777&form=6&db=m The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice : Dabigatran etexilate and atherosclerosis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23382482&form=6&db=m N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23409043&form=6&db=m Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23488775&form=6&db=m Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. ongoing research,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23826181&form=6&db=m Thrombin generation in the Glasgow Myocardial Infarction Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24015809&form=6&db=m Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24026641&form=6&db=m New insights into modulation of thrombin formation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24241912&form=6&db=m Thrombin generation and atherosclerosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24336942&form=6&db=m Targeting factor Xa and thrombin: impact on coagulation and beyond. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24338998&form=6&db=m Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385341&form=6&db=m Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24701228&form=6&db=m Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25069814&form=6&db=m Short-term venous stasis induces fibrinolytic activation but not thrombin formation. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25298033&form=6&db=m Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25491152&form=6&db=m The hemostatic system as a regulator of inflammation in atherosclerosis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26085454&form=6&db=m Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26149036&form=6&db=m Acute and persistent platelet and coagulant activities in atherothrombosis. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26321081&form=6&db=m Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26392754&form=6&db=m Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26467184&form=6&db=m Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26559689&form=6&db=m Vorapaxar in the secondary prevention of atherothrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26769047&form=6&db=m Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26826018&form=6&db=m EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26961097&form=6&db=m Regenerated Endothelium and Its Senescent Response to Aggregating Platelets. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27010400&form=6&db=m Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,2 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27034473&form=6&db=m Loss of Biglycan Enhances Thrombin Generation in ApoE-Deficient Mice Implications for Inflammation and Atherosclerosis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27431644&form=6&db=m Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27597926&form=6&db=m Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28923781&form=6&db=m Low dose of alcohol attenuates pro-atherosclerotic activity of thrombin. causal interaction,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29622563&form=6&db=m Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29991487&form=6&db=m Protein Kinase C? Via Activating Transcription Factor 2-Mediated CD36 Expression and Foam Cell Formation of Ly6Chi Cells Contributes to Atherosclerosis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30269382&form=6&db=m Role of thrombin in the pathogenesis of atherosclerosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30423352&form=6&db=m Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes. unassigned - 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31233979&form=6&db=m Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31467874&form=6&db=m Baicalin Protects against Thrombin-Induced Cell Injury in Human Umbilical Vein Endothelial Cells. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31632389&form=6&db=m Platelet-Derived Exosomal MicroRNA-25-3p Inhibits Coronary Vascular Endothelial Cell Inflammation Through Adam10 via the NF-?B Signaling Pathway in ApoE-/- Mice. ongoing research,unassigned 2,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32725990&form=6&db=m Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE-/--LDLR-/- Double-Knockout Mice. ongoing research,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32764787&form=6&db=m Thrombin generation's role in predicting coronary disease severity. causal interaction,unassigned 4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32792902&form=6&db=m Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33202269&form=6&db=m A Heparin based dual ratiometric sensor for Thrombin. causal interaction,unassigned 3,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33458764&form=6&db=m Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33874983&form=6&db=m Mitochondrial protein CMPK2 regulates IFN alpha-enhanced foam cell formation, potentially contributing to premature atherosclerosis in SLE. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1284251&form=6&db=m Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7578891&form=6&db=m Challenges in the development of orally bioavailable thrombin active site inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8629598&form=6&db=m Effects of aspirin on status of thrombin generation in atrial fibrillation. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9133507&form=6&db=m Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9540779&form=6&db=m Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10582976&form=6&db=m Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12935411&form=6&db=m Hypercoagulability existing in the local left atrium of patient with mitral stenosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12947359&form=6&db=m Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12955372&form=6&db=m Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. causal interaction,ongoing research,therapeutic application,unassigned 2,4,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14606349&form=6&db=m [Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status] causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14624047&form=6&db=m Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14643116&form=6&db=m Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14688636&form=6&db=m Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15028346&form=6&db=m Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15075048&form=6&db=m Stroke prevention using an oral thrombin inhibitor in atrial fibrillation. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15087604&form=6&db=m A review of the clinical uses of ximelagatran in thrombosis syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102593&form=6&db=m American Heart Association scientific sessions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15143301&form=6&db=m Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15151465&form=6&db=m Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15159043&form=6&db=m Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15222274&form=6&db=m An overview of anticoagulants, antiplatelet agents, and the combination in patients with mechanical heart valves. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15253941&form=6&db=m Will oral antithrombin agents replace warfarin? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15306086&form=6&db=m Direct thrombin inhibition to prevent stroke in atrial fibrillation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15341703&form=6&db=m New anticoagulants and their potential impact on the treatment of thromboembolic disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15353058&form=6&db=m Cardiology. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15376471&form=6&db=m Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15566318&form=6&db=m Novel therapies for the prevention of stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15610639&form=6&db=m SPORTIF III and SPORTIF V: Stroke Prevention Using the Direct Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619610&form=6&db=m The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619613&form=6&db=m New possibilities in anticoagulant management of atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15624339&form=6&db=m The role of oral direct thrombin inhibitors in atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15629364&form=6&db=m Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15644791&form=6&db=m Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15696910&form=6&db=m Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15785149&form=6&db=m Anticoagulation for atrial fibrillation in the elderly. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15812201&form=6&db=m Preventing stroke in atrial fibrillation: the SPORTIF programme. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821834&form=6&db=m Emerging role of direct thrombin inhibitors in nonvalvular atrial fibrillation: potential and peril. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15902370&form=6&db=m [Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15937202&form=6&db=m Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15989549&form=6&db=m The immediate future for the medical treatment of atrial fibrillation. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16025234&form=6&db=m Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16076267&form=6&db=m Ximelagatran for stroke prevention in atrial fibrillation. ongoing research,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16102051&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16123916&form=6&db=m Prevention of stroke in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16144513&form=6&db=m Ximelagatran--recent comparisons with warfarin. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16248832&form=6&db=m Will this be the end of the anticoagulation clinic for patients with atrial fibrillation? therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305522&form=6&db=m Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16325029&form=6&db=m Trials and tribulations of non-inferiority: the ximelagatran experience. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16449807&form=6&db=m Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. Pooled Analysis from the SPORTIF III and V Studies. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16475045&form=6&db=m New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16511607&form=6&db=m Ximelagatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16636210&form=6&db=m Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16774980&form=6&db=m Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16786467&form=6&db=m [Anticoagulation with atrial fibrillation] causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16884319&form=6&db=m Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070169&form=6&db=m Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17124098&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17289744&form=6&db=m Effect of hypertension on anticoagulated patients with atrial fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296878&form=6&db=m Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17347079&form=6&db=m [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17483128&form=6&db=m Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17512549&form=6&db=m A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17673721&form=6&db=m Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17885258&form=6&db=m Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17950801&form=6&db=m Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study). causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18215612&form=6&db=m Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18266660&form=6&db=m Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18573110&form=6&db=m Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18598697&form=6&db=m Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18778188&form=6&db=m New therapeutic option for thromboembolism--dabigatran etexilate. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19178132&form=6&db=m Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19411876&form=6&db=m Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice. causal interaction,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19690349&form=6&db=m Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19690350&form=6&db=m Direct thrombin inhibitors in atrial fibrillation reloaded. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20076850&form=6&db=m Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20424539&form=6&db=m Dabigatran: ready for prime time? causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20446854&form=6&db=m Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460350&form=6&db=m Ex Vivo Thrombin Generation in Patients With Venous Thromboembolic Disease or Atrial Fibrillation on Long-Term Oral Anticoagulation. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460986&form=6&db=m Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20617417&form=6&db=m Novel anticoagulant therapy: principle and practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20655037&form=6&db=m Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20716144&form=6&db=m Cutting through the statistical fog: understanding and evaluating non-inferiority trials. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20809275&form=6&db=m [New oral anticoagulants : Better than vitamin K antagonists?] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21068702&form=6&db=m Dabigatran etexilate (Pradaxa)--a new oral anticoagulant. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21125969&form=6&db=m Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21143166&form=6&db=m Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer? therapeutic application,unassigned 1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21172721&form=6&db=m Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21241354&form=6&db=m Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21291575&form=6&db=m [New antithrombotics for atrial fibrillation.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21429525&form=6&db=m Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21481181&form=6&db=m S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533567&form=6&db=m Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21537165&form=6&db=m Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21538731&form=6&db=m Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21663525&form=6&db=m Clopidogrel hydrogen sulphate for atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21748501&form=6&db=m Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21784372&form=6&db=m Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21788545&form=6&db=m The use of dabigatran in elderly patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21881389&form=6&db=m Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21887485&form=6&db=m Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21925716&form=6&db=m Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21956604&form=6&db=m Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21960064&form=6&db=m Preventing cardioembolic stroke in atrial fibrillation with dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21972820&form=6&db=m Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21988948&form=6&db=m Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22012548&form=6&db=m [Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22122184&form=6&db=m Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22141450&form=6&db=m Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22193838&form=6&db=m Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22212177&form=6&db=m Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22252796&form=6&db=m Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22298812&form=6&db=m The Pharmacology and Therapeutic Use of Dabigatran Etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22306274&form=6&db=m Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22370770&form=6&db=m Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22413715&form=6&db=m Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22431533&form=6&db=m Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22444784&form=6&db=m Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22539097&form=6&db=m [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22565859&form=6&db=m [Pharmacology of the new oral anticoagulants]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22576960&form=6&db=m Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22638877&form=6&db=m Anticoagulation-related intracranial hemorrhages. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22645678&form=6&db=m Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22668618&form=6&db=m New oral anticoagulants: will they replace warfarin? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682209&form=6&db=m [Dabigatran: a new therapeutic alternative in the prevention of stroke]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22683118&form=6&db=m Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22739760&form=6&db=m Dabigatran for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22787066&form=6&db=m Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22826692&form=6&db=m An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22828994&form=6&db=m [New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22839715&form=6&db=m [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22868623&form=6&db=m Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22869389&form=6&db=m A comparison of bleeding complications post-ablation between warfarin and dabigatran. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22910132&form=6&db=m Evaluating and assessing dabigatran drug interactions. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22916053&form=6&db=m Atrial fibrillation in the elderly. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22928173&form=6&db=m Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22955200&form=6&db=m Vitamin K antagonists. Ready to be replaced? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22958146&form=6&db=m Gastrointestinal disorders and dabigatran. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22970730&form=6&db=m Hemorrhagic complications associated with dabigatran use. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23026659&form=6&db=m What did we learn from new oral anticoagulant treatment? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23031622&form=6&db=m Dabigatran in clinical practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23043126&form=6&db=m Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23058974&form=6&db=m Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23108916&form=6&db=m Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23114798&form=6&db=m [Dabigatran therapy--perioperative management and interpretation of coagulation tests]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23121681&form=6&db=m A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23160017&form=6&db=m [New oral anticoagulants: recommendations, precautions and perspectives for use]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23212788&form=6&db=m Positive Outcome After Intentional Overdose of Dabigatran. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23213626&form=6&db=m Stroke prevention: managing modifiable risk factors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23219111&form=6&db=m Removal of dabigatran by hemodialysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23220847&form=6&db=m Acute management of bleeding in patients on novel oral anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23221509&form=6&db=m Dabigatran, a Cause of Hematologic Emergency. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23224686&form=6&db=m Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23239209&form=6&db=m Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"? causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23258203&form=6&db=m [Waiting for the new oral anticoagulants: questions and answers about dabigatran]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389759&form=6&db=m Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. therapeutic application,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389892&form=6&db=m Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23400738&form=6&db=m The pharmacology and therapeutic use of dabigatran etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23435652&form=6&db=m The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23466965&form=6&db=m Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23474519&form=6&db=m Dabigatran overdose secondary to acute kidney injury and amiodarone use. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23514988&form=6&db=m Insights into atrial fibrillation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23522810&form=6&db=m Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23547700&form=6&db=m Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23597859&form=6&db=m Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23631181&form=6&db=m [Direct oral thrombin inhibitor, "dabigatran"]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23631182&form=6&db=m [Factor Xa inhibitor (rivaroxaban and drugs under investigation)]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23632424&form=6&db=m [Stroke prevention in atrial fibrillation : old and new anticoagulants]. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23670031&form=6&db=m Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23704302&form=6&db=m Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23803980&form=6&db=m Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23810130&form=6&db=m Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23818798&form=6&db=m Transitions of care in anticoagulated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23835467&form=6&db=m New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23850368&form=6&db=m Dental management considerations for a patient taking dabigatran etexilate: a case report. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23860880&form=6&db=m The pharmacology of novel oral anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23878175&form=6&db=m Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23920075&form=6&db=m Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23991661&form=6&db=m Dabigatran versus warfarin in patients with mechanical heart valves. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23993157&form=6&db=m [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23997448&form=6&db=m Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24029592&form=6&db=m The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation. unassigned - 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24041930&form=6&db=m Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. causal interaction,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24063505&form=6&db=m Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24147516&form=6&db=m Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24151507&form=6&db=m Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24182477&form=6&db=m Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24183214&form=6&db=m The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24226379&form=6&db=m Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. causal interaction,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24231693&form=6&db=m Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24288086&form=6&db=m Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24291856&form=6&db=m [Evidence of novel oral anticoagulants (NOAC)]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24319080&form=6&db=m Dabigatran Use in the Real World A Multihospital System Experience. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24378048&form=6&db=m [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385325&form=6&db=m Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24400656&form=6&db=m The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24432039&form=6&db=m Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24484861&form=6&db=m Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24492353&form=6&db=m Increased risk of myocardial infarction with dabigatran: fact or fiction? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24508114&form=6&db=m Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24509332&form=6&db=m Impaired renal function and bleeding in elderly treated with dabigatran. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24556890&form=6&db=m Practical aspects of new oral anticoagulant use in atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24592851&form=6&db=m A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. unassigned - 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24592919&form=6&db=m Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. diagnostic usage,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24624626&form=6&db=m [Management of major bleeding complications in patients on long-term treatment with oral anticoagulants]. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24668159&form=6&db=m A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24677203&form=6&db=m Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24711240&form=6&db=m [Perioperative management and therapy of bleeding complications]. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24733535&form=6&db=m Anticoagulation in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24734407&form=6&db=m A case of dabigatran-associated acute renal failure. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24736256&form=6&db=m [Hemodialysis to remove anticoagulant dabigatran during emergencies]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24777926&form=6&db=m [The effects of continuous renal replacement therapy (CRRT) and intermittent haemodialysis (IHD) in the treatment of dabigatran overdose. Case report]. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24803917&form=6&db=m Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24813481&form=6&db=m [Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24814537&form=6&db=m Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24815541&form=6&db=m ?T -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24861794&form=6&db=m Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24963788&form=6&db=m Analysis of the influence of dabigatran on coagulation factors and inhibitors. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24973113&form=6&db=m Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. unassigned - 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24987943&form=6&db=m Use of Extracorporeal Techniques in the Removal of Dabigatran. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25068444&form=6&db=m Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25084117&form=6&db=m Continuation of dabigatran therapy in "real-world" practice in Hong Kong. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25103614&form=6&db=m Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25116016&form=6&db=m [Non-valvular atrial fibrillation: direct thrombin inhibitors versus VKA]. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138549&form=6&db=m Dabigatran: patient management in specific clinical settings. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25156858&form=6&db=m Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25172669&form=6&db=m On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25215263&form=6&db=m Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25216104&form=6&db=m Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25327048&form=6&db=m Direct thrombin inhibitors versus warfarin in nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25431993&form=6&db=m Monitoring and reversal strategies for new oral anticoagulants. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25457584&form=6&db=m A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25466835&form=6&db=m CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25490355&form=6&db=m [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25518887&form=6&db=m Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger. unassigned - 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25565675&form=6&db=m Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25633777&form=6&db=m Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25682085&form=6&db=m Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25762815&form=6&db=m Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25793127&form=6&db=m Thrombus formation in left atrium on dabigatran therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25815177&form=6&db=m Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25830002&form=6&db=m Acute myocardial infarction after switching from warfarin to dabigatran. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25918026&form=6&db=m Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26019695&form=6&db=m An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26048399&form=6&db=m Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26048605&form=6&db=m Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26077323&form=6&db=m Antidotes to non-vitamin K oral anticoagulants: necessary or not? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26096376&form=6&db=m Dabigatran: Experience in standard clinical practice. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26109251&form=6&db=m Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26174611&form=6&db=m Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26219486&form=6&db=m Impact of dabigatran on platelet function and fibrinolysis. ongoing research,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26270886&form=6&db=m Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26319777&form=6&db=m Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26425251&form=6&db=m Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26432747&form=6&db=m Dabigatran for left ventricular thrombus. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26452739&form=6&db=m Pradaxa-induced esophageal ulcer. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26458452&form=6&db=m [Novel oral anticoagulants (NOAC)]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26519741&form=6&db=m The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26521117&form=6&db=m Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26596056&form=6&db=m [COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION]. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26629800&form=6&db=m Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26674596&form=6&db=m Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26843571&form=6&db=m Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26846610&form=6&db=m Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26881855&form=6&db=m A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate. diagnostic usage,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26892845&form=6&db=m Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26994821&form=6&db=m Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27094310&form=6&db=m A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184172&form=6&db=m Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27342651&form=6&db=m Apixaban to prevent stroke in patients with atrial fibrillation: a review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27364823&form=6&db=m The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27502864&form=6&db=m Defining nonvalvular atrial fibrillation: A quest for clarification. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27526541&form=6&db=m [Monitoring of Oral Thrombin Inhibitor]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27571947&form=6&db=m Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27740983&form=6&db=m Imaging of Hemorrhagic Stroke. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27797449&form=6&db=m Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27903864&form=6&db=m Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27910004&form=6&db=m Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27992120&form=6&db=m Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28060970&form=6&db=m [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation]. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28140308&form=6&db=m [Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay]. causal interaction,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28290913&form=6&db=m [Modern Approaches to Prevention of Thromboembolic Complications in Patients With Nonvalvular Atrial Fibrillation With a Direct Thrombin Inhibitor Dabigatran]. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28294796&form=6&db=m [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28373761&form=6&db=m Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28396988&form=6&db=m The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28412907&form=6&db=m Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28416406&form=6&db=m Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28426920&form=6&db=m Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28439778&form=6&db=m Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28445598&form=6&db=m Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: reply. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28496648&form=6&db=m Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28496748&form=6&db=m Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28509761&form=6&db=m Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28740848&form=6&db=m Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28805310&form=6&db=m Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28878572&form=6&db=m Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29043124&form=6&db=m Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29255511&form=6&db=m Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29299030&form=6&db=m Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation. ongoing research,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29563449&form=6&db=m Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29633066&form=6&db=m Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29801760&form=6&db=m Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects. causal interaction,unassigned 2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29849330&form=6&db=m Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29867495&form=6&db=m Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29904298&form=6&db=m Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29975925&form=6&db=m Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30439321&form=6&db=m [Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30742307&form=6&db=m Statins and the risk of bleeding in patients taking dabigatran. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30936131&form=6&db=m Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. therapeutic application,unassigned 1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31005062&form=6&db=m The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31020242&form=6&db=m A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31388437&form=6&db=m Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31537027&form=6&db=m Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. therapeutic application,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31670852&form=6&db=m Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31758517&form=6&db=m Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32166540&form=6&db=m Monitoring the roles of prothrombin activation fragment 1 and 2 (F1?+?2) in patients with atrial fibrillation receiving rivaroxaban and apixaban. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32377955&form=6&db=m Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban. diagnostic usage,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32478836&form=6&db=m Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32576132&form=6&db=m A Case of Liver Failure Due to Dabigatran Treated with Venovenous He-modiafiltration and Idarucizumab. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32617467&form=6&db=m Left atrial appendage thrombus on full-dose dabigatran treatment: a case report. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32688432&form=6&db=m Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32689602&form=6&db=m Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. therapeutic application,unassigned 4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32792902&form=6&db=m Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32946856&form=6&db=m Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation. unassigned - 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33055222&form=6&db=m In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke. diagnostic usage,unassigned 3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33116897&form=6&db=m Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33486497&form=6&db=m Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33593994&form=6&db=m Comparative effectiveness of oral anticoagulants in everyday practice. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33612323&form=6&db=m Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR). causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33667955&form=6&db=m Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33707842&form=6&db=m Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34127530&form=6&db=m Coagulation derangement and risk factors for valve thrombosis following transcatheter aortic valve implantation. diagnostic usage,unassigned 1,0 3.4.21.5 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34235983&form=6&db=m Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17285619&form=6&db=m Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20638758&form=6&db=m [Acquired factor V deficiency: A rare bleeding disorder with variable clinical presentations.] unassigned - 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21168185&form=6&db=m Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease. causal interaction,unassigned 4,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23604378&form=6&db=m Effects of calorie restriction and ?-3 dietary fat on aging in short-and long-lived rodents. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27385196&form=6&db=m Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29232721&form=6&db=m The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease. causal interaction,unassigned 4,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33912688&form=6&db=m Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34128791&form=6&db=m Osteopontin: another piece in the systemic lupus erythematosus immunopathology puzzle. unassigned - 3.4.21.5 Azotemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3322525&form=6&db=m Use of clinical pathology in evaluation of horses with colic. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Azotemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7474966&form=6&db=m Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7294547&form=6&db=m An outbreak of pseudobacteremia caused by Enterobacter cloacae from a phlebotomist's vial of thrombin. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28957943&form=6&db=m Complete antithrombin replacement for anticoagulation for cardiopulmonary bypass to repair severe infective mitral valve endocarditis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32478836&form=6&db=m Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2206823&form=6&db=m Disseminated intravascular coagulation and bacterial infections in the elderly. diagnostic usage,unassigned 4,0 3.4.21.5 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8521647&form=6&db=m [A case of thrombocytopenia due to heparin therapy for a progressing ischemic stroke] causal interaction,unassigned 2,0 3.4.21.5 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21165674&form=6&db=m Fibrinogenolytic and anticoagulant activities in the tissue covering the stingers of marine stingrays Dasyatis sephen and Aetobatis narinari. causal interaction,unassigned 1,0 3.4.21.5 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27108773&form=6&db=m Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=588478&form=6&db=m Binding of thrombin to functionally defective platelets: a hypothesis on the nature of the thrombin receptor. diagnostic usage,unassigned 1,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1748654&form=6&db=m Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. ongoing research,unassigned 2,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2618560&form=6&db=m [Genetic markers and thrombin reaction in a family of Bernard-Soulier syndrome] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7740483&form=6&db=m Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of 14C-serotonin by human platelets pretreated with chymotrypsin or serratia marcescens protease. ongoing research,unassigned 2,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8110787&form=6&db=m Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of Bothrops jararaca. unassigned - 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8407908&form=6&db=m Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation. causal interaction,unassigned 2,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8963719&form=6&db=m Defective thrombin-induced calcium changes and aggregation of Bernard-Soulier platelets are not associated with deficient moderate-affinity receptors. ongoing research,unassigned 2,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9371310&form=6&db=m Molecular abnormalities in Glanzmann's thrombasthenia, Bernard-Soulier syndrome, and platelet-type von Willebrand's disease. diagnostic usage,unassigned 3,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10089893&form=6&db=m Molecular characterization of two mutations in platelet glycoprotein (GP) Ib alpha in two Finnish Bernard-Soulier syndrome families. causal interaction,unassigned 3,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11437595&form=6&db=m Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity. diagnostic usage,unassigned 3,0 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14717981&form=6&db=m Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. unassigned - 3.4.21.5 Bernard-Soulier Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23995613&form=6&db=m Novel genetic abnormalities in Bernard-Soulier syndrome in India. causal interaction,unassigned 3,0 3.4.21.5 beta-Thalassemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7299541&form=6&db=m Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major. diagnostic usage,unassigned 3,0 3.4.21.5 beta-Thalassemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20543538&form=6&db=m Protein C levels in beta-thalassemia major patients in the east Nile delta of Egypt. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Bicuspid Aortic Valve Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Bile Duct Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13264505&form=6&db=m [Plasma antithrombin and thrombin inhibitor in liver parenchymal and bile duct disease.] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.5 Biliary Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17190285&form=6&db=m How to improve bilio-stasis in liver surgery. therapeutic application,unassigned 2,0 3.4.21.5 Biliary Tract Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14196266&form=6&db=m [STUDIES ON THE THROMBIN TEST IN LIVER AND BILIARY TRACT DISEASES.] ongoing research,unassigned 4,0 3.4.21.5 Biliary Tract Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Biliary Tract Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10690613&form=6&db=m Experimental and clinical studies on liver regeneration following transcatheter portal embolization. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=912108&form=6&db=m [Coagulation factors in human born blisters (author's transl)] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1590826&form=6&db=m Effect of spontaneous pathology and thrombin on leukocyte adhesion to rat aortic endothelium. ongoing research,unassigned 1,0 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9854715&form=6&db=m Rapid preparation of small-volume autologous fibrinogen concentrate and its same day use in bleb leaks after glaucoma filtration surgery. unassigned - 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10461011&form=6&db=m The procoagulant effect of thrombin on fibrin(ogen)-bound platelets. causal interaction,unassigned 4,0 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11765149&form=6&db=m The use of autologous fibrinogen concentrate in treating ocular hypotony after glaucoma filtration surgery. unassigned - 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19883336&form=6&db=m Skin autoimmunity and blood coagulation. causal interaction,unassigned 1,0 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20477646&form=6&db=m Activation of blood coagulation in autoimmune skin disorders. causal interaction,unassigned 3,0 3.4.21.5 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22272909&form=6&db=m Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases. causal interaction,unassigned 2,0 3.4.21.5 Blood Coagulation Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4184473&form=6&db=m [On the diagnosis of blood coagulation disorders in obstetrics by means of the thrombin time determination] diagnostic usage,unassigned 4,0 3.4.21.5 Blood Coagulation Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16091733&form=6&db=m Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Blood Coagulation Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549306&form=6&db=m Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Blood Platelet Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8228559&form=6&db=m Failure to mobilize intracellular calcium in response to thrombin in a patient with familial thrombocytopathy characterized by macrothrombocytopenia and abnormal platelet membrane complexes. therapeutic application,unassigned 1,0 3.4.21.5 Blood Platelet Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16871542&form=6&db=m Thrombin generation in patients with cirrhosis: the role of platelets. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Bone Diseases, Metabolic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441362&form=6&db=m PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1846537&form=6&db=m Thrombin effects on osteoblastic cells. II. Structure-function relationships. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153536&form=6&db=m Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2164318&form=6&db=m Second messengers in thrombin-stimulated bone resorption. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2357220&form=6&db=m Experimental considerations on the measurement of prostaglandins during long-time incubations of neonatal mouse calvaria. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2778756&form=6&db=m Effect of auranofin on resorption, prostaglandin synthesis and ultrastructure of bone cells in cultured mouse calvaria. unassigned - 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3126818&form=6&db=m Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3500299&form=6&db=m Cyclosporine A inhibits bone resorption in cultured neonatal mouse calvaria. therapeutic application,unassigned 1,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3922796&form=6&db=m Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3936122&form=6&db=m Prostaglandin-related bone resorption in cultured neonatal mouse calvaria: evaluation of biopotency of nonsteroidal anti-inflammatory drugs. unassigned - 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6860783&form=6&db=m Thrombin, a stimulator of bone resorption. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7528372&form=6&db=m Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants. therapeutic application,unassigned 1,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8382276&form=6&db=m Suramin is a potent inhibitor of calcemic hormone- and growth factor-induced bone resorption in vitro. ongoing research,unassigned 3,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610746&form=6&db=m Expression of the thrombin receptor in developing bone and associated tissues. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10974200&form=6&db=m Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11276866&form=6&db=m Role of bacterial proteinases in matrix destruction and modulation of host responses. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20214889&form=6&db=m RANKL induces components of the extrinsic coagulation pathway in osteoclasts. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23419317&form=6&db=m Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism. ongoing research,unassigned 3,0 3.4.21.5 Bradycardia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29983855&form=6&db=m Pulmonary Arterial Hypertension and Endothelial Dysfunction Is Linked to NADPH Oxidase-Derived Superoxide Formation in Venous Thrombosis and Pulmonary Embolism in Mice. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Brain Concussion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22394293&form=6&db=m Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Brain Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17027887&form=6&db=m Thrombin in inflammatory brain diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Brain Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28344073&form=6&db=m Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. causal interaction,unassigned 4,0 3.4.21.5 Brain Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7490619&form=6&db=m Intracerebral infusion of thrombin as a cause of brain edema. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7976664&form=6&db=m A novel aspect of thrombin in the tissue reaction following central nervous system injury. causal interaction,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8738389&form=6&db=m The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8755765&form=6&db=m Thrombin-soaked gelatin sponge and brain edema in rats. diagnostic usage,unassigned 1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9010429&form=6&db=m Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9202268&form=6&db=m Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,3 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626295&form=6&db=m Plasminogen activators potentiate thrombin-induced brain injury. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10356108&form=6&db=m Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10837811&form=6&db=m The effects of thrombin preconditioning on focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11259759&form=6&db=m Effects of hypothermia on thrombin-induced brain edema formation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11259772&form=6&db=m Activation of p44/42 mitogen activated protein kinases in thrombin-induced brain tolerance. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11384620&form=6&db=m Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11450078&form=6&db=m Induction of colligin may attenuate brain edema following intracerebral hemorrhage. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11450080&form=6&db=m Thrombin preconditioning, heat shock proteins and thrombin-induced brain edema. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11919511&form=6&db=m Thrombin-receptor activation and thrombin-induced brain tolerance. therapeutic application,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12168313&form=6&db=m Effects of brain hypothermia on brain edema formation after intracerebral hemorrhage in rats. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12485396&form=6&db=m The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14663340&form=6&db=m Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. therapeutic application,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753395&form=6&db=m Brain edema from intracerebral hemorrhage. ongoing research,unassigned 1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753426&form=6&db=m Thrombin exacerbates brain edema in focal cerebral ischemia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753484&form=6&db=m Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753487&form=6&db=m Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753495&form=6&db=m A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569485&form=6&db=m Effect of thrombin on blood brain barrier permeability and its mechanism. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15637325&form=6&db=m Holo-transferrin and thrombin can interact to cause brain damage. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15665510&form=6&db=m Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15975137&form=6&db=m The role of thrombin in gliomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15978174&form=6&db=m Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages. unassigned - 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16463887&form=6&db=m Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16463890&form=6&db=m Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16463894&form=6&db=m Intracerebral hemorrhage induces edema and oxidative stress and alters N-methyl-D-aspartate receptor subunits expression. causal interaction,unassigned 1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16528196&form=6&db=m Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16671455&form=6&db=m Up-regulation of brain ceruloplasmin in thrombin preconditioning. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,2 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17416972&form=6&db=m Thrombin inhibits aquaporin 4 expression through protein kinase C-dependent pathway in cultured astrocytes. causal interaction,unassigned 1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17904058&form=6&db=m Expression of matrix metalloproteinse-9 in thrombin-induced brain edema formation in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18182734&form=6&db=m [Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18442833&form=6&db=m The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19064789&form=6&db=m Thrombin and brain recovery after intracerebral hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066094&form=6&db=m Hyperbaric oxygen for experimental intracerebral hemorrhage. therapeutic application,unassigned 1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228846&form=6&db=m Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,4 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19388346&form=6&db=m Thrombin enhances glioma growth. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19519655&form=6&db=m Cytopathological alterations and therapeutic approaches in Binswanger's disease. causal interaction,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20437588&form=6&db=m Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. therapeutic application,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20541575&form=6&db=m Time course of upregulation of inflammatory mediators in the hemorrhagic brain in rats: correlation with brain edema. causal interaction,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846511&form=6&db=m Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21725759&form=6&db=m Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23564130&form=6&db=m Protease activated receptor-1 and brain edema formation in glioma models. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24323586&form=6&db=m Short period of early reperfusion aggravates blood-brain barrier dysfunction during permanent focal ischemia in rats. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25523640&form=6&db=m Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25597485&form=6&db=m Thrombin hemostatic matrix leading to acute cerebral edema and sterile fluid collection formation post-tumor resection: two cases. causal interaction,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25691153&form=6&db=m Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26002077&form=6&db=m Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-9-releasing cell type constituting the blood-brain barrier in vitro. causal interaction,unassigned 3,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26376816&form=6&db=m A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463965&form=6&db=m Thrombin Preconditioning in Surgical Brain Injury in Rats. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27181591&form=6&db=m Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30123875&form=6&db=m Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30562971&form=6&db=m Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32724861&form=6&db=m Testing the effect of PAR1 inhibitors on Plasmodium falciparum-induced loss of endothelial cell barrier function. therapeutic application,unassigned 4,0 3.4.21.5 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Brain Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10837811&form=6&db=m The effects of thrombin preconditioning on focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Brain Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31137455&form=6&db=m Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=440517&form=6&db=m [Secondary blood coagulation disturbances after severe head injuries (author's transl)] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=707171&form=6&db=m Disturbances of the coagulatory system in patients with severe cerebral trauma. I. diagnostic usage,unassigned 3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3332541&form=6&db=m Thrombin is a potent mitogen for rat astroblasts but not for oligodendroblasts and neuroblasts in primary culture. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8429047&form=6&db=m Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9202268&form=6&db=m Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,3 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9433490&form=6&db=m Regulation of neurons and astrocytes by thrombin and protease nexin-1. Relationship to brain injury. causal interaction,unassigned 1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626295&form=6&db=m Plasminogen activators potentiate thrombin-induced brain injury. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10568717&form=6&db=m Effects of alpha-thrombin on superoxide dismutase levels in human cerebral microvascular endothelial cells. causal interaction,unassigned 3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10709874&form=6&db=m Thrombin inhibitor ameliorates secondary damage in rat brain injury: suppression of inflammatory cells and vimentin-positive astrocytes. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11807394&form=6&db=m Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,3 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12485396&form=6&db=m The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12885431&form=6&db=m Nestin expression after experimental intracerebral hemorrhage. unassigned - 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14747742&form=6&db=m Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15009638&form=6&db=m Prothrombin overexpressed in post-natal neurones requires blood factors for activation in the mouse brain. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15637325&form=6&db=m Holo-transferrin and thrombin can interact to cause brain damage. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15933250&form=6&db=m The deleterious or beneficial effects of different agents in intracerebral hemorrhage: think big, think small, or is hematoma size important? causal interaction,unassigned 3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16145537&form=6&db=m Acute subdural hematoma: new model delineation and effects of coagulation inhibitors. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16463887&form=6&db=m Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16528196&form=6&db=m Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16683250&form=6&db=m Chronic thrombin exposure results in an increase in apolipoprotein-E levels. causal interaction,unassigned 3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17261733&form=6&db=m Brain injury after intracerebral hemorrhage: the role of thrombin and iron. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17498698&form=6&db=m Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury. causal interaction,unassigned 4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17629581&form=6&db=m The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17702959&form=6&db=m Mouse model of in situ thromboembolic stroke and reperfusion. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18182734&form=6&db=m [Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343677&form=6&db=m Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons. unassigned - 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18436875&form=6&db=m Effects of thrombin on neurogenesis after intracerebral hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18841278&form=6&db=m Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19061541&form=6&db=m Minocycline reduces intracerebral hemorrhage-induced brain injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066081&form=6&db=m Increase in brain thrombin activity after experimental intracerebral hemorrhage. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066083&form=6&db=m Concomitant intracerebral infusion of tissue plasminogen activator and thrombin leads to brain injury. causal interaction,unassigned 2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066084&form=6&db=m Microglial activation and brain injury after intracerebral hemorrhage. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228846&form=6&db=m Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,4 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19359644&form=6&db=m Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19427359&form=6&db=m Long-time course of protease-activated receptor-1 expression after intracerebral hemorrhage in rats. causal interaction,unassigned 2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19726015&form=6&db=m Effect of minimally invasive surgery for cerebral hematoma evacuation in different stages on motor evoked potential and thrombin in dog model of intracranial hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19812969&form=6&db=m Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19931359&form=6&db=m Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20515663&form=6&db=m Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in organotypic slice culture. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20881130&form=6&db=m Transient receptor potential canonical 3 (TRPC3) mediates thrombin-induced astrocyte activation and upregulates its own expression in cortical astrocytes. unassigned - 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21172324&form=6&db=m The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKC?/PKC? signaling. ongoing research,unassigned 2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21725765&form=6&db=m Thrombin preconditioning attenuates iron-induced neuronal death. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21748282&form=6&db=m Oral anticoagulant-associated intracerebral hemorrhage. causal interaction,unassigned 3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22015349&form=6&db=m Thrombin-induced autophagy: a potential role in intracerebral hemorrhage. ongoing research,unassigned 1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22463118&form=6&db=m Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22687694&form=6&db=m Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23000356&form=6&db=m PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23674527&form=6&db=m Transient receptor potential canonical 3 inhibitor Pyr3 improves outcomes and attenuates astrogliosis after intracerebral hemorrhage in mice. ongoing research,unassigned 1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24326390&form=6&db=m Hydrocephalus after intraventricular hemorrhage: the role of thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24667910&form=6&db=m Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463946&form=6&db=m Src Family Kinases in Brain Edema After Acute Brain Injury. therapeutic application,unassigned 1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463965&form=6&db=m Thrombin Preconditioning in Surgical Brain Injury in Rats. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463977&form=6&db=m Acetazolamide Attenuates Thrombin-Induced Hydrocephalus. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26661165&form=6&db=m Inhibition of prostaglandin E2 receptor EP3 mitigates thrombin-induced brain injury. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26869387&form=6&db=m Role of Lipocalin-2 in Thrombin-Induced Brain Injury. ongoing research,unassigned 1,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27993122&form=6&db=m In models of intracerebral hemorrhage, rivaroxaban is superior to warfarin to limit blood brain barrier disruption and hematoma expansion. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28202418&form=6&db=m ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia. ongoing research,unassigned 4,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33111257&form=6&db=m Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-?B Signaling. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33392917&form=6&db=m Effects of Thrombin on the Neurovascular Unit in Cerebral Ischemia. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9423797&form=6&db=m Thrombin and its precursor in human cerebrospinal fluid. causal interaction,unassigned 4,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12485396&form=6&db=m The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15165703&form=6&db=m Thrombin, a mediator of neurotoxicity and memory impairment. causal interaction,unassigned 4,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437307&form=6&db=m Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes. causal interaction,unassigned 4,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27431453&form=6&db=m Thrombin preferentially induces autophagy in glia cells in the rat central nervous system. therapeutic application,unassigned 4,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29135354&form=6&db=m Depression following traumatic brain injury in mice is associated with down-regulation of hippocampal astrocyte glutamate transporters by thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30291825&form=6&db=m Early posttraumatic changes in coagulation and fibrinolysis systems in isolated severe traumatic brain injury patients and its influence on immediate outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,2 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32009953&form=6&db=m Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32332338&form=6&db=m Thrombin Hemostatic Matrix Reduces Heterotopic Ossification in Acetabular Fractures fixed via the Kocher-Langenbeck Approach. unassigned - 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33111257&form=6&db=m Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-?B Signaling. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2145826&form=6&db=m Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8768731&form=6&db=m Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10681455&form=6&db=m The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10837811&form=6&db=m The effects of thrombin preconditioning on focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11259772&form=6&db=m Activation of p44/42 mitogen activated protein kinases in thrombin-induced brain tolerance. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11384620&form=6&db=m Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11692028&form=6&db=m Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11749837&form=6&db=m Effects and mechanisms of triacetylshikimic acid on platelet adhesion to neutrophils induced by thrombin and reperfusion after focal cerebral ischemia in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11919511&form=6&db=m Thrombin-receptor activation and thrombin-induced brain tolerance. therapeutic application,unassigned 4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12165407&form=6&db=m Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12485396&form=6&db=m The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12811011&form=6&db=m Argatroban in thrombotic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12812386&form=6&db=m The prevalence of protein C, protein S, and antithrombin III deficiency in non-APS/SLE Chinese adults with noncardiac cerebral ischemia. therapeutic application,unassigned 1,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14705148&form=6&db=m Transient focal ischemia in rat brain differentially regulates mRNA expression of protease-activated receptors 1 to 4. unassigned - 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753426&form=6&db=m Thrombin exacerbates brain edema in focal cerebral ischemia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961162&form=6&db=m Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16397902&form=6&db=m Preconditioning with thrombin can be protective or worsen damage after endothelin-1-induced focal ischemia in rats. ongoing research,unassigned 3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16427045&form=6&db=m Thrombin in ischemic neuronal death. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437307&form=6&db=m Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes. causal interaction,unassigned 4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19719823&form=6&db=m Coagulation factor Xa activates thrombin in ischemic neural tissue. causal interaction,unassigned 4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846511&form=6&db=m Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21142878&form=6&db=m A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21725765&form=6&db=m Thrombin preconditioning attenuates iron-induced neuronal death. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22811450&form=6&db=m Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia. causal interaction,unassigned 4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22921458&form=6&db=m Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23949634&form=6&db=m Endogenous Protease Nexin-1 Protects against Cerebral Ischemia. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24985053&form=6&db=m Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25669912&form=6&db=m Dabigatran abrogates brain endothelial cell permeability in response to thrombin. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26342829&form=6&db=m Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28379489&form=6&db=m New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30123875&form=6&db=m Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33392917&form=6&db=m Effects of Thrombin on the Neurovascular Unit in Cerebral Ischemia. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33720950&form=6&db=m Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2116223&form=6&db=m Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10664248&form=6&db=m The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12579295&form=6&db=m Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16528196&form=6&db=m Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24413553&form=6&db=m Brain Tumors Enhance Plasmatic Coagulation: The Role of Hemeoxygenase-1. unassigned - 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32123604&form=6&db=m Efficacy of a topical gelatin-thrombin hemostatic matrix, FLOSEAL®, in intracranial tumor resection. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Breast Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533764&form=6&db=m The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1670992&form=6&db=m Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2033094&form=6&db=m Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7639713&form=6&db=m Lysophospholipids activate ovarian and breast cancer cells. unassigned - 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9040797&form=6&db=m Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin. unassigned - 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9678618&form=6&db=m Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9701242&form=6&db=m Thrombin receptor overexpression in malignant and physiological invasion processes. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10027305&form=6&db=m Role of thrombin receptor in breast cancer invasiveness. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10963995&form=6&db=m Effects of thrombin/thrombosis in angiogenesis and tumour progression. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11073830&form=6&db=m PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. ongoing research,unassigned 2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11278329&form=6&db=m Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. causal interaction,unassigned 1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12492586&form=6&db=m Acquired resistance to activated protein C in breast cancer patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,2 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14966279&form=6&db=m Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. causal interaction,unassigned 4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16309184&form=6&db=m Alteration in platelet function in patients with early breast cancer. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16444429&form=6&db=m The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18097747&form=6&db=m The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18372913&form=6&db=m Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18757438&form=6&db=m Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19891966&form=6&db=m Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20190559&form=6&db=m Role of thrombin as a tumor growth factor. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20434002&form=6&db=m Tissue factor in cancer progression and angiogenesis. causal interaction,unassigned 2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20798593&form=6&db=m Use of dabigatran etexilate to reduce breast cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21247495&form=6&db=m Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. unassigned - 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21430357&form=6&db=m Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients. causal interaction,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533764&form=6&db=m The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21799402&form=6&db=m Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21838758&form=6&db=m Breast Cancer Chemotherapy Induces the Release of Cell Free DNA, a Novel Procoagulant Stimulus. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21917301&form=6&db=m Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22359194&form=6&db=m The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,4 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22555532&form=6&db=m Comparison of breast carcinoma prognostic/predictive biomarkers on cell blocks obtained by various methods: Cellient, formalin and thrombin. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24139816&form=6&db=m [Interest of a thrombin and fibrinogen combipatch in preventing breast cancer seroma after lymph node dissection]. therapeutic application,unassigned 1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24489651&form=6&db=m TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response. therapeutic application,unassigned 3,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24678687&form=6&db=m Determination of HER2/neu Status: A Pilot Study Comparing HER2/neu Dual In Situ Hybridization DNA Probe Cocktail Assay Performed on Cell Blocks to Immunohistochemisty and Fluorescence In Situ Hybridization Performed on Histologic Specimens. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26489727&form=6&db=m Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27027841&form=6&db=m Role of tissue factor expression in thrombin generation by canine tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161699&form=6&db=m PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161723&form=6&db=m PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27284959&form=6&db=m Protease-Triggered, Integrin-Targeted Cellular Uptake of Recombinant Protein Micelles. unassigned - 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28187434&form=6&db=m Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells. diagnostic usage,unassigned 3,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075792&form=6&db=m Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29346400&form=6&db=m The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation. therapeutic application,unassigned 1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29600521&form=6&db=m Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-Kinase in breast cancer. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29769125&form=6&db=m Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32397009&form=6&db=m Thrombin generation predicts early recurrence in breast cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32854772&form=6&db=m Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33154306&form=6&db=m Role of platelet aggregation in metastatic breast cancer patients. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33585786&form=6&db=m Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Bronchial Hyperreactivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11306243&form=6&db=m Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells. therapeutic application,unassigned 1,0 3.4.21.5 Bronchiolitis Obliterans http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10409227&form=6&db=m alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors. therapeutic application,unassigned 1,0 3.4.21.5 Bronchitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14531295&form=6&db=m [Coagulation activity in the airways of asthmatic patients] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Budd-Chiari Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17928037&form=6&db=m Budd-Chiari syndrome in a young female with factor V Leiden mutation: successful treatment with lepirudin, a direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Budd-Chiari Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23941968&form=6&db=m Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Burkitt Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510689&form=6&db=m Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Calciphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28856671&form=6&db=m Direct oral anticoagulant medications in calciphylaxis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Candidiasis, Oral http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11778360&form=6&db=m [Molecular pathogenesis of oral candidiasis (candidosis)] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11080597&form=6&db=m Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12215760&form=6&db=m [Future potential indications for an oral thrombin inhibitor] ongoing research,unassigned 1,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14521590&form=6&db=m Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15607697&form=6&db=m Blood coagulation factors as inflammatory mediators. causal interaction,unassigned 4,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15944410&form=6&db=m Thrombomodulin enhances the invasive activity of mouse mammary tumor cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15969748&form=6&db=m Ovarian cancer, the coagulation pathway, and inflammation. unassigned - 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16193294&form=6&db=m Expression of protease-activated receptors and tissue factor in human liver. causal interaction,unassigned 3,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17586662&form=6&db=m Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17695537&form=6&db=m Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer. unassigned - 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18048360&form=6&db=m Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214911&form=6&db=m The pivotal role of thrombin in cancer biology and tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19622365&form=6&db=m A new type of thrombin inhibitor, noncytotoxic phospholipase A(2), from the Naja haje cobra venom. causal interaction,unassigned 4,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22848234&form=6&db=m Protease-activated receptors in cancer: A systematic review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24710407&form=6&db=m Thrombin drives tumorigenesis in colitis-associated colon cancer. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25496996&form=6&db=m The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. causal interaction,unassigned 2,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29369476&form=6&db=m Platelets contribute to the initiation of colitis-associated cancer by promoting immunosuppression. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29703481&form=6&db=m Mechanisms coupling thrombin to metastasis and tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30728369&form=6&db=m Transcriptomic profiles of tumor-associated neutrophils reveal prominent roles in enhancing angiogenesis in liver tumorigenesis in zebrafish. unassigned - 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423826&form=6&db=m Clinical trials with anticoagulant and antiplatelet therapies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1596884&form=6&db=m Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1845869&form=6&db=m Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2114816&form=6&db=m Fibrinogen-fibrin transformation in situ in renal cell carcinoma. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2176873&form=6&db=m Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. ongoing research,unassigned 2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2448891&form=6&db=m Effect of urokinase on the proliferation of primary cultures of human prostatic cells. ongoing research,unassigned 4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2823201&form=6&db=m Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants. causal interaction,unassigned 4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2824013&form=6&db=m Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3102391&form=6&db=m Thrombin stimulates arachidonate metabolism in murine tumor cells. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3629545&form=6&db=m Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines. unassigned - 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3985042&form=6&db=m Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6571789&form=6&db=m Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6573546&form=6&db=m Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7366122&form=6&db=m Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation. diagnostic usage,unassigned 4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7617521&form=6&db=m Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data. ongoing research,unassigned 4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8331683&form=6&db=m Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8545606&form=6&db=m Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578452&form=6&db=m The enigma PAI-2. Gene expression, evolutionary and functional aspects. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9392328&form=6&db=m Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9438526&form=6&db=m Alcoholism and carcinoma change the intracellular pH and activate platelet Na+/H+-exchange in men. ongoing research,unassigned 1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9453463&form=6&db=m Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9701694&form=6&db=m Transient increase in thrombin generation during radiotherapy of uterine carcinoma: A preliminary study using thrombin-antithrombin III complex measurements. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9816228&form=6&db=m Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9863356&form=6&db=m [Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma] diagnostic usage,unassigned 2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10365767&form=6&db=m Circulating vascular endothelial growth factor correlates with systemic thrombin generation in patients with pancreatic carcinoma. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10444752&form=6&db=m Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10651140&form=6&db=m Sphingolipid receptor signaling and function in human bladder carcinoma cells: inhibition of LPA- but enhancement of thrombin-stimulated cell motility. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10672900&form=6&db=m Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10807779&form=6&db=m Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11371929&form=6&db=m Stimulation of protease activated receptors on RT4 cells mediates arachidonic acid release via Ca2+ independent phospholipase A2. ongoing research,unassigned 4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743661&form=6&db=m PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12231573&form=6&db=m Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12414665&form=6&db=m Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12579295&form=6&db=m Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12975470&form=6&db=m Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. unassigned - 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15559761&form=6&db=m PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16696024&form=6&db=m Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17496204&form=6&db=m Trousseau's syndrome: multiple definitions and multiple mechanisms. therapeutic application,unassigned 1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549306&form=6&db=m Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17900407&form=6&db=m The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18595237&form=6&db=m Elevated plasma D-dimer as a predictor of postoperative complications after radical cystectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18691491&form=6&db=m Microarray studies of factor VIIa-activated cancer cells. unassigned - 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21860019&form=6&db=m Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22685255&form=6&db=m Effect of thrombin receptor expression on microvessel endothelial cells, and survival by coagulation state in oesophageal squamous cell carcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26071675&form=6&db=m Preoperative D-dimers as an independent prognostic marker in cervical carcinoma. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26469700&form=6&db=m Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32865287&form=6&db=m Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.5 Carcinoma, Bronchogenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8187130&form=6&db=m Treatment of malignant tracheobronchial stenosis by Dacron mesh-covered Z-stents. therapeutic application,unassigned 1,0 3.4.21.5 Carcinoma, Embryonal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8395401&form=6&db=m Cyclic AMP-mediated augmentation of thrombomodulin gene expression: cell type-dependent usage of control regions. ongoing research,unassigned 4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2767927&form=6&db=m Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3217915&form=6&db=m Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells. ongoing research,unassigned 4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7730438&form=6&db=m Demonstration of the presence of protease-cutting site in the spacer of hepatitis B viral Pol protein. ongoing research,unassigned 2,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585041&form=6&db=m Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. ongoing research,unassigned 4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10532550&form=6&db=m Inhibitor against coagulation factor V after liver transplantation. therapeutic application,unassigned 3,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10690613&form=6&db=m Experimental and clinical studies on liver regeneration following transcatheter portal embolization. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17323377&form=6&db=m Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17516031&form=6&db=m alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19360302&form=6&db=m Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation. causal interaction,unassigned 1,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20890897&form=6&db=m Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21586224&form=6&db=m [High expression of thrombin receptor PAR1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma in early stage]. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Carcinoma, Intraductal, Noninfiltrating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161710&form=6&db=m PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion. ongoing research,unassigned 3,0 3.4.21.5 Carcinoma, Intraductal, Noninfiltrating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31962001&form=6&db=m Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33481255&form=6&db=m A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21833453&form=6&db=m Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. causal interaction,unassigned 4,0 3.4.21.5 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23875077&form=6&db=m Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.5 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29848718&form=6&db=m The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=654301&form=6&db=m [The embolization of inoperable hypernephromas with autogenous fibrin and thrombin] therapeutic application,unassigned 1,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1183357&form=6&db=m [Occlusion of the renal artery by intra-arterial injection of thrombin in a case of inoperable renal tumour (author's transl)] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2114816&form=6&db=m Fibrinogen-fibrin transformation in situ in renal cell carcinoma. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3350846&form=6&db=m Thrombin: implications for intratumor therapy against metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3985042&form=6&db=m Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6690183&form=6&db=m Tumour infarction after pre-operative embolisation of renal carcinoma. therapeutic application,unassigned 3,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7366122&form=6&db=m Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation. diagnostic usage,unassigned 4,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743661&form=6&db=m PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12175550&form=6&db=m The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12231573&form=6&db=m Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12579295&form=6&db=m Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16525676&form=6&db=m PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. unassigned - 3.4.21.5 Carcinoma, Small Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423826&form=6&db=m Clinical trials with anticoagulant and antiplatelet therapies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Carcinoma, Small Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2823201&form=6&db=m Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants. causal interaction,unassigned 4,0 3.4.21.5 Carcinoma, Small Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2824013&form=6&db=m Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578452&form=6&db=m The enigma PAI-2. Gene expression, evolutionary and functional aspects. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9392328&form=6&db=m Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.5 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9816228&form=6&db=m Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12414665&form=6&db=m Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26071675&form=6&db=m Preoperative D-dimers as an independent prognostic marker in cervical carcinoma. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Carcinosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1281930&form=6&db=m Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Carcinosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3629545&form=6&db=m Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines. unassigned - 3.4.21.5 Carcinosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9392328&form=6&db=m Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.5 Cardiac Tamponade http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24062924&form=6&db=m Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiomegaly http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25869400&form=6&db=m c-Src/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction. causal interaction,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6233800&form=6&db=m [Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12735590&form=6&db=m Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34235983&form=6&db=m Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Cardiomyopathy, Dilated http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15238823&form=6&db=m Activation of coagulation system in dilated cardiomyopathy: comparison of patients with and without left ventricular thrombus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.5 Cardiomyopathy, Dilated http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27888761&form=6&db=m Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Cardiomyopathy, Hypertrophic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17923461&form=6&db=m Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Cardiomyopathy, Hypertrophic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18639352&form=6&db=m Acute myocardial infarction with diminutive right coronary artery and obstructive hypertrophic cardiomyopathy without significant coronary stenoses. causal interaction,unassigned 4,0 3.4.21.5 Cardiomyopathy, Hypertrophic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31659736&form=6&db=m Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy. therapeutic application,unassigned 2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7828214&form=6&db=m Daily variations of functional parameters and density distribution in human blood platelets. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8198374&form=6&db=m Hirudin: clinical potential of a thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8282198&form=6&db=m The discovery and characterization of a novel nucleotide-based thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8314016&form=6&db=m Fibrinogen plasma levels as a marker of thrombin activation in diabetes. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8792770&form=6&db=m Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8872133&form=6&db=m Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol. diagnostic usage,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9211051&form=6&db=m Direct thrombin inhibitors in cardiovascular disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9667850&form=6&db=m New thrombin inhibitors in cardiovascular disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11231110&form=6&db=m Computational modelling of inhibitor binding to human thrombin. causal interaction,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11577023&form=6&db=m Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11770866&form=6&db=m Platelet regulation of thrombin generation in cardiovascular disease. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11945154&form=6&db=m Leech thrombin inhibitors. therapeutic application,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12149106&form=6&db=m Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12913786&form=6&db=m Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12970124&form=6&db=m Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. unassigned - 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15257013&form=6&db=m Pathophysiologic roles of the fibrinogen gamma chain. causal interaction,unassigned 3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15644790&form=6&db=m Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. therapeutic application,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15902370&form=6&db=m [Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549253&form=6&db=m Unchecked thrombin is bad news for troubled arteries. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17950494&form=6&db=m Structure of a novel thrombin inhibitor with an uncharged D-amino acid as P1 residue. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18019946&form=6&db=m Tissue factor in thrombosis and hemorrhage. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18311550&form=6&db=m [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19142984&form=6&db=m Anti inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes. causal interaction,unassigned 3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228706&form=6&db=m Is thrombin a key player in the 'coagulation-atherogenesis' maze? causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21244899&form=6&db=m Thrombin receptor function and cardiovascular disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21848510&form=6&db=m Aptamers as Therapeutics in Cardiovascular Diseases. causal interaction,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22547173&form=6&db=m Direct thrombin inhibitors in cardiovascular disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22647223&form=6&db=m Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. diagnostic usage,unassigned 3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23611368&form=6&db=m Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24468615&form=6&db=m Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity. causal interaction,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24660469&form=6&db=m Antiplatelet aggregation effects of phenanthrenes from Calanthe arisanensis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24902855&form=6&db=m PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes. causal interaction,unassigned 2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24912033&form=6&db=m Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection. therapeutic application,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25085378&form=6&db=m Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. causal interaction,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25113995&form=6&db=m Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status. causal interaction,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25332735&form=6&db=m Real-time measurement of thrombin generation using continuous droplet microfluidics. causal interaction,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25540034&form=6&db=m Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25703517&form=6&db=m The Effect of Omega-3 Polyunsaturated Fatty Acids on Fibrin and Thrombin Generation in Healthy Subjects and Subjects with Cardiovascular Disease. ongoing research,unassigned 3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25819728&form=6&db=m Screening of direct thrombin inhibitors from Radix Salviae Miltiorrhizae by a peak fractionation approach. therapeutic application,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26083038&form=6&db=m Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26286125&form=6&db=m Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study. therapeutic application,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27385196&form=6&db=m Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27436431&form=6&db=m Proximity Binding and Metal Ion-Dependent DNAzyme Cyclic Amplification-Integrated Aptasensor for Label-Free and Sensitive Electrochemical Detection of Thrombin. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27458694&form=6&db=m Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27475864&form=6&db=m Popular naturally occurring antioxidants as potential anticoagulant drugs. causal interaction,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27513692&form=6&db=m Coagulation and non-coagulation effects of thrombin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27613563&form=6&db=m Does Lipid Profile Affect Thrombin Generation During Ramadan Fasting in Patients With Cardiovascular Risks? ongoing research,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27922933&form=6&db=m The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28225026&form=6&db=m Blood-based omic profiling supports female susceptibility to tobacco smoke-induced cardiovascular diseases. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28276481&form=6&db=m Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29614519&form=6&db=m Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets-Results from the Gutenberg Health Study. causal interaction,unassigned 3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30268122&form=6&db=m Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30269382&form=6&db=m Role of thrombin in the pathogenesis of atherosclerosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30569853&form=6&db=m In silico Prediction of Inhibitory Constant of Thrombin Inhibitors Using Machine Learning. causal interaction,unassigned 3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31078120&form=6&db=m A review of global coagulation assays - Is there a role in thrombosis risk prediction? causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31689079&form=6&db=m Aluminum Metasurface with Hybrid Multipolar Plasmons for 1000-Fold Broadband Visible Fluorescence Enhancement and Multiplexed Biosensing. ongoing research,unassigned 1,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31806688&form=6&db=m Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32278295&form=6&db=m Highly sensitive host-guest mode homogenous electrochemical thrombin signal amplification aptasensor based on tetraferrocene label. diagnostic usage,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32649856&form=6&db=m A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. causal interaction,unassigned 4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32792902&form=6&db=m Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33054057&form=6&db=m Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33314013&form=6&db=m High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Carotid Artery Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16359510&form=6&db=m Factor V Leiden improves in vivo hemostasis in murine hemophilia models. unassigned - 3.4.21.5 Carotid Artery Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20858477&form=6&db=m Glybenclamide: an antidiabetic with in vivo antithrombotic activity. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Carotid Artery Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21826574&form=6&db=m Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child. therapeutic application,unassigned 4,0 3.4.21.5 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7867200&form=6&db=m Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12892834&form=6&db=m Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18315550&form=6&db=m Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20930120&form=6&db=m Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25278288&form=6&db=m Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.5 Carotid Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15984896&form=6&db=m Place of drug therapy in the treatment of carotid stenosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Carotid Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17903894&form=6&db=m Thrombocyte activation increases with the degree of carotid artery stenosis. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Carotid Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18327410&form=6&db=m Increased thrombin generation in persons with echogenic carotid plaques. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.5 Carotid Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19796792&form=6&db=m Coagulation activation and ultrasound characteristics in patients with carotid artery disease. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Carotid Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20589203&form=6&db=m Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Carotid Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25033981&form=6&db=m Increased thrombin generation potential in symptomatic versus asymptomatic moderate or severe carotid stenosis and relationship with cerebral microemboli. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3347459&form=6&db=m Use of fibrin glue in ocular surgery. diagnostic usage,unassigned 3,0 3.4.21.5 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19027724&form=6&db=m Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: role of recombinant hirudin variant III. therapeutic application,unassigned 4,0 3.4.21.5 Celiac Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25793906&form=6&db=m Onset of Thrombin Generation Occurs More Rapidly in Pediatric Patients With Celiac Disease. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Central Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Central Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Central Nervous System Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33642398&form=6&db=m Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Central Nervous System Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Cerebral Amyloid Angiopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33946588&form=6&db=m Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6306770&form=6&db=m Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115). causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8613842&form=6&db=m Edema from intracerebral hemorrhage: the role of thrombin. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9010429&form=6&db=m Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9202268&form=6&db=m Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,3 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626295&form=6&db=m Plasminogen activators potentiate thrombin-induced brain injury. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10356108&form=6&db=m Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10837811&form=6&db=m The effects of thrombin preconditioning on focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10844028&form=6&db=m Potentiation of NMDA receptor function by the serine protease thrombin. causal interaction,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11259759&form=6&db=m Effects of hypothermia on thrombin-induced brain edema formation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11807394&form=6&db=m Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,3 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11919511&form=6&db=m Thrombin-receptor activation and thrombin-induced brain tolerance. therapeutic application,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12468805&form=6&db=m Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12485396&form=6&db=m The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12885431&form=6&db=m Nestin expression after experimental intracerebral hemorrhage. unassigned - 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753426&form=6&db=m Thrombin exacerbates brain edema in focal cerebral ischemia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753484&form=6&db=m Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753486&form=6&db=m Effect of delayed argatroban treatment on intracerebral hemorrhage-induced edema in the rat. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753487&form=6&db=m Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15075717&form=6&db=m Novel therapies for intracerebral hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15315344&form=6&db=m Experimental study on the PAR-1 expression around hemotoma following intracerebral hemorrhage in rats. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569485&form=6&db=m Effect of thrombin on blood brain barrier permeability and its mechanism. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15665510&form=6&db=m Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15933250&form=6&db=m The deleterious or beneficial effects of different agents in intracerebral hemorrhage: think big, think small, or is hematoma size important? causal interaction,unassigned 3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16146604&form=6&db=m [Expression of intercellular adhesion molecule-1 and neutrophil infiltration induced by injection of thrombin in rats] causal interaction,unassigned 3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16330215&form=6&db=m Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16463894&form=6&db=m Intracerebral hemorrhage induces edema and oxidative stress and alters N-methyl-D-aspartate receptor subunits expression. causal interaction,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16528196&form=6&db=m Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16671455&form=6&db=m Up-regulation of brain ceruloplasmin in thrombin preconditioning. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,2 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17021183&form=6&db=m Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. ongoing research,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17261733&form=6&db=m Brain injury after intracerebral hemorrhage: the role of thrombin and iron. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17395859&form=6&db=m SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17498698&form=6&db=m Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17904058&form=6&db=m Expression of matrix metalloproteinse-9 in thrombin-induced brain edema formation in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17940541&form=6&db=m Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats. ongoing research,unassigned 2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343677&form=6&db=m Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons. unassigned - 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18436875&form=6&db=m Effects of thrombin on neurogenesis after intracerebral hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18574711&form=6&db=m Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18582441&form=6&db=m 3CB2, a marker of radial glia, expression after experimental intracerebral hemorrhage: role of thrombin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19061541&form=6&db=m Minocycline reduces intracerebral hemorrhage-induced brain injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19063881&form=6&db=m Long-term treatment with nicotine suppresses neurotoxicity of, and microglial activation by, thrombin in cortico-striatal slice cultures. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19064789&form=6&db=m Thrombin and brain recovery after intracerebral hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066080&form=6&db=m Intracerebral hemorrhage injury mechanisms: glutamate neurotoxicity, thrombin, and Src. causal interaction,unassigned 3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066081&form=6&db=m Increase in brain thrombin activity after experimental intracerebral hemorrhage. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19066084&form=6&db=m Microglial activation and brain injury after intracerebral hemorrhage. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19359644&form=6&db=m Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19427359&form=6&db=m Long-time course of protease-activated receptor-1 expression after intracerebral hemorrhage in rats. causal interaction,unassigned 2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19812969&form=6&db=m Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20437588&form=6&db=m Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. therapeutic application,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20515663&form=6&db=m Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in organotypic slice culture. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20819545&form=6&db=m Expression of thrombin and its associated protein in cerebellum of human and rat after intracerebral hemorrhage. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21162277&form=6&db=m [Dynamic and long-lasting expression of thrombin receptor-1 after intracerebral hemorrhage in rats]. ongoing research,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21172324&form=6&db=m The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKC?/PKC? signaling. ongoing research,unassigned 2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21244583&form=6&db=m Analysis of thrombin-antithrombin complex contents in plasma and hematoma fluid of hypertensive intracerebral hemorrhage patients after clot removal. causal interaction,unassigned 3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21507817&form=6&db=m Controversies of anticoagulation reversal in life-threatening bleeds. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21708357&form=6&db=m Coated-platelet levels are elevated in patients with transient ischemic attack. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21725759&form=6&db=m Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21725765&form=6&db=m Thrombin preconditioning attenuates iron-induced neuronal death. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21752338&form=6&db=m HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. therapeutic application,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21803126&form=6&db=m Systemic administration of argatroban inhibits protease-activated receptor-1 expression in perihematomal tissue in rats with intracerebral hemorrhage. ongoing research,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21911784&form=6&db=m Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21998060&form=6&db=m Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22015349&form=6&db=m Thrombin-induced autophagy: a potential role in intracerebral hemorrhage. ongoing research,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22190365&form=6&db=m PDGFR-? inhibition preserves blood-brain barrier after intracerebral hemorrhage. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22267830&form=6&db=m Letter by Moll regarding article, "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran". therapeutic application,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22687694&form=6&db=m Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23043906&form=6&db=m Thrombin promotes the expression of thrombospondin-1 and -2 in a rat model of intracerebral hemorrhage. ongoing research,unassigned 3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23228810&form=6&db=m Sesamin suppresses activation of microglia and p44/42 MAPK pathway, which confers neuroprotection in rat intracerebral hemorrhage. therapeutic application,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23585819&form=6&db=m Effect of Iron Chelators on Methemoglobin and Thrombin Preconditioning. unassigned - 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23932349&form=6&db=m Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24323711&form=6&db=m Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24323862&form=6&db=m Excitatory and Mitogenic Signaling in Cell Death, Blood-brain Barrier Breakdown, and BBB Repair after Intracerebral Hemorrhage. therapeutic application,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24326390&form=6&db=m Hydrocephalus after intraventricular hemorrhage: the role of thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25036511&form=6&db=m Effects of thrombin on the secondary cerebral injury of perihematomal tissues of rats after intracerebral hemorrhage. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25669912&form=6&db=m Dabigatran abrogates brain endothelial cell permeability in response to thrombin. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26021875&form=6&db=m Impaired adult hippocampal neurogenesis and cognitive ability in a mouse model of intrastriatal hemorrhage. causal interaction,unassigned 2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26035221&form=6&db=m Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation. therapeutic application,unassigned 1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26342829&form=6&db=m Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26376816&form=6&db=m A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463978&form=6&db=m Effects of Aerobic Capacity on Thrombin-Induced Hydrocephalus and White Matter Injury. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27477964&form=6&db=m Effect of thrombin preconditioning on migration of subventricular zone-derived cells after intracerebral hemorrhage in rats. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27841083&form=6&db=m Thrombin-induced apoptosis in neurons through activation of c-Jun-N-terminal kinase. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28344073&form=6&db=m Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28496748&form=6&db=m Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30527680&form=6&db=m Thrombin promotes pericyte coverage by Tie2 activation in a rat model of intracerebral hemorrhage. ongoing research,unassigned 2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31601371&form=6&db=m Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31830857&form=6&db=m The Cerebral Thrombin System Is Activated after Intracerebral Hemorrhage and Contributes to Secondary Lesion Growth and Poor Neurological Outcome in C57Bl/6 Mice. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31924407&form=6&db=m Interactions between rat cortico-striatal slice cultures and neutrophil-like HL60 cells under thrombin challenge: Toward elucidation of pathological events in intracerebral hemorrhage. unassigned - 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32808155&form=6&db=m Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage. causal interaction,unassigned 4,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33175864&form=6&db=m High CSF thrombin concentration and activity is associated with an unfavorable outcome in patients with intracerebral hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1988604&form=6&db=m Treatment of intractable arterial hemorrhage during stereotactic brain biopsy with thrombin. Report of three patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7843647&form=6&db=m Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8248977&form=6&db=m Hematologic abnormalities occur in both cortical and lacunar infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9361377&form=6&db=m Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10750365&form=6&db=m A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11323005&form=6&db=m The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11464470&form=6&db=m [Antithrombotic therapy in cerebral infarction] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12355032&form=6&db=m Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16464362&form=6&db=m Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21512172&form=6&db=m Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30564010&form=6&db=m The role of thrombin in central nervous system activity and stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Cerebrospinal Fluid Leak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28146023&form=6&db=m Effective Repair of Dural Tear Using Bioabsorbable Sheet with Fibrin Glue. unassigned - 3.4.21.5 Cerebrospinal Fluid Leak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10229740&form=6&db=m Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15376471&form=6&db=m Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22288673&form=6&db=m Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22918734&form=6&db=m PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23064666&form=6&db=m Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12213235&form=6&db=m Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21360607&form=6&db=m Looking at the proteases from a simple perspective. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23429536&form=6&db=m Absence of myocardial calcium-independent phospholipase A2? results in impaired PGE2 production and decreased survival in mice with acute Trypanosoma cruzi infection. causal interaction,unassigned 1,0 3.4.21.5 Chickenpox http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15946215&form=6&db=m Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Cholangiocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12002913&form=6&db=m The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Cholangiocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Cholangitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33469808&form=6&db=m Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Choledocholithiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33469808&form=6&db=m Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1331412&form=6&db=m Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL. ongoing research,unassigned 2,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2451825&form=6&db=m Effect of cholera toxin on histamine release from bone marrow-derived mouse mast cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2845929&form=6&db=m Thrombin exerts a dual effect on stimulated adenylate cyclase in hamster fibroblasts, an inhibition via a GTP-binding protein and a potentiation via activation of protein kinase C. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3040750&form=6&db=m Possible involvement of a GTP-binding protein, the substrate of islet-activating protein, in receptor-mediated signaling responsible for cell proliferation. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6356133&form=6&db=m Colloidal gold: a pluripotent receptor probe. diagnostic usage,unassigned 3,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7763968&form=6&db=m Determination of the conformations of bound peptides using NMR-transferred nOe techniques. unassigned - 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7854206&form=6&db=m Mechanisms of cholera toxin prevention of thrombin- and PMA-induced endothelial cell barrier dysfunction. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8180340&form=6&db=m Regulation of thrombin-induced endothelial cell activation by bacterial toxins. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9589368&form=6&db=m Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons. therapeutic application,unassigned 1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10895075&form=6&db=m Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12842101&form=6&db=m Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23261689&form=6&db=m Electrogenerated trisbipyridyl Ru(II)-/nitrilotriacetic-polypyrene copolymer for the easy fabrication of label-free photoelectrochemical immunosensor and aptasensor: application to the determination of thrombin and anti-cholera toxin antibody. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Cholestasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21037076&form=6&db=m The Coagulation System Contributes to {alpha}V{beta}6 Integrin Expression and Liver Fibrosis Induced by Cholestasis. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Cholesteatoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16785139&form=6&db=m A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Chondrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20175118&form=6&db=m Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Choroidal Effusions http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1562129&form=6&db=m Recurrent hemorrhagic choroidal detachment associated with disseminated intravascular coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Chronic Limb-Threatening Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16079449&form=6&db=m A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Chronic Limb-Threatening Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19155057&form=6&db=m A direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable critical limb ischemia. therapeutic application,unassigned 3,0 3.4.21.5 Chronic Limb-Threatening Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32252612&form=6&db=m Altered coagulation profile in peripheral artery disease patients. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16634701&form=6&db=m Emerging drugs for chronic urticaria. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16675340&form=6&db=m Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17204316&form=6&db=m Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17961199&form=6&db=m Severe chronic urticaria is associated with elevated plasma levels of D-dimer. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20400886&form=6&db=m Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test. causal interaction,unassigned 4,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21083568&form=6&db=m Increase of coagulation potential in chronic spontaneous urticaria. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25572563&form=6&db=m Increased thrombin generation potential in patients with chronic spontaneous urticaria. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26122507&form=6&db=m Activation of the Intrinsic Coagulation Pathway in Patients With Chronic Urticaria. diagnostic usage,unassigned 4,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26554248&form=6&db=m Activation of the Blood Coagulation System in Patients with Chronic Spontaneous Urticaria. diagnostic usage,unassigned 3,0 3.4.21.5 Chronic Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28787094&form=6&db=m Mast cells are critical for the limitation of thrombin-induced skin inflammation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Classical Swine Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34491714&form=6&db=m Isothermal Self-Primer EXPonential Amplification Reaction (SPEXPAR) for Highly Sensitive Detection of Single-Stranded Nucleic Acids and Proteins. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 coagulation factor ixa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620866&form=6&db=m Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 coagulation factor ixa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6713090&form=6&db=m Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10749569&form=6&db=m Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice. causal interaction,unassigned 3,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12881304&form=6&db=m Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. causal interaction,unassigned 4,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16268461&form=6&db=m Generation of genetically-altered mice producing very low levels of coagulation factorVII. ongoing research,unassigned 3,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16772740&form=6&db=m Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17095860&form=6&db=m Congenital combined defects of factor VII: a critical review. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20632246&form=6&db=m Recombinant activated factor VII: mechanisms of action and current indications. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22419573&form=6&db=m Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23992369&form=6&db=m Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015059&form=6&db=m Recombinant activated factor VII in clinical practice: a 2014 update. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25973586&form=6&db=m The Story of Serum Prothrombin Conversion Accelerator, Proconvertin, Stable Factor, Cothromboplastin, Prothrombin Accelerator or Autoprothrombin I, and Their Subsequent Merging into Factor VII. causal interaction,unassigned 2,0 3.4.21.5 coagulation factor viia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26073368&form=6&db=m Recombinant activated factor VII: 30 years of research and innovation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 coagulation factor xa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6372111&form=6&db=m Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 coagulation factor xa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585046&form=6&db=m Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity. causal interaction,unassigned 3,0 3.4.21.5 coagulation factor xa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19204776&form=6&db=m Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 coagulation factor xa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22008904&form=6&db=m Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry. causal interaction,unassigned 3,0 3.4.21.5 coagulation factor xa deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23664564&form=6&db=m Six novel missense mutations causing factor X deficiency and application of thrombin generation test. causal interaction,unassigned 2,0 3.4.21.5 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3629878&form=6&db=m Identification of factor XI deficiency in Holstein-Friesian cattle in Britain. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7730123&form=6&db=m Factor XI deficiency in Kerry Blue Terriers. causal interaction,unassigned 4,0 3.4.21.5 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9139250&form=6&db=m [Thrombocyte dysfunction in children with albinism] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20398070&form=6&db=m Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26160656&form=6&db=m The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. causal interaction,unassigned 4,0 3.4.21.5 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29497672&form=6&db=m Anesthetic management using peripheral nerve block in patients with factor XI deficiency: a case report. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 coagulation factor xiia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11597947&form=6&db=m Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Coinfection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16467309&form=6&db=m Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. ongoing research,unassigned 2,0 3.4.21.5 Coinfection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24581101&form=6&db=m A cost effective endovascular approach for management of post-catheterization profunda femoris artery pseudoaneurysm using thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Colic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3954219&form=6&db=m Hemostatic abnormalities in equine colic. diagnostic usage,unassigned 4,0 3.4.21.5 Colic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15061486&form=6&db=m The coagulation system in horses with colic. diagnostic usage,unassigned 4,0 3.4.21.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18772359&form=6&db=m Thrombin mediates the extraintestinal thrombosis associated with experimental colitis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24710407&form=6&db=m Thrombin drives tumorigenesis in colitis-associated colon cancer. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30105021&form=6&db=m The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review. therapeutic application,unassigned 3,0 3.4.21.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30907672&form=6&db=m Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33201214&form=6&db=m Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Colitis, Ischemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14712380&form=6&db=m Ischemic colitis following translumbar thrombin injection for treatment of endoleak. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8789309&form=6&db=m Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10911390&form=6&db=m Acquired inhibitor of thrombin associated with an ulcerative colitis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16437691&form=6&db=m Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17308963&form=6&db=m Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19865055&form=6&db=m Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Colitis-Associated Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24710407&form=6&db=m Thrombin drives tumorigenesis in colitis-associated colon cancer. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1799331&form=6&db=m [Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors] ongoing research,unassigned 4,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1871716&form=6&db=m Cellular localization of activated factor X by Xa-specific probes. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7834643&form=6&db=m Solid tumor cells express functional "tethered ligand" thrombin receptor. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8611404&form=6&db=m Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9820166&form=6&db=m Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12707033&form=6&db=m Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15383630&form=6&db=m Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17721608&form=6&db=m Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. causal interaction,unassigned 3,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19058300&form=6&db=m Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21993963&form=6&db=m Thrombin-dependent modulation of ?1-integrin-mediated signaling up-regulates prolidase and HIF-1? through p-FAK in colorectal cancer cells. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26238780&form=6&db=m Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30462538&form=6&db=m The role of coagulation and platelets in colon cancer-associated thrombosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16091733&form=6&db=m Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20857420&form=6&db=m Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,1 3.4.21.5 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161738&form=6&db=m PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Coma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30439321&form=6&db=m [Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12479886&form=6&db=m Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants. therapeutic application,unassigned 1,0 3.4.21.5 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20183534&form=6&db=m A new fibrin sealant from Crotalus durissus terrificus venom: applications in medicine. unassigned - 3.4.21.5 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26590919&form=6&db=m The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC. diagnostic usage,unassigned 4,0 3.4.21.5 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31839802&form=6&db=m Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: a systematic review. ongoing research,unassigned 3,0 3.4.21.5 Confusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11285600&form=6&db=m From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Confusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711741&form=6&db=m A reunification of the US ("NIH") and International Unit into a single standard for Thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3629878&form=6&db=m Identification of factor XI deficiency in Holstein-Friesian cattle in Britain. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18184550&form=6&db=m [Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia] diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21524474&form=6&db=m Hemophilia A in cardiac operations: a model of reduced thrombin generation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Congenital Disorders of Glycosylation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31736265&form=6&db=m Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation. causal interaction,unassigned 4,0 3.4.21.5 Congenital, Hereditary, and Neonatal Diseases and Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31271700&form=6&db=m Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Congenital, Hereditary, and Neonatal Diseases and Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31736265&form=6&db=m Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation. causal interaction,unassigned 4,0 3.4.21.5 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19373890&form=6&db=m The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Contracture http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8720698&form=6&db=m Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current. ongoing research,unassigned 3,0 3.4.21.5 Contracture http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10942729&form=6&db=m Effects of microtubules and microfilaments on [Ca(2+)](i) and contractility in a reconstituted fibroblast fiber. diagnostic usage,unassigned 2,0 3.4.21.5 Contracture http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12499124&form=6&db=m Effects of monocrotaline pyrrole and thrombin on pulmonary endothelial cell junction and matrix adhesion proteins. therapeutic application,unassigned 3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1424043&form=6&db=m Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2678451&form=6&db=m [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?] diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2972304&form=6&db=m Thrombin and plasmin activity in coronary artery disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7634295&form=6&db=m [Chronic ischemic cardiopathy: antiplatelet agents and anticoagulants, new protocols for prevention and treatment] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8109546&form=6&db=m Platelet aggregation, coronary artery disease progression and future coronary events. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8115978&form=6&db=m Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8456753&form=6&db=m Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8552614&form=6&db=m Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8557285&form=6&db=m New thrombin inhibiting strategies for coronary artery disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578525&form=6&db=m Advances in antithrombotic therapy: novel agents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8735810&form=6&db=m Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8901652&form=6&db=m Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9257498&form=6&db=m Haemostatic function in coronary artery disease (CAD). diagnostic usage,unassigned 4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9355897&form=6&db=m Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9458447&form=6&db=m A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531028&form=6&db=m Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9648727&form=6&db=m Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9808597&form=6&db=m Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9878933&form=6&db=m Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10334417&form=6&db=m Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10365287&form=6&db=m The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10418800&form=6&db=m Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10505540&form=6&db=m Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10543929&form=6&db=m Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603519&form=6&db=m Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608030&form=6&db=m Plasma Markers of Procoagulant Activity Among Individuals with Coronary Artery Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608043&form=6&db=m No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10940351&form=6&db=m Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10972534&form=6&db=m Identification of new single-nucleotide polymorphisms in the thrombin receptor gene and their effects on coronary artery diseases in Koreans. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11073858&form=6&db=m Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11167667&form=6&db=m Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11397720&form=6&db=m Coagulation activity and clinical outcome in unstable coronary artery disease. therapeutic application,unassigned 2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12127916&form=6&db=m Thrombin inhibitors in acute coronary artery disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12559940&form=6&db=m Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease. causal interaction,unassigned 4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14512086&form=6&db=m The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961168&form=6&db=m Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201277&form=6&db=m Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15230222&form=6&db=m [The role of thrombin activatable fibrinolysis inhibitors (TAFI) in coronary artery disease] causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15882894&form=6&db=m Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15894964&form=6&db=m Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15965353&form=6&db=m Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen. therapeutic application,unassigned 3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15983678&form=6&db=m Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16675000&form=6&db=m Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16845256&form=6&db=m Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17270293&form=6&db=m Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of thrombosis, fibrinolysis and atherosclerotic burden. diagnostic usage,unassigned 3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17642204&form=6&db=m [The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17726318&form=6&db=m Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17934000&form=6&db=m IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17944993&form=6&db=m Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17966595&form=6&db=m [Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18054069&form=6&db=m Relevance of hemostasis on restenosis in clinically stable patients undergoing elective PTCA. diagnostic usage,unassigned 3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18925517&form=6&db=m Correlations between platelet-derived microvesicles and thrombin generation in patients with coronary artery disease. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228864&form=6&db=m Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19618315&form=6&db=m Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19804135&form=6&db=m Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19806256&form=6&db=m The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20002542&form=6&db=m Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20013532&form=6&db=m Prostate-specific antigen, prostate cancer, and disorders of hemostasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20805114&form=6&db=m Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20844798&form=6&db=m Ensembles of uncertain mathematical models can identify network response to therapeutic interventions. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21555871&form=6&db=m The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21617138&form=6&db=m Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22316436&form=6&db=m Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22415084&form=6&db=m Expression of Junctional Adhesion Molecule-C on the Surface of Platelets Supports Adhesion, but not Differentiation, of Human CD34 Cells in Vitro. causal interaction,unassigned 3,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22562594&form=6&db=m Platelet function and inhibition in ischemic heart disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22795340&form=6&db=m Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease. therapeutic application,unassigned 2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23236969&form=6&db=m Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23313628&form=6&db=m Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24435325&form=6&db=m Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27010400&form=6&db=m Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,2 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27171403&form=6&db=m Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,2 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27597926&form=6&db=m Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28128747&form=6&db=m Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28374620&form=6&db=m Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,4 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28477533&form=6&db=m Increased plasma thrombin potential is associated with stable coronary artery disease: An angiographically-controlled study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28969064&form=6&db=m Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29768939&form=6&db=m Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,3 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30146935&form=6&db=m Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30422037&form=6&db=m Increased platelet reactivity and platelet-leukocyte aggregation after elective coronary bypass surgery. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31758517&form=6&db=m Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32056358&form=6&db=m Remote ischemic preconditioning inhibits platelet ?IIb ?3 activation in coronary artery disease patients receiving dual antiplatelet therapy: A randomized trial. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=89993&form=6&db=m Short heparin thrombin clotting time, increased fibrinogen and platelet aggregates count in coronary disease: a probable hypercoagulable state. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2962911&form=6&db=m The effect of exercise on thrombin and plasmin generation in middle-aged men. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6233800&form=6&db=m [Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8248690&form=6&db=m [Clinical significance of endothelial dysfunction: studies of human coronary circulation in vivo] unassigned - 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8704425&form=6&db=m [Relationship between anti-coagulation system changes of coronary heart disease patients and different syndrome-type in TCM] diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8865525&form=6&db=m Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134645&form=6&db=m Thrombin generation markers and coronary heart disease risk factors in a Polish population sample. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9506337&form=6&db=m Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9576150&form=6&db=m Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10498131&form=6&db=m Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10754393&form=6&db=m Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10907447&form=6&db=m [New medical anticoagulants] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10940351&form=6&db=m Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246536&form=6&db=m Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11675344&form=6&db=m Thrombogenic potential of human coronary atherosclerotic plaques. causal interaction,unassigned 4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15320782&form=6&db=m Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16503463&form=6&db=m Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,1,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278189&form=6&db=m Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19065903&form=6&db=m [Intervening effect of naoxintong on anti-platelet treatment with aspirin] diagnostic usage,unassigned 2,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21454811&form=6&db=m Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21555871&form=6&db=m The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22359579&form=6&db=m RNA-seq Reveals Novel Transcriptome of Genes and Their Isoforms in Human Pulmonary Microvascular Endothelial Cells Treated with Thrombin. causal interaction,unassigned 4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28139555&form=6&db=m [Evaluation of the hemostatic potential at coronary artery bypass surgery during long-term aspirin therapy]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32764787&form=6&db=m Thrombin generation's role in predicting coronary disease severity. causal interaction,unassigned 4,0 3.4.21.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33469808&form=6&db=m Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2117619&form=6&db=m Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578530&form=6&db=m Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8813448&form=6&db=m Increased plasma concentration of fibrin monomer in acute myocardial infarction with early reperfusion. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8901653&form=6&db=m Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,3 3.4.21.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13848447&form=6&db=m Heparin resistance, measured by the plasma heparin thrombin time, in patients on long-term anticoagulatn therapy with phenylindanedione following coronary occlusion. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,2 3.4.21.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14402593&form=6&db=m Heparin resistance in acute coronary occlusion measured by the plasma heparin thrombin time. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1389732&form=6&db=m Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,3 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2661588&form=6&db=m Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7930280&form=6&db=m Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. causal interaction,unassigned 2,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111795&form=6&db=m Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9495304&form=6&db=m Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9589189&form=6&db=m Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11775622&form=6&db=m Platelet-dependent thrombin generation in patients with unstable angina pectoris. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,1 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15227406&form=6&db=m Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators. causal interaction,unassigned 4,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17966595&form=6&db=m [Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34066261&form=6&db=m Fibrinolysis in Platelet Thrombi. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1451271&form=6&db=m Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1555478&form=6&db=m Role of heparin in coronary thrombolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1900222&form=6&db=m Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2508092&form=6&db=m Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6541103&form=6&db=m Coronary thrombolysis with recombinant human tissue-type plasminogen activator. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7886362&form=6&db=m [Unstable angina pectoris: coagulation disorder and its therapy] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7954631&form=6&db=m Increased lysophosphatidylcholine content induced by thrombin receptor stimulation in adult rabbit cardiac ventricular myocytes. unassigned - 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8029802&form=6&db=m Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8613969&form=6&db=m Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,3 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778585&form=6&db=m A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883275&form=6&db=m Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8921778&form=6&db=m Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9514177&form=6&db=m Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10213277&form=6&db=m Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10328604&form=6&db=m Platelet-dependent and procoagulant mechanisms in arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11349627&form=6&db=m [Direct thrombin antagonists] causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11514372&form=6&db=m Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11723016&form=6&db=m Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. causal interaction,unassigned 4,0 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15031124&form=6&db=m Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16153930&form=6&db=m Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Coronary Vasospasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3681697&form=6&db=m Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Coronary Vasospasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7123259&form=6&db=m Coronary vascular reactivity after acute myocardial ischemia. causal interaction,unassigned 4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32335281&form=6&db=m Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32371744&form=6&db=m Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors. therapeutic application,unassigned 1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32490889&form=6&db=m Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32551814&form=6&db=m Coagulation Dysfunction. unassigned - 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32581015&form=6&db=m Coagulation Panel in Patients with SARS-CoV2 Infection (COVID-19). diagnostic usage,unassigned 4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32586214&form=6&db=m The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. causal interaction,unassigned 3,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32596339&form=6&db=m D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. diagnostic usage,unassigned 4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32619329&form=6&db=m Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32668058&form=6&db=m Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32762118&form=6&db=m In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32779783&form=6&db=m Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32790951&form=6&db=m Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32860301&form=6&db=m Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32870433&form=6&db=m Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32892505&form=6&db=m Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32922211&form=6&db=m Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32938299&form=6&db=m Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19. causal interaction,unassigned 2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32945081&form=6&db=m COVID-19 patients exhibit reduced procoagulant platelet responses. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33023681&form=6&db=m Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019. causal interaction,unassigned 1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33119703&form=6&db=m The values of coagulation function in COVID-19 patients. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33126772&form=6&db=m Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33196292&form=6&db=m COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33224575&form=6&db=m Cardiovascular risk in COVID-19 infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33239231&form=6&db=m Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33302737&form=6&db=m Protease-activated receptor 1 as a potential therapeutic target for COVID-19. causal interaction,unassigned 4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33332362&form=6&db=m Coronavirus-induced coagulopathy during the course of disease. diagnostic usage,unassigned 4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33414384&form=6&db=m SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33482677&form=6&db=m Thrombin Generation in Patients with Coronavirus Disease 2019. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33509706&form=6&db=m Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: A thromboelastographic study. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33537537&form=6&db=m Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33544518&form=6&db=m Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,2,1 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33560374&form=6&db=m Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. diagnostic usage,unassigned 2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33618796&form=6&db=m Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33662799&form=6&db=m Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33832398&form=6&db=m Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33833254&form=6&db=m Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34059141&form=6&db=m Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases. diagnostic usage,unassigned 3,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34110529&form=6&db=m Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34130315&form=6&db=m Extracorporeal Membrane Oxygenation Induces Early Alterations in Coagulation and Fibrinolysis Profiles in COVID-19 Patients with Acute Respiratory Distress Syndrome. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34177896&form=6&db=m Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34221178&form=6&db=m SARS-CoV-2 and Plasma Hypercoagulability. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34375505&form=6&db=m Persistent endotheliopathy in the pathogenesis of long COVID syndrome. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34469011&form=6&db=m Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection. unassigned - 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2747858&form=6&db=m The incidence and significance of hemostatic abnormalities in patients with head injuries. diagnostic usage,unassigned 4,0 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9428558&form=6&db=m Procoagulant activity in patients with isolated severe head trauma. causal interaction,unassigned 1,0 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10372628&form=6&db=m Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10568717&form=6&db=m Effects of alpha-thrombin on superoxide dismutase levels in human cerebral microvascular endothelial cells. causal interaction,unassigned 3,0 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18199772&form=6&db=m Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults. ongoing research,unassigned 4,0 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18596881&form=6&db=m Thrombin: is it on a par with seizures and epilepsy? ongoing research,unassigned 3,0 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18639059&form=6&db=m Role of coagulopathy in patients with head trauma. unassigned - 3.4.21.5 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32009953&form=6&db=m Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Creutzfeldt-Jakob Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18466171&form=6&db=m Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8789309&form=6&db=m Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21287673&form=6&db=m Thrombin generation in pediatric patients with Crohn's disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24291018&form=6&db=m Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease. therapeutic application,unassigned 1,0 3.4.21.5 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33201214&form=6&db=m Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Crush Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23805723&form=6&db=m [Coagulation and fibrinolytic activity of lymph in various pathological conditions (review of own and literature data)]. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Cushing Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10803470&form=6&db=m Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. causal interaction,unassigned 4,0 3.4.21.5 Cushing Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23408210&form=6&db=m Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Cushing Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34115342&form=6&db=m Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Cystadenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9735390&form=6&db=m Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Cystitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524153&form=6&db=m [New hemostatic therapy of bleeding of bladder by technique of drip-irrigation using a thrombin solution] diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Cystitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24262631&form=6&db=m Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Cystitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33645436&form=6&db=m Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Cystitis, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952710&form=6&db=m Prostacyclin production in tryptase and thrombin stimulated human bladder endothelial cells: effect of pretreatment with phospholipase A2 and cyclooxygenase inhibitors. unassigned - 3.4.21.5 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=820658&form=6&db=m Bioplast fibrin coagulum in large cystic defects of the jaw. therapeutic application,unassigned 1,0 3.4.21.5 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17273888&form=6&db=m Leptomeningeal cyst due to vacuum extraction delivery in a twin infant. unassigned - 3.4.21.5 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30562335&form=6&db=m Complete Excision of a Simple Dacryops Using Fibrin Sealant and Trypan Blue Mixture. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Cytochrome-c Oxidase Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16181984&form=6&db=m Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency. causal interaction,causal interaction,diagnostic usage,diagnostic usage,ongoing research,ongoing research,therapeutic application,therapeutic application 4,4,4,4,1,1,1,1 3.4.21.5 Death, Sudden, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8173709&form=6&db=m Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Death, Sudden, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12749780&form=6&db=m Morning sudden cardiac death. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Decompression Sickness http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=531993&form=6&db=m Effects of aspirin and dipyridamole on platelet function, hematology, and blood chemistry of saturation divers. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Decompression Sickness http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14652070&form=6&db=m Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8665233&form=6&db=m Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. causal interaction,unassigned 2,0 3.4.21.5 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20169734&form=6&db=m [Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest] diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28446591&form=6&db=m NFAT5-sensitive Orai1 expression and store-operated Ca(2+) entry in megakaryocytes. unassigned - 3.4.21.5 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29614518&form=6&db=m Hypobaric Hypoxia Causes Elevated Thrombin Generation Mediated by FVIII that is Balanced by Decreased Platelet Activation. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10420069&form=6&db=m Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14534609&form=6&db=m Content of autoantibodies to bradykinin and beta-amyloid(1-42) as a criterion for biochemical differences between Alzheimer's dementias. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15550013&form=6&db=m Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23628464&form=6&db=m Reservations against new oral anticoagulants after stroke and cerebral bleeding. unassigned - 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25079808&form=6&db=m Targeting thrombin: an inflammatory neurotoxin in Alzheimer's disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32792902&form=6&db=m Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33252072&form=6&db=m Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells. unassigned - 3.4.21.5 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10229740&form=6&db=m Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11065234&form=6&db=m Thrombin and antithrombin in Binswanger's disease. unassigned - 3.4.21.5 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11121687&form=6&db=m Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21676170&form=6&db=m Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24740641&form=6&db=m Early detection of thrombin activity in neuroinflammatory disease. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24810631&form=6&db=m Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26285165&form=6&db=m Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32236088&form=6&db=m Thrombin regulates the ability of Schwann cells to support neuritogenesis and to maintain the integrity of the nodes of Ranvier. unassigned - 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17393026&form=6&db=m Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. causal interaction,unassigned 3,0 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18226917&form=6&db=m Elevated levels of soluble ST2 protein in dengue virus infected patients. diagnostic usage,unassigned 4,0 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22391061&form=6&db=m Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23740201&form=6&db=m Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23890510&form=6&db=m Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case--control study comparing dengue fever patients with and without bleeding manifestations. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25231318&form=6&db=m Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis. diagnostic usage,unassigned 4,0 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26546555&form=6&db=m Novel interactions of domain III from the envelope glycoprotein of dengue 2 virus with human plasma proteins. therapeutic application,unassigned 1,0 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27714828&form=6&db=m A propeptide-independent protease from Tannerella sp.6_1_58FAA_CT1 displays trypsin-like specificity. unassigned - 3.4.21.5 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32544159&form=6&db=m Multivariate time-series analysis of biomarkers from a dengue cohort offers new approaches for diagnosis and prognosis. diagnostic usage,unassigned 4,0 3.4.21.5 Dermatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33458623&form=6&db=m PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Dermatitis Herpetiformis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12165736&form=6&db=m Levels of F(1+2) prothrombin fragments and thrombin - antithrombin III (TAT) complexes in patients with dermatitis herpetiformis. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Dermatitis, Atopic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16801112&form=6&db=m Platelet aggregation in atopic dermatitis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1397782&form=6&db=m Generation of thrombin activity in relation to factor VIII:C concentrations and vascular complications in type 1 (insulin-dependent) diabetes mellitus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1518179&form=6&db=m [Evaluation of platelet intracellular calcium ion concentrations with flow cytometry] diagnostic usage,unassigned 4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1772997&form=6&db=m Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2140088&form=6&db=m The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. unassigned - 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2144055&form=6&db=m Primary platelet activation in recent-onset type 1 diabetes mellitus. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2184068&form=6&db=m Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. causal interaction,unassigned 2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2935351&form=6&db=m Dissociation of thrombin generation and platelet secretion in diabetes mellitus. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2971234&form=6&db=m Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4661652&form=6&db=m Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8339853&form=6&db=m Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8606265&form=6&db=m Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8679990&form=6&db=m [Mobilization of intracellular Ca2+ by ADP and thrombin in platelets of patients with diabetes mellitus with vascular complications] causal interaction,unassigned 1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10077454&form=6&db=m Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11020468&form=6&db=m Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19069453&form=6&db=m [Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy] diagnostic usage,unassigned 1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20361492&form=6&db=m [Platelet abnormalities in type 2 diabetes mellitus] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20640482&form=6&db=m Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20837908&form=6&db=m Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus. ongoing research,unassigned 4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22470429&form=6&db=m Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24899357&form=6&db=m Clot properties and cardiovascular disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25052834&form=6&db=m Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25239438&form=6&db=m Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25681465&form=6&db=m The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25782437&form=6&db=m Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. causal interaction,unassigned 2,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27187380&form=6&db=m Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients. ongoing research,unassigned 4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27324099&form=6&db=m Intracellular and extracellular pH dynamics in the human placenta from diabetes mellitus. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27776253&form=6&db=m Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29710485&form=6&db=m Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus. causal interaction,unassigned 1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30873661&form=6&db=m Endothelial HNF4? potentiates angiogenic dysfunction via enhancement of vascular endothelial growth factor resistance in T2DM. diagnostic usage,unassigned 3,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33478293&form=6&db=m Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33761732&form=6&db=m Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34131781&form=6&db=m Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1315991&form=6&db=m Reduced guanine nucleotide-stimulated polyphosphoinositide specific phospholipase C in platelet hyperaggregation in IDDM. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2144055&form=6&db=m Primary platelet activation in recent-onset type 1 diabetes mellitus. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2548908&form=6&db=m Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM. causal interaction,unassigned 1,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976649&form=6&db=m Acute changes in blood glucose concentration do not promote thrombin generation or fibrin breakdown in type 1 diabetes. therapeutic application,unassigned 2,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8339853&form=6&db=m Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8508616&form=6&db=m Thrombin generation and factor VIII:C levels in patients with type 1 diabetes complicated by nephropathy. diagnostic usage,unassigned 2,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065996&form=6&db=m Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9258280&form=6&db=m Increased intracellular calcium and altered phorbol dibutyrate binding to intact platelets in young subjects with insulin-dependent and non-insulin-dependent diabetes mellitus. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9392498&form=6&db=m Altered platelet membrane dynamic properties in type 1 diabetes. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14652638&form=6&db=m Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM. unassigned - 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16801088&form=6&db=m Do determinants of platelet function co-segregate with genetic markers of type 1 diabetes mellitus? unassigned - 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19069453&form=6&db=m [Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy] diagnostic usage,unassigned 1,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19422461&form=6&db=m Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20837908&form=6&db=m Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus. ongoing research,unassigned 4,0 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27776253&form=6&db=m Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.5 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32691481&form=6&db=m Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children. causal interaction,unassigned 3,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1149944&form=6&db=m Antifibrin action of phenformin. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7599351&form=6&db=m Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8606265&form=6&db=m Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9258280&form=6&db=m Increased intracellular calcium and altered phorbol dibutyrate binding to intact platelets in young subjects with insulin-dependent and non-insulin-dependent diabetes mellitus. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10077454&form=6&db=m Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10331423&form=6&db=m Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11020468&form=6&db=m Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17785358&form=6&db=m Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,1 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17957564&form=6&db=m Platelet free cytosolic calcium concentration during ageing of type 2 diabetic patients. causal interaction,unassigned 1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18302528&form=6&db=m Carbonylation of platelet proteins occurs as consequence of oxidative stress and thrombin activation, and is stimulated by ageing and type 2 diabetes. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228864&form=6&db=m Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20640482&form=6&db=m Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21078616&form=6&db=m The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21955218&form=6&db=m Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24306139&form=6&db=m Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,2 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25052834&form=6&db=m Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25928628&form=6&db=m Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27187380&form=6&db=m Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients. ongoing research,unassigned 4,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27396242&form=6&db=m Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27776253&form=6&db=m Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29710485&form=6&db=m Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus. causal interaction,unassigned 1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32588382&form=6&db=m Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441513&form=6&db=m Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33529332&form=6&db=m Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes. ongoing research,unassigned 1,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34077393&form=6&db=m The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes. diagnostic usage,unassigned 2,0 3.4.21.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34131781&form=6&db=m Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Diabetes, Gestational http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31311294&form=6&db=m Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Diabetic Angiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2776651&form=6&db=m Increased intraglomerular thrombin formation in diabetic microangiopathy. causal interaction,unassigned 2,0 3.4.21.5 Diabetic Angiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2783675&form=6&db=m Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.5 Diabetic Angiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3319468&form=6&db=m Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Diabetic Foot http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17244316&form=6&db=m Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. therapeutic application,unassigned 2,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2148199&form=6&db=m [Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14682222&form=6&db=m [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy] causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19401193&form=6&db=m Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis. unassigned - 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21566100&form=6&db=m Thrombin and diabetic nephropathy. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21955218&form=6&db=m Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27733370&form=6&db=m Protease-activated receptors in kidney disease progression. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32709711&form=6&db=m Podocyte Integrin-?3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy. therapeutic application,unassigned 1,0 3.4.21.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441513&form=6&db=m Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Diabetic Neuropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31276565&form=6&db=m The role of thrombin in the pathogenesis of diabetic neuropathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2927890&form=6&db=m Intermittent intraocular thrombin as an adjunct to vitrectomy. unassigned - 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3703495&form=6&db=m The use of intravitreal thrombin to control hemorrhage during vitrectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7123542&form=6&db=m Plasma soluble fibrin monomer complexes in the development of diabetic retinopathy. unassigned - 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8606265&form=6&db=m Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20435588&form=6&db=m High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment. unassigned - 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26305236&form=6&db=m Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27261371&form=6&db=m Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. ongoing research,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=75159&form=6&db=m [Use of partial thromboplastin time and thrombin time in the diagnosis of disseminated intravascular coagulation] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=118542&form=6&db=m Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=365218&form=6&db=m Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. therapeutic application,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=434223&form=6&db=m Lack of fibrin formation in exercise-induced activation of coagulation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=462421&form=6&db=m Plasma thrombin assay using a chromogenic substrate in disseminated intravascular coagulation due to snake bite envenomation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=503267&form=6&db=m Effect of beta-adrenergic blockade by propranolol upon intravascular coagulation in the rat kidney. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=540036&form=6&db=m Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma. ongoing research,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=603216&form=6&db=m Coagulation disorders in severely and critically injured patients. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=849773&form=6&db=m [Experimental studies on disseminated intravascular coagulation (author's transl)] unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=918899&form=6&db=m The influence of durgs on disseminated intravascular coagulation (DIC). II. Effects of naturally occurring and synthetic thrombin inhibitors. therapeutic application,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=950176&form=6&db=m The appearance of schistocytes in the peripheral blood in correlation to the degree of disseminated intravascular coagulation. An experimental study in rats. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1002004&form=6&db=m Rat liver macrophages will not phagocytose fibrin during disseminated intravascular coagulation. ongoing research,unassigned 2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1028590&form=6&db=m [Effect of 4-amidinophenylpyruvic acid on the generalized Sanarelli-Shwartzman phenomenon] ongoing research,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1091153&form=6&db=m Effects of intravascular clotting on the activation of the complement system: The role of the platelet. therapeutic application,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1148085&form=6&db=m Thrombin-induced disseminated intravascular coagulation in the dog. I: Demonstration of microthrombi in lung. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1148086&form=6&db=m Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1198409&form=6&db=m Studies in experimental animals on disseminated intravascular coagulation (DIC). therapeutic application,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1282866&form=6&db=m Disseminated intravascular coagulation. Approach to treatment. causal interaction,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1329405&form=6&db=m Hematological parameters and visceral lesions relationships in rabbit viral hemorrhagic disease. diagnostic usage,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1468720&form=6&db=m Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1574711&form=6&db=m Pathways of coagulation/fibrinolysis activation in malignancy. causal interaction,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1601644&form=6&db=m Massive pulmonary embolism presenting as disseminated intravascular coagulation. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1689102&form=6&db=m Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1691327&form=6&db=m [Mathematical assessment of the blood prothrombinase-thrombin activity by the autocoagulation test] causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719808&form=6&db=m Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1754855&form=6&db=m Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1776888&form=6&db=m Enhanced thrombin generation in patients receiving intensive care. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1803613&form=6&db=m Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1884620&form=6&db=m Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. therapeutic application,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1894189&form=6&db=m Hirudin in disseminated intravascular coagulation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1894198&form=6&db=m Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. therapeutic application,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1944144&form=6&db=m [Disseminated intravascular coagulation in the early stage after severe burn: the role of excessive thrombin generation] causal interaction,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1951313&form=6&db=m Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2129128&form=6&db=m Localization of tissue plasminogen activator on experimental thrombi in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2206823&form=6&db=m Disseminated intravascular coagulation and bacterial infections in the elderly. diagnostic usage,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2479264&form=6&db=m Thrombin generation in patients with thrombotic thrombocytopenic purpura. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2747858&form=6&db=m The incidence and significance of hemostatic abnormalities in patients with head injuries. diagnostic usage,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2941007&form=6&db=m New approaches for the detection of early activation products in thrombotic states. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3086470&form=6&db=m Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3104578&form=6&db=m Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis. therapeutic application,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3425309&form=6&db=m Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome. diagnostic usage,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3428717&form=6&db=m Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3537068&form=6&db=m Disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3603410&form=6&db=m Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3835286&form=6&db=m [Effect of MD-805, a synthetic thrombin inhibitor, on disseminated intravascular coagulation developing in hematological disorders] therapeutic application,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3988169&form=6&db=m [Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4156098&form=6&db=m Effects of alpha and beta receptor stimulating and blocking agents on experimental disseminated intravascular coagulation. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4281540&form=6&db=m Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4777267&form=6&db=m [The influence of a synthetic thrombin inhibitor on the disseminated intravascular coagulation in the rabbit (author's transl)] ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5029417&form=6&db=m Hemodynamics of disseminated intravascular coagulation. Effects of intra-aortic thrombin infusions on renal and mesenteric blood flow in the dog. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230075&form=6&db=m Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6333254&form=6&db=m [Activation of the blood kallikrein-kinin system in disseminated intravascular coagulation in rats. The significance of the pulmonary component and an attempt at correction with aspirin] unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6354132&form=6&db=m The role of Kupffer's cells in disseminated intravascular coagulation. A morphologic study in thrombin-infused rabbits. ongoing research,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6439471&form=6&db=m Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. therapeutic application,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6592007&form=6&db=m Thrombin generation in acute promyelocytic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6721249&form=6&db=m Microvascular alterations in thrombin-induced experimental disseminated intravascular coagulation in the dog. ongoing research,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6727275&form=6&db=m [Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma] causal interaction,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6737775&form=6&db=m Effects of prolonged poisoning by Russell's viper venom on blood coagulation, platelets and fibrinolysis. diagnostic usage,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6839984&form=6&db=m [Thrombocytopenia and disseminated intravascular coagulation in low-dose heparin prophylaxis] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489960&form=6&db=m Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686692&form=6&db=m Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7720338&form=6&db=m Thrombin does not alter vascular hyporeactivity in models of endotoxin-induced septic shock in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7747347&form=6&db=m [Relationship between thrombinemia and free radical processes in the blood] ongoing research,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8039760&form=6&db=m Fibrinogen survival and fibrinopeptide A in acute leukemia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8276034&form=6&db=m Effect of platelet on protein degradation in rat skeletal muscle. ongoing research,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8899954&form=6&db=m Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. causal interaction,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8952855&form=6&db=m Plasmatic parameters of coagulation activation in thrombotic microangiopathy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9097085&form=6&db=m Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9233566&form=6&db=m Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366764&form=6&db=m Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9623718&form=6&db=m Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9657433&form=6&db=m Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9723580&form=6&db=m Disseminated intravascular coagulation: clinical and laboratory aspects. causal interaction,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9773406&form=6&db=m The sepsis-coagulant axis: a review. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819023&form=6&db=m Tissue factor expression by monocytes: regulation and pathophysiological roles. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9820705&form=6&db=m High-dose antithrombin III treatment of severely injured patients: results of a prospective study. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9864925&form=6&db=m Acute generalized, widespread bleeding. Diagnosis and management. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10613651&form=6&db=m Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10688831&form=6&db=m Lepirudin blunts endotoxin-induced coagulation activation. therapeutic application,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11143939&form=6&db=m [Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.] causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740686&form=6&db=m Fibrinolysis in disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740689&form=6&db=m Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. diagnostic usage,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12010802&form=6&db=m Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. therapeutic application,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12774341&form=6&db=m Role of DIC in multiple organ failure. causal interaction,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14749872&form=6&db=m [Role of the innate immune response in sepsis] unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15025804&form=6&db=m Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15164604&form=6&db=m [Evaluation of thrombin in urine as a real-time indicator of clotting activation in glomerulonephritis] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15366648&form=6&db=m Disseminated intravascular coagulation associated with aortic dissecting aneurysm. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15471542&form=6&db=m An unusual case of an ulcerative colitis flare resulting in disseminated intravascular coagulopathy and a bladder hematoma: a case report. ongoing research,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613012&form=6&db=m Platelet function in sepsis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15650541&form=6&db=m Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15869787&form=6&db=m A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15878322&form=6&db=m Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15963468&form=6&db=m A prothrombin activator (Lopap) modulating inflammation, coagulation and cell survival mechanisms. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16295470&form=6&db=m Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases. diagnostic usage,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16708116&form=6&db=m Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17235277&form=6&db=m The pathogenesis and management of disseminated intravascular coagulation. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17456623&form=6&db=m Inhibition of thrombin in plasma by heparin or arginine. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17561232&form=6&db=m The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17636194&form=6&db=m Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18067862&form=6&db=m Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria. causal interaction,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18160570&form=6&db=m Coagulation Activation by Lipopolysaccharides. diagnostic usage,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18294351&form=6&db=m Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery. diagnostic usage,unassigned 2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18479738&form=6&db=m Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19584041&form=6&db=m Crosstalk between coagulation and inflammation in mastitis and metritis in dairy cows. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630782&form=6&db=m Vascular and dendritic cell coagulation signaling in sepsis progression. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20102984&form=6&db=m Appropriate use of D-dimer in hospital patients. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21255822&form=6&db=m Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: In vitro effect of thrombin on monocyte CD163 shedding. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21337164&form=6&db=m Coagulation studies. causal interaction,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21415977&form=6&db=m Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. causal interaction,unassigned 4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22268136&form=6&db=m Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22923022&form=6&db=m The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23358225&form=6&db=m Crocetin administration ameliorates endotoxin-induced disseminated intravascular coagulation in rabbits. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23684364&form=6&db=m Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23804232&form=6&db=m Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin. causal interaction,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23954259&form=6&db=m Decreased thrombomodulin mRNA expression on peripheral monocytes in disseminated intravascular coagulation patients relates to poor outcomes: The ex vivo effects of lipopolysaccharide and thrombin on monocyte thrombomodulin and CD14 mRNA. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24675694&form=6&db=m Poor prognosis of hypocoagulability assessed by thrombin generation assay in disseminated intravascular coagulation. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24782510&form=6&db=m Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. ongoing research,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25214765&form=6&db=m Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25467085&form=6&db=m Ex vivo thrombin generation patterns in septic patients with and without disseminated intravascular coagulation. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25994766&form=6&db=m Active but inoperable thrombin is accumulated in a plasma protein layer surrounding Streptococcus pyogenes. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26203764&form=6&db=m Protein Z efficiently depletes thrombin generation in disseminated intravascular coagulation with poor prognosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27276832&form=6&db=m Treatment of Disseminated Intravascular Coagulation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27578502&form=6&db=m Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation. therapeutic application,unassigned 1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27911985&form=6&db=m Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study. diagnostic usage,unassigned 3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28288667&form=6&db=m Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29376305&form=6&db=m [State of homeostasis under administration of bear fat in rats with exogenous and endogenous thrombinemia]. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29968773&form=6&db=m Phospholipase D1 regulation of TNF-alpha protects against responses to LPS. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30453810&form=6&db=m New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30849454&form=6&db=m Elevated plasma levels of hepatocyte growth factor in rats experimentally envenomated with Bothrops jararaca venom: Role of snake venom metalloproteases. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31175488&form=6&db=m Lipopolysaccharide-Induced Hemolysis Is Abolished by Inhibition of Thrombin Generation but Not Inhibition of Platelet Aggregation. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,1,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31346989&form=6&db=m Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32127275&form=6&db=m Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery-Results of a Randomized Controlled Trial. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32722805&form=6&db=m Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33224575&form=6&db=m Cardiovascular risk in COVID-19 infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33410894&form=6&db=m Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation. unassigned - 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34182474&form=6&db=m Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34369427&form=6&db=m Dielectric Blood Coagulometry for the Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Prospective Observational Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34428280&form=6&db=m Disseminated intravascular coagulation and its immune mechanisms. unassigned - 3.4.21.5 Down Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=758215&form=6&db=m Acquired coagulation inhibitor delaying fibrinopeptide release. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Down Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15448146&form=6&db=m Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. unassigned - 3.4.21.5 Down Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16627481&form=6&db=m Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. ongoing research,unassigned 2,0 3.4.21.5 Drug Resistant Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26391563&form=6&db=m Thrombin decreases expression of the glutamate transporter GLAST and inhibits glutamate uptake in primary cortical astrocytes via the Rho kinase pathway. causal interaction,unassigned 4,0 3.4.21.5 Drug-Related Side Effects and Adverse Reactions http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16801109&form=6&db=m Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Drug-Related Side Effects and Adverse Reactions http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28639463&form=6&db=m Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Duodenal Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1582586&form=6&db=m Endoscopic local injection of ethanolamine oleate and thrombin as an effective treatment for bleeding duodenal ulcer: a controlled trial. therapeutic application,unassigned 4,0 3.4.21.5 Duodenal Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9424908&form=6&db=m [Evaluation of using fibrin tissue adhesive (Beriplast) and preparations of thrombin and adrenalin in injection hemostasis methods for gastric and duodenal ulcer hemorrhage. Randomized, prospective clinical trial] ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33761732&form=6&db=m Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Dyspnea http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25922720&form=6&db=m Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Ecchymosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18685441&form=6&db=m Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Ecchymosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33053536&form=6&db=m Comparison of curative effect between different anticoagulation regimens in continuous renal replacement therapy after cardiac valve replacement. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1138817&form=6&db=m Blood coagulation profile in Indian patients with pre-eclampsia and eclampsia. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9597760&form=6&db=m Platelets from eclampsia patients have reduced membrane microviscosity and lower activities of the signalling enzymes. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Edema, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11460520&form=6&db=m Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Ehrlichiosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8890464&form=6&db=m Platelet dysfunction associated with experimental acute canine ehrlichiosis. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Eisenmenger Complex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29802795&form=6&db=m Dual endothelin-1 receptor antagonism attenuates platelet-mediated derangements of blood coagulation in Eisenmenger syndrome. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507362&form=6&db=m Alterations of haemostatic markers in various subtypes and phases of stroke. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21887485&form=6&db=m Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21937274&form=6&db=m Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. causal interaction,unassigned 2,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24063505&form=6&db=m Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25597592&form=6&db=m Individualized antithrombotic therapy. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26420134&form=6&db=m Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). therapeutic application,unassigned 4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116215&form=6&db=m Thrombin Generation in Acute Ischaemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28140308&form=6&db=m [Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay]. causal interaction,unassigned 2,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28373761&form=6&db=m Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29043124&form=6&db=m Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29335786&form=6&db=m Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32247819&form=6&db=m Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity? therapeutic application,unassigned 4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32404035&form=6&db=m Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. therapeutic application,unassigned 3,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33132228&form=6&db=m Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source?- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial. therapeutic application,unassigned 4,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33504190&form=6&db=m Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33588594&form=6&db=m Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34495626&form=6&db=m Embolic Stroke Model with Magnetic Nanoparticles. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1320300&form=6&db=m Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2954258&form=6&db=m Indices of fibrinogen proteolysis and platelet activation during the resolution of pulmonary embolism. therapeutic application,unassigned 1,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3681697&form=6&db=m Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6874470&form=6&db=m Granulocytes mediate the increase in pulmonary vascular permeability after thrombin embolism. causal interaction,unassigned 2,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9199818&form=6&db=m Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10443518&form=6&db=m Intraoperative embolus formation during cardiopulmonary bypass affects the release of S100B. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15151465&form=6&db=m Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619610&form=6&db=m The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15701910&form=6&db=m Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16025234&form=6&db=m Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. therapeutic application,unassigned 3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17258798&form=6&db=m The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19690349&form=6&db=m Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19787562&form=6&db=m New anticoagulants in atrial fibrillation. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19906551&form=6&db=m Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20076850&form=6&db=m Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. therapeutic application,unassigned 3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20345495&form=6&db=m New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21144965&form=6&db=m Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21172721&form=6&db=m Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533567&form=6&db=m Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21956604&form=6&db=m Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21960064&form=6&db=m Preventing cardioembolic stroke in atrial fibrillation with dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22122184&form=6&db=m Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22298812&form=6&db=m The Pharmacology and Therapeutic Use of Dabigatran Etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22417716&form=6&db=m New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22516070&form=6&db=m Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22565859&form=6&db=m [Pharmacology of the new oral anticoagulants]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22595814&form=6&db=m Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22739760&form=6&db=m Dabigatran for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22952215&form=6&db=m Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23160166&form=6&db=m An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. therapeutic application,unassigned 2,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23258203&form=6&db=m [Waiting for the new oral anticoagulants: questions and answers about dabigatran]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23400738&form=6&db=m The pharmacology and therapeutic use of dabigatran etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23466965&form=6&db=m Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23547700&form=6&db=m Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23810130&form=6&db=m Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23818798&form=6&db=m Transitions of care in anticoagulated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24029592&form=6&db=m The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation. unassigned - 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24052915&form=6&db=m A Comparison of Methods for Estimating Glomerular Filtration Rate for a Population in Hawai'i with Non-Valvular Atrial Fibrillation. diagnostic usage,unassigned 3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24231693&form=6&db=m Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24288086&form=6&db=m Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24319080&form=6&db=m Dabigatran Use in the Real World A Multihospital System Experience. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24373340&form=6&db=m Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24378048&form=6&db=m [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24492353&form=6&db=m Increased risk of myocardial infarction with dabigatran: fact or fiction? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24508114&form=6&db=m Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24556890&form=6&db=m Practical aspects of new oral anticoagulant use in atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24614113&form=6&db=m Oral anticoagulants for Asian patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24624626&form=6&db=m [Management of major bleeding complications in patients on long-term treatment with oral anticoagulants]. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24668159&form=6&db=m A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24677203&form=6&db=m Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24734407&form=6&db=m A case of dabigatran-associated acute renal failure. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24813481&form=6&db=m [Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24973113&form=6&db=m Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. unassigned - 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138549&form=6&db=m Dabigatran: patient management in specific clinical settings. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25440361&form=6&db=m Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25830002&form=6&db=m Acute myocardial infarction after switching from warfarin to dabigatran. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26048605&form=6&db=m Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26270886&form=6&db=m Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26452739&form=6&db=m Pradaxa-induced esophageal ulcer. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27465882&form=6&db=m Novel oral anticoagulant management issues for the stroke clinician. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29239808&form=6&db=m Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. causal interaction,unassigned 3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29849330&form=6&db=m Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage. therapeutic application,unassigned 3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29904298&form=6&db=m Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy. therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29975925&form=6&db=m Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30936131&form=6&db=m Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. therapeutic application,unassigned 1,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31005062&form=6&db=m The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31165346&form=6&db=m Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31388437&form=6&db=m Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31537027&form=6&db=m Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. therapeutic application,unassigned 3,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32048978&form=6&db=m A Rare Case Report Of Dabigatran Induced Oral Ulcers. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32247819&form=6&db=m Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity? therapeutic application,unassigned 4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32452286&form=6&db=m Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32689602&form=6&db=m Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. therapeutic application,unassigned 4,0 3.4.21.5 Embolism, Fat http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=603216&form=6&db=m Coagulation disorders in severely and critically injured patients. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395131&form=6&db=m Antithrombin activity of an algal polysaccharide. unassigned - 3.4.21.5 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12594292&form=6&db=m Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24250922&form=6&db=m The effects of trypsin on rat brain astrocyte activation. unassigned - 3.4.21.5 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27397090&form=6&db=m Differential effects on glial activation by a direct versus an indirect thrombin inhibitor. therapeutic application,unassigned 4,0 3.4.21.5 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30018633&form=6&db=m Thrombin Inhibition Reduces the Expression of Brain Inflammation Markers upon Systemic LPS Treatment. therapeutic application,unassigned 4,0 3.4.21.5 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15605378&form=6&db=m Increased thrombin inhibition in experimental autoimmune encephalomyelitis. therapeutic application,unassigned 2,0 3.4.21.5 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17027887&form=6&db=m Thrombin in inflammatory brain diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24740641&form=6&db=m Early detection of thrombin activity in neuroinflammatory disease. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24810631&form=6&db=m Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27478856&form=6&db=m Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo. ongoing research,unassigned 4,0 3.4.21.5 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33411219&form=6&db=m Thrombin generation and activity in multiple sclerosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15605378&form=6&db=m Increased thrombin inhibition in experimental autoimmune encephalomyelitis. therapeutic application,unassigned 2,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17027887&form=6&db=m Thrombin in inflammatory brain diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24740641&form=6&db=m Early detection of thrombin activity in neuroinflammatory disease. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24810631&form=6&db=m Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27478856&form=6&db=m Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo. ongoing research,unassigned 4,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30692962&form=6&db=m A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis. ongoing research,unassigned 1,0 3.4.21.5 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33411219&form=6&db=m Thrombin generation and activity in multiple sclerosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Encephalopathy, Bovine Spongiform http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395131&form=6&db=m Antithrombin activity of an algal polysaccharide. unassigned - 3.4.21.5 Endemic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665393&form=6&db=m Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. unassigned - 3.4.21.5 Endocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10193740&form=6&db=m The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11090397&form=6&db=m CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair. unassigned - 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743570&form=6&db=m Colonic necrosis subsequent to catheter-directed thrombin embolization of the inferior mesenteric artery via the superior mesenteric artery: a complication in the management of a type II endoleak. therapeutic application,unassigned 2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12835992&form=6&db=m Successful treatment of a type-II endoleak with percutaneous CT-guided thrombin injection in a patient after endovascular abdominal aortic aneurysm repair. therapeutic application,unassigned 4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14712380&form=6&db=m Ischemic colitis following translumbar thrombin injection for treatment of endoleak. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14748629&form=6&db=m AneuRx stent-graft failure four years after TAA exclusion. unassigned - 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753310&form=6&db=m The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14760606&form=6&db=m Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac. therapeutic application,unassigned 4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15322573&form=6&db=m EVAR: critical applied aortic morphology relevant to type-II endoleaks following device enhancement in patients with abdominal aortic aneurysms. unassigned - 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15345000&form=6&db=m Direct thrombin injection into aneurysmal sac in a patient with a type II endoleak. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15772728&form=6&db=m Percutaneous ultrasound-guided thrombin injection for endoleaks: an alternative. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16187152&form=6&db=m Percutaneous ultrasound-guided thrombin injection of endoleaks. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17484533&form=6&db=m Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17924731&form=6&db=m Strategies to Reduce the Rate of Type II Endoleaks: Routine Intraoperative Embolization of the Inferior Mesenteric Artery and Thrombin Injection Into the Aneurysm Sac. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,2 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19238645&form=6&db=m [Transarterial occlusion of type 1 endoleak of the aortic arch by coil embolization and thrombin injection after endovascular therapy of retrograde Stanford A dissection] therapeutic application,unassigned 3,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22328619&form=6&db=m A case of hybrid repair of ruptured abdominal aortic aneurysm with use of thrombin for acute treatment of type II endoleak. therapeutic application,unassigned 4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23184247&form=6&db=m [Endovascular treatment of abdominal aortic aneurysms: 6 years of experience at a single centre.] ongoing research,unassigned 2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23592808&form=6&db=m Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion. therapeutic application,unassigned 2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24356053&form=6&db=m Type II endoleak: a problem to be solved. therapeutic application,unassigned 4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25862362&form=6&db=m Inexplicable late type Ia endoleak associated with the low-profile Ovation endograft in a patient with favorable neck anatomy: treatment with transcaval coil embolization. unassigned - 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28787245&form=6&db=m Laser-assisted transprosthesial coil embolization combined with thrombin injection for treatment of an endoleak type II after endovascular aneurysm repair. therapeutic application,unassigned 4,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30655925&form=6&db=m Percutaneous direct thrombin injection with hydrodissection to manage type II endoleak after endovascular abdominal aortic aneurysm repair. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30905367&form=6&db=m Transcaval embolization as the preferred approach. ongoing research,unassigned 2,0 3.4.21.5 Endoleak http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31890070&form=6&db=m Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9701694&form=6&db=m Transient increase in thrombin generation during radiotherapy of uterine carcinoma: A preliminary study using thrombin-antithrombin III complex measurements. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26916311&form=6&db=m Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33217600&form=6&db=m Application of thrombin gel matrix for the prevention of lymphocele in patients with endometrial cancer: A prospective randomized trial. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15755869&form=6&db=m Possible involvement of thrombin/protease-activated receptor 1 system in the pathogenesis of endometriosis. unassigned - 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18936546&form=6&db=m Novel therapeutic strategies for endometriosis: a pathophysiological perspective. causal interaction,unassigned 4,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26912000&form=6&db=m The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28681683&form=6&db=m Coagulation Status in Women With Endometriosis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29880183&form=6&db=m Chemical pleurodesis with autologous blood and freeze-dried concentrated human thrombin improved spontaneous pneumothorax and thoracic endometriosis: The first case involving a pregnant woman. therapeutic application,unassigned 1,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32784640&form=6&db=m Assessment of Coagulation Parameters in Women Affected by Endometriosis: Validation Study and Systematic Review of the Literature. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33966422&form=6&db=m Noninvasive evaluation of ovarian endometriosis: a single-center experience. diagnostic usage,unassigned 4,0 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33983443&form=6&db=m Endometrial epithelial-mesenchymal transition (EMT) by menstruation-related inflammatory factors during hypoxia. unassigned - 3.4.21.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34001444&form=6&db=m Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation. causal interaction,unassigned 3,0 3.4.21.5 Endophthalmitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8610806&form=6&db=m Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10993801&form=6&db=m Thrombin and leukocyte recruitment in endotoxemia. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12362234&form=6&db=m Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483060&form=6&db=m Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483072&form=6&db=m Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12750166&form=6&db=m Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14597986&form=6&db=m Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. ongoing research,unassigned 3,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14652636&form=6&db=m Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. diagnostic usage,unassigned 4,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118518&form=6&db=m Human models of endotoxemia and recombinant human activated protein C. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16168073&form=6&db=m Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. therapeutic application,unassigned 4,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16413239&form=6&db=m Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16529602&form=6&db=m Bacterial endotoxin as inhibitor of the enzymatic activity of human thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17068159&form=6&db=m Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630786&form=6&db=m The many faces of tissue factor. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20149415&form=6&db=m Tissue factor expression in blood cells. causal interaction,unassigned 3,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20519970&form=6&db=m Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia. unassigned - 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20601223&form=6&db=m Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats. diagnostic usage,unassigned 2,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20858853&form=6&db=m An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26369367&form=6&db=m A novel fibrinogenase from Agkistrodon acutus venom protects against LPS-induced endotoxemia via regulating NF-?B pathway. therapeutic application,unassigned 2,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27403788&form=6&db=m Low-grade endotoxemia and clotting activation in the early phase of pneumonia. causal interaction,unassigned 3,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28839178&form=6&db=m Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs. diagnostic usage,unassigned 1,0 3.4.21.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30584841&form=6&db=m The influence of hypoxia on platelet function and plasmatic coagulation during systemic inflammation in humans in vivo. unassigned - 3.4.21.5 Enterocolitis, Necrotizing http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Enterocolitis, Necrotizing http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32366656&form=6&db=m Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Eosinophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26540111&form=6&db=m Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia. therapeutic application,unassigned 1,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9423797&form=6&db=m Thrombin and its precursor in human cerebrospinal fluid. causal interaction,unassigned 4,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15334192&form=6&db=m New developments in the treatment of neurological diseases. therapeutic application,unassigned 4,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21893397&form=6&db=m Extracellular proteases in epilepsy. causal interaction,unassigned 3,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23467310&form=6&db=m Treating seizures and epilepsy with anticoagulants? causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25992517&form=6&db=m Lack of association between the prothrombin rs1799963 polymorphism and juvenile myoclonic epilepsy. causal interaction,unassigned 3,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27295570&form=6&db=m An electrochemical aptasensor based on TiO2/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343583&form=6&db=m Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30391321&form=6&db=m Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Epilepsy, Temporal Lobe http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30391321&form=6&db=m Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3703495&form=6&db=m The use of intravitreal thrombin to control hemorrhage during vitrectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9002129&form=6&db=m Thrombin in the management of full thickness macular holes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.5 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20435588&form=6&db=m High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment. unassigned - 3.4.21.5 Epistaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9157594&form=6&db=m Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Epistaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12541471&form=6&db=m [The determination of activated partial thromboplastin time, coagulate time and thrombin time in patients with epistaxis of indeterminate cause] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Epistaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13231211&form=6&db=m [Injury of internal carotid with uncontrollable epistaxis, cured by intra-arterial thrombin injection; with an experimental contribution.] therapeutic application,unassigned 1,0 3.4.21.5 Epistaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18685441&form=6&db=m Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Epistaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23266225&form=6&db=m A novel mutation in the FGB: c.1105C>T turns the codon for amino acid B? Q339 into a stop codon causing hypofibrinogenemia. therapeutic application,unassigned 1,0 3.4.21.5 Epistaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28821888&form=6&db=m Risk factors for epistaxis in patients followed in general practices in Germany. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Erythema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012979&form=6&db=m Thrombin generation as a predictor of radiotherapy induced skin erythema. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,4 3.4.21.5 Erythromelalgia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883266&form=6&db=m Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719808&form=6&db=m Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1920861&form=6&db=m [Clinical usefulness of the measurement of plasma D-dimer levels] causal interaction,unassigned 3,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2227247&form=6&db=m Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2666352&form=6&db=m [Diagnosis and therapy of gastrointestinal hemorrhage] causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3201893&form=6&db=m Pathophysiology of shock and DIC complicating endoscopic embolization with thrombin for esophageal varices. unassigned - 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3501025&form=6&db=m [Clinical study on coagulation, fibrinolysis, and complement systems after endoscopic injection sclerotherapy of esophageal varices with human thrombin] diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3504050&form=6&db=m Sclerotherapy of esophageal varices by consecutive injection of anhydrous ethanol: 1% polydocanol and thrombin. therapeutic application,unassigned 2,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3712779&form=6&db=m [Pathology of shock accompanying endoscopic embolization of esophageal varices using thrombin] unassigned - 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4057591&form=6&db=m [Pathology and treatment of shock and DIC which complicate endoscopic embolization of esophageal varices with thrombin] therapeutic application,unassigned 4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6978620&form=6&db=m Injection sclerotherapy of esophageal varices using ethanolamine oleate. therapeutic application,unassigned 1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7084644&form=6&db=m Absence of disseminated intravascular coagulation with endoscopic sclerosis of esophageal varices. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7797110&form=6&db=m Recent advances in the endoscopic management of variceal bleeding. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7959239&form=6&db=m Thrombin--an effective treatment for gastric variceal haemorrhage. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807700&form=6&db=m The management of variceal bleeding. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395749&form=6&db=m Endoscopic treatments for portal hypertension. therapeutic application,unassigned 1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10219838&form=6&db=m Thrombin is effective in arresting bleeding from gastric variceal hemorrhage. therapeutic application,unassigned 4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10643628&form=6&db=m Endoscopic treatments for portal hypertension. therapeutic application,unassigned 1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12094854&form=6&db=m Endoscopic use of human thrombin in bleeding gastric varices. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12895210&form=6&db=m Review article: the management of acute variceal bleeding. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18534583&form=6&db=m The use of thrombin injections in the management of bleeding gastric varices: a single-center experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24892515&form=6&db=m Outcomes of endoscopic human thrombin injection in the management of gastric varices. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30196518&form=6&db=m Role and safety of human thrombin injection for the treatment of bleeding gastric varices. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33196506&form=6&db=m Preservation of thrombin generation in cirrhosis despite abnormal results of international normalized ratio: implications for invasive procedures. diagnostic usage,unassigned 1,0 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33669257&form=6&db=m Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,4 3.4.21.5 Esophageal and Gastric Varices http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33728506&form=6&db=m Safety and Efficacy of Thrombin for Bleeding Gastric Varices: A Systematic Review and Meta-Analysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.5 Esophageal Perforation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28638430&form=6&db=m Treatment of Esophageal Perforation with Primary Closure and Reinforcement Using TachoSil. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Esophageal Squamous Cell Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22685255&form=6&db=m Effect of thrombin receptor expression on microvessel endothelial cells, and survival by coagulation state in oesophageal squamous cell carcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Esophageal Squamous Cell Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26469700&form=6&db=m Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2318520&form=6&db=m Platelet phospholipase C activity in salt-dependent hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2338678&form=6&db=m Basal and stimulated cytosolic platelet calcium in essential hypertension. causal interaction,unassigned 1,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2510665&form=6&db=m [Phospholipase C hypersensitivity in hypertensive rats results from innate and acquired factors] causal interaction,unassigned 4,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3098837&form=6&db=m Platelets in human essential hypertension: in vitro hyperreactivity to thrombin. ongoing research,unassigned 4,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8089832&form=6&db=m Effect of antihypertensive treatment on intracellular calcium concentration and intracellular pH in essential hypertension. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112658&form=6&db=m Prothrombin activation fragment 1 + 2 and thrombin-antithrombin-III complexes in plasma of patients with essential arterial hypertension. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11090789&form=6&db=m Inhibition of platelet aggregability by losartan in essential hypertension. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11408749&form=6&db=m Increased indexes of thrombin activation in advanced stages of hypertension. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Eye Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18636965&form=6&db=m PKC isoenzymes differentially modulate the effect of thrombin on MAPK-dependent RPE proliferation. causal interaction,unassigned 1,0 3.4.21.5 Eye Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20672289&form=6&db=m Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation. diagnostic usage,unassigned 1,0 3.4.21.5 Eye Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22300615&form=6&db=m Thrombin stimulates stress fiber assembly in RPE cells by PKC/CPI-17-mediated MLCP inactivation. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Eye Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32860953&form=6&db=m Thrombin-activated PAR1 membrane expression is regulated by Rab11a-RCP complex dissociation. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Eye Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2238322&form=6&db=m [Use of thrombin in the prevention and arrest of intraocular hemorrhage during vitrectomy in traumatic hemophthalmos] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.5 Eye Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3041323&form=6&db=m [Results of the surgical treatment of eye injuries complicated by hemophthalmos, using thrombin] therapeutic application,unassigned 4,0 3.4.21.5 Eye Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3041323&form=6&db=m [Results of the surgical treatment of eye injuries complicated by hemophthalmos, using thrombin] therapeutic application,unassigned 4,0 3.4.21.5 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10097809&form=6&db=m Acquired factor V inhibitors. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19861681&form=6&db=m Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20182366&form=6&db=m Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient. causal interaction,unassigned 3,0 3.4.21.5 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21320286&form=6&db=m Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma. causal interaction,unassigned 3,0 3.4.21.5 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26346326&form=6&db=m Refractory Epistaxis due to Severe Factor V Deficiency with Inhibitor. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32250000&form=6&db=m Thrombin generation assay is a useful pre-operative tool to predict non-bleeding risk in a patient with mild factor V deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Factor VII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20632246&form=6&db=m Recombinant activated factor VII: mechanisms of action and current indications. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Factor VII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015059&form=6&db=m Recombinant activated factor VII in clinical practice: a 2014 update. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Factor X Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6372111&form=6&db=m Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Factor X Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585046&form=6&db=m Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity. causal interaction,unassigned 3,0 3.4.21.5 Factor X Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19204776&form=6&db=m Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Factor X Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22008904&form=6&db=m Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry. causal interaction,unassigned 3,0 3.4.21.5 Factor X Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23664564&form=6&db=m Six novel missense mutations causing factor X deficiency and application of thrombin generation test. causal interaction,unassigned 2,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3629878&form=6&db=m Identification of factor XI deficiency in Holstein-Friesian cattle in Britain. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7730123&form=6&db=m Factor XI deficiency in Kerry Blue Terriers. causal interaction,unassigned 4,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9139250&form=6&db=m [Thrombocyte dysfunction in children with albinism] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9616154&form=6&db=m Blood coagulation in hemophilia A and hemophilia C. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20398070&form=6&db=m Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26160656&form=6&db=m The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. causal interaction,unassigned 4,0 3.4.21.5 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29497672&form=6&db=m Anesthetic management using peripheral nerve block in patients with factor XI deficiency: a case report. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Factor XII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11597947&form=6&db=m Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Factor XIII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18277134&form=6&db=m Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Factor XIII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27902939&form=6&db=m Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement. causal interaction,unassigned 2,0 3.4.21.5 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2394005&form=6&db=m Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9877507&form=6&db=m Plasma coagulation profiles in patients with severe primary pulmonary hypertension. unassigned - 3.4.21.5 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21384745&form=6&db=m Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension. ongoing research,unassigned 2,0 3.4.21.5 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24744867&form=6&db=m Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14584854&form=6&db=m Comparison of the coagulation profile of fatty liver haemorrhagic syndrome-susceptible laying hens and normal laying hens. unassigned - 3.4.21.5 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20008134&form=6&db=m Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,1 3.4.21.5 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22841818&form=6&db=m Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138021&form=6&db=m Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28737512&form=6&db=m Thrombin promotes diet-induced obesity through fibrin-driven inflammation. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Febrile Neutropenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929114&form=6&db=m Thrombin generation in children with febrile neutropenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Fetal Death http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19736615&form=6&db=m Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Fetal Death http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25854178&form=6&db=m The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications. unassigned - 3.4.21.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4002923&form=6&db=m [Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17264954&form=6&db=m Thrombin activation of endometrial endothelial cells: a possible role in intrauterine growth restriction. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22138583&form=6&db=m Placental syndecan expression is altered in human idiopathic fetal growth restriction. causal interaction,unassigned 1,0 3.4.21.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25854178&form=6&db=m The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications. unassigned - 3.4.21.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29296764&form=6&db=m Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins. causal interaction,unassigned 4,0 3.4.21.5 Fibroma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20996004&form=6&db=m Fibrin foam and thrombin as used in the surgical removal of a large fibromyxoma of the mandible. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1281156&form=6&db=m Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2446997&form=6&db=m The interaction between fibrinogen and 3H-arginine labelled proteins derived from fibrosarcoma in the presence of thrombin. ongoing research,unassigned 2,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3053360&form=6&db=m The interaction between fibrinogen and 3H-L-arginine cationic peptides derived from fibrosarcoma in the presence of thrombin. ongoing research,unassigned 1,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6127164&form=6&db=m Regulation of prostaglandin synthesis mediated by thrombin and B2 bradykinin receptors in a fibrosarcoma cell line. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6683249&form=6&db=m Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,3 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692450&form=6&db=m Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12466243&form=6&db=m Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12855585&form=6&db=m Generation and role of angiostatin in human platelets. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Folic Acid Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9367351&form=6&db=m Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. unassigned - 3.4.21.5 Foot Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17244316&form=6&db=m Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. therapeutic application,unassigned 2,0 3.4.21.5 Fournier Gangrene http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30834105&form=6&db=m Low thrombin tissue sealant ARTISS (Baxter), in complex primary closure after Fournier's gangrene. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Gastritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15274665&form=6&db=m Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Gastrointestinal Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14847076&form=6&db=m Gelfoam and thrombin in treatment of massive upper gastrointestinal hemorrhage. therapeutic application,unassigned 4,0 3.4.21.5 Gastrointestinal Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15397541&form=6&db=m Thrombin in the control of upper gastrointestinal hemorrhage; report of three cases. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Gastrointestinal Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25918557&form=6&db=m Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran. therapeutic application,unassigned 1,0 3.4.21.5 Gastrointestinal Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30988720&form=6&db=m Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Gastroparesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32320636&form=6&db=m Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control. causal interaction,unassigned 3,0 3.4.21.5 Genetic Diseases, Inborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8183895&form=6&db=m Glycoprotein IIb-IIIa and the translocation of Rap2B to the platelet cytoskeleton. ongoing research,unassigned 1,0 3.4.21.5 Genetic Diseases, Inborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14693325&form=6&db=m Hypercoagulability in sickle cell disease: a curious paradox. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Genetic Diseases, Inborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30206474&form=6&db=m Two successful cases of DIEP flaps for breast reconstruction in patients with Factor V Leiden. causal interaction,unassigned 4,0 3.4.21.5 Genital Diseases, Female http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2717986&form=6&db=m Wound hematoma: prophylaxis with topical thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2992771&form=6&db=m Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines. ongoing research,unassigned 3,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8077213&form=6&db=m Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid beta-protein precursor. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9559943&form=6&db=m Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10421070&form=6&db=m PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10686592&form=6&db=m Meizothrombin, an intermediate of prothrombin activation, stimulates human glioblastoma cells by interaction with PAR-1-type thrombin receptors. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11352644&form=6&db=m A novel PAR-1-type thrombin receptor signaling pathway: cyclic AMP-independent activation of PKA in SNB-19 glioblastoma cells. unassigned - 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15975137&form=6&db=m The role of thrombin in gliomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17470200&form=6&db=m Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23204518&form=6&db=m Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. unassigned - 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24620969&form=6&db=m Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24790104&form=6&db=m The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25691153&form=6&db=m Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26459764&form=6&db=m Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation. ongoing research,unassigned 2,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27600331&form=6&db=m Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30619047&form=6&db=m A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30649824&form=6&db=m Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1973084&form=6&db=m Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro. ongoing research,unassigned 2,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2161346&form=6&db=m Thrombin reverts the beta-adrenergic agonist-induced morphological response in rat glioma C6 cells. ongoing research,unassigned 2,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7669979&form=6&db=m [Ca2+]i oscillations in single rat glioma cells induced by thrombin through activation of cell surface receptors. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8456423&form=6&db=m Protease nexin 1 is expressed in the human placenta. ongoing research,unassigned 3,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8978498&form=6&db=m Signaling effects of alpha-thrombin and SFLLRN in rat glioma C6 cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9010429&form=6&db=m Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9064647&form=6&db=m Activity of protein kinase C is necessary for sustained thrombin-induced [Ca2+]i oscillations in rat glioma cells. therapeutic application,unassigned 1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9413947&form=6&db=m Thrombin has a bimodal effect on glioma cell growth. ongoing research,unassigned 4,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10447240&form=6&db=m Investigation of PAR-1-type thrombin receptors in rat glioma C6 cells with a novel monoclonal anti-PAR-1 antibody (Mab COR7-6H9). ongoing research,unassigned 3,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10896200&form=6&db=m Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11701759&form=6&db=m Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells. unassigned - 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956584&form=6&db=m The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753495&form=6&db=m A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15975137&form=6&db=m The role of thrombin in gliomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16143343&form=6&db=m Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16409493&form=6&db=m More on: The role of thrombin in gliomas. ongoing research,unassigned 2,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16463890&form=6&db=m Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16839352&form=6&db=m On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. causal interaction,unassigned 1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17958740&form=6&db=m Thrombin-induced cell proliferation and platelet-derived growth factor-AB release from A172 human glioblastoma cells. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19108760&form=6&db=m Thrombin up-regulates vascular endothelial growth factor in experimental gliomas. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19388346&form=6&db=m Thrombin enhances glioma growth. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21994479&form=6&db=m Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23564130&form=6&db=m Protease activated receptor-1 and brain edema formation in glioma models. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24620969&form=6&db=m Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25691153&form=6&db=m Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27041573&form=6&db=m Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. therapeutic application,unassigned 1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29322662&form=6&db=m Reply to more on: the role of thrombin in gliomas. ongoing research,unassigned 1,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29322670&form=6&db=m More on: the role of thrombin in gliomas. ongoing research,unassigned 2,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32507767&form=6&db=m Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation. causal interaction,unassigned 4,0 3.4.21.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33947134&form=6&db=m Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1464028&form=6&db=m [Extracapillary glomerulonephritis with fibrin deposits. Role of thrombin] therapeutic application,unassigned 1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1846634&form=6&db=m Thrombin increases proliferation and decreases fibrinolytic activity of kidney glomerular epithelial cells. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2125090&form=6&db=m Thrombin regulates components of the fibrinolytic system in human mesangial cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2256477&form=6&db=m Coagulation factors in nephrotic syndrome. therapeutic application,unassigned 1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7856719&form=6&db=m Constitutive expression and modulation of the functional thrombin receptor in the human kidney. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9102146&form=6&db=m [Role of thrombin and its receptor in the pathogenesis of severe forms of human glomerulonephritis with fibrin deposits] ongoing research,unassigned 2,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9518426&form=6&db=m [Affinity sorbents with tripeptide morpholine ligands for isolation of proteases] diagnostic usage,unassigned 3,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9844159&form=6&db=m Role of thrombin in mesangial proliferative glomerulonephritis. unassigned - 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10739796&form=6&db=m Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11522858&form=6&db=m Cultured rat glomerular epithelial cells show gene expression and production of transforming growth factor-beta: expression is enhanced by thrombin. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12654066&form=6&db=m Endothelin-1 in children with acute poststreptococcal glomerulonephritis and hypertension. causal interaction,unassigned 3,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15025804&form=6&db=m Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15164604&form=6&db=m [Evaluation of thrombin in urine as a real-time indicator of clotting activation in glomerulonephritis] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17469034&form=6&db=m Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25742509&form=6&db=m Urinary thrombin: a novel marker of glomerular inflammation for the diagnosis of crescentic glomerulonephritis (prospective observational study). causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26397418&form=6&db=m Nanostructured bioluminescent sensor for rapidly detecting thrombin. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27733370&form=6&db=m Protease-activated receptors in kidney disease progression. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11107640&form=6&db=m [The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Goiter http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9621649&form=6&db=m [The use of the new biological adhesive preparation fibrin polymer in thyroid surgery] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=315978&form=6&db=m Fibrin deposition and clearance in chronic granulomatous inflammation: correlation with T-cell function and proteinase inhibitor activity in tissue. therapeutic application,unassigned 3,0 3.4.21.5 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27275592&form=6&db=m The collagen, fibrinogen and thrombin biological adhesive is effective in treating experimental liver injuries. unassigned - 3.4.21.5 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27679945&form=6&db=m Collagen, fibrinogen and thrombin biological addesive is effective in treating experimental liver injuries. unassigned - 3.4.21.5 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33458623&form=6&db=m PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Granulomatosis with Polyangiitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26540111&form=6&db=m Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia. therapeutic application,unassigned 1,0 3.4.21.5 Gray Platelet Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3359044&form=6&db=m Immunocytochemical localization of fibrinogen during thrombin-induced aggregation of washed human platelets. ongoing research,unassigned 2,0 3.4.21.5 Gray Platelet Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3580300&form=6&db=m Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 3.4.21.5 Gray Platelet Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17137471&form=6&db=m Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives. causal interaction,unassigned 1,0 3.4.21.5 Guillain-Barre Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Hantavirus Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20579693&form=6&db=m Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Head Injuries, Closed http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9474270&form=6&db=m Coagulopathy in acute head injury--a study of its role as a prognostic indicator. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Hearing Loss, Sensorineural http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24690481&form=6&db=m Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. unassigned - 3.4.21.5 Hearing Loss, Sudden http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25966556&form=6&db=m [The correlation analysis of coagulation detection and blood routine parameters of sudden hearing loss]. diagnostic usage,unassigned 4,0 3.4.21.5 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27481496&form=6&db=m Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European Study. therapeutic application,unassigned 4,0 3.4.21.5 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31102491&form=6&db=m Disseminated intravascular coagulation in cardiac arrest and resuscitation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8302075&form=6&db=m Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14698650&form=6&db=m Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17056945&form=6&db=m Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17383385&form=6&db=m Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17915295&form=6&db=m Thrombin generation determined by calibrated automated thrombography (CAT) in pediatric patients with congenital heart disease. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18600087&form=6&db=m Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18958342&form=6&db=m Thrombin generation in paediatric patients with congenital heart disease. Determination by calibrated automated thrombography. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29136561&form=6&db=m Calibrated automated thrombogram values in infants with cardiac surgery before and after cardiopulmonary bypass. causal interaction,unassigned 4,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=52896&form=6&db=m Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2744631&form=6&db=m Fibrinopeptide A levels in patients with acute ischaemic heart disease. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7418178&form=6&db=m The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783668&form=6&db=m Thrombin generation and activation of the thrombomodulin protein C system in open heart surgery depend on the underlying cardiac disease. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11096650&form=6&db=m Low Molecular Weight Heparin and Coronary Intervention. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12668887&form=6&db=m Direct thrombin inhibitors in cardiac disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18778188&form=6&db=m New therapeutic option for thromboembolism--dabigatran etexilate. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26715178&form=6&db=m Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27888761&form=6&db=m Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32485818&form=6&db=m Design, Synthesis and Characterization of Cyclic NU172 Analogues: A Biophysical and Biological Insight. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34042583&form=6&db=m Coagulation parameters may predict clinical outcomes in patients with septic acute kidney injury. diagnostic usage,unassigned 3,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901445&form=6&db=m Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid. therapeutic application,unassigned 3,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8449196&form=6&db=m Platelet function, thrombin and fibrinolytic activity in patients with heart failure. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102593&form=6&db=m American Heart Association scientific sessions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16331363&form=6&db=m [Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.] therapeutic application,unassigned 3,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20864906&form=6&db=m Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23932866&form=6&db=m Anemic comorbidity reduces capacity of endogenous thrombin generation and is associated with consumptive coagulopathy in patients with heart failure. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25072553&form=6&db=m Bivalirudin for treatment of LVAD thrombosis: a case series. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25919061&form=6&db=m Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. causal interaction,unassigned 1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26919336&form=6&db=m Thrombin inhibition during PCI in heart failure patients. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27354285&form=6&db=m Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27479215&form=6&db=m Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy. ongoing research,unassigned 1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28982031&form=6&db=m Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30089551&form=6&db=m Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30146935&form=6&db=m Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30340765&form=6&db=m Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). causal interaction,unassigned 3,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30717886&form=6&db=m A Prothrombotic State in Patients With a History of Left Ventricular Thrombus. diagnostic usage,unassigned 4,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31356557&form=6&db=m Successful COMPASS, disappointing COMMANDER HF, what have we learned from these two trials? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32004876&form=6&db=m High-intensity interval training recuperates capacity of endogenous thrombin generation in heart failure patients with reduced ejection fraction. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Heart Rupture http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9973029&form=6&db=m Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.5 Heart Rupture http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24062924&form=6&db=m Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 HELLP Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10625202&form=6&db=m Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth. causal interaction,unassigned 4,0 3.4.21.5 HELLP Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33081902&form=6&db=m [Change and significance of coagulation function and von Willebrand factor antigen level in HELLP syndrome]. diagnostic usage,unassigned 4,0 3.4.21.5 Hemangioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2550931&form=6&db=m Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin. ongoing research,unassigned 4,0 3.4.21.5 Hemangioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178727&form=6&db=m Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Hemangioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30067324&form=6&db=m [Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma]. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.5 Hemangioma, Cavernous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901445&form=6&db=m Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid. therapeutic application,unassigned 3,0 3.4.21.5 Hemangiosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26336498&form=6&db=m Use of dressing with human fibrin and thrombin during resection of a right atrial angiosarcoma. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Hemangiosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28029283&form=6&db=m Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines. ongoing research,unassigned 3,0 3.4.21.5 Hemarthrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31006077&form=6&db=m Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.5 Hematologic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24128303&form=6&db=m Dissecting the contribution of thrombin exosite I in the recognition of thrombin binding aptamer. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hematologic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28738658&form=6&db=m An ultrasensitive chemiluminescence aptasensor for thrombin detection based on iron porphyrin catalyzing luminescence desorbed from chitosan modified magnetic oxide graphene composite. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25316386&form=6&db=m Thrombin Generation among Sudanese Patients with Hematological Malignancies. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25338593&form=6&db=m [Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies]. diagnostic usage,unassigned 2,0 3.4.21.5 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28840985&form=6&db=m Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30099724&form=6&db=m Elevated extracellular trap formation and contact system activation in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31346989&form=6&db=m Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32443373&form=6&db=m Use of intrapulmonary administration of thrombin in hematological malignancy patients with alveolar haemorrhage: A case series. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,3 3.4.21.5 Hematoma, Subdural http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29972840&form=6&db=m [The use of Idarucizumab in intracerebral bleeding - a case report]. diagnostic usage,unassigned 3,0 3.4.21.5 Hematoma, Subdural http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30591020&form=6&db=m Thrombin contributes to the injury development and neurological deficit after acute subdural hemorrhage in rats only in collaboration with additional blood-derived factors. causal interaction,unassigned 3,0 3.4.21.5 Hematoma, Subdural, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16145537&form=6&db=m Acute subdural hematoma: new model delineation and effects of coagulation inhibitors. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Hematoma, Subdural, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19426108&form=6&db=m Irrigation with thrombin solution reduces recurrence of chronic subdural hematoma in high risk patients. - Preliminary report - causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Hematuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2454021&form=6&db=m [Effect of thrombin on hematuria after operation for benign prostatic hyperplasia] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,4 3.4.21.5 Hematuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14881221&form=6&db=m Thrombin in treatment of hematuria of renal origin. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hematuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17943349&form=6&db=m Postpyelolithotomy renal artery pseudoaneurysm management with percutaneous thrombin injection: a case report. therapeutic application,unassigned 2,0 3.4.21.5 Hematuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214627&form=6&db=m Percutaneous Cyanoacrylate Glue Injection into the Renal Pseudoaneurysm to Control Intractable Hematuria After Percutaneous Nephrolithotomy. therapeutic application,unassigned 1,0 3.4.21.5 Hematuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30880546&form=6&db=m Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hematuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33645436&form=6&db=m Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Hemochromatosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23578325&form=6&db=m The adaptability of red blood cells. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Hemochromatosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25811447&form=6&db=m Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload. diagnostic usage,unassigned 2,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5935364&form=6&db=m Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria. ongoing research,unassigned 2,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6038307&form=6&db=m Paroxysmal nocturnal hemoglobinuria. Mechanism of the enhancement of hemolysis by bovine thrombin. unassigned - 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13560567&form=6&db=m Paroxysmal nocturnal hemoglobinuria: the role of properdin in the diagnostic thrombin test. diagnostic usage,unassigned 4,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13564006&form=6&db=m The mechanism of action of preparations of thrombin on hemolysis of red cells from patients with paroxysmal nocturnal hemoglobinuria. ongoing research,unassigned 4,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13795056&form=6&db=m Highly purified thrombin, esterase thrombin, and the paroxysmal nocturnal hemoglobinuria hemolytic system. therapeutic application,unassigned 1,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13823503&form=6&db=m Thrombin generation and clot retraction studies in paroxysmal nocturnal hemoglobinuria. therapeutic application,unassigned 1,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15434011&form=6&db=m Paroxysmal nocturnal hemoglobinuria; a specific test for the disease based on the ability of thrombin to activate the hemolytic factor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33867725&form=6&db=m Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5935364&form=6&db=m Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria. ongoing research,unassigned 2,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6038307&form=6&db=m Paroxysmal nocturnal hemoglobinuria. Mechanism of the enhancement of hemolysis by bovine thrombin. unassigned - 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13560567&form=6&db=m Paroxysmal nocturnal hemoglobinuria: the role of properdin in the diagnostic thrombin test. diagnostic usage,unassigned 4,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13564006&form=6&db=m The mechanism of action of preparations of thrombin on hemolysis of red cells from patients with paroxysmal nocturnal hemoglobinuria. ongoing research,unassigned 4,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13756212&form=6&db=m [Role of thrombin in the mechanism of hemolysis and nocturnal paroxysmal hemoglobinuria.] unassigned - 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13795056&form=6&db=m Highly purified thrombin, esterase thrombin, and the paroxysmal nocturnal hemoglobinuria hemolytic system. therapeutic application,unassigned 1,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13823503&form=6&db=m Thrombin generation and clot retraction studies in paroxysmal nocturnal hemoglobinuria. therapeutic application,unassigned 1,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15434011&form=6&db=m Paroxysmal nocturnal hemoglobinuria; a specific test for the disease based on the ability of thrombin to activate the hemolytic factor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33867725&form=6&db=m Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Hemolytic-Uremic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1803613&form=6&db=m Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Hemolytic-Uremic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9674202&form=6&db=m [Markers of thrombin generation in kidney failure of children with epidemic hemolytic uremic syndrome] diagnostic usage,unassigned 2,0 3.4.21.5 Hemolytic-Uremic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11777999&form=6&db=m Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Hemolytic-Uremic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12644926&form=6&db=m Cardiac ischemia during hemolytic uremic syndrome. therapeutic application,unassigned 2,0 3.4.21.5 Hemolytic-Uremic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Hemoperitoneum http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29487653&form=6&db=m Ultrasound-guided percutaneous periarterial thrombin injection for paracentesis-related hemoperitoneum. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=617788&form=6&db=m Characteristics and thrombogenicity of factor IX concentrate. causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=667368&form=6&db=m Problems in the detection of carriers of hemophilia A: the influence of stress and thrombin. causal interaction,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1569180&form=6&db=m Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine). causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1973901&form=6&db=m CRM+ haemophilia A due to a missense mutation (372----Cys) at the internal heavy chain thrombin cleavage site. causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2104766&form=6&db=m Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A. ongoing research,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2109644&form=6&db=m Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A. ongoing research,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2499363&form=6&db=m Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A. ongoing research,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2506948&form=6&db=m An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620866&form=6&db=m Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3082349&form=6&db=m Binding of human thrombin to human factor VIII:RAg. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8011517&form=6&db=m Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8052958&form=6&db=m Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8146208&form=6&db=m von Willebrand's disease and hemophilia are associated with diminished thromboxane A2 (TXA2) formation in clotting whole blood. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8647012&form=6&db=m [Hemophilia B in a mixed breed male dog: treatment of a hemorrhagic crisis with fresh frozen plasma] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9376587&form=6&db=m An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9594277&form=6&db=m Detection by denaturing gradient gel electrophoresis of an Arg1689Cys mutation in a Chinese patient with mild hemophilia A. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9616154&form=6&db=m Blood coagulation in hemophilia A and hemophilia C. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10666207&form=6&db=m Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10850557&form=6&db=m Models of blood coagulation. therapeutic application,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11057863&form=6&db=m The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11092210&form=6&db=m The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11547359&form=6&db=m Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11686321&form=6&db=m The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11735103&form=6&db=m The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11806995&form=6&db=m Mechanism of factor VIIa-dependent coagulation in hemophilia blood. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11851753&form=6&db=m Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,1 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12058364&form=6&db=m Effect of factor VIII deficiency on generation of thrombin: a biomechanical approach. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12410647&form=6&db=m Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12487778&form=6&db=m Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12525825&form=6&db=m The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871322&form=6&db=m The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12941038&form=6&db=m An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13034911&form=6&db=m A thrombin generation test; the application in haemophilia and thrombocytopenia. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13034912&form=6&db=m A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia. diagnostic usage,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13351547&form=6&db=m The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14597971&form=6&db=m Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14629472&form=6&db=m Monitoring the bioavailability of FEIBA with a thrombin generation assay. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14697207&form=6&db=m A cell-based model of coagulation and the role of factor VIIa. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14872417&form=6&db=m Experiences with recombinant human factor VIIa in patients with thrombocytopenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15385042&form=6&db=m Thrombin generation assay and other universal tests for monitoring haemophilia therapy. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719893&form=6&db=m Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15735797&form=6&db=m Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16011583&form=6&db=m Thrombin generation and phenotypic correlation in haemophilia A. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16128902&form=6&db=m Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16224390&form=6&db=m Potential role of recombinant factor VIIa as a hemostatic agent. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16409469&form=6&db=m Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16420569&form=6&db=m The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. diagnostic usage,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16684000&form=6&db=m New approaches for measuring coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16697480&form=6&db=m Mechanism of action, development and clinical experience of recombinant FVIIa. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16706977&form=6&db=m Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16787497&form=6&db=m Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16832569&form=6&db=m Platelets as modifiers of clinical phenotype in hemophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16973498&form=6&db=m Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16984362&form=6&db=m Factor VIII and thrombin generation assays: relevance to pharmacokinetic studies in haemophilia A. diagnostic usage,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17059471&form=6&db=m Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17393033&form=6&db=m Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: are these results really discordant? diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17414211&form=6&db=m Recombinant factor VIIa: its background, development and clinical use. therapeutic application,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17555451&form=6&db=m A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17672884&form=6&db=m Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17880440&form=6&db=m Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,3 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17973850&form=6&db=m Correlation of thromboelastographic patterns with clinical presentation and rationale for use of antifibrinolytics in severe haemophilia patients. causal interaction,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18019946&form=6&db=m Tissue factor in thrombosis and hemorrhage. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18047548&form=6&db=m Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18129761&form=6&db=m The coagulation defect in hemophilia with particular reference to the conversion of prothrombin to thrombin and the evolution of the prothrombin conversion accelerator. diagnostic usage,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18190585&form=6&db=m The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18268016&form=6&db=m The nature of the stable blood clot procoagulant activities. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18371162&form=6&db=m Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18510527&form=6&db=m New assays for monitoring haemophilia treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18523449&form=6&db=m Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18641016&form=6&db=m Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18841276&form=6&db=m Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18874455&form=6&db=m Increased thrombin inactivation in a case of sporadic haemophilia. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19002040&form=6&db=m Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012951&form=6&db=m Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19236780&form=6&db=m [Clinical analysis and laboratory findings in a patient with acquired hemophilia a.] diagnostic usage,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19490067&form=6&db=m Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19563500&form=6&db=m Thrombin generation and bleeding in haemophilia A. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19659796&form=6&db=m Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19718468&form=6&db=m Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19719549&form=6&db=m Thrombin generation testing in haemophilia comprehensive care centres. therapeutic application,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878339&form=6&db=m Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19937483&form=6&db=m A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20050927&form=6&db=m Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20148980&form=6&db=m Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. diagnostic usage,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20201962&form=6&db=m Pseudoaneurysm in association with a knee endoprothesis operation in an inhibitor-positive haemophilia A patient - treatment with local thrombin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20586795&form=6&db=m Plasma and cellular contributions to fibrin network formation, structure and stability. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20609014&form=6&db=m First 20 years with recombinant FVIIa (NovoSeven). therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20632246&form=6&db=m Recombinant activated factor VII: mechanisms of action and current indications. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20644466&form=6&db=m A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20810929&form=6&db=m Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20977448&form=6&db=m Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20978999&form=6&db=m Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21155966&form=6&db=m Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21225093&form=6&db=m A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21275959&form=6&db=m Thrombin generation in patients with acquired haemophilia and clinical bleeding risk. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21371192&form=6&db=m Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21389323&form=6&db=m Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21524474&form=6&db=m Hemophilia A in cardiac operations: a model of reduced thrombin generation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21545000&form=6&db=m [Prophylaxis in patients with haemophilia complicated by inhibitors]. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21605333&form=6&db=m Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. diagnostic usage,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21682825&form=6&db=m Platelets significantly modify procoagulant activities in haemophilia A. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21899664&form=6&db=m The influence of prophylactic factor VIII in severe haemophilia A. causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21920012&form=6&db=m Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1. therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21933309&form=6&db=m Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22355108&form=6&db=m Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22395575&form=6&db=m Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients With Hemophilia Having Inhibitors. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22491732&form=6&db=m Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22500053&form=6&db=m TAFI made stickier. causal interaction,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22530574&form=6&db=m Management of bleeding disorders: basic science. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22534727&form=6&db=m Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22632160&form=6&db=m Mechanisms and monitoring of bypassing agent therapy. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22658294&form=6&db=m Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22951415&form=6&db=m Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22989180&form=6&db=m Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23144741&form=6&db=m Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23174035&form=6&db=m Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23319573&form=6&db=m Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23372761&form=6&db=m From principle to practice: bridging the gap in patient profiling. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23387870&form=6&db=m Platelet activation and aggregation: the importance of thrombin activity. A laboratory model. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23517528&form=6&db=m Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23611257&form=6&db=m Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. causal interaction,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23659442&form=6&db=m Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study. therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23869089&form=6&db=m Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. causal interaction,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23889493&form=6&db=m Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23929304&form=6&db=m Congenital Factor XI Deficiency: An Update. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24118398&form=6&db=m Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24193375&form=6&db=m An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24258360&form=6&db=m Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24354488&form=6&db=m Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24354535&form=6&db=m Joint health scores in a haemophilia A cohort from Pakistan with minimal or no access to factor VIII concentrate: correlation with thrombin generation and underlying mutation. ongoing research,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24354581&form=6&db=m FXIII: mechanisms of action in the treatment of hemophilia A. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385539&form=6&db=m Cardiovascular risk in patients with hemophilia. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24418773&form=6&db=m Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24452774&form=6&db=m Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24619589&form=6&db=m Turoctocog alfa for the treatment of hemophilia A. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24806320&form=6&db=m Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24860049&form=6&db=m [Thrombin generation assays and their clinical application]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015059&form=6&db=m Recombinant activated factor VII in clinical practice: a 2014 update. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25158984&form=6&db=m Thrombin generation in a patient with an acquired high-titre factor V inhibitor. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25185418&form=6&db=m Comparison of two laboratory assays in monitoring the efficacy of different prophylaxis regimens for severe haemophilia. therapeutic application,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25232061&form=6&db=m In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25354749&form=6&db=m Evaluation of Thrombin Generation Assay in Patients With Hemophilia. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25422177&form=6&db=m Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25849132&form=6&db=m An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25944555&form=6&db=m Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26028157&form=6&db=m [Thrombin generation test]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26073368&form=6&db=m Recombinant activated factor VII: 30 years of research and innovation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26340413&form=6&db=m Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26388112&form=6&db=m Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use. therapeutic application,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26466980&form=6&db=m Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. causal interaction,ongoing research,therapeutic application,unassigned 2,4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26517283&form=6&db=m Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26595153&form=6&db=m Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26879158&form=6&db=m Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27094310&form=6&db=m A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27166132&form=6&db=m The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27207416&form=6&db=m Flow and delta-P dictate where thrombin, fibrin, and von Willebrand Factor will be found. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27480994&form=6&db=m A new parameter in the thrombin generation assay, mean velocity to peak thrombin, reflects factor VIII activity in patients with haemophilia A. diagnostic usage,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27761968&form=6&db=m Expression and release of platelet protein disulphide isomerase in patients with haemophilia A. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27913544&form=6&db=m Treatment of rare factor deficiencies in 2016. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28205396&form=6&db=m Can the diagnostic reliability of the thrombin generation test as a global haemostasis assay be improved? The impact of calcium chloride concentration. therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28296129&form=6&db=m Comparing Thrombin Generation in Patients with Hemophilia A and Patients on Vitamin K Antagonists. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28384182&form=6&db=m Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28550758&form=6&db=m Platelets and hemophilia: A review of the literature. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28594458&form=6&db=m Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28656617&form=6&db=m Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. diagnostic usage,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28691885&form=6&db=m Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. therapeutic application,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28830606&form=6&db=m Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28851065&form=6&db=m The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29181141&form=6&db=m Correlation to FVIII:C in Two Thrombin Generation Tests: TGA-CAT and INNOVANCE ETP. diagnostic usage,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29317453&form=6&db=m Targeting anticoagulant protein S to improve hemostasis in hemophilia. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29468639&form=6&db=m Factor XIa-triggered thrombin generation in severe haemophilia A. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29472355&form=6&db=m Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. therapeutic application,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29662861&form=6&db=m Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29845491&form=6&db=m Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. causal interaction,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29855112&form=6&db=m Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A. causal interaction,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30112856&form=6&db=m Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30137664&form=6&db=m A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. therapeutic application,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30302740&form=6&db=m Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30408848&form=6&db=m Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30451376&form=6&db=m Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30529268&form=6&db=m Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A. diagnostic usage,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30579150&form=6&db=m Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30755437&form=6&db=m Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30922616&form=6&db=m Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. therapeutic application,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31039049&form=6&db=m Current and emerging biologics for the treatment of hemophilia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31164248&form=6&db=m The central role of thrombin in bleeding disorders. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31383642&form=6&db=m Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31444162&form=6&db=m Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31471127&form=6&db=m From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31562694&form=6&db=m A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31624791&form=6&db=m Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31639831&form=6&db=m A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31676141&form=6&db=m Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31699786&form=6&db=m A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A. ongoing research,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31982077&form=6&db=m Pseudoaneurysm in a patient with haemophilia A: thrombin injection plugs the hole. therapeutic application,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31990756&form=6&db=m Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,2 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32066048&form=6&db=m Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,4 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32108578&form=6&db=m Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A. diagnostic usage,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32110761&form=6&db=m Global coagulation assays in hemophilia A: A comparison to conventional assays. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32212299&form=6&db=m Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. ongoing research,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32359012&form=6&db=m Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32430703&form=6&db=m LPS-induced expression and release of monocyte tissue factor in patients with haemophilia. causal interaction,unassigned 1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32467424&form=6&db=m A bispecific antibody demonstrates limited measurability in routine coagulation assays. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32749057&form=6&db=m Commentary on "Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms". unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32897618&form=6&db=m Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32979031&form=6&db=m Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. therapeutic application,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33054058&form=6&db=m A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A. ongoing research,unassigned 2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33115272&form=6&db=m Computationally Driven Discovery in Coagulation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33202269&form=6&db=m A Heparin based dual ratiometric sensor for Thrombin. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33313469&form=6&db=m MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. diagnostic usage,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33398908&form=6&db=m Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33433420&form=6&db=m Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A. diagnostic usage,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441362&form=6&db=m PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33550714&form=6&db=m Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33657623&form=6&db=m The Art and Science of Building a Computational Model to Understand Hemostasis. unassigned - 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33749973&form=6&db=m Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experience. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33846873&form=6&db=m Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33915599&form=6&db=m An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33955860&form=6&db=m Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis? causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33996250&form=6&db=m RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34026796&form=6&db=m Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34077951&form=6&db=m FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34106506&form=6&db=m Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. diagnostic usage,unassigned 3,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34115433&form=6&db=m Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34177966&form=6&db=m Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor. causal interaction,unassigned 4,0 3.4.21.5 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34330995&form=6&db=m Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1772782&form=6&db=m No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. therapeutic application,unassigned 1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1782333&form=6&db=m Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2265248&form=6&db=m Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. therapeutic application,unassigned 1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2320433&form=6&db=m Haemophilia B caused by mutation of a potential thrombin cleavage site in factor IX. causal interaction,unassigned 3,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620866&form=6&db=m Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6713090&form=6&db=m Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11806995&form=6&db=m Mechanism of factor VIIa-dependent coagulation in hemophilia blood. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12406066&form=6&db=m Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12524235&form=6&db=m Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871314&form=6&db=m How factor VIIa works in hemophilia. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13351547&form=6&db=m The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14597971&form=6&db=m Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719893&form=6&db=m Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15735797&form=6&db=m Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16051741&form=6&db=m Aminoglycoside suppression of nonsense mutations in severe hemophilia. unassigned - 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16420569&form=6&db=m The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. diagnostic usage,unassigned 4,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17663728&form=6&db=m Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17880464&form=6&db=m Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22951415&form=6&db=m Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23773548&form=6&db=m Recalcitrant peroneal artery pseudoaneurysm in a patient with Hemophilia B. therapeutic application,unassigned 3,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25795563&form=6&db=m Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28406575&form=6&db=m Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30230231&form=6&db=m Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30453348&form=6&db=m Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31006077&form=6&db=m Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.5 Hemophilia B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31639831&form=6&db=m A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Hemoptysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2670463&form=6&db=m Treatment of hemoptysis patients by thrombin and fibrinogen-thrombin infusion therapy using a fiberoptic bronchoscope. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.5 Hemoptysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7098189&form=6&db=m [Thrombin instillation therapy through the fiberoptic bronchoscope in cases of hemoptysis (author's transl)] causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Hemoptysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12076916&form=6&db=m Treatment of massive hemoptysis with intraarterial thrombin injection of a bronchial artery. therapeutic application,unassigned 4,0 3.4.21.5 Hemoptysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13335878&form=6&db=m [Local treatment of tuberculous hemoptysis by thrombase.] therapeutic application,unassigned 4,0 3.4.21.5 Hemoptysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14931508&form=6&db=m [Hemoptysis and thrombase aerosols.] unassigned - 3.4.21.5 Hemoptysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29351111&form=6&db=m Novel Bronchoscopic Management of Airway Bleeding With Absorbable Gelatin and Thrombin Slurry. therapeutic application,unassigned 4,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1333302&form=6&db=m Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. diagnostic usage,unassigned 3,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3083799&form=6&db=m Multiple myeloma with polyneuropathy and coagulopathy. A case report of the polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin change (POEMS) syndrome. therapeutic application,unassigned 1,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11085063&form=6&db=m [Uremic coagulopathy. Role of thrombin] causal interaction,unassigned 4,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14264681&form=6&db=m [DISTURBANCES IN THE CHAIN-REACTION OF THROMBIN FORMATION CAUSING HEMORRHAGIC DIATHESIS.] unassigned - 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14270015&form=6&db=m [DISTURBANCES IN THE CHAIN-REACTION OF THROMBIN FORMATION AS A CAUSE OF HEMORRHAGIC DIATHESIS.] causal interaction,unassigned 1,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14923184&form=6&db=m [The use of thrombin in hemorrhagic diathesis.] therapeutic application,unassigned 3,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18544417&form=6&db=m Tissue factor-independent effects of recombinant factor VIIa on hemostasis. causal interaction,unassigned 3,0 3.4.21.5 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27911985&form=6&db=m Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study. diagnostic usage,unassigned 3,0 3.4.21.5 Hemorrhagic Fever with Renal Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1975230&form=6&db=m Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis. diagnostic usage,unassigned 4,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923645&form=6&db=m Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603520&form=6&db=m Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12064194&form=6&db=m [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis] therapeutic application,unassigned 3,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20936927&form=6&db=m Prevention of cardioembolic stroke in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22353706&form=6&db=m A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27740983&form=6&db=m Imaging of Hemorrhagic Stroke. therapeutic application,unassigned 3,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31833869&form=6&db=m Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Hemostatic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2356569&form=6&db=m Liver damage induced in rats by malathion impurities. therapeutic application,unassigned 1,0 3.4.21.5 Hemostatic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19085768&form=6&db=m Standardization and clinical utility of thrombin-generation assays. unassigned - 3.4.21.5 Hemostatic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630796&form=6&db=m Empirical and theoretical phenotypic discrimination. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Hemostatic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21299582&form=6&db=m Monitoring unfractionated heparin therapy in dogs by measuring thrombin generation. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Hemostatic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29578657&form=6&db=m Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Hemostatic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31157200&form=6&db=m Supramolecular Aptamers on Graphene Oxide for Efficient Inhibition of Thrombin Activity. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hepatic Encephalopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27073448&form=6&db=m Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Hepatic Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13973768&form=6&db=m The relationship of liver insufficiency to fibrinolytic hemorrhage as demonstrated by the serial thrombin time. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Hepatic Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150304&form=6&db=m The coagulation cascade in cirrhosis. unassigned - 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5734077&form=6&db=m [The behavior of Owren's thrombin time in the course of MHV-3 mouse hepatitis] causal interaction,unassigned 1,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8769597&form=6&db=m Transmission of serum hepatitis. 1970. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9063379&form=6&db=m Acquired factor VIII inhibitors in nonhemophilic patients. causal interaction,unassigned 2,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9855188&form=6&db=m A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin. diagnostic usage,unassigned 1,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11994472&form=6&db=m Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. causal interaction,unassigned 2,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13069260&form=6&db=m Human thrombin as vehicle of infection in homologous serum hepatitis. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14873544&form=6&db=m Epidemic of homologous serum hepatitis apparently caused by human thrombin. unassigned - 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15268797&form=6&db=m [Hfgl2/fibroleukin expression in liver and peripheral blood mononuclear cells (PBMC) and its correlation with disease severity] causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15485631&form=6&db=m Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. therapeutic application,unassigned 2,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23297820&form=6&db=m Peliosis hepatis mimicking hepatic malignancy: A case report. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34066706&form=6&db=m Thrombin Generation in Chronic Liver Diseases-A Pilot Study. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.5 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34383422&form=6&db=m Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis? causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hepatitis A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1154308&form=6&db=m Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hepatitis A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18466171&form=6&db=m Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18466171&form=6&db=m Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23297820&form=6&db=m Peliosis hepatis mimicking hepatic malignancy: A case report. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25769583&form=6&db=m Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease. causal interaction,unassigned 1,0 3.4.21.5 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33708932&form=6&db=m A cohort study of hepatectomy-related complications and prediction model for postoperative liver failure after major liver resection in 1,441 patients without obstructive jaundice. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34059778&form=6&db=m A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8605614&form=6&db=m Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18466171&form=6&db=m Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27182154&form=6&db=m Thrombin activation and liver inflammation in advanced hepatitis C virus infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33544577&form=6&db=m Modular Combination of Proteolysis-Responsive Transcription and Spherical Nucleic Acids for Smartphone-Based Colorimetric Detection of Protease Biomarkers. diagnostic usage,unassigned 1,0 3.4.21.5 Hepatitis C, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18005014&form=6&db=m Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Hepatitis E http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29321328&form=6&db=m Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Hepatorenal Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27073448&form=6&db=m Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Hermanski-Pudlak Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9157599&form=6&db=m Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency--a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor. unassigned - 3.4.21.5 Hermanski-Pudlak Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12008957&form=6&db=m Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. unassigned - 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2164668&form=6&db=m Mammalian cell transient expression of tissue factor for the production of antigen. ongoing research,unassigned 3,0 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2847155&form=6&db=m Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7827501&form=6&db=m A fast method for obtaining highly pure recombinant herpes simplex virus type 1 thymidine kinase. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9391056&form=6&db=m Coagulation initiated on herpesviruses. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9662464&form=6&db=m Effects of viral activation of the vessel wall on inflammation and thrombosis. causal interaction,unassigned 1,0 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9736916&form=6&db=m Peptidomimetic design. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461934&form=6&db=m Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22374699&form=6&db=m Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11449671&form=6&db=m A specific thrombin inhibitor, argatroban, alleviates herpes zoster-associated pain. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.5 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26090670&form=6&db=m Angiopoietin-1 Regulates Brain Endothelial Permeability through PTPN-2 Mediated Tyrosine Dephosphorylation of Occludin. therapeutic application,unassigned 1,0 3.4.21.5 HIV Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14982749&form=6&db=m Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. ongoing research,unassigned 1,0 3.4.21.5 HIV Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15109955&form=6&db=m Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 HIV Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22438347&form=6&db=m HIV infection is associated with decreased thrombin generation. causal interaction,unassigned 4,0 3.4.21.5 HIV Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24759134&form=6&db=m Coagulation and morbidity in treated HIV infection. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Homozygous Familial Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9974403&form=6&db=m Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling. unassigned - 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7644116&form=6&db=m Thrombin and TGF-beta promote human leptomeningeal cell proliferation in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23338707&form=6&db=m Thrombin-induced TGF-?1 pathway: a cause of communicating hydrocephalus post subarachnoid hemorrhage. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24326390&form=6&db=m Hydrocephalus after intraventricular hemorrhage: the role of thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24667910&form=6&db=m Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463978&form=6&db=m Effects of Aerobic Capacity on Thrombin-Induced Hydrocephalus and White Matter Injury. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30955248&form=6&db=m Thrombin disrupts vascular endothelial-cadherin and leads to hydrocephalus via protease-activated receptors-1 pathway. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31433571&form=6&db=m Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33642398&form=6&db=m Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34399800&form=6&db=m Impact of sex differences on thrombin-induced hydrocephalus and white matter injury: the role of neutrophils. ongoing research,unassigned 1,0 3.4.21.5 Hydrocephalus, Normal Pressure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33642398&form=6&db=m Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877315&form=6&db=m Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. unassigned - 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12126749&form=6&db=m The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12717003&form=6&db=m Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15175421&form=6&db=m Intrathecal protease-activated receptor stimulation produces thermal hyperalgesia through spinal cyclooxygenase activity. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16251448&form=6&db=m Protease-activated receptor-1 and platelet-derived growth factor in spinal cord neurons are implicated in neuropathic pain after nerve injury. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21944723&form=6&db=m The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,2 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26708087&form=6&db=m Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC. unassigned - 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28059686&form=6&db=m The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29196860&form=6&db=m Role of Thrombin in Soluble Thrombomodulin-Induced Suppression of Peripheral HMGB1-Mediated Allodynia in Mice. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31666085&form=6&db=m Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. therapeutic application,unassigned 1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1991383&form=6&db=m Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries. therapeutic application,unassigned 3,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2029501&form=6&db=m Platelet function in Watanabe heritable hyperlipidemic rabbits. Decreased sensitivity to thromboxane A2. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2029502&form=6&db=m Long-term cholesterol feeding alters the reactivity of primate coronary microvessels to platelet products. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2299267&form=6&db=m Thrombin-induced inositol phosphate production by platelets from rats with diet-induced or genetically determined hypercholesterolemia. ongoing research,unassigned 1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3087655&form=6&db=m Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8049200&form=6&db=m Effects of chronic administration of ethanol on platelets from rabbits with diet-induced hypercholesterolemia. Unchanged characteristics and responses to ADP but reduction of enhanced thrombin-induced, TxA2-independent platelet responses. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8560403&form=6&db=m Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578530&form=6&db=m Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8696958&form=6&db=m Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,2 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8879945&form=6&db=m Pathophysiology and initial management of the acute coronary syndromes. causal interaction,unassigned 4,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9207626&form=6&db=m Platelet-dependent thrombin generation in patients with hyperlipidemia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10193729&form=6&db=m Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608000&form=6&db=m Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11075617&form=6&db=m Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,3,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687759&form=6&db=m Antithrombotic actions of statins. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12067144&form=6&db=m Different mechanisms of fibrinolysis impairment among dyslipidemic subjects. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12478815&form=6&db=m Dyslipidemias and fibrinolysis. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15208865&form=6&db=m [Effect of surgical menopause on the development of cardiovascular diseases] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15629370&form=6&db=m CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24784951&form=6&db=m Statins decrease thrombin generation in patients with hypercholesterolemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26769047&form=6&db=m Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33636573&form=6&db=m Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Hyperemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1709905&form=6&db=m [Multivariate analysis for the understanding of typical diabetic hemostasis criteria. 1: Plasma markers] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Hyperemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17497605&form=6&db=m [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] therapeutic application,unassigned 4,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2274914&form=6&db=m Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon. causal interaction,unassigned 4,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2593829&form=6&db=m Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. causal interaction,unassigned 3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4029510&form=6&db=m Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. causal interaction,unassigned 3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7621998&form=6&db=m Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11302472&form=6&db=m Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17547839&form=6&db=m Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17942824&form=6&db=m Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependent actin cytoskeleton organization. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18487475&form=6&db=m Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19142984&form=6&db=m Anti inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes. causal interaction,unassigned 3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19422461&form=6&db=m Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22931303&form=6&db=m Assessment of acute moderate hyperglycemia on traditional and thromboelastometry coagulation parameters in healthy adult horses. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25239438&form=6&db=m Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25298619&form=6&db=m MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression. causal interaction,unassigned 4,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30625393&form=6&db=m Regulation of mitochondrial function as a promising target in platelet activation-related diseases. unassigned - 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30797812&form=6&db=m Hindbrain astrocytes and glucose counter-regulation. causal interaction,unassigned 3,0 3.4.21.5 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33143626&form=6&db=m A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications. causal interaction,unassigned 4,0 3.4.21.5 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102483&form=6&db=m The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10527405&form=6&db=m Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12200374&form=6&db=m Effect of hyperhomocysteinemia on protein C activation and activity. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18612269&form=6&db=m Hyperhomocysteinemia, antithrombin consumption, and early venous graft closure in surgical coronary revascularization. causal interaction,unassigned 4,0 3.4.21.5 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19943541&form=6&db=m [Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21346557&form=6&db=m Some considerations about the hypercoagulable states and their treatments. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8222771&form=6&db=m The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima. causal interaction,unassigned 3,0 3.4.21.5 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11788478&form=6&db=m Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. diagnostic usage,unassigned 1,0 3.4.21.5 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17547839&form=6&db=m Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25042561&form=6&db=m Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26742564&form=6&db=m Thrombin stimulates insulin secretion via protease-activated receptor-3. causal interaction,unassigned 1,0 3.4.21.5 Hyperkalemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16731303&form=6&db=m Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Hyperkalemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20170696&form=6&db=m Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane. unassigned - 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=425066&form=6&db=m Platelet functions in relation to dietary fats in farmers from two regions of France. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=455600&form=6&db=m Normal levels of fibrinopeptide A in patients with primary hyperlipidemia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5436060&form=6&db=m [Effect of alimentary lipemia on thrombin generation in the plasma of healthy persons and in arteriosclerosis] diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6753232&form=6&db=m Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6986741&form=6&db=m Heparin and atherosclerosis. A review of old and recent findings. ongoing research,unassigned 2,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8292090&form=6&db=m Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. unassigned - 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8911271&form=6&db=m In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. diagnostic usage,unassigned 1,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9207626&form=6&db=m Platelet-dependent thrombin generation in patients with hyperlipidemia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16521918&form=6&db=m [Evaluation of thrombin generation and clot bound thrombin in plasma of hyperlipidemic patients treated with statins] diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17477084&form=6&db=m [Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29356352&form=6&db=m VIIaAT complexes, procoagulant phospholipids, and thrombin generation during postprandial lipemia. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Hyperlipoproteinemia Type II http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Hyperlipoproteinemia Type II http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7112508&form=6&db=m The effect of human plasma on platelet function in familial hypercholesterolemia. unassigned - 3.4.21.5 Hyperlipoproteinemia Type II http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33626480&form=6&db=m Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? causal interaction,unassigned 1,0 3.4.21.5 Hyperlipoproteinemia Type V http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Hyperlipoproteinemia Type V http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4074453&form=6&db=m Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Hyperlipoproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Hyperlipoproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4074453&form=6&db=m Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1426157&form=6&db=m Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits. causal interaction,unassigned 4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1455404&form=6&db=m Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. ongoing research,unassigned 1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1519216&form=6&db=m Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects. ongoing research,unassigned 2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1524366&form=6&db=m [Hypersensitivity accidents to thrombin following the use of biological glues] diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1725944&form=6&db=m Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites. diagnostic usage,unassigned 4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2063351&form=6&db=m The hypersensitivity to thrombin of platelets from diabetic rats is not due to increased thrombin binding. unassigned - 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2227132&form=6&db=m Reduced membrane fluidity in platelets from diabetic patients. therapeutic application,unassigned 2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2822575&form=6&db=m Hypersensitivity of phospholipase C in platelets of spontaneously hypertensive rats. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3078948&form=6&db=m Progressive relaxation of Go-arrest controls and altered responsiveness to insulin, EGF and thrombin in CCL39 lung fibroblasts over-expressing myc and ras oncogenes. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3190819&form=6&db=m Thrombin binding to platelets from hypercholesterolaemic rats. causal interaction,unassigned 1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3606733&form=6&db=m The effect of dietary saturated fat and cholesterol on platelet function, platelet survival and response to continuous aortic injury in rats. ongoing research,unassigned 1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4045197&form=6&db=m An innate host response to the neoplastic cell: syngeneic rat tumor cells can elicit a rapid de novo lymphoid procoagulant response. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6256088&form=6&db=m Hypersensitivity of platelets to thrombin: formation of stable thrombin-receptor complexes and the role of shape change. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10876222&form=6&db=m Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12003722&form=6&db=m Pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15855136&form=6&db=m Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15931315&form=6&db=m Iatrogenic pseudoaneurysm of femoral artery: case report and literature review. unassigned - 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19004374&form=6&db=m Platelets from diabetic pigs exhibit hypersensitivity to thrombin. unassigned - 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21950643&form=6&db=m New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22936376&form=6&db=m Protocol for Obtaining Platelet-Rich Plasma (PRP), Platelet-Poor Plasma (PPP), and Thrombin for Autologous Use. therapeutic application,unassigned 2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23141924&form=6&db=m Fc?RIIa ligation induces platelet hypersensitivity to thrombotic stimuli. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26120548&form=6&db=m Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27019085&form=6&db=m Asthma is associated with enhanced thrombin formation and impaired fibrinolysis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28052306&form=6&db=m Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28059686&form=6&db=m The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29362190&form=6&db=m Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy? diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29633298&form=6&db=m Severe allergic reaction: A rare complication of ultrasound-guided injection of thrombin in a femoral pseudoaneurysm. therapeutic application,unassigned 2,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30243238&form=6&db=m Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31601777&form=6&db=m A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hypersensitivity, Delayed http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1534318&form=6&db=m Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1772997&form=6&db=m Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1852102&form=6&db=m Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3532721&form=6&db=m Blood platelets in human essential hypertension. therapeutic application,unassigned 1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3852574&form=6&db=m [Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients] causal interaction,unassigned 3,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5675775&form=6&db=m [Thrombin activity in the blood of patients with coronary insufficiency and hypertension] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,1 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6176042&form=6&db=m Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6223170&form=6&db=m [Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension] therapeutic application,unassigned 2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8255159&form=6&db=m Normal thrombin binding leads to greater fibrinogen binding and increased platelet aggregation in spontaneously hypertensive rats. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8712013&form=6&db=m [Effects of taurine and enalapril on blood pressure, platelet aggregation and the regression of left ventricular hypertrophy in two-kidney-one-clip renovascular hypertensive rats] unassigned - 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8761314&form=6&db=m Cell calcium handling and intracellular pH regulation in hereditary hypertriglyceridemic rats: reduced platelet response to thrombin stimulation. ongoing research,unassigned 3,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8963881&form=6&db=m [Pre- and postpartum hemostatic characteristics in pregnancy-related hypertension and pre-eclampsia in comparison with normotensive pregnancies] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9168786&form=6&db=m Vascular thrombin receptor regulation in hypertensive rats. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9488228&form=6&db=m Cytosolic pH and calcium in Dahl salt-sensitive and salt-resistant rats: the relationship to plasma lipids. causal interaction,unassigned 1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11408749&form=6&db=m Increased indexes of thrombin activation in advanced stages of hypertension. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12149106&form=6&db=m Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12149566&form=6&db=m Hemostasis imbalance in experimental hypertension. causal interaction,unassigned 4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12372926&form=6&db=m Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14555559&form=6&db=m Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102593&form=6&db=m American Heart Association scientific sessions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15353058&form=6&db=m Cardiology. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16504676&form=6&db=m Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17289744&form=6&db=m Effect of hypertension on anticoagulated patients with atrial fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278189&form=6&db=m Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18633427&form=6&db=m Association of aortic valve sclerosis with thrombin generation in hypertensive patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19065903&form=6&db=m [Intervening effect of naoxintong on anti-platelet treatment with aspirin] diagnostic usage,unassigned 2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19736615&form=6&db=m Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21384745&form=6&db=m Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension. ongoing research,unassigned 2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21728962&form=6&db=m Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation. causal interaction,unassigned 4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21851966&form=6&db=m Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation - The Hoorn Study. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24313434&form=6&db=m [Preeclampsia and thrombin generation test]. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24744867&form=6&db=m Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28218264&form=6&db=m Hypertension: Thrombin amplification loop in hypertension. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28478796&form=6&db=m Platelet-derived miR-142-3p induces apoptosis of endothelial cells in hypertension. unassigned - 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29470366&form=6&db=m Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30597342&form=6&db=m Enhanced thrombin generation in patients with arterial hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175151&form=6&db=m Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,4 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33478293&form=6&db=m Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33761732&form=6&db=m Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33868765&form=6&db=m Perioperative Hidden Blood Loss in Elderly Cervical Spondylosis Patients With Anterior Cervical Discectomy Fusion and Influencing Factors. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34404541&form=6&db=m The dynamics of thrombin formation in patients with pulmonary arterial hypertension. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34445374&form=6&db=m Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Hypertension, Portal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3151&form=6&db=m Portal hypertension and gastric lesions in the rat. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Hypertension, Portal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33669257&form=6&db=m Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,4 3.4.21.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8963881&form=6&db=m [Pre- and postpartum hemostatic characteristics in pregnancy-related hypertension and pre-eclampsia in comparison with normotensive pregnancies] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1554199&form=6&db=m Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2077021&form=6&db=m Role of hemodynamics and vagus nerves in development of fibrin-induced pulmonary edema. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3441903&form=6&db=m Effects of antiplatelet drugs on pulmonary responses to thrombin in anesthetized rabbits. unassigned - 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8141259&form=6&db=m Thrombin receptor activation peptide induces pulmonary vasoconstriction. causal interaction,unassigned 4,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8186352&form=6&db=m Antithrombin III deficiency in neonatal respiratory distress syndrome. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8214923&form=6&db=m Chronic hypoxic pulmonary hypertension. Is thrombin involved? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8777977&form=6&db=m The role of thrombosis in severe pulmonary hypertension. causal interaction,unassigned 3,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14555559&form=6&db=m Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15134338&form=6&db=m Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. causal interaction,unassigned 3,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15968404&form=6&db=m Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19363122&form=6&db=m Chronic Exposure to Fibrin and Fibrinogen Differentially Regulates Intracellular Ca2+ in Human Pulmonary Arterial Smooth Muscle and Endothelial Cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23785394&form=6&db=m Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension. ongoing research,unassigned 4,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24744867&form=6&db=m Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Hyperthyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26184174&form=6&db=m Hypothyroidism Exacerbates Thrombophilia in Female Rats Fed with a High Fat Diet. ongoing research,unassigned 4,0 3.4.21.5 Hyperthyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28137735&form=6&db=m Contact system activation and high thrombin generation in hyperthyroidism. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9207626&form=6&db=m Platelet-dependent thrombin generation in patients with hyperlipidemia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12067144&form=6&db=m Different mechanisms of fibrinolysis impairment among dyslipidemic subjects. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30939111&form=6&db=m Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Hypertrophy, Left Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18639352&form=6&db=m Acute myocardial infarction with diminutive right coronary artery and obstructive hypertrophic cardiomyopathy without significant coronary stenoses. causal interaction,unassigned 4,0 3.4.21.5 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17016788&form=6&db=m [Retinal neovascularization in a traumatic microhyphema] causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Hypoalbuminemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6464012&form=6&db=m Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia. causal interaction,unassigned 3,0 3.4.21.5 Hypoalbuminemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25855774&form=6&db=m Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome. unassigned - 3.4.21.5 Hypoalbuminemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33636573&form=6&db=m Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Hypoglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3319468&form=6&db=m Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypoglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7623161&form=6&db=m Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. ongoing research,unassigned 3,0 3.4.21.5 Hypoglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10837811&form=6&db=m The effects of thrombin preconditioning on focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Hypoglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32320636&form=6&db=m Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control. causal interaction,unassigned 3,0 3.4.21.5 Hypospadias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10215545&form=6&db=m Homozygous alpha-thalassemia associated with hypospadias in three survivors. therapeutic application,unassigned 1,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=262805&form=6&db=m Effect of reticuloendothelial blockade on the development of hypotension after trauma, sepsis, and intravascular coagulation. unassigned - 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2227247&form=6&db=m Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3775692&form=6&db=m Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4194272&form=6&db=m Induction of hypotension in rhesus monkeys and rabbits by intravenous thrombin infusion. therapeutic application,unassigned 1,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8325311&form=6&db=m The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents--lack of relationship to pretreatment streptokinase resistance. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9033393&form=6&db=m Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10482282&form=6&db=m A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis. ongoing research,unassigned 4,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11231675&form=6&db=m Different hypotensive responses to intravenous bovine and human thrombin preparations in swine. therapeutic application,unassigned 2,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14525995&form=6&db=m Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. ongoing research,unassigned 2,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18294351&form=6&db=m Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery. diagnostic usage,unassigned 2,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18706698&form=6&db=m Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19025114&form=6&db=m Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23640650&form=6&db=m Renal involvement in sepsis: a prospective single-center study of 136 cases. causal interaction,unassigned 3,0 3.4.21.5 Hypothyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19959491&form=6&db=m Thrombin -Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Hypothyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21257724&form=6&db=m Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Hypoxia-Ischemia, Brain http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31137455&form=6&db=m Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7564789&form=6&db=m Role of thrombin in pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18785126&form=6&db=m [Protein C system in patients with idiopathic pulmonary fibrosis - preliminary report.] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19060230&form=6&db=m Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. therapeutic application,unassigned 3,0 3.4.21.5 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25199049&form=6&db=m Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Ileus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31593122&form=6&db=m Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Iliac Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12093076&form=6&db=m The occlusion of an internal iliac aneurysm by the trans-catheter injection of thrombin. therapeutic application,unassigned 2,0 3.4.21.5 Immunoglobulin Light-chain Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585046&form=6&db=m Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity. causal interaction,unassigned 3,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8768731&form=6&db=m Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9469624&form=6&db=m Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10837811&form=6&db=m The effects of thrombin preconditioning on focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20087365&form=6&db=m Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22683118&form=6&db=m Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22985597&form=6&db=m EMBOLIC MIDDLE CEREBRAL ARTERY OCCLUSION MODEL USING THROMBIN AND FIBRINOGEN COMPOSED CLOTS IN RAT. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23900720&form=6&db=m Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26390857&form=6&db=m Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26851772&form=6&db=m A novel histochemical method for the visualization of thrombin activity in the nervous system. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26861077&form=6&db=m Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28428349&form=6&db=m Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28443061&form=6&db=m A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=315978&form=6&db=m Fibrin deposition and clearance in chronic granulomatous inflammation: correlation with T-cell function and proteinase inhibitor activity in tissue. therapeutic application,unassigned 3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1823881&form=6&db=m Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2190648&form=6&db=m Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2840476&form=6&db=m Measurement of intracellular calcium concentration in intact monolayers of human endothelial cells. therapeutic application,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2847155&form=6&db=m Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8131786&form=6&db=m Herpes simplex virus and atherosclerosis. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8605614&form=6&db=m Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8890464&form=6&db=m Platelet dysfunction associated with experimental acute canine ehrlichiosis. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9371356&form=6&db=m Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. ongoing research,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9622218&form=6&db=m The coagulation profile in hepatosplenic schistosomiasis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9662464&form=6&db=m Effects of viral activation of the vessel wall on inflammation and thrombosis. causal interaction,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9690602&form=6&db=m Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs. causal interaction,unassigned 3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11227291&form=6&db=m [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11269335&form=6&db=m Increasing endothelial cell permeability improves the efficiency of myocyte adenoviral vector infection. causal interaction,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11500090&form=6&db=m A bacterially produced virus enhancing factor from an entomopoxvirus enhances nucleopolyhedrovirus infection in armyworm larvae. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11885409&form=6&db=m Recombinant human activated protein C in severe sepsis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958322&form=6&db=m Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12699690&form=6&db=m Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid. ongoing research,unassigned 2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12788788&form=6&db=m Role of CaM kinase II and ERK activation in thrombin-induced endothelial cell barrier dysfunction. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13069260&form=6&db=m Human thrombin as vehicle of infection in homologous serum hepatitis. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15274665&form=6&db=m Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15946215&form=6&db=m Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16104949&form=6&db=m Vacuolating cytotoxin A is associated with increased thrombin generation in gastric mucosa. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16451735&form=6&db=m Thrombocytopenia in the experimental leptospirosis of guinea pig is not related to disseminated intravascular coagulation. therapeutic application,unassigned 2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16551735&form=6&db=m Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidual cells: implications for preterm labor. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17068293&form=6&db=m Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461934&form=6&db=m Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17525899&form=6&db=m Thromboembolic complications in pediatric hematologic malignancies. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19068496&form=6&db=m Femoral pseudoaneurysms post-cardiac catheterization surgically treated: evolution and prognosis. therapeutic application,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19389728&form=6&db=m Thrombin and Interleukin-1{beta} Decrease HOX Gene Expression in Human First Trimester Decidual Cells: Implications for Pregnancy Loss. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19491165&form=6&db=m The frequency of bleeding complications after invasive dental treatment in patients receiving single and dual antiplatelet therapy. therapeutic application,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19498123&form=6&db=m Protein C in critical illness. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19558279&form=6&db=m Topical thrombins: benefits and risks. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20614389&form=6&db=m Disseminated intravascular coagulation in infectious disease. causal interaction,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20684237&form=6&db=m [Thrombin inhibitors which display antibacterial activity] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21360607&form=6&db=m Looking at the proteases from a simple perspective. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21370218&form=6&db=m Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. causal interaction,unassigned 3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21826574&form=6&db=m Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child. therapeutic application,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22161772&form=6&db=m Human cytomegalovirus infection and atherothrombosis. causal interaction,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22227959&form=6&db=m Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22318336&form=6&db=m Herpesviruses enhance fibrin clot lysis. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22374699&form=6&db=m Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22516575&form=6&db=m New insights into pathways that determine the link between infection and thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22653975&form=6&db=m Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23628464&form=6&db=m Reservations against new oral anticoagulants after stroke and cerebral bleeding. unassigned - 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24759132&form=6&db=m The procoagulant envelope virus surface: contribution to enhanced infection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25239678&form=6&db=m Evaluation of hemostaseological status of pigs experimentally infected with African swine fever virus. diagnostic usage,unassigned 3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25852676&form=6&db=m Effect of Puumala hantavirus infection on human umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue factor expression and fibrinolysis regulator release. causal interaction,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26975606&form=6&db=m Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27073448&form=6&db=m Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27182154&form=6&db=m Thrombin activation and liver inflammation in advanced hepatitis C virus infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27365652&form=6&db=m DIAGNOSING DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE INFECTION : CAN WE DO WITHOUT FDP & D-DIMER. diagnostic usage,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27472897&form=6&db=m A host basal transcription factor is a key component for infection of rice by TALE-carrying bacteria. therapeutic application,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27802302&form=6&db=m A Predictive Model for Assessing Surgery-Related Acute Kidney Injury Risk in Hypertensive Patients: A Retrospective Cohort Study. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29105740&form=6&db=m Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29232721&form=6&db=m The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease. causal interaction,unassigned 4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30102144&form=6&db=m Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30439321&form=6&db=m [Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31011714&form=6&db=m Liver stiffness and thrombin generation in compensated cirrhosis. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31084878&form=6&db=m The host basal transcription factor IIA subunits coordinate for facilitating infection of TALEs-carrying bacterial pathogens in rice. diagnostic usage,unassigned 1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31095299&form=6&db=m A novel medical device coating prevents Staphylococcus aureus biofilm formation on medical device surfaces. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31560950&form=6&db=m The repertoire of family A-peptide GPCRs in archaic hominins. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31593122&form=6&db=m Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32716728&form=6&db=m Self-Assembling Peptide Solution Accelerates Hemostasis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32768535&form=6&db=m A Bail Out Solution for an Urgent Situation: Endovascular Exclusion and Embolization of an Infected Femoral Pseudoaneurysm. ongoing research,unassigned 2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32983675&form=6&db=m Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33228042&form=6&db=m Concentration- and pH-Dependent Oligomerization of the Thrombin-Derived C-Terminal Peptide TCP-25. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33294754&form=6&db=m Salvage of autogenous dialysis access with balloon-assisted thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33426762&form=6&db=m Short-term prognosis and influencing factors of patients with acute kidney injury treated with prolonged intermittent renal replacement therapy. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33642398&form=6&db=m Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33837227&form=6&db=m Role of a thrombin generation assay in the prediction of infection severity. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929114&form=6&db=m Thrombin generation in children with febrile neutropenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34107707&form=6&db=m Analysis of the relationship between serum amyloid protein A, procalcitonin, C-reactive protein, and peripherally inserted central catheter infection in patients with malignant tumor. diagnostic usage,unassigned 2,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34177896&form=6&db=m Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34221178&form=6&db=m SARS-CoV-2 and Plasma Hypercoagulability. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34383422&form=6&db=m Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis? causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34469011&form=6&db=m Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection. unassigned - 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7785949&form=6&db=m D-dimer tests detect both plasmin and neutrophil elastase derived split products. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8735810&form=6&db=m Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8789309&form=6&db=m Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11953689&form=6&db=m Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118529&form=6&db=m Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15545995&form=6&db=m A role for proteinase-activated receptor-1 in inflammatory bowel diseases. causal interaction,unassigned 4,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19763358&form=6&db=m Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19914688&form=6&db=m Increased thrombin generation in inflammatory bowel diseases. causal interaction,unassigned 4,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164759&form=6&db=m Increased procoagulant function of microparticles in pediatric inflammatory bowel disease: role in increased thrombin generation. causal interaction,unassigned 2,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23531480&form=6&db=m Thrombin generation and microparticles in inflammatory bowel diseases. therapeutic application,unassigned 1,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24916589&form=6&db=m Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33201214&form=6&db=m Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Inflammatory Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23280128&form=6&db=m Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. unassigned - 3.4.21.5 Influenza in Birds http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30086897&form=6&db=m A label-free light-up fluorescent sensing platform based upon hybridization chain reaction amplification and DNA triplex assembly. unassigned - 3.4.21.5 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17068293&form=6&db=m Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19766141&form=6&db=m Extraction of catalytically active neuraminidase of H5N1 influenza virus using thrombin proteolytic cleavage. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24665136&form=6&db=m Influenza virus H1N1 activates platelets through Fc?RIIA signaling and thrombin generation. therapeutic application,unassigned 1,0 3.4.21.5 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28003564&form=6&db=m Anticoagulation increases alveolar hemorrhage in mice infected with influenza A. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34059141&form=6&db=m Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases. diagnostic usage,unassigned 3,0 3.4.21.5 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34344944&form=6&db=m Critical role of oxidized LDL receptor-1 in intravascular thrombosis in a severe influenza mouse model. diagnostic usage,unassigned 2,0 3.4.21.5 Insulin Coma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14378265&form=6&db=m [Blood fibrinogenase in insulin shock, in electroshock, and in epileptic seizure.] therapeutic application,unassigned 1,0 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14602768&form=6&db=m Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19966184&form=6&db=m Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22028447&form=6&db=m Heparin-binding EGF-like growth factor (HB-EGF) mediates 5-HT-induced insulin resistance through activation of EGF receptor-ERK1/2-mTOR pathway. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26291802&form=6&db=m Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26742564&form=6&db=m Thrombin stimulates insulin secretion via protease-activated receptor-3. causal interaction,unassigned 1,0 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27396242&form=6&db=m Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28502917&form=6&db=m The Role of Heparin Cofactor ? in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Insulinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8190093&form=6&db=m Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines. unassigned - 3.4.21.5 Intermittent Claudication http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17826235&form=6&db=m Platelet activation increases with the severity of peripheral arterial disease: implications for clinical management. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Intestinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11447011&form=6&db=m Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(-) secretion in human intestinal epithelial cells. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Intestinal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15634544&form=6&db=m [Clinical study of hemostatic molecular markers expression in patients with cancer.] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Intestinal Obstruction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34292211&form=6&db=m The Diagnostic Value of Coagulation Indicators and Inflammatory Markers in Distinguishing Between Strangulated and Simple Intestinal Obstruction. diagnostic usage,unassigned 2,0 3.4.21.5 Intracranial Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30803339&form=6&db=m Lyophilizing thrombin powder-based treatment for hemostasis during coil embolization of ruptured cerebral aneurysm: Two case reports. therapeutic application,unassigned 3,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7299541&form=6&db=m Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major. diagnostic usage,unassigned 3,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9920839&form=6&db=m Association of a common polymorphism in the factor XIII gene with venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19726015&form=6&db=m Effect of minimally invasive surgery for cerebral hematoma evacuation in different stages on motor evoked potential and thrombin in dog model of intracranial hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21041570&form=6&db=m Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22367842&form=6&db=m Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23242974&form=6&db=m Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? ongoing research,unassigned 1,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23397554&form=6&db=m Anticoagulation therapy for atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23519385&form=6&db=m Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage. ongoing research,unassigned 2,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24323711&form=6&db=m Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24452610&form=6&db=m New antithrombotics for secondary prevention of acute coronary syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25245227&form=6&db=m Thromboelastographic profiles of the premature infants with and without intracranial hemorrhage at birth: a pilot study. causal interaction,unassigned 2,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25828970&form=6&db=m Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes. diagnostic usage,unassigned 2,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26714677&form=6&db=m Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage : A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. therapeutic application,unassigned 2,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27465882&form=6&db=m Novel oral anticoagulant management issues for the stroke clinician. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692682&form=6&db=m Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30453810&form=6&db=m New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30848768&form=6&db=m [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Intracranial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1988604&form=6&db=m Treatment of intractable arterial hemorrhage during stereotactic brain biopsy with thrombin. Report of three patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Intracranial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26261773&form=6&db=m Steps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhage. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9401066&form=6&db=m Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization. unassigned - 3.4.21.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9469624&form=6&db=m Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9469625&form=6&db=m Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10494665&form=6&db=m Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke. causal interaction,unassigned 3,0 3.4.21.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12811008&form=6&db=m Development of argatroban as an anticoagulant and antithrombin agent in Japan. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Iron Overload http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25811447&form=6&db=m Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload. diagnostic usage,unassigned 2,0 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2957821&form=6&db=m Platelet function and thrombin activity in patients with recent cerebral transient ischemic attacks. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10775022&form=6&db=m Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11700498&form=6&db=m Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12869718&form=6&db=m Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26219486&form=6&db=m Impact of dabigatran on platelet function and fibrinolysis. ongoing research,unassigned 2,0 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33314013&form=6&db=m High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33838480&form=6&db=m Thrombin generation is associated with ischemic stroke at a young age. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2718198&form=6&db=m Hemostatic markers in acute stroke. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8589208&form=6&db=m Thrombin inhibition in the acute phase of ischaemic stroke using argatroban. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9469623&form=6&db=m Development of argatroban, a direct thrombin inhibitor, and its clinical application. diagnostic usage,unassigned 1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10588458&form=6&db=m Hemostatic markers in ischemic stroke of undetermined etiology. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11139833&form=6&db=m LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11214426&form=6&db=m Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11214663&form=6&db=m Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,2 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12058880&form=6&db=m Treatment of acute ischemic stroke: recent progress. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12235794&form=6&db=m [Strategy for circulatory disturbance] therapeutic application,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753484&form=6&db=m Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961162&form=6&db=m Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15073383&form=6&db=m Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15155959&form=6&db=m Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. therapeutic application,unassigned 3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15208865&form=6&db=m [Effect of surgical menopause on the development of cardiovascular diseases] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15306752&form=6&db=m Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15692116&form=6&db=m Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15846799&form=6&db=m Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16198396&form=6&db=m Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16340184&form=6&db=m Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16763191&form=6&db=m Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17417744&form=6&db=m Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17673721&form=6&db=m Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18598697&form=6&db=m Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150392&form=6&db=m Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2. causal interaction,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19280866&form=6&db=m Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19806263&form=6&db=m Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20461165&form=6&db=m Treatment for Patients with Acute Ischemic Stroke Presenting beyond Six Hours of Ischemic Symptom Onset : Effectiveness of Intravenous Direct Thrombin Inhibitor, Argatroban. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21041570&form=6&db=m Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21225480&form=6&db=m Stroke prevention in atrial fibrillation: atrial appendage closure. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21454811&form=6&db=m Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21512172&form=6&db=m Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21638139&form=6&db=m Prevention of cardioembolic stroke. causal interaction,unassigned 3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21708357&form=6&db=m Coated-platelet levels are elevated in patients with transient ischemic attack. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21767237&form=6&db=m Chronic hyper-reactivity of platelets resulting in enhanced monocyte recruitment in patients after ischaemic stroke. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21932989&form=6&db=m The use of a desktop scanning electron microscope as a diagnostic tool in studying fibrin networks of thrombo-embolic ischemic stroke. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22065286&form=6&db=m Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. ongoing research,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22683118&form=6&db=m Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23064666&form=6&db=m Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23266689&form=6&db=m Acidosis, magnesium and acetylsalicylic acid: effects on thrombin. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23394539&form=6&db=m New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke. therapeutic application,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23900720&form=6&db=m Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24063505&form=6&db=m Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24985053&form=6&db=m Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25063764&form=6&db=m Platelet Reactivity in Patients With Stroke and Hyperlipidemia, GPIb? Assessment. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25066647&form=6&db=m Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25604482&form=6&db=m Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26096376&form=6&db=m Dabigatran: Experience in standard clinical practice. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26390857&form=6&db=m Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26670085&form=6&db=m Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26825622&form=6&db=m The influence of immunoglobulin class G from blood plasma of patients with stroke on the activity of some parameters of hemostasis system. unassigned - 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26861077&form=6&db=m Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27094310&form=6&db=m A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184031&form=6&db=m Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27264767&form=6&db=m Looking for Our Ten Years Results for Coronary Heart Disease and Ischemic Stroke Group for the Standpoint of Haemostasis. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27465882&form=6&db=m Novel oral anticoagulant management issues for the stroke clinician. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28062625&form=6&db=m High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116215&form=6&db=m Thrombin Generation in Acute Ischaemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28344073&form=6&db=m Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. causal interaction,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28419510&form=6&db=m Increase of aquaporin 9 expression in astrocytes participates in astrogliosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28443061&form=6&db=m A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692682&form=6&db=m Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28879581&form=6&db=m Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29255511&form=6&db=m Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29335786&form=6&db=m Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29706441&form=6&db=m Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29761540&form=6&db=m Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30309801&form=6&db=m Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30564010&form=6&db=m The role of thrombin in central nervous system activity and stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30718498&form=6&db=m ?-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-? in stroke. therapeutic application,unassigned 1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31127075&form=6&db=m Independent ischemic stroke risk factors in older Americans: a systematic review. diagnostic usage,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31388437&form=6&db=m Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32305521&form=6&db=m Antithrombin gamma attenuates macrophage/microglial activation and brain damage after transient focal cerebral ischemia in mice. causal interaction,unassigned 4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32667287&form=6&db=m Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33055222&form=6&db=m In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke. diagnostic usage,unassigned 3,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33314013&form=6&db=m High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33708936&form=6&db=m The effects of heatwaves and cold spells on patients admitted with acute ischemic stroke. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33720950&form=6&db=m Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33838480&form=6&db=m Thrombin generation is associated with ischemic stroke at a young age. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34109507&form=6&db=m Increased procoagulant platelet levels are predictive of death in COVID-19. causal interaction,unassigned 4,0 3.4.21.5 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=914190&form=6&db=m [1st studies on the problem of rectal resorption of MPS in the treatment of arthroses] diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6228031&form=6&db=m Anticoagulant properties of three mucopolysaccharides used in rheumatology. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976643&form=6&db=m Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14854769&form=6&db=m [Hemophilic arthropathies; good results of lavage with thrombin solutions.] therapeutic application,unassigned 2,0 3.4.21.5 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14953493&form=6&db=m [Successful results of intra-articular injections of thrombin solutions, after irrigation of the joint in the treatment of hemophilic joint diseases.] therapeutic application,unassigned 4,0 3.4.21.5 Kasabach-Merritt Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901445&form=6&db=m Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid. therapeutic application,unassigned 3,0 3.4.21.5 Kidney Calculi http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3932682&form=6&db=m Coagulum pyelolithotomy: impact on unrecognized stones. unassigned - 3.4.21.5 Kidney Cortex Necrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5662752&form=6&db=m Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15780084&form=6&db=m Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells. unassigned - 3.4.21.5 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28382370&form=6&db=m Impact of fibrinogen carbamylation on fibrin clot formation and stability. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1938222&form=6&db=m Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8183585&form=6&db=m [Local microviscosity of platelet membranes from patients with chronic renal failure on hemodialysis] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9144032&form=6&db=m Increased thrombin generation in patients with chronic renal failure. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9506272&form=6&db=m Increased thrombin and plasmin generation in chronic renal failure. causal interaction,unassigned 3,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9922347&form=6&db=m Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11085063&form=6&db=m [Uremic coagulopathy. Role of thrombin] causal interaction,unassigned 4,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12735590&form=6&db=m Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15247979&form=6&db=m Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. causal interaction,unassigned 3,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15264185&form=6&db=m Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. diagnostic usage,unassigned 4,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569338&form=6&db=m A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16420568&form=6&db=m Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,4 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23180880&form=6&db=m Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24400802&form=6&db=m Vitamin k antagonists: beyond bleeding. therapeutic application,unassigned 4,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27079417&form=6&db=m Atrial fibrillation in dialysis patients: time to abandon warfarin? therapeutic application,unassigned 4,0 3.4.21.5 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34086880&form=6&db=m Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Kidney Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11755953&form=6&db=m The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Kidney Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12382022&form=6&db=m Does renal carcinoma affect the expression of P-selectin on platelets? therapeutic application,unassigned 1,0 3.4.21.5 Kidney Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15386385&form=6&db=m von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Klinefelter Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31505312&form=6&db=m Testosterone treatment and association with thrombin generation and coagulation inhibition in Klinefelter syndrome: A cross-sectional study. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Klinefelter Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33382882&form=6&db=m Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. diagnostic usage,unassigned 3,0 3.4.21.5 Laryngeal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25592110&form=6&db=m Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Lecithin Cholesterol Acyltransferase Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Leiomyoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17102682&form=6&db=m Topical thrombin-related corneal calcification. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Leiomyosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12607994&form=6&db=m [Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis] causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Leishmaniasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10097324&form=6&db=m Evaluation of secondary haemostasis in canine leishmaniasis. diagnostic usage,unassigned 4,0 3.4.21.5 Leprosy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12175102&form=6&db=m Markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with antiphospholipid antibodies. diagnostic usage,unassigned 2,0 3.4.21.5 Leptospirosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1084021&form=6&db=m Coagulation studies in leptospirosis. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Leptospirosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31548314&form=6&db=m Evaluating the moonlight role of supramolecule ErpY-like lipoprotein of Leptospira in thrombin-catalyzed fibrin clot inhibition, binding to complement factors H & -I, and its diagnostic potential. unassigned - 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1000464&form=6&db=m The effect of cytosine arabinoside on platelet aggregation. unassigned - 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1324917&form=6&db=m Molecular cloning of the rat vascular smooth muscle thrombin receptor. Evidence for in vitro regulation by basic fibroblast growth factor. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1527727&form=6&db=m Thrombin, but not thromboxane, stimulates megakaryocytic differentiation in human megakaryoblastic leukemia cells. ongoing research,unassigned 2,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1550592&form=6&db=m Thrombin-induced calcium oscillation in human platelets and MEG-01, a megakaryoblastic leukemia cell line. unassigned - 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1714407&form=6&db=m Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias. therapeutic application,unassigned 1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153685&form=6&db=m Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2323642&form=6&db=m Thrombin generation in acute myeloblastic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2369938&form=6&db=m Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2386901&form=6&db=m The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6531754&form=6&db=m High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6592007&form=6&db=m Thrombin generation in acute promyelocytic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531260&form=6&db=m In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. causal interaction,unassigned 3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8039760&form=6&db=m Fibrinogen survival and fibrinopeptide A in acute leukemia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8372434&form=6&db=m Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8470059&form=6&db=m Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. causal interaction,unassigned 3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8750618&form=6&db=m Interleukins and colony stimulating factors in human myeloid leukemia cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9473306&form=6&db=m alpha-Thrombin inhibits signal transducers and activators of transcription 3 signaling by interleukin-6, leukemia inhibitory factor, and ciliary neurotrophic factor in CCL39 cells. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9814983&form=6&db=m Analysis of a Ca2+-activated K+ channel that mediates hyperpolarization via the thrombin receptor pathway. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127398&form=6&db=m Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12490231&form=6&db=m Antithrombin activity of some constituents from Origanum vulgare. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,2 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17525899&form=6&db=m Thromboembolic complications in pediatric hematologic malignancies. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17938766&form=6&db=m [Coagulation and formation of malignant effusions] ongoing research,unassigned 3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18788619&form=6&db=m [Study of fibrinolysis inhibitors in 117 acute leukemia patients] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21336167&form=6&db=m Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23324297&form=6&db=m Successful treatment of spontaneous rupture of the internal carotid artery in an acute promyelocytic leukemia patient using ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23628020&form=6&db=m [Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance]. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24144040&form=6&db=m Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27064425&form=6&db=m Thrombin Maybe Plays an Important Role in MK Differentiation into Platelets. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28303518&form=6&db=m Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28593927&form=6&db=m Laboratory characterization of leukemic cell procoagulants. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30099724&form=6&db=m Elevated extracellular trap formation and contact system activation in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30453810&form=6&db=m New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929114&form=6&db=m Thrombin generation in children with febrile neutropenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1331412&form=6&db=m Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL. ongoing research,unassigned 2,0 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1654787&form=6&db=m Thrombin stimulates the production of phosphatidylinositol 3,4-bisphosphate in human erythroleukemia cells. ongoing research,unassigned 4,0 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695902&form=6&db=m Effect of protein kinase A on inositide metabolism and rap 1 G-protein in human erythroleukemia cells. ongoing research,unassigned 4,0 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7630424&form=6&db=m Analysis of receptor-G protein interactions in permeabilized cells. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8390469&form=6&db=m Internalization and recycling of activated thrombin receptors. unassigned - 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11752134&form=6&db=m Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis. therapeutic application,unassigned 1,0 3.4.21.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12656674&form=6&db=m Antisense-mediated loss of calcium homoeostasis endoplasmic reticulum protein (CHERP; ERPROT213-21) impairs Ca2+ mobilization, nuclear factor of activated T-cells (NFAT) activation and cell proliferation in Jurkat T-lymphocytes. ongoing research,unassigned 4,0 3.4.21.5 Leukemia, Megakaryoblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8555487&form=6&db=m Thrombin receptors activate potassium and chloride channels. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Leukemia, Myelogenous, Chronic, BCR-ABL Positive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24365376&form=6&db=m Commonly used drugs in hematologic disorders. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Leukemia, Myeloid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8750618&form=6&db=m Interleukins and colony stimulating factors in human myeloid leukemia cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2323642&form=6&db=m Thrombin generation in acute myeloblastic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2369938&form=6&db=m Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3181338&form=6&db=m Identification and characterization of human hemopoietic mast cell colonies. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3525766&form=6&db=m The clinical and biological correlates of coagulopathy in children with acute leukemia. diagnostic usage,unassigned 2,0 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6590923&form=6&db=m [Blood coagulation changes in children with acute myelogenous leukemia: thrombin effect or proteolysis] diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6592007&form=6&db=m Thrombin generation in acute promyelocytic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30453810&form=6&db=m New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31228869&form=6&db=m Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation. diagnostic usage,unassigned 2,0 3.4.21.5 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2369938&form=6&db=m Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.5 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6592007&form=6&db=m Thrombin generation in acute promyelocytic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531260&form=6&db=m In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. causal interaction,unassigned 3,0 3.4.21.5 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8470059&form=6&db=m Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. causal interaction,unassigned 3,0 3.4.21.5 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23324297&form=6&db=m Successful treatment of spontaneous rupture of the internal carotid artery in an acute promyelocytic leukemia patient using ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30453810&form=6&db=m New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Leukocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=847788&form=6&db=m Pleocytosis and elevation of prostaglandins F2a and E2 in cerebrospinal fluid following intracisternal injection of thrombin. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Leukocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11019959&form=6&db=m Multi-cellular activation in vivo by endotoxin in humans--limited protection by adenosine infusion. unassigned - 3.4.21.5 Leukopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3456403&form=6&db=m Pulmonary hemodynamic effects of antisheep serum-induced leukopenia. ongoing research,unassigned 4,0 3.4.21.5 Leukopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10903607&form=6&db=m Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.5 Leukostasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3938413&form=6&db=m Experimental studies on the adult respiratory distress syndrome: effects of induced DIC; granulocytes and elastase in mini pigs. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Livedo Reticularis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19280866&form=6&db=m Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1447499&form=6&db=m Disseminated intravascular coagulation in liver cirrhosis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719808&form=6&db=m Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3988169&form=6&db=m [Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4076847&form=6&db=m Acquired thrombin inhibitor in a patient with liver cirrhosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5904206&form=6&db=m Evaluation of fibrinolysis in hepatic cirrhosis. Relation of serial thrombin time and euglobulin lysis time. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7071809&form=6&db=m Progressive antithrombin activity and the concentration of three thrombin inhibitors in liver cirrhosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7126483&form=6&db=m Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7603083&form=6&db=m Thrombin clotting time and fibrin polymerization in liver cirrhosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11503051&form=6&db=m [The characteristics of clinical course of chronic hepatitis B and liver cirrhosis pathology of child patient] unassigned - 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11867180&form=6&db=m Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. causal interaction,unassigned 1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15479692&form=6&db=m A role for thrombin in liver fibrosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17962354&form=6&db=m Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis. therapeutic application,unassigned 4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18005014&form=6&db=m Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19816608&form=6&db=m Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? causal interaction,unassigned 3,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21037076&form=6&db=m The Coagulation System Contributes to {alpha}V{beta}6 Integrin Expression and Liver Fibrosis Induced by Cholestasis. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23546632&form=6&db=m Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24913997&form=6&db=m Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event. unassigned - 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26785615&form=6&db=m Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association? causal interaction,unassigned 1,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27182154&form=6&db=m Thrombin activation and liver inflammation in advanced hepatitis C virus infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28472132&form=6&db=m Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28638347&form=6&db=m Bile Acids Do Not Contribute to the Altered Calcium Homeostasis of Platelets from Rats with Biliary Cirrhosis. unassigned - 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29739329&form=6&db=m Thrombin and factor Xa link the coagulation system with liver fibrosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30288660&form=6&db=m Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30988720&form=6&db=m Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31158377&form=6&db=m Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats. therapeutic application,unassigned 4,0 3.4.21.5 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32715285&form=6&db=m Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4041&form=6&db=m Platelet aggregation in portal cirrhosis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=621288&form=6&db=m Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=870000&form=6&db=m Acquired dysfibrinogenaemia in acute and chronic liver disease. therapeutic application,unassigned 1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=882964&form=6&db=m Prolonged thrombin clotting times in liver disease. unassigned - 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1909901&form=6&db=m Thrombin activation and increased fibrinolysis in patients with chronic liver disease. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2195867&form=6&db=m Fibrinolysis and fibrinogenolysis in liver disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2527002&form=6&db=m Thrombin and plasmin generation in patients with liver disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3194893&form=6&db=m Effect of liver damage on the level of coagulation factor II, X and VII in human and bovine plasma. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4077019&form=6&db=m [Hemostatic studies on acquired abnormal fibrinogenemia in severe liver diseases and umbilical cord blood] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6695916&form=6&db=m The multiple coagulopathies of biliary atresia. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6839020&form=6&db=m The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. ongoing research,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7172607&form=6&db=m Relation of simple clotting tests to clotting factor levels in liver disease. diagnostic usage,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7618714&form=6&db=m Quantification of thrombelastographic changes after blood component transfusion in patients with liver disease in the intensive care unit. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657283&form=6&db=m Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. causal interaction,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9434921&form=6&db=m The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease. causal interaction,unassigned 3,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9560761&form=6&db=m Coagulation abnormalities in 22 cats with naturally occurring liver disease. diagnostic usage,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13432375&form=6&db=m [Thrombin time in liver diseases.] diagnostic usage,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14122937&form=6&db=m [INFLUENCE OF THE "COTHROMBIN PLASMATIC FACTOR" IN THE INCREASE OF THROMBIN TIME IN LIVER DISEASE PATIENTS.] causal interaction,unassigned 2,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15534097&form=6&db=m Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17068159&form=6&db=m Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18469550&form=6&db=m Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19022928&form=6&db=m Coagulation and fibrosis in chronic liver disease. causal interaction,unassigned 3,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22712870&form=6&db=m Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22841818&form=6&db=m Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23482736&form=6&db=m Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April). therapeutic application,unassigned 1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23638693&form=6&db=m Clinical utility of viscoelastic tests of coagulation in patients with liver disease. causal interaction,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24164805&form=6&db=m Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,1 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138021&form=6&db=m Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25541032&form=6&db=m Thrombin generation test in children and adolescents with chronic liver disease. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25769583&form=6&db=m Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease. causal interaction,unassigned 1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25847196&form=6&db=m Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26200653&form=6&db=m Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26258657&form=6&db=m Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study. diagnostic usage,unassigned 1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27071046&form=6&db=m Alterations in Fibrin Structure in Patients with Liver Diseases. therapeutic application,unassigned 1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27144445&form=6&db=m Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association? therapeutic application,unassigned 2,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28478207&form=6&db=m Thrombin generation in patients with non-cirrhotic vascular liver diseases treated or not treated with vitamin K antagonist. therapeutic application,unassigned 2,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28737512&form=6&db=m Thrombin promotes diet-induced obesity through fibrin-driven inflammation. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28843665&form=6&db=m Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30609442&form=6&db=m Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. diagnostic usage,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30986390&form=6&db=m AGA Clinical Practice Update: Coagulation in Cirrhosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31653415&form=6&db=m Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury. causal interaction,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32087412&form=6&db=m Thrombin dynamics in children with liver disease or extrahepatic portal vein obstruction or shunt. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32196929&form=6&db=m Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyser. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32629499&form=6&db=m In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32715285&form=6&db=m Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32808155&form=6&db=m Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage. causal interaction,unassigned 4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32984220&form=6&db=m Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. unassigned - 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33219597&form=6&db=m Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. therapeutic application,unassigned 1,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34066706&form=6&db=m Thrombin Generation in Chronic Liver Diseases-A Pilot Study. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34472786&form=6&db=m Coagulation Profile and its Correlation with Severity of Liver Dysfunction and Gastrointestinal Bleed in Alcoholic Liver Disease Patients. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Liver Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3704722&form=6&db=m Hyperfibrinogenemia as a cause of prolonged thrombin clotting time. diagnostic usage,unassigned 3,0 3.4.21.5 Liver Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6083925&form=6&db=m [Substitution of antithrombin III by synthetic thrombin inhibitors] therapeutic application,unassigned 3,0 3.4.21.5 Liver Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10493559&form=6&db=m Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes. diagnostic usage,unassigned 3,0 3.4.21.5 Liver Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12921505&form=6&db=m Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Liver Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28455937&form=6&db=m Pitfalls in the Use of Anticoagulants. therapeutic application,unassigned 4,0 3.4.21.5 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3065544&form=6&db=m [Increased thrombin synthesis in patients with fulminant hepatic failure and its treatment with antithrombin III evaluated by plasma levels of thrombin-antithrombin III complex] diagnostic usage,unassigned 3,0 3.4.21.5 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22568491&form=6&db=m Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.5 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23515053&form=6&db=m Hemostasis in patients with acute kidney injury secondary to acute liver failure. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24164805&form=6&db=m Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,1 3.4.21.5 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6096471&form=6&db=m The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer. diagnostic usage,unassigned 4,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510986&form=6&db=m Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7844912&form=6&db=m [Evaluation of serum thrombomodulin in patients with interstitial pneumonia] ongoing research,unassigned 3,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8186352&form=6&db=m Antithrombin III deficiency in neonatal respiratory distress syndrome. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395719&form=6&db=m Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12461737&form=6&db=m Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15302675&form=6&db=m Effects of inhaled thrombin receptor agonists in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15344597&form=6&db=m Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma). causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15572532&form=6&db=m Thrombin induces collagen gel contraction partially through PAR1 activation and PKC-epsilon. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17433115&form=6&db=m Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells. causal interaction,unassigned 3,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18342628&form=6&db=m PKCdelta mediates thrombin-augmented fibroblast-mediated collagen gel contraction. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24279877&form=6&db=m Thrombin Increases Lung Fibroblast Survival While Promoting Alveolar Epithelial Cell Apoptosis via the ER Stress Marker CHOP. causal interaction,unassigned 2,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26640170&form=6&db=m Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28407300&form=6&db=m Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1701928&form=6&db=m Significance of thrombin in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1709710&form=6&db=m [The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder] ongoing research,unassigned 3,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1715176&form=6&db=m Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2666653&form=6&db=m Fibrinopeptide A reactive peptides and procoagulant activity in bronchoalveolar lavage: relationship to rheumatoid interstitial lung disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15751279&form=6&db=m The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21312187&form=6&db=m Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24279877&form=6&db=m Thrombin Increases Lung Fibroblast Survival While Promoting Alveolar Epithelial Cell Apoptosis via the ER Stress Marker CHOP. causal interaction,unassigned 2,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31777820&form=6&db=m Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease. therapeutic application,unassigned 3,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33545964&form=6&db=m Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33861685&form=6&db=m Associations of D-dimer with CT Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8874868&form=6&db=m Haemostatic changes in the pulmonary blood during cardiopulmonary bypass. causal interaction,unassigned 4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395719&form=6&db=m Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10806208&form=6&db=m Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246985&form=6&db=m [Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung] causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12573983&form=6&db=m Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12682461&form=6&db=m Anticoagulant therapy in acute lung injury. therapeutic application,unassigned 4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12947134&form=6&db=m Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15855637&form=6&db=m Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. ongoing research,unassigned 4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16909370&form=6&db=m The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18938186&form=6&db=m The coagulation system and pulmonary endothelial function in acute lung injury. causal interaction,unassigned 1,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18952113&form=6&db=m The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia. causal interaction,unassigned 2,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20494024&form=6&db=m Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21312187&form=6&db=m Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23549752&form=6&db=m Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury. ongoing research,unassigned 1,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23583295&form=6&db=m Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-?B and activator protein-1. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24506791&form=6&db=m Thrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Akt-dependent NF-?B/p300 activation. causal interaction,unassigned 4,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26176623&form=6&db=m Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice. unassigned - 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27190065&form=6&db=m Early coagulation events induce acute lung injury in a rat model of blunt traumatic brain injury. therapeutic application,unassigned 2,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30254103&form=6&db=m Hematopoietic protease nexin-1 protects against lung injury by preventing thrombin signaling in mice. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30995477&form=6&db=m PAR2-Mediated cAMP Generation Suppresses TRPV4-Dependent Ca2+ Signaling in Alveolar Macrophages to Resolve TLR4-Induced Inflammation. therapeutic application,unassigned 1,0 3.4.21.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33832398&form=6&db=m Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1452461&form=6&db=m Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2467397&form=6&db=m Abnormal haemostasis in small cell lung cancer. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2999116&form=6&db=m The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin. ongoing research,unassigned 4,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111321&form=6&db=m [Selected parameters of coagulation, fibrinolysis and antibodies to fibrinogen in lung cancer] diagnostic usage,unassigned 2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8954171&form=6&db=m Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12195692&form=6&db=m Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19776082&form=6&db=m Air-leak management after upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a pilot trial comparing sealant and standard treatment. therapeutic application,unassigned 4,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20807657&form=6&db=m Glycosaminoglycans and activated contact system in cancer patient plasmas. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22665038&form=6&db=m Cooperation of protease-activated receptor 1 and integrin ???5 in thrombin-mediated lung cancer cell invasion. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25861627&form=6&db=m PTEN plays an important role in thrombin-mediated lung cancer cell functions. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26919453&form=6&db=m Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA. ongoing research,unassigned 2,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27566553&form=6&db=m TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30309427&form=6&db=m [Analysis of the Incidence of Lower Extremity Venous Thrombosis and Its Related Risk Factors in Admitted Patients with Lung Cancer]. diagnostic usage,unassigned 4,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30746232&form=6&db=m Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30891644&form=6&db=m Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking. unassigned - 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32647187&form=6&db=m Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,3 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33478293&form=6&db=m Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33481255&form=6&db=m A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=698389&form=6&db=m Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE). diagnostic usage,unassigned 2,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=993337&form=6&db=m The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7709951&form=6&db=m Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8274747&form=6&db=m Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. unassigned - 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8499632&form=6&db=m Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. diagnostic usage,unassigned 2,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10233892&form=6&db=m Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10616019&form=6&db=m Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16543967&form=6&db=m Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. causal interaction,unassigned 2,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18180618&form=6&db=m Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20029948&form=6&db=m Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus. therapeutic application,unassigned 3,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25890027&form=6&db=m Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28361572&form=6&db=m Characterization of the thrombin generation profile in systemic lupus erythematosus. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30471875&form=6&db=m [Hemorrhagic syndrome due to a heparin-like anticoagulant in a patient with systemic lupus erythematosus]. unassigned - 3.4.21.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34128791&form=6&db=m Osteopontin: another piece in the systemic lupus erythematosus immunopathology puzzle. unassigned - 3.4.21.5 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9097912&form=6&db=m Calorie restriction decreases platelet-derived growth factor (PDGF)-A and thrombin receptor mRNA expression in autoimmune murine lupus nephritis. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Lymphocele http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21926956&form=6&db=m [Fibrinogen and thrombin coated patch use on collagen support for lymphocele prevention after lumbar-aortic lymphadenectomy in gynecological neoplasms]. therapeutic application,unassigned 2,0 3.4.21.5 Lymphocele http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33217600&form=6&db=m Application of thrombin gel matrix for the prevention of lymphocele in patients with endometrial cancer: A prospective randomized trial. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2595662&form=6&db=m Procoagulant activity of T lymphoblastoid cells in extrinsic and intrinsic coagulation systems. diagnostic usage,unassigned 3,0 3.4.21.5 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9885253&form=6&db=m Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. causal interaction,unassigned 3,0 3.4.21.5 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21176357&form=6&db=m [Relationship between coagulation function and international prognostic index in lymphoma patients]. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21336167&form=6&db=m Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33372544&form=6&db=m Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Lymphoma, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9885253&form=6&db=m Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. causal interaction,unassigned 3,0 3.4.21.5 Lymphoma, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27064425&form=6&db=m Thrombin Maybe Plays an Important Role in MK Differentiation into Platelets. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Lymphoma, Non-Hodgkin http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1714407&form=6&db=m Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias. therapeutic application,unassigned 1,0 3.4.21.5 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25310246&form=6&db=m Different Effects of Thrombin on VEGF Secretion, Proliferation, and Permeability in Polarized and Non-polarized Retinal Pigment Epithelial Cells. therapeutic application,unassigned 1,0 3.4.21.5 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29222552&form=6&db=m Animal Models of Retinal Vein Occlusion. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1412153&form=6&db=m Monocyte tissue factor expression induced by Plasmodium falciparum-infected erythrocytes. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1823881&form=6&db=m Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19401406&form=6&db=m Coagulation Status and Platelet Functions in Children with Severe Falciparum Malaria and their Correlation of Outcome. diagnostic usage,unassigned 4,0 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22338574&form=6&db=m Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases. therapeutic application,unassigned 1,0 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23223529&form=6&db=m Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector. unassigned - 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26743539&form=6&db=m Alterations of blood coagulation in controlled human malaria infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28592490&form=6&db=m Functional analyses yield detailed insight into the mechanism of thrombin inhibition by the antihemostatic salivary protein cE5 from Anopheles gambiae. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Malaria, Cerebral http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27624125&form=6&db=m Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence. ongoing research,unassigned 1,0 3.4.21.5 Malaria, Cerebral http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32724861&form=6&db=m Testing the effect of PAR1 inhibitors on Plasmodium falciparum-induced loss of endothelial cell barrier function. therapeutic application,unassigned 4,0 3.4.21.5 Marfan Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19584041&form=6&db=m Crosstalk between coagulation and inflammation in mastitis and metritis in dairy cows. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 3.4.21.5 Mastocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1543755&form=6&db=m Involvement of protein kinase C in thrombin-induced translocation of Gi2 alpha from the membrane to the cytosol in mouse mastocytoma P-815 cells. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Mastocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1708239&form=6&db=m Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells. unassigned - 3.4.21.5 Mastocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1900833&form=6&db=m Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1596884&form=6&db=m Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1657377&form=6&db=m Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1873799&form=6&db=m Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3480526&form=6&db=m Identification of a synthetic nonapeptide sequence that inhibits motility in culture of a melanoma subclone that possesses a high metastatic potential. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6566616&form=6&db=m Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. diagnostic usage,unassigned 1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7527241&form=6&db=m Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7712465&form=6&db=m Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7744600&form=6&db=m The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8473056&form=6&db=m Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8940162&form=6&db=m The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. ongoing research,unassigned 4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9030240&form=6&db=m Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9392328&form=6&db=m Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9649116&form=6&db=m Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9759619&form=6&db=m Prothrombin and its derivatives stimulate motility of melanoma cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10807779&form=6&db=m Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11310795&form=6&db=m Gene regulation in melanoma progression by the AP-2 transcription factor. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11372726&form=6&db=m Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11828253&form=6&db=m Transient resistance to B16F10 melanoma growth and metastasis in CD43-/- mice. ongoing research,unassigned 1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12231573&form=6&db=m Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12741683&form=6&db=m Transcriptional regulation of metastasis-related genes in human melanoma. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12789289&form=6&db=m Role and regulation of the thrombin receptor (PAR-1) in human melanoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15031212&form=6&db=m Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15280447&form=6&db=m Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15492257&form=6&db=m Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15523674&form=6&db=m Regulation of gene expression in melanoma: new approaches for treatment. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15539922&form=6&db=m Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15567463&form=6&db=m Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17721608&form=6&db=m Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. causal interaction,unassigned 3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18315603&form=6&db=m Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18600758&form=6&db=m Microcarrier culture of bowes melanoma cells in serum-free medium with Human plasma fraction IV-4+ V. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18974154&form=6&db=m Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19438723&form=6&db=m Thrombin-mediated impairment of fibroblast growth factor-2 activity. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20505748&form=6&db=m The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21043730&form=6&db=m Regulatory Effect of Cell Density on the Platelet-aggregating Activity of Human Melanoma Cell Line. diagnostic usage,unassigned 1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21135163&form=6&db=m Sequential binding of ?V?3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. ongoing research,unassigned 2,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21147226&form=6&db=m Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment. unassigned - 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21187389&form=6&db=m Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21378407&form=6&db=m The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22009534&form=6&db=m PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22262064&form=6&db=m Fibrin serves as a divalent ligand that regulates neutrophil-mediated melanoma cells adhesion to endothelium under shear conditions. unassigned - 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24405508&form=6&db=m miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26504080&form=6&db=m Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27117228&form=6&db=m Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29346400&form=6&db=m The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation. therapeutic application,unassigned 1,0 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30235481&form=6&db=m Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells? unassigned - 3.4.21.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30273953&form=6&db=m Heparanase and Thrombin: Common Signalling Pathways in Melanoma Cells? causal interaction,unassigned 1,0 3.4.21.5 Melanoma, Amelanotic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1281930&form=6&db=m Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Melanoma, Amelanotic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1596884&form=6&db=m Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Melanoma, Amelanotic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1845869&form=6&db=m Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.5 Melanoma, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3089587&form=6&db=m Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Melanoma, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7306988&form=6&db=m Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. causal interaction,unassigned 1,0 3.4.21.5 Melanoma, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10963995&form=6&db=m Effects of thrombin/thrombosis in angiogenesis and tumour progression. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 MELAS Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27993886&form=6&db=m Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency. causal interaction,unassigned 3,0 3.4.21.5 Melioidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18567449&form=6&db=m Production and purification of Burkholderia pseudomallei BipD protein. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Melioidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28296884&form=6&db=m Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Memory Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26021875&form=6&db=m Impaired adult hippocampal neurogenesis and cognitive ability in a mouse model of intrastriatal hemorrhage. causal interaction,unassigned 2,0 3.4.21.5 Memory Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26410080&form=6&db=m Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice. causal interaction,unassigned 3,0 3.4.21.5 Memory Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27624844&form=6&db=m Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Meningioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10421070&form=6&db=m PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10691848&form=6&db=m Defective fibrinogen polymerization associated with a novel gamma279Ala-->Asp mutation. diagnostic usage,unassigned 2,0 3.4.21.5 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871326&form=6&db=m Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. therapeutic application,unassigned 1,0 3.4.21.5 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15244237&form=6&db=m Successful use of recombinant factor VIIa for management of severe menorrhagia in an adolescent with an acquired inhibitor of human thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29336529&form=6&db=m High prevalence of reduced thrombin generation and/or decreased platelet response in women with unexplained heavy menstrual bleeding. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Mesenteric Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31875702&form=6&db=m Prothrombin Arg541Trp Mutation Leads to Defective PC (Protein C) Pathway Activation and Constitutes a Novel Genetic Risk Factor for Venous Thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Mesothelioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7628870&form=6&db=m Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth. ongoing research,unassigned 4,0 3.4.21.5 Mesothelioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9030240&form=6&db=m Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24899357&form=6&db=m Clot properties and cardiovascular disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15760260&form=6&db=m The top 12 advances in vascular medicine. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16570157&form=6&db=m Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16635606&form=6&db=m Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20619835&form=6&db=m Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21907177&form=6&db=m Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23408210&form=6&db=m Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26512756&form=6&db=m Increased RhoA/Rho-Kinase Activity and Markers of Endothelial Dysfunction in Young Adult Subjects with Metabolic Syndrome. diagnostic usage,unassigned 2,0 3.4.21.5 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31808596&form=6&db=m The intestinal microbiome potentially affects thrombin generation in human subjects. therapeutic application,unassigned 1,0 3.4.21.5 Metrorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32596863&form=6&db=m Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment. therapeutic application,unassigned 3,0 3.4.21.5 Migraine Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11437906&form=6&db=m The elusive role of thrombin in migraine. unassigned - 3.4.21.5 Migraine Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 MINOCA http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31249940&form=6&db=m Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA). causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Mirizzi Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31032465&form=6&db=m EUS-guided thrombin injection of cystic artery pseudoaneurysm leading to Mirizzi's syndrome and hemobilia. therapeutic application,unassigned 2,0 3.4.21.5 Mitral Valve Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8870174&form=6&db=m Platelet and blood clotting activation in patients with mitral valve prolapse. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Mitral Valve Prolapse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Mitral Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7646626&form=6&db=m Coagulation activity is increased in the left atrium of patients with mitral stenosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Mitral Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9114782&form=6&db=m Effect of mitral valvuloplasty in mitral stenosis on coagulation activity. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Mitral Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10731487&form=6&db=m Increased left atrial thrombin generation in mitral stenosis is not reflected in arterial prothrombin fragment 1+2 levels. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Mitral Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10995591&form=6&db=m Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin fragment 1+2 in mitral stenosis. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Mitral Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12935411&form=6&db=m Hypercoagulability existing in the local left atrium of patient with mitral stenosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Mitral Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24842885&form=6&db=m Changes in Platelet, Coagulation, and Fibrinolytic Activities in Mitral Stenosis After Percutaneous Mitral Valvotomy: Role of Hemodynamic Changes and Systemic Inflammation. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Monoclonal Gammopathy of Undetermined Significance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26759370&form=6&db=m Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Mononeuropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Mucopolysaccharidoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24277967&form=6&db=m Heparin Cofactor II Thrombin Complex as a Biomarker for Mucopolysaccharidosis: Indian Experience. therapeutic application,unassigned 4,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=102100&form=6&db=m [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma] diagnostic usage,unassigned 3,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1247286&form=6&db=m Gamma globulin inhibition of fibrin clot formation. unassigned - 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2935559&form=6&db=m A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9136969&form=6&db=m Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. causal interaction,unassigned 4,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10517116&form=6&db=m [Increased thrombin time in a patient with multiple myeloma] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11456488&form=6&db=m Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin. diagnostic usage,unassigned 2,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11672511&form=6&db=m Bleeding diathesis in multiple myeloma. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25302852&form=6&db=m Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. ongoing research,unassigned 1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25828972&form=6&db=m Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. diagnostic usage,unassigned 2,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25907422&form=6&db=m Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26083985&form=6&db=m Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,1 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161715&form=6&db=m PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27931131&form=6&db=m Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28365523&form=6&db=m Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. diagnostic usage,unassigned 4,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692431&form=6&db=m Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28865304&form=6&db=m Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29916838&form=6&db=m Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway. ongoing research,unassigned 1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30099724&form=6&db=m Elevated extracellular trap formation and contact system activation in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30405097&form=6&db=m Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30656281&form=6&db=m Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30793294&form=6&db=m Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31421013&form=6&db=m The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12594292&form=6&db=m Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17027887&form=6&db=m Thrombin in inflammatory brain diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343583&form=6&db=m Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29318029&form=6&db=m Thrombin generation correlates with disease duration in multiple sclerosis (MS): Novel insights into the MS-associated prothrombotic state. causal interaction,unassigned 3,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29731736&form=6&db=m Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis. therapeutic application,unassigned 1,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30105021&form=6&db=m The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review. therapeutic application,unassigned 3,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33411219&form=6&db=m Thrombin generation and activity in multiple sclerosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Muscular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Muscular Dystrophies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14733957&form=6&db=m Expression of trypsin-like proteases and protease nexin-1 in mdx mouse muscles. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25811447&form=6&db=m Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload. diagnostic usage,unassigned 2,0 3.4.21.5 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30099724&form=6&db=m Elevated extracellular trap formation and contact system activation in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Myeloproliferative Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5512090&form=6&db=m [Abnormalities of thrombocyte function in myeloproliferative disorders. I. Defective thrombocyte aggregation by ADP, collagen, noradrenaline and thrombin] unassigned - 3.4.21.5 Myeloproliferative Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7833251&form=6&db=m Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Myeloproliferative Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8735810&form=6&db=m Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Myeloproliferative Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11991237&form=6&db=m Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=509807&form=6&db=m Platelet hyperreactivity to thrombin in patients with myocardial infarction and normal or slightly abnormal coronary arteries. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1387346&form=6&db=m Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1389732&form=6&db=m Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,3 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1552097&form=6&db=m Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1576116&form=6&db=m Persistent generation of thrombin after acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1774011&form=6&db=m [Contributory changes in variables of coagulation and fibrinolysis to the patency of coronary arteries in patients with acute myocardial infarction] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1900225&form=6&db=m Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1984896&form=6&db=m Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. ongoing research,unassigned 1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2100876&form=6&db=m Functional and antigenic antithrombin III in angina pectoris and acute myocardial infarction patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2119139&form=6&db=m Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2203397&form=6&db=m Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2272456&form=6&db=m [Comparative analysis of thrombin and anti-thrombin antibody levels in donors and myocardial infarction patients] diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2277786&form=6&db=m [Assessment of hemostasis in patients with myocardial infarction complicated by deep venous thrombosis] causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2335864&form=6&db=m [Thrombin and anti-thrombin antibody levels in the blood of patients with acute myocardial infarction] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2510363&form=6&db=m Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2599544&form=6&db=m Prostaglandin E1 (PGE1): effect on the human fibrinolytic system. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3135862&form=6&db=m Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3568326&form=6&db=m Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3613046&form=6&db=m Thromboxane A2 synthesizing activity of platelets in coronary artery diseases. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3624659&form=6&db=m Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3672428&form=6&db=m Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6197872&form=6&db=m Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6697455&form=6&db=m Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6785974&form=6&db=m Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7075276&form=6&db=m Association of recurrent myocardial infarction with hemostatic factors: a prospective study. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507363&form=6&db=m Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7578891&form=6&db=m Challenges in the development of orally bioavailable thrombin active site inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7585777&form=6&db=m Thrombin inhibitors in acute myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7699733&form=6&db=m Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7728844&form=6&db=m Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7798503&form=6&db=m Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7805216&form=6&db=m Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863966&form=6&db=m Activation of blood coagulation by plaque rupture: mechanisms and prevention. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923644&form=6&db=m Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923646&form=6&db=m Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7930274&form=6&db=m Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8043909&form=6&db=m Thrombinogenesis and its pharmacological modulation in atherosclerosis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8094535&form=6&db=m Thrombin generation and myocardial infarction during infusion of tissue-plasminogen activator. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8149522&form=6&db=m A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8173709&form=6&db=m Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8542870&form=6&db=m Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8568564&form=6&db=m Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin. diagnostic usage,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8568567&form=6&db=m Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578530&form=6&db=m Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8603017&form=6&db=m Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8667188&form=6&db=m Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8696958&form=6&db=m Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,2 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8732376&form=6&db=m Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8746200&form=6&db=m Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. causal interaction,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778585&form=6&db=m A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8790025&form=6&db=m Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8806332&form=6&db=m Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8870177&form=6&db=m Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin? causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883267&form=6&db=m Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8901653&form=6&db=m Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,3 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9005443&form=6&db=m Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9031450&form=6&db=m Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9257498&form=6&db=m Haemostatic function in coronary artery disease (CAD). diagnostic usage,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9323066&form=6&db=m Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9459313&form=6&db=m Association of a common polymorphism in the factor XIII gene with myocardial infarction. causal interaction,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9502626&form=6&db=m Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9527072&form=6&db=m Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease. diagnostic usage,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531029&form=6&db=m Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626825&form=6&db=m Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9671009&form=6&db=m Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy). therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9676792&form=6&db=m Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9878933&form=6&db=m Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9920839&form=6&db=m Association of a common polymorphism in the factor XIII gene with venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9973029&form=6&db=m Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9988016&form=6&db=m Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy). therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10079109&form=6&db=m Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. unassigned - 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10087435&form=6&db=m Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10329069&form=6&db=m The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10342131&form=6&db=m [Pathophysiology of acute coronary syndromes] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10362188&form=6&db=m A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10364817&form=6&db=m [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10413853&form=6&db=m [Blood coagulation and fibrinolysis in arteriosclerosis] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10426846&form=6&db=m Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10468144&form=6&db=m Thrombin inhibitors as anticoagulant agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10577463&form=6&db=m Newer antithrombin agents in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10590183&form=6&db=m Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10598899&form=6&db=m Development and evaluation of a new canine myocardial infarction model using a closed-chest injection of thrombogenic material. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603519&form=6&db=m Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608050&form=6&db=m A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study. therapeutic application,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639214&form=6&db=m Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639631&form=6&db=m The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis" causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639632&form=6&db=m The Narrow Therapeutic Index of Thrombin Inhibition: Implications for Newer Antithrombotic Therapies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10640797&form=6&db=m Failure of thrombin generation markers to triage patients presenting with chest pain. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10728020&form=6&db=m Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10767116&form=6&db=m Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10810775&form=6&db=m Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10980840&form=6&db=m Direct thrombin inhibitors as adjuncts to thrombolytic therapy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11030473&form=6&db=m Desirudin: a review of its use in the management of thrombotic disorders. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11057876&form=6&db=m The -5061/D polymorphism of the thrombin receptor (PAR-1) gene is not related to myocardial infarction in the ECTIM study. The Etude Cas-Temoins de l'Infarctus du Myocarde. MONICA Members Group. unassigned - 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127437&form=6&db=m Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11136505&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11223439&form=6&db=m Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11567669&form=6&db=m The thrombolytic paradox. unassigned - 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11686357&form=6&db=m Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11830196&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11888508&form=6&db=m Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11950430&form=6&db=m Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12091125&form=6&db=m Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12182909&form=6&db=m Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. unassigned - 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12524220&form=6&db=m The dynamics of thrombin formation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12644344&form=6&db=m The evolving role of direct thrombin inhibitors in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12749780&form=6&db=m Morning sudden cardiac death. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12769712&form=6&db=m G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12843003&form=6&db=m Coagulation activation and long-term outcome in acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12876638&form=6&db=m Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute percutaneous coronary angioplasty. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13678873&form=6&db=m Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14606349&form=6&db=m [Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status] causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14607082&form=6&db=m Targeting thrombin--rational drug design from natural mechanisms. causal interaction,unassigned 1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14642154&form=6&db=m Advances in antithrombin therapy for ST-elevation myocardial infarction. causal interaction,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14715345&form=6&db=m Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14985171&form=6&db=m Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15031124&form=6&db=m Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15049722&form=6&db=m Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15077087&form=6&db=m Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,3 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15208865&form=6&db=m [Effect of surgical menopause on the development of cardiovascular diseases] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15353058&form=6&db=m Cardiology. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15353822&form=6&db=m Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15373236&form=6&db=m [Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction] causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15379714&form=6&db=m Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15521923&form=6&db=m Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15650548&form=6&db=m Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15724919&form=6&db=m [Effects of exercise on markers of hemostatic activation in young survivors of myocardial infarction] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992034&form=6&db=m Low molecular weight heparin in acute stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16123917&form=6&db=m Prevention of cardiovascular events after acute coronary syndrome. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16175024&form=6&db=m Update on acute coronary syndromes and ST-elevation myocardial infarction. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16194202&form=6&db=m Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16331363&form=6&db=m [Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.] therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16649726&form=6&db=m Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17103113&form=6&db=m Direct thrombin inhibitors - a survey of recent developments. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17314111&form=6&db=m Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18215612&form=6&db=m Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18224254&form=6&db=m Thrombin receptor and ventricular arrhythmias after acute myocardial infarction. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18412079&form=6&db=m What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18520714&form=6&db=m Long-term anticoagulation in patients with coronary disease, and future developments. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18926355&form=6&db=m The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19231390&form=6&db=m Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19232896&form=6&db=m Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. therapeutic application,unassigned 2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19238188&form=6&db=m Influence of aromatic and aliphatic moieties on thrombin inhibitors potency. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19350119&form=6&db=m Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. causal interaction,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371202&form=6&db=m Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552570&form=6&db=m Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19631970&form=6&db=m Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19717185&form=6&db=m Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19880163&form=6&db=m Tissue factor-induced Thrombin Generation in the Fasting and Postprandial State among Elderly Survivors of Myocardial Infarction. unassigned - 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20013532&form=6&db=m Prostate-specific antigen, prostate cancer, and disorders of hemostasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20384472&form=6&db=m Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20386871&form=6&db=m Thrombin and its receptor enhance ST segment elevation in acute myocardial infarction by activating the K(ATP) channel. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20412272&form=6&db=m Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20655037&form=6&db=m Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21143375&form=6&db=m Thrombin generation in patients with a first acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21255134&form=6&db=m Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21894805&form=6&db=m Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22339254&form=6&db=m In the Bivalirudin Era, are we still Looking for a Potent Antiplatelet Agent? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22381096&form=6&db=m The ECG as decision support in STEMI. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22409291&form=6&db=m Cost effectiveness of anticoagulation in acute coronary syndromes. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23410540&form=6&db=m Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23530022&form=6&db=m Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23826181&form=6&db=m Thrombin generation in the Glasgow Myocardial Infarction Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23856196&form=6&db=m Intramyocardial thrombin promotes angiogenesis and improves cardiac function in an experimental rabbit model of acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24062924&form=6&db=m Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24075284&form=6&db=m Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors. therapeutic application,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24339381&form=6&db=m Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24433621&form=6&db=m Thrombin induced platelet-fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24484867&form=6&db=m Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25135288&form=6&db=m Oral antiplatelet therapy in acute coronary syndromes: recent developments. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25278289&form=6&db=m Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25288467&form=6&db=m Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay. diagnostic usage,unassigned 4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25681465&form=6&db=m The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26000897&form=6&db=m What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction? causal interaction,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26064435&form=6&db=m Effects of thrombin and thrombin receptor activation on cardiac function after acute myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26338971&form=6&db=m Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26396552&form=6&db=m Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26495264&form=6&db=m Oral direct thrombin inhibition: a double-edged sword? causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26876014&form=6&db=m Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). ongoing research,unassigned 1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27171403&form=6&db=m Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,2 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27259089&form=6&db=m Procedural outcomes with use of the flash ostial system in aorto-coronary ostial lesions. therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27431644&form=6&db=m Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27541144&form=6&db=m Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28062625&form=6&db=m High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28267691&form=6&db=m Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28363222&form=6&db=m Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. causal interaction,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28581998&form=6&db=m Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28662704&form=6&db=m Thrombocytopenia induced by dabigatran: two case reports. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29421012&form=6&db=m Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29695176&form=6&db=m Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30321554&form=6&db=m Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition? causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30324870&form=6&db=m Oral antiplatelet agents in cardiovascular disease. therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31754904&form=6&db=m Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31758517&form=6&db=m Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32184977&form=6&db=m Plaque herniation after stenting the culprit lesion with myocardial bridging in ST elevation myocardial infarction: A case report. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34401468&form=6&db=m Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34540112&form=6&db=m The clinical effects of IABP pumps combined with tirofiban in the treatment of acute myocardial infarction and on patients' serum levels. unassigned - 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1440501&form=6&db=m Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1604440&form=6&db=m Effects of exercise test on plasma markers of an activation of coagulation and/or fibrinolysis in patients with symptomatic or silent myocardial ischemia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695765&form=6&db=m [Contents of natural antibodies to thrombin and alpha-2-macroglobulins in the blood of donors and patients with ischemic heart disease] diagnostic usage,unassigned 2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719294&form=6&db=m Inhibition of thrombin-induced endothelium-dependent relaxation after coronary ischemia in the dog: possible role of the coagulation cascade. therapeutic application,unassigned 1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1850329&form=6&db=m Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1908538&form=6&db=m [Signs of thrombin formation in venous occlusion in patients with ischemic heart disease and the role of the protein C activation system in its utilization] causal interaction,unassigned 4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1984896&form=6&db=m Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. ongoing research,unassigned 1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7048597&form=6&db=m Mediation of cardiac ischemia by thromboxanes released from human platelets. unassigned - 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641350&form=6&db=m Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7733378&form=6&db=m Activation of thrombin receptor increases intracellular Na+ during myocardial ischemia. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8968361&form=6&db=m Cardiovascular actions of thrombin receptor activation in vivo. causal interaction,unassigned 3,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9355897&form=6&db=m Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9527073&form=6&db=m Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9576150&form=6&db=m Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9671009&form=6&db=m Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy). therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9801927&form=6&db=m Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9808597&form=6&db=m Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9988016&form=6&db=m Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy). therapeutic application,unassigned 3,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10334417&form=6&db=m Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603519&form=6&db=m Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639214&form=6&db=m Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11107640&form=6&db=m [The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15205585&form=6&db=m Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15208865&form=6&db=m [Effect of surgical menopause on the development of cardiovascular diseases] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15850606&form=6&db=m The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16943248&form=6&db=m Calcium-independent phospholipase A2-catalyzed plasmalogen hydrolysis in hypoxic human coronary artery endothelial cells. therapeutic application,unassigned 1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19027114&form=6&db=m Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,3,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19124943&form=6&db=m Bivalirudin: a new promising direct antithrombin. unassigned - 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19372304&form=6&db=m The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs. ongoing research,unassigned 2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19559265&form=6&db=m Thrombin in myocardial ischemia-reperfusion during cardiac surgery. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20008957&form=6&db=m Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury. unassigned - 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460385&form=6&db=m Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20589203&form=6&db=m Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20837908&form=6&db=m Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus. ongoing research,unassigned 4,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26189289&form=6&db=m [THE TEST OF GENERATION OF THROMBIN IN DYNAMICS IN PATIENTS AFTER TRANSCUTANEOUS CORONARY INTERVENTION]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29654769&form=6&db=m Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30807054&form=6&db=m [The advantage of test on thrombin generation for evaluation of hemostasis potential under implementation of coronary bypass surgery in patients with ischemic heart disease.] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,3 3.4.21.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32764787&form=6&db=m Thrombin generation's role in predicting coronary disease severity. causal interaction,unassigned 4,0 3.4.21.5 Myocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18663937&form=6&db=m [Total index of thrombocyte aggregation in patients with an acute viral myocarditis] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Myocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24203054&form=6&db=m Coagulation, protease-activated receptors, and viral myocarditis. ongoing research,unassigned 2,0 3.4.21.5 Myocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26696253&form=6&db=m The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Myocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31754904&form=6&db=m Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Myoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33228345&form=6&db=m [Changes of coagulation function in patients with adenomyosis and its clinical significance]. diagnostic usage,unassigned 1,0 3.4.21.5 Myotonic Dystrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6294258&form=6&db=m Normal platelet aggregation in myotonic dystrophy. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Myotonic Dystrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Myotoxicity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25453603&form=6&db=m New immunization protocol to produce crotalic antivenom combining Crotalus durissus terrificus venom and its PLA2. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Nasal Polyps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26122502&form=6&db=m Chronic Rhinosinusitis and the Coagulation System. causal interaction,unassigned 3,0 3.4.21.5 Nasal Polyps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28234145&form=6&db=m Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Nasopharyngeal Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31210089&form=6&db=m Routine coagulation molecules predict nasopharyngeal carcinoma and associated metastases. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neonatal Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21555796&form=6&db=m Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1281930&form=6&db=m Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1326909&form=6&db=m [The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma] therapeutic application,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1596884&form=6&db=m Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1657377&form=6&db=m Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1845869&form=6&db=m Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1873799&form=6&db=m Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3089587&form=6&db=m Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3350846&form=6&db=m Thrombin: implications for intratumor therapy against metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3742892&form=6&db=m Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3941458&form=6&db=m Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat. ongoing research,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3985042&form=6&db=m Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7306988&form=6&db=m Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. causal interaction,unassigned 1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7366122&form=6&db=m Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657523&form=6&db=m The role of thrombin in tumor cell metastasis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7712465&form=6&db=m Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7744600&form=6&db=m The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7831573&form=6&db=m Role of platelet integrin GPIIb-GPIIIa, fibronectin, von Willebrand factor, and thrombin in platelet-tumor interaction in vitro and metastasis in vivo. causal interaction,unassigned 1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8205553&form=6&db=m Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8473056&form=6&db=m Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578473&form=6&db=m Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9735390&form=6&db=m Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10598926&form=6&db=m Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692450&form=6&db=m Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10807779&form=6&db=m Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10963995&form=6&db=m Effects of thrombin/thrombosis in angiogenesis and tumour progression. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11278329&form=6&db=m Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. causal interaction,unassigned 1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11303045&form=6&db=m Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395381&form=6&db=m Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. causal interaction,unassigned 2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11721472&form=6&db=m Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11919159&form=6&db=m RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11990479&form=6&db=m Molecular regulation of blood clotting in tumor biology. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12002913&form=6&db=m The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023846&form=6&db=m Mechanism of thrombin-induced angiogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12192302&form=6&db=m Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12408470&form=6&db=m Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12941039&form=6&db=m Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12955005&form=6&db=m Role of thrombin in tumor angiogenesis, implantation, and metastasis. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15031212&form=6&db=m Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15034798&form=6&db=m Role of thrombin in angiogenesis and tumor progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15075670&form=6&db=m Special pharmacokinetics of dipetarudin suggests a potential antitumor activity of this thrombin inhibitor. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15265791&form=6&db=m Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15539922&form=6&db=m Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15634362&form=6&db=m Protease-activated receptor 1: a role in prostate cancer metastasis. causal interaction,unassigned 3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16470154&form=6&db=m Thrombosis in children with malignancy. unassigned - 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16584624&form=6&db=m [Thrombin and angiogenesis of cancer - review.] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16618733&form=6&db=m Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673267&form=6&db=m Thrombin generation and the pathogenesis of cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16689759&form=6&db=m Experimental metastasis and primary tumor growth in mice with hemophilia A. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16760856&form=6&db=m Cancer and thromboembolism: from biology to clinics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17097558&form=6&db=m Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17492768&form=6&db=m PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17605891&form=6&db=m [Thrombin and tumor metastasis - review] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18048360&form=6&db=m Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18097747&form=6&db=m The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18315549&form=6&db=m Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18379065&form=6&db=m A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18519689&form=6&db=m Twist is required for thrombin-induced tumor angiogenesis and growth. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18559512&form=6&db=m Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18645920&form=6&db=m Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18837414&form=6&db=m [Construction and application of a new prokaryotic expression vector derivative of pBV220] ongoing research,unassigned 1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19067186&form=6&db=m Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214911&form=6&db=m The pivotal role of thrombin in cancer biology and tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19217469&form=6&db=m Cancer and thrombosis in women - molecular mechanisms. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19308689&form=6&db=m Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19558435&form=6&db=m Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. ongoing research,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19922946&form=6&db=m Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors. causal interaction,unassigned 1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19959474&form=6&db=m Heparin enhances serpin inhibition of the cysteine protease cathepsin L. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20175118&form=6&db=m Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20190559&form=6&db=m Role of thrombin as a tumor growth factor. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20194899&form=6&db=m Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. diagnostic usage,unassigned 1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20442298&form=6&db=m Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20722743&form=6&db=m Does haemophilia influence cancer-related mortality in HIV-negative patients? causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20798593&form=6&db=m Use of dabigatran etexilate to reduce breast cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20807657&form=6&db=m Glycosaminoglycans and activated contact system in cancer patient plasmas. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20857420&form=6&db=m Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20886199&form=6&db=m Oral thrombostatin FM19 inhibits prostate cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20890897&form=6&db=m Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21147226&form=6&db=m Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment. unassigned - 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21247495&form=6&db=m Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. unassigned - 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21360607&form=6&db=m Looking at the proteases from a simple perspective. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21378407&form=6&db=m The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21788337&form=6&db=m Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22009534&form=6&db=m PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22359194&form=6&db=m The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,4 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682116&form=6&db=m Hemostatic factors, innate immunity and malignancy. causal interaction,unassigned 2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22704840&form=6&db=m Nanochannels for diagnostic of thrombin-related diseases in human blood. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22848234&form=6&db=m Protease-activated receptors in cancer: A systematic review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24175924&form=6&db=m Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24862150&form=6&db=m Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25592110&form=6&db=m Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25945811&form=6&db=m Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26238780&form=6&db=m Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26383051&form=6&db=m Thrombin Inhibition and Cyclophosphamide Synergistically Block Tumor Progression and Metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26573921&form=6&db=m Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161702&form=6&db=m PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161723&form=6&db=m PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27189210&form=6&db=m Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27794633&form=6&db=m Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27852034&form=6&db=m Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28849814&form=6&db=m Mechanistic insights into thrombin's switch between "slow" and "fast" forms. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29291033&form=6&db=m Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer. causal interaction,unassigned 4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29566097&form=6&db=m The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29703481&form=6&db=m Mechanisms coupling thrombin to metastasis and tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30654498&form=6&db=m Thrombin Generation and Cancer: Contributors and Consequences. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31356193&form=6&db=m Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas. unassigned - 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31943198&form=6&db=m Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32032807&form=6&db=m Targeting hemostasis-related moieties for tumor treatment. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32262992&form=6&db=m Three label-free thrombin aptasensors based on aptamers and [Ru(bpy)2(o-mopip)]2. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32647187&form=6&db=m Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,3 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33478293&form=6&db=m Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33481255&form=6&db=m A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34373558&form=6&db=m A KLK4 proteinase substrate capture approach to antagonize PAR1. causal interaction,unassigned 3,0 3.4.21.5 Neoplasm Micrometastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18645920&form=6&db=m Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=420161&form=6&db=m Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=879100&form=6&db=m Antithrombin III and Factor VIII in patients with neoplasms. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1183357&form=6&db=m [Occlusion of the renal artery by intra-arterial injection of thrombin in a case of inoperable renal tumour (author's transl)] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1281930&form=6&db=m Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1309855&form=6&db=m Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423816&form=6&db=m Hemostatic alterations in cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423819&form=6&db=m The role of fibrin in tumor metastasis. therapeutic application,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423826&form=6&db=m Clinical trials with anticoagulant and antiplatelet therapies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1434539&form=6&db=m Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1459470&form=6&db=m Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1469781&form=6&db=m [Evaluation of hypercoagulable state in patients with malignancies by using prothrombin fragment F1 + 2] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1473006&form=6&db=m Comparison of stimulated tissue factor expression by brain microvascular endothelial cells from normotensive (WKY) and hypertensive (SHR) rats. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1511773&form=6&db=m Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1574711&form=6&db=m Pathways of coagulation/fibrinolysis activation in malignancy. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1596884&form=6&db=m Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1612123&form=6&db=m Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1670992&form=6&db=m Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1725393&form=6&db=m Endothelin-1 secretion from cultured rabbit gastric epithelial cells. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1733560&form=6&db=m Highly purified human alpha-thrombin promotes morphological transformation of BALB/c 3T3 cells. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1799331&form=6&db=m [Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors] ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1845869&form=6&db=m Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1847620&form=6&db=m Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1871716&form=6&db=m Cellular localization of activated factor X by Xa-specific probes. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1880155&form=6&db=m Heparanase activity in cultured endothelial cells. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1897511&form=6&db=m A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer. therapeutic application,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901445&form=6&db=m Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1913476&form=6&db=m Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2102790&form=6&db=m Clotting factors in tumour tissue: implications for cancer therapy. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2113968&form=6&db=m Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2114816&form=6&db=m Fibrinogen-fibrin transformation in situ in renal cell carcinoma. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2116223&form=6&db=m Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153429&form=6&db=m Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153685&form=6&db=m Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2160956&form=6&db=m Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2283362&form=6&db=m Promotion of transendothelial neutrophil passage by human thrombin. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2290027&form=6&db=m Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor. Comparison with umbilical vein endothelial cells. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2368789&form=6&db=m Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2387553&form=6&db=m Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2473322&form=6&db=m Human cultured endothelial cells do secrete endothelin-1. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2550484&form=6&db=m Tumor necrosis factor causes amplification of arachidonic acid metabolism in response to interleukin 1, bradykinin, and other agonists. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2628235&form=6&db=m Human tumor cells cultured "in vitro" activate platelet function by producing ADP or thrombin. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2823201&form=6&db=m Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2824013&form=6&db=m Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2824041&form=6&db=m Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2838152&form=6&db=m Thrombin-specific sites of fibrinogen in small cell carcinoma of the lung. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2992771&form=6&db=m Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3015428&form=6&db=m EL-4 tumor cell-induced human and rabbit platelet aggregations. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3036247&form=6&db=m Bryostatins mimic the effects of phorbol esters in intact human platelets. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3047021&form=6&db=m Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3047022&form=6&db=m Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3097827&form=6&db=m Thrombin stimulates arachidonate metabolism in murine tumor cells. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3102391&form=6&db=m Thrombin stimulates arachidonate metabolism in murine tumor cells. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3148526&form=6&db=m Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3170028&form=6&db=m Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3178864&form=6&db=m Phosphatidylcholine synthesis in platelets is stimulated by diacylglycerol but not by phorbol ester. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3278915&form=6&db=m Protein kinase C is differentially regulated by thrombin, insulin, and epidermal growth factor in human mammary tumor cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3308497&form=6&db=m Role of thrombin in the proliferative response of T-47D mammary tumor cells. Mitogenic action and pleiotropic modifications induced together with epidermal growth factor and insulin. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3334244&form=6&db=m Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3350846&form=6&db=m Thrombin: implications for intratumor therapy against metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3357198&form=6&db=m Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3409246&form=6&db=m Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3422589&form=6&db=m A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3456576&form=6&db=m Identification of a thrombin sequence with growth factor activity on macrophages. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3474062&form=6&db=m Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3479634&form=6&db=m Platelet enhancement of tumor cell adhesion to subendothelial matrix: role of platelet cytoskeleton and platelet membrane. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3603435&form=6&db=m Measurement of heparin in plasma: influence of inter-subject and circadian variability in heparin sensitivity according to method. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3701069&form=6&db=m Amidolytic assay for procoagulant activity of lymphoid and tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3718412&form=6&db=m [Biochemistry of tumor cell thrombosis: thrombin as growth hormone] causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3742892&form=6&db=m Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3802083&form=6&db=m Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3941029&form=6&db=m Platelet-aggregating activities of metastasizing tumor cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3941458&form=6&db=m Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3980164&form=6&db=m Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4053025&form=6&db=m Tumor cell generation of thrombin via functional prothrombinase assembly. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6287488&form=6&db=m Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6299977&form=6&db=m A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6322701&form=6&db=m [Studies on platelet aggregation induced by human cultured carcinoma cell lines] therapeutic application,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6341911&form=6&db=m [Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells] causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6386144&form=6&db=m Role of plasma, platelets, and endothelial cells in tumor metastasis. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6480287&form=6&db=m Platelet-aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6540917&form=6&db=m [Ultrasound diagnosis of venous tumor thrombi in kidney cancer. A prospective study] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6573546&form=6&db=m Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6648893&form=6&db=m Interaction of human tumor cells with human platelets and the coagulation system. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6683249&form=6&db=m Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6690183&form=6&db=m Tumour infarction after pre-operative embolisation of renal carcinoma. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6698246&form=6&db=m [Biological effects of thrombin] causal interaction,diagnostic usage,ongoing research,unassigned 3,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6895104&form=6&db=m The chemotherapy of C3H mice bearing Gardner lymphosarcoma with bovine fibrinogen-methotrexate derivative. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7016920&form=6&db=m A factor X-activating cysteine protease from malignant tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7272951&form=6&db=m Thrombin inhibition by malignant and normal cells: a cell-bound antithrombin effect. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7284973&form=6&db=m Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7306974&form=6&db=m Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7320057&form=6&db=m Emergence of hamster fibroblast tumors in nude mice--evidence for in vivo selection leading to loss of growth factor requirement. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7330831&form=6&db=m Growth regulation of vessel wall cells and of tumor cells by thrombin, factor XIII and fibronectin. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7366122&form=6&db=m Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7391657&form=6&db=m Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7482405&form=6&db=m Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7499022&form=6&db=m Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507301&form=6&db=m Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514451&form=6&db=m The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7518511&form=6&db=m Characterization of platelet activity in neuroblastoma. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7522656&form=6&db=m Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523771&form=6&db=m Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7537712&form=6&db=m Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538076&form=6&db=m Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7564468&form=6&db=m Characteristic biological features of human megakaryoblastic leukaemia cell lines. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7628870&form=6&db=m Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7631759&form=6&db=m PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7644116&form=6&db=m Thrombin and TGF-beta promote human leptomeningeal cell proliferation in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657523&form=6&db=m The role of thrombin in tumor cell metastasis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686887&form=6&db=m Thrombin increases the metastatic potential of tumor cells. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7744600&form=6&db=m The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7771466&form=6&db=m Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7813562&form=6&db=m DP-1904, a specific inhibitor of thromboxane A2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7834643&form=6&db=m Solid tumor cells express functional "tethered ligand" thrombin receptor. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7922503&form=6&db=m Agonist-stimulated release of von Willebrand factor and procoagulant factor VIII in rats with and without risk factors for stroke. therapeutic application,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7964991&form=6&db=m Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8049446&form=6&db=m Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8174632&form=6&db=m PMA inhibits the growth of human fibroblasts after the induction of immediate-early genes. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8178946&form=6&db=m Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8182139&form=6&db=m Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8205553&form=6&db=m Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8225173&form=6&db=m [Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection] causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8248272&form=6&db=m Mononuclear cell-conditioned medium enhances thrombin-stimulated PGI2 production by human umbilical vein endothelial cells in culture. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8296393&form=6&db=m Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8331683&form=6&db=m Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8388220&form=6&db=m An intracisternal A-particle DNA sequence is closely linked to the thrombomodulin gene in some strains of laboratory mice. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8473056&form=6&db=m Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8491554&form=6&db=m Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8497849&form=6&db=m Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578473&form=6&db=m Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8600159&form=6&db=m Tumor necrosis factor decreases thrombin receptor expression in endothelial cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8603016&form=6&db=m Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8611404&form=6&db=m Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8756006&form=6&db=m Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8777276&form=6&db=m Bradykinin and thrombin synergistically potentiate interleukin 1 and tumour necrosis factor induced prostanoid biosynthesis in human dental pulp fibroblasts. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8796383&form=6&db=m Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807578&form=6&db=m rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8846045&form=6&db=m Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8854822&form=6&db=m [A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin] therapeutic application,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8912673&form=6&db=m Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8952025&form=6&db=m Regulation of P-selectin expression by inflammatory mediators in canine jugular endothelial cells. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8954171&form=6&db=m Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8972713&form=6&db=m Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9030240&form=6&db=m Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065993&form=6&db=m Blood coagulation and thrombosis in patients with ovarian malignancy. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9067294&form=6&db=m P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112126&form=6&db=m Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122041&form=6&db=m Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9201241&form=6&db=m Mechanisms involved in the early interaction between HeLa cells, platelets and endothelial cells in vitro under the influence of thrombin. Effects of acetylsalicylic acid and Na-salicylate. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9247594&form=6&db=m Organ-selective regulation of vascular adhesion protein-1 expression in man. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9277499&form=6&db=m Distinct mechanisms for N-acetylcysteine inhibition of cytokine-induced E-selectin and VCAM-1 expression. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9310485&form=6&db=m Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9392328&form=6&db=m Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9415039&form=6&db=m Role of E- and P-selectin in migration of monocytes and polymorphonuclear leucocytes to cytokine and chemoattractant-induced cutaneous inflammation in the rat. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9423797&form=6&db=m Thrombin and its precursor in human cerebrospinal fluid. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9466566&form=6&db=m Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9495249&form=6&db=m Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9507819&form=6&db=m Pseudotumors after renal parenchymal sparing surgery. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9510143&form=6&db=m Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2). causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9516131&form=6&db=m GAS6 inhibits granulocyte adhesion to endothelial cells. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9526590&form=6&db=m Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9577162&form=6&db=m [Thrombosis and coronary disease: neutrophils, nitric oxide and aspirin] causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9594445&form=6&db=m Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9607122&form=6&db=m Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626949&form=6&db=m Endothelial cell monolayers as a model system to investigate dengue shock syndrome. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9649116&form=6&db=m Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9701242&form=6&db=m Thrombin receptor overexpression in malignant and physiological invasion processes. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9731747&form=6&db=m Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9735390&form=6&db=m Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9766679&form=6&db=m Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9816228&form=6&db=m Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819023&form=6&db=m Tissue factor expression by monocytes: regulation and pathophysiological roles. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9820166&form=6&db=m Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9828595&form=6&db=m Bombesin, calcium homeostasis and tumour growth. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9839700&form=6&db=m Synergistic interactions of bradykinin, thrombin, interleukin 1 and tumor necrosis factor on prostanoid biosynthesis in human periodontal-ligament cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9886911&form=6&db=m Fibrin monomer increases platelet adherence to tumor cells in a flowing system: a possible role in metastasis? ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10023691&form=6&db=m Actions of heparin that may affect the malignant process. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10397725&form=6&db=m Regulation of tissue factor pathway inhibitor expression in smooth muscle cells. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10400316&form=6&db=m Effect of ceramide on interleukin-6 synthesis in osteoblast-like cells. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10404779&form=6&db=m Stimulation of proteinase activated receptor-2 causes endothelial cells to promote blood coagulation in vitro. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10421070&form=6&db=m PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10444752&form=6&db=m Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10499626&form=6&db=m Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10544927&form=6&db=m Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10598926&form=6&db=m Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10613651&form=6&db=m Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10664248&form=6&db=m The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10672900&form=6&db=m Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10690613&form=6&db=m Experimental and clinical studies on liver regeneration following transcatheter portal embolization. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692450&form=6&db=m Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10709909&form=6&db=m Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10749718&form=6&db=m Translational inhibition of E-selectin expression stimulates P-selectin-dependent neutrophil recruitment. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10807779&form=6&db=m Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10838595&form=6&db=m Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10891293&form=6&db=m Tumor angiogenesis: thrombin and metalloproteinases in focus. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10903607&form=6&db=m Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10919717&form=6&db=m Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10925365&form=6&db=m Thrombin induces apoptosis in human tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10949654&form=6&db=m On the mechanism(s) of thrombin induced angiogenesis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10959148&form=6&db=m Thrombosis and cancer. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10963995&form=6&db=m Effects of thrombin/thrombosis in angiogenesis and tumour progression. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10974200&form=6&db=m Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10987834&form=6&db=m Thrombin-induced activation of cultured rodent microglia. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11071061&form=6&db=m Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11071621&form=6&db=m Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11073830&form=6&db=m PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11080597&form=6&db=m Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127398&form=6&db=m Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11143939&form=6&db=m [Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.] causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11186273&form=6&db=m Signaling mechanism in the induction of apoptosis by thrombin in human tumor cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11292192&form=6&db=m Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11303045&form=6&db=m Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11356985&form=6&db=m Proteinase-activated receptors. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11372726&form=6&db=m Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11373337&form=6&db=m PreproEndothelin-1 expression in human mesangial cells: evidence for a p38 mitogen-activated protein kinase/protein kinases-C-dependent mechanism. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395381&form=6&db=m Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11398190&form=6&db=m Mechanisms of cell death in primary cortical neurons and PC12 cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11468178&form=6&db=m Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11504518&form=6&db=m Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11549781&form=6&db=m Treatment of venous thrombosis in the cancer patient. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11557600&form=6&db=m Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11582948&form=6&db=m Coagulation and fibrinolysis in chronic venous insufficiency. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11583026&form=6&db=m Decrease in platelet serotonin level in uterine cervix cancer patients. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11686329&form=6&db=m Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687948&form=6&db=m The hemostatic system and angiogenesis in malignancy. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11721472&form=6&db=m Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740417&form=6&db=m Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11841339&form=6&db=m The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11849398&form=6&db=m Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11885024&form=6&db=m Platelets and cancer: implications for antiangiogenic therapy. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11910193&form=6&db=m Effects of lopap on human endothelial cells and platelets. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11919159&form=6&db=m RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11964083&form=6&db=m Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11990464&form=6&db=m Tumor cell prothrombotic properties. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11990465&form=6&db=m Fibrinogen and tumor cell metastasis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11990479&form=6&db=m Molecular regulation of blood clotting in tumor biology. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12002913&form=6&db=m The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12012324&form=6&db=m Human alpha-thrombin stimulates proliferation of interferon-gamma differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023846&form=6&db=m Mechanism of thrombin-induced angiogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12094854&form=6&db=m Endoscopic use of human thrombin in bleeding gastric varices. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12124231&form=6&db=m Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. diagnostic usage,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12127234&form=6&db=m Anticancer and antithrombin activity of Russian plants. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12176889&form=6&db=m Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12192302&form=6&db=m Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12195692&form=6&db=m Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12215760&form=6&db=m [Future potential indications for an oral thrombin inhibitor] ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12460914&form=6&db=m Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12466122&form=6&db=m Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12467301&form=6&db=m Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12490231&form=6&db=m Antithrombin activity of some constituents from Origanum vulgare. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12532337&form=6&db=m Mutation analysis of the non-muscle myosin light chain kinase (MLCK) deletion constructs on CV1 fibroblast contractile activity and proliferation. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12540969&form=6&db=m Correlates of thrombin generation in patients with advanced prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12559270&form=6&db=m Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12573983&form=6&db=m Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12607994&form=6&db=m [Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis] causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12657945&form=6&db=m Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12671767&form=6&db=m [Improvement of hemostasis in laparoscopic and open partial nephrectomy with gelatin thrombin matrix (FloSeal)] ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12747959&form=6&db=m Rho GTPases and the regulation of endothelial permeability. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12789289&form=6&db=m Role and regulation of the thrombin receptor (PAR-1) in human melanoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12812042&form=6&db=m [Reactions of derivatives of beta-lactam antibiotics with non-antibacterial biological activity] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12839265&form=6&db=m Role of endothelin in human hypertension. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12873428&form=6&db=m Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12941039&form=6&db=m Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12955005&form=6&db=m Role of thrombin in tumor angiogenesis, implantation, and metastasis. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12970125&form=6&db=m Tissue factor, thrombin, and cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14521590&form=6&db=m Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14588154&form=6&db=m Role of NADPH oxidases in the control of vascular gene expression. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14652636&form=6&db=m Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713810&form=6&db=m Use of gelatin matrix thrombin tissue sealant as an effective hemostatic agent during laparoscopic partial nephrectomy. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753495&form=6&db=m A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14760083&form=6&db=m Soluble CD40 ligand plasma levels in lung cancer. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15034796&form=6&db=m Tissue factor and fibrin in tumor angiogenesis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15034798&form=6&db=m Role of thrombin in angiogenesis and tumor progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15075670&form=6&db=m Special pharmacokinetics of dipetarudin suggests a potential antitumor activity of this thrombin inhibitor. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15143072&form=6&db=m Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15175791&form=6&db=m New nonlipid effects of statins and their clinical relevance in cardiovascular disease. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201277&form=6&db=m Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15265791&form=6&db=m Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15274665&form=6&db=m Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15280447&form=6&db=m Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15302675&form=6&db=m Effects of inhaled thrombin receptor agonists in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15350527&form=6&db=m A paradoxical pro-apoptotic effect of thrombin on smooth muscle cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15386385&form=6&db=m von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15501980&form=6&db=m Fibrinogen-coated droplets of olive oil for delivery of docetaxel to a fibrin(ogen)-rich ascites form of a murine mammary tumor. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15534097&form=6&db=m Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15539922&form=6&db=m Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15550035&form=6&db=m Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15559761&form=6&db=m PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15567463&form=6&db=m Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613014&form=6&db=m Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613918&form=6&db=m Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15634362&form=6&db=m Protease-activated receptor 1: a role in prostate cancer metastasis. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15650061&form=6&db=m Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15739188&form=6&db=m c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15766657&form=6&db=m Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15781388&form=6&db=m 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15795099&form=6&db=m Activation of the coagulation system in cancerogenesis and metastasation. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15796165&form=6&db=m Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan). unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15822938&form=6&db=m Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15841323&form=6&db=m Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15944410&form=6&db=m Thrombomodulin enhances the invasive activity of mouse mammary tumor cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16091733&form=6&db=m Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16138000&form=6&db=m Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16172186&form=6&db=m Preconditioning of primary human endothelial cells with inflammatory mediators alters the "set point" of the cell. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16191106&form=6&db=m Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16195337&form=6&db=m A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16209522&form=6&db=m Phelligridimer A, a highly oxygenated and unsaturated 26-membered macrocyclic metabolite with antioxidant activity from the fungus Phellinus igniarius. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16271051&form=6&db=m Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16284240&form=6&db=m Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16338747&form=6&db=m Aquaporin 4 is increased in association with human immunodeficiency virus dementia: implications for disease pathogenesis. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16470154&form=6&db=m Thrombosis in children with malignancy. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16479463&form=6&db=m Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16528196&form=6&db=m Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16534415&form=6&db=m Defective Arachidonate Release and PGE2 Production in Gialpha2-Deficient Intestinal and Colonic Subepithelial Myofibroblasts. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16584624&form=6&db=m [Thrombin and angiogenesis of cancer - review.] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598390&form=6&db=m Large femoral aneurysm as a late complication after vessel closure device application. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16618733&form=6&db=m Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16627481&form=6&db=m Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16637463&form=6&db=m Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673261&form=6&db=m Thrombin biology in the 21st century: implications in hemostasis, inflammation, coagulopathies, and cancer. Proceedings of a seminar. September, 2005. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673267&form=6&db=m Thrombin generation and the pathogenesis of cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16696024&form=6&db=m Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16738003&form=6&db=m Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16760856&form=6&db=m Cancer and thromboembolism: from biology to clinics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16775574&form=6&db=m Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16783843&form=6&db=m The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16801104&form=6&db=m Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16855354&form=6&db=m Mechanisms of cancer-induced thrombosis in cancer. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16938121&form=6&db=m Histamine differentially interacts with tumor necrosis factor-alpha and thrombin in endothelial tissue factor induction: the role of c-Jun NH2-terminal kinase. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17000906&form=6&db=m Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17097558&form=6&db=m Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17139380&form=6&db=m Chronological expression of PAR isoforms in acute liver injury and its amelioration by PAR2 blockade in a rat model of sepsis. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17158457&form=6&db=m Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translocation in endothelial cells. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17323377&form=6&db=m Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17392178&form=6&db=m Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17396228&form=6&db=m Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. diagnostic usage,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17479173&form=6&db=m [Thrombin induced tumour growth - pharmacological control] causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549306&form=6&db=m Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17586662&form=6&db=m Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17605891&form=6&db=m [Thrombin and tumor metastasis - review] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17617142&form=6&db=m Laparoscopic partial nephrectomy for selected central tumours: omitting the bolster. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17663729&form=6&db=m Redundant signaling of tissue factor and thrombin in cancer progression? causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17692904&form=6&db=m Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17695537&form=6&db=m Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17721608&form=6&db=m Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17877125&form=6&db=m [Expression evaluation of in loco coagulation system in colorectal cancer] causal interaction,diagnostic usage,ongoing research,unassigned 2,1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17896950&form=6&db=m Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17900407&form=6&db=m The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17923461&form=6&db=m Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17938766&form=6&db=m [Coagulation and formation of malignant effusions] ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18000795&form=6&db=m Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18023719&form=6&db=m The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18048360&form=6&db=m Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18097747&form=6&db=m The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18182712&form=6&db=m [Changes of prethrombotic state indexes in patients with malignant cancer] causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18182734&form=6&db=m [Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18221492&form=6&db=m Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18235964&form=6&db=m Procoagulant properties of human MV3 melanoma cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278179&form=6&db=m Thrombin and protease-activated receptors (PARs) in atherothrombosis. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18336754&form=6&db=m Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18379065&form=6&db=m A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18433463&form=6&db=m Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18501098&form=6&db=m Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18519689&form=6&db=m Twist is required for thrombin-induced tumor angiogenesis and growth. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18559512&form=6&db=m Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18632433&form=6&db=m Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18634754&form=6&db=m Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-alpha. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18640330&form=6&db=m Comparison of blood activation in the wound, active vent, and cardiopulmonary bypass circuit. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18645920&form=6&db=m Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18645922&form=6&db=m Diverse roles of tissue factor-expressing cell subsets in tumor progression. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18710787&form=6&db=m JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18757438&form=6&db=m Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18820708&form=6&db=m p53 controls hPar1 function and expression. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18841290&form=6&db=m Platelet-derived microparticles and coagulation activation in breast cancer patients. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18952113&form=6&db=m The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18988801&form=6&db=m Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012979&form=6&db=m Thrombin generation as a predictor of radiotherapy induced skin erythema. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19014947&form=6&db=m Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19058300&form=6&db=m Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19061541&form=6&db=m Minocycline reduces intracerebral hemorrhage-induced brain injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19133144&form=6&db=m Modulation of human uterine smooth muscle cell collagen contractility by thrombin, Y-27632, TNF alpha and indomethacin. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19141156&form=6&db=m Factor V deficiency: a concise review. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19182372&form=6&db=m Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214911&form=6&db=m The pivotal role of thrombin in cancer biology and tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19217469&form=6&db=m Cancer and thrombosis in women - molecular mechanisms. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19235177&form=6&db=m Scoring ligand similarity in structure-based virtual screening. therapeutic application,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19250659&form=6&db=m Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19265041&form=6&db=m TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19276228&form=6&db=m Progestin and thrombin regulate tissue factor expression in human term decidual cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19277413&form=6&db=m Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19302289&form=6&db=m Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19308689&form=6&db=m Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19333145&form=6&db=m Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure. diagnostic usage,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19351827&form=6&db=m Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19388346&form=6&db=m Thrombin enhances glioma growth. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19438723&form=6&db=m Thrombin-mediated impairment of fibroblast growth factor-2 activity. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19444623&form=6&db=m Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19558435&form=6&db=m Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19661489&form=6&db=m Tissue Factor and PAR2 Signaling in the Tumor Microenvironment. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19678640&form=6&db=m Single gold nanoparticles counter: an ultrasensitive detection platform for one-step homogeneous immunoassays and DNA hybridization assays. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19683795&form=6&db=m Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19691582&form=6&db=m Thrombin physiology and pathophysiology. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737091&form=6&db=m A Differential Role for Endocytosis in Receptor-mediated Activation of Nox1. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19738103&form=6&db=m New antithrombotic drugs: potential for use in oncology. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19922946&form=6&db=m Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19965691&form=6&db=m Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20013531&form=6&db=m The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20013532&form=6&db=m Prostate-specific antigen, prostate cancer, and disorders of hemostasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20101252&form=6&db=m Altered adhesive properties of cord blood endothelial outgrowth cells expressing IL-1ra. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20175118&form=6&db=m Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20190559&form=6&db=m Role of thrombin as a tumor growth factor. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20445954&form=6&db=m Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20458441&form=6&db=m The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20505748&form=6&db=m The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20563836&form=6&db=m Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20600562&form=6&db=m A novel recombinant snake venom metalloproteinase from Agkistrodon acutus protects against taurocholate-induced severe acute pancreatitis in rats. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20638758&form=6&db=m [Acquired factor V deficiency: A rare bleeding disorder with variable clinical presentations.] unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20656333&form=6&db=m Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20722743&form=6&db=m Does haemophilia influence cancer-related mortality in HIV-negative patients? causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20798593&form=6&db=m Use of dabigatran etexilate to reduce breast cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20807657&form=6&db=m Glycosaminoglycans and activated contact system in cancer patient plasmas. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20857420&form=6&db=m Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20870277&form=6&db=m Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20886199&form=6&db=m Oral thrombostatin FM19 inhibits prostate cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21043751&form=6&db=m Tumor cells induce platelet aggregation and intraplatelet calcium ion movements. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21062231&form=6&db=m The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21147226&form=6&db=m Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21187389&form=6&db=m Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21292162&form=6&db=m p38 MAPK controls prothrombin expression by regulated RNA 3' end processing. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21300402&form=6&db=m The effects of thrombin and cytokines upon the biomechanics and remodeling of isolated amnion membrane, in vitro. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21359410&form=6&db=m An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21360607&form=6&db=m Looking at the proteases from a simple perspective. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21364541&form=6&db=m Targeting Tumor Vasculature With an Oncolytic Virus. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21370218&form=6&db=m Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21464402&form=6&db=m Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21473829&form=6&db=m [Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model.] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21672368&form=6&db=m A 24-h work shift in intensive care personnel: biological pathways between work stress and ill health. diagnostic usage,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21700444&form=6&db=m Bi-cell surface plasmon resonance detection of aptamer mediated thrombin capture in serum. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21723081&form=6&db=m The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21788337&form=6&db=m Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21801147&form=6&db=m Therapeutic Roles of Heparin Anticoagulants in Cancer and Related Disorders. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21822525&form=6&db=m Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options. therapeutic application,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21833453&form=6&db=m Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21902713&form=6&db=m Stimulus-dependent release of tissue-regenerating factors by equine platelets. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21917301&form=6&db=m Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21953059&form=6&db=m Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21970128&form=6&db=m Markers of coagulation activation after hepatic resection for cancer: evidence of sustained upregulation of coagulation. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21994479&form=6&db=m Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22012586&form=6&db=m Selective recognition of co-assembled thrombin aptamer and docetaxel on mesoporous silica nanoparticles against tumor cell proliferation. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22139321&form=6&db=m Effects of Lower Concentration Thrombin on High-Mobility Group Box 1 Protein-Mediated Inflammatory Responses. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22314607&form=6&db=m Thrombin and cancer: from molecular basis to therapeutic implications. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22316436&form=6&db=m Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22322591&form=6&db=m Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22359194&form=6&db=m The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22359579&form=6&db=m RNA-seq Reveals Novel Transcriptome of Genes and Their Isoforms in Human Pulmonary Microvascular Endothelial Cells Treated with Thrombin. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22391038&form=6&db=m Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22419573&form=6&db=m Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22437887&form=6&db=m Caffeine induces endothelial tissue factor expression via phosphatidylinositol 3-kinase inhibition. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22665038&form=6&db=m Cooperation of protease-activated receptor 1 and integrin ???5 in thrombin-mediated lung cancer cell invasion. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682116&form=6&db=m Hemostatic factors, innate immunity and malignancy. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682118&form=6&db=m New and old anticoagulants in cancer. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682132&form=6&db=m Oncogenic regulation of tissue factor and thrombosis in cancer. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22848234&form=6&db=m Protease-activated receptors in cancer: A systematic review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22886693&form=6&db=m Myosin Light Chain Kinase Signaling in Endothelial Barrier Dysfunction. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22925132&form=6&db=m Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23050240&form=6&db=m Modeling and simulation of procoagulant circulating tumor cells in flow. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23236465&form=6&db=m Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23273404&form=6&db=m Altered plasma fibrin clot properties in patients with digestive tract cancers: Links with the increased thrombin generation. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23280128&form=6&db=m Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23297820&form=6&db=m Peliosis hepatis mimicking hepatic malignancy: A case report. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23432672&form=6&db=m Osteogenic Peptides in Bone Regeneration. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23511931&form=6&db=m Concentration dependent anti-inflammatory effects thrombin on polyphosphate-mediated inflammatory responses in vitro and in vivo. ongoing research,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23628464&form=6&db=m Reservations against new oral anticoagulants after stroke and cerebral bleeding. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23691951&form=6&db=m Coagulation and metastasis: what does the experimental literature tell us? causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23955016&form=6&db=m Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23971903&form=6&db=m Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24024878&form=6&db=m Influence of endothelial cell protein C receptor on breast cancer development. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24079350&form=6&db=m Intra-arterial infusion of thrombin: Animal experiments. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24176950&form=6&db=m Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24278345&form=6&db=m Nanomechanics of the endothelial glycocalyx in experimental sepsis. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24345495&form=6&db=m [Advances on mechanisms of coagulation with non-small cell lung cancer]. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24370062&form=6&db=m [Role of CD47 in hematologic malignancies]. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24413553&form=6&db=m Brain Tumors Enhance Plasmatic Coagulation: The Role of Hemeoxygenase-1. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24437937&form=6&db=m Universal surface-enhanced Raman scattering amplification detector for ultrasensitive detection of multiple target analytes. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24468615&form=6&db=m Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24489651&form=6&db=m TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24503617&form=6&db=m A New Paradigm for the Treatment of Alzheimer's Disease: Targeting Vascular Activation. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24596353&form=6&db=m Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer - Relationship with Clinical Outcome. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24599439&form=6&db=m Thrombosis in brain tumors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24620969&form=6&db=m Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24699825&form=6&db=m PAR-3 Knockdown Enhances Adhesion Rate of PANC-1 Cells via Increased Expression of Integrin?v and E-Cadherin. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24710407&form=6&db=m Thrombin drives tumorigenesis in colitis-associated colon cancer. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24740120&form=6&db=m Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24862150&form=6&db=m Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24912033&form=6&db=m Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25020199&form=6&db=m Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25023347&form=6&db=m Effects of cancer on platelets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25038529&form=6&db=m Epigenetic regulation of tissue factor inducibility in endothelial cell senescence. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25114412&form=6&db=m Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25127596&form=6&db=m Development of aptamer-conjugated magnetic graphene/gold nanoparticle hybrid nanocomposites for specific enrichment and rapid analysis of thrombin by MALDI-TOF MS. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25130770&form=6&db=m Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25163932&form=6&db=m Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25232445&form=6&db=m A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25268161&form=6&db=m Mechanisms of hepatocyte growth factor activation in cancer tissues. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25496996&form=6&db=m The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25502723&form=6&db=m Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25561973&form=6&db=m Fibronectin Matrix Formation is a Prerequisite for Colonization of Kidney Tumor Cells in Fibrin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25592110&form=6&db=m Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25691153&form=6&db=m Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25696887&form=6&db=m Flamethrowers: blood cells and cancer thrombosis risk. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25730478&form=6&db=m Effect of ascorbate on plasminogen activator inhibitor-1 expression and release from platelets and endothelial cells in an in-vitro model of sepsis. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25731570&form=6&db=m [Fibrin glue injection therapy with diluted thrombin for complicated postoperative fistulas following digestive surgery]. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25743884&form=6&db=m Cancer-associated thrombosis: investigating the role of new oral anticoagulants. therapeutic application,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25771088&form=6&db=m [Biomolecular markers in cancer-associated thromboembolism]. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25813285&form=6&db=m Heparin modulates chemokines in human endometrial stromal cells by interaction with tumor necrosis factor ? and thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25886560&form=6&db=m Insoluble fibrinogen particles for harvesting and expanding attachment-dependent cells and for trapping suspended cancer cells in the presence of blood. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25945811&form=6&db=m Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26163243&form=6&db=m Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26189037&form=6&db=m Survival After Solid Cancers in Antithrombotic Trials. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26238780&form=6&db=m Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26285165&form=6&db=m Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26302981&form=6&db=m Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26383051&form=6&db=m Thrombin Inhibition and Cyclophosphamide Synergistically Block Tumor Progression and Metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463974&form=6&db=m Role of Protease-Activated Receptor-1 in Glioma Growth. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26475410&form=6&db=m Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26481421&form=6&db=m Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26489727&form=6&db=m Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26504080&form=6&db=m Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26546690&form=6&db=m Trousseau's syndrome: cancer-associated thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26573921&form=6&db=m Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26597313&form=6&db=m Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. diagnostic usage,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26662117&form=6&db=m Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26916311&form=6&db=m Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26945262&form=6&db=m 'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26955703&form=6&db=m [Thrombocytopenia induced by lipopolysaccharide may be not related to coagulation and inflammatory response]. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26957205&form=6&db=m Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27027841&form=6&db=m Role of tissue factor expression in thrombin generation by canine tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27094310&form=6&db=m A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27108773&form=6&db=m Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161675&form=6&db=m OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161699&form=6&db=m PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161702&form=6&db=m PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161710&form=6&db=m PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161714&form=6&db=m PO-24 - Determinants of thrombin generation in gynaecological malignancies. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161723&form=6&db=m PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161731&form=6&db=m PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161738&form=6&db=m PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27189210&form=6&db=m Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27261371&form=6&db=m Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343380&form=6&db=m (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27458694&form=6&db=m Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27513209&form=6&db=m Inhibition of coagulation proteases Xa and IIa decreases ischemia-reperfusion injuries in a preclinical renal transplantation model. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27566553&form=6&db=m TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27597146&form=6&db=m Plasma composition distribution in cancer: Discrimination by thrombin and factor Xa generation. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27600331&form=6&db=m Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27602496&form=6&db=m Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27609342&form=6&db=m The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27766025&form=6&db=m Tissue factor: A potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27794633&form=6&db=m Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27852034&form=6&db=m Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27877881&form=6&db=m Crosslinked duplex DNA nanogels that target specified proteins. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28004386&form=6&db=m Proinflammatory signaling functions of thrombin in cancer. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28058802&form=6&db=m Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28145534&form=6&db=m Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28316070&form=6&db=m The involvement of thrombin in the pathogenesis of glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28389332&form=6&db=m Alkylation of phosphorothioated thrombin binding aptamers improves the selectivity of inhibition of tumor cell proliferation upon anticoagulation. causal interaction,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28429138&form=6&db=m Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF?, in Peripheral Blood. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28439721&form=6&db=m Incidence of thromboembolic events after use of gelatin-thrombin-based hemostatic matrix during intracranial tumor surgery. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28489922&form=6&db=m Contribution of thrombin-reactive brain pericytes to blood-brain barrier dysfunction in an in vivo mouse model of obesity-associated diabetes and an in vitro rat model. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28497580&form=6&db=m The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28662718&form=6&db=m Thrombin-induced, TNFR-dependent miR-181c downregulation promotes MLL1 and NF-?B target gene expression in human microglia. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692314&form=6&db=m Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692431&form=6&db=m Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28793219&form=6&db=m Stiff Substrates Increase Inflammation-Induced Endothelial Monolayer Tension and Permeability. ongoing research,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28833193&form=6&db=m Coagulation and fibrinolysis in gastric cancer. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28856225&form=6&db=m Development of a sandwich ELISA for the thrombin light chain identified by serum proteome analysis. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28930804&form=6&db=m Venous Thromboembolism in Gynecological Malignancy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28957707&form=6&db=m Label-free visualization and quantification of single cell signaling activity using metal-clad waveguide (MCWG)-based microscopy. ongoing research,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28991281&form=6&db=m Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29031893&form=6&db=m In an in-vitro model using human fetal membranes, 17-? hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075790&form=6&db=m Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075792&form=6&db=m Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29244471&form=6&db=m Endothelial dysfunction in experimental hyperhomocysteinemia. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29291033&form=6&db=m Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29389738&form=6&db=m Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29431737&form=6&db=m A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29505702&form=6&db=m Fibrinolytic abnormalities associated with progression of pediatric solid tumors. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29655462&form=6&db=m Obesity, Thrombotic Risk, and Inflammation in Cancer. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29705335&form=6&db=m Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29761522&form=6&db=m Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29927556&form=6&db=m Role of Hypercoagulable State for Predictive Ovarian Malignancy in Women with a Pelvic Mass. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29959891&form=6&db=m Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30055672&form=6&db=m In an in-vitro model using human fetal membranes, ?-lipoic acid inhibits inflammation induced fetal membrane weakening. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30099724&form=6&db=m Elevated extracellular trap formation and contact system activation in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30104289&form=6&db=m Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30235479&form=6&db=m Pro-Coagulant and Pro-Thrombotic Effects of Paclitaxel Mediated by Red Blood Cells. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30243238&form=6&db=m Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30244327&form=6&db=m Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30356007&form=6&db=m The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30428081&form=6&db=m Arsenic May Act as a Pro-Metastatic Carcinogen Through Promoting Tumor Cell-Induced Platelet Aggregation. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30462538&form=6&db=m The role of coagulation and platelets in colon cancer-associated thrombosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30565930&form=6&db=m Ultrasensitive Ambient Mass Spectrometry Immunoassays: Multiplexed Detection of Proteins in Serum and on Cell Surfaces. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30592140&form=6&db=m Targeting nucleolin to obstruct vasculature feeding with an intelligent DNA nanorobot. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30619047&form=6&db=m A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30649824&form=6&db=m Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30654498&form=6&db=m Thrombin Generation and Cancer: Contributors and Consequences. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30746232&form=6&db=m Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30796650&form=6&db=m Rhamnan sulfate extracted from Monostroma nitidum attenuates blood coagulation and inflammation of vascular endothelial cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30826094&form=6&db=m Anticancer Activities of Tumor-killing Nanorobots. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30834072&form=6&db=m Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31034495&form=6&db=m Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31064688&form=6&db=m Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31118073&form=6&db=m Sex differences in the expression of cell adhesion molecules on microvesicles derived from cultured human brain microvascular endothelial cells treated with inflammatory and thrombotic stimuli. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31323706&form=6&db=m Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31336159&form=6&db=m Evaluation of the Activity of Heparin Injected into the Fully Implantable Catheter for Chemotherapy (Portocath) between Two Moments of Use. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31373849&form=6&db=m The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31433171&form=6&db=m Smart Nanotherapeutic Targeting of Tumor Vasculature. causal interaction,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31511575&form=6&db=m Interplay of Plasmodium falciparum and thrombin in brain endothelial barrier disruption. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31621739&form=6&db=m The synergistic effect of Au-COF nanosheets and artificial peroxidase Au@ZIF-8(NiPd) rhombic dodecahedra for signal amplification for biomarker detection. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31704834&form=6&db=m Prothrombin 3'end Gene Variants in Patients With Sporadic Colon Adenocarcinoma. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31862357&form=6&db=m US-triggered ultra-sensitive "thrombus constructor" for precise tumor therapy. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31882836&form=6&db=m Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31915300&form=6&db=m Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31918352&form=6&db=m Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31943198&form=6&db=m Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31962001&form=6&db=m Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31994911&form=6&db=m Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32027788&form=6&db=m Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32032807&form=6&db=m Targeting hemostasis-related moieties for tumor treatment. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32068332&form=6&db=m Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32131129&form=6&db=m Thrombin Promotes Macrophage Polarization into M1-Like Phenotype to Induce Inflammatory Responses. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32200762&form=6&db=m Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. therapeutic application,unassigned 1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32261431&form=6&db=m Three-dimensional porous microarray of gold modified electrode for ultrasensitive and simultaneous assay of various cancer biomarkers. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32329494&form=6&db=m Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32507767&form=6&db=m Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation. causal interaction,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32553958&form=6&db=m In vitro antitumor and anti-angiogenic activities of a shrimp chondroitin sulfate. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32572197&form=6&db=m Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32647187&form=6&db=m Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,3 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32854772&form=6&db=m Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32874809&form=6&db=m Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32983675&form=6&db=m Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32999289&form=6&db=m Controllable gelation of artificial extracellular matrix for altering mass transport and improving cancer therapies. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33152619&form=6&db=m Injured tissues favor cancer cell implantation via fibrin deposits on scar zones. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33182048&form=6&db=m Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-?B inactivation. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33209887&form=6&db=m Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33270819&form=6&db=m Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33355322&form=6&db=m Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33385797&form=6&db=m Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33450154&form=6&db=m Light Chain Mutation Effects on the Dynamics of Thrombin. therapeutic application,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33478293&form=6&db=m Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33481255&form=6&db=m A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33571724&form=6&db=m Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33711899&form=6&db=m Preeclampsia-associated homeostasis changes in pregnant woman after ART. diagnostic usage,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33789664&form=6&db=m Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33790709&form=6&db=m Successful Enucleation of a Large Pancreatic Head Schwannoma. ongoing research,unassigned 2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33805059&form=6&db=m A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33834977&form=6&db=m [The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward]. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929114&form=6&db=m Thrombin generation in children with febrile neutropenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33947134&form=6&db=m Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33966422&form=6&db=m Noninvasive evaluation of ovarian endometriosis: a single-center experience. diagnostic usage,unassigned 4,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33968695&form=6&db=m The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34066284&form=6&db=m Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34154000&form=6&db=m Thrombin: A Pivotal Player in Hemostasis and Beyond. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34233467&form=6&db=m Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34269109&form=6&db=m Development of an Image-Based HCS-Compatible Method for Endothelial Barrier Function Assessment. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34373558&form=6&db=m A KLK4 proteinase substrate capture approach to antagonize PAR1. causal interaction,unassigned 3,0 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34436814&form=6&db=m Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy. unassigned - 3.4.21.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34477192&form=6&db=m Highly stable surface-enhanced Raman spectroscopy assay on abnormal thrombin levels in the blood plasma of cancer patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11071621&form=6&db=m Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23050240&form=6&db=m Modeling and simulation of procoagulant circulating tumor cells in flow. ongoing research,unassigned 2,0 3.4.21.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12811009&form=6&db=m Current perspective on antithrombin drugs. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Nephrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7919427&form=6&db=m In vivo measurements of fibrin formation and degradation in nephrotic patients. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Nephrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28424276&form=6&db=m Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=82495&form=6&db=m Human alpha2-macroglobulin and its antitrypsic and antithrombin activities in serum and plasma. causal interaction,unassigned 3,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695187&form=6&db=m A study of impaired fibrin polymerization in patients with the nephrotic syndrome. unassigned - 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836241&form=6&db=m [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2291954&form=6&db=m [Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2414802&form=6&db=m [Howie's antithrombin activity and thrombin inhibitors in the nephrotic syndrome] therapeutic application,unassigned 3,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2418377&form=6&db=m Concentration of three thrombin inhibitors in the nephrotic syndrome in adults. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2465224&form=6&db=m Mechanisms of the development of acquired antithrombin III deficiency in the experimental nephrotic syndromes. causal interaction,unassigned 3,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521695&form=6&db=m Molecular markers of hemostasis activation in nephrotic syndrome. diagnostic usage,unassigned 4,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2930939&form=6&db=m Nephrotic syndrome: a platelet hyperaggregability state. causal interaction,unassigned 4,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6171906&form=6&db=m Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome. causal interaction,unassigned 1,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6464012&form=6&db=m Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia. causal interaction,unassigned 3,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6557709&form=6&db=m [Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7749766&form=6&db=m The prolonged thrombin time of nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8238000&form=6&db=m Hemostatic molecular markers in nephrotic syndrome. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439147&form=6&db=m Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18541230&form=6&db=m Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats. causal interaction,unassigned 3,0 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25855774&form=6&db=m Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome. unassigned - 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28424276&form=6&db=m Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929117&form=6&db=m The assesment of prothrombotic potential using thrombin generation assay in pediatric patients with nephrotic syndrome: preliminary study. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11807394&form=6&db=m Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,3 3.4.21.5 Neurilemmoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27771530&form=6&db=m Thrombin and protein C pathway in peripheral nerve Schwann cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Neurilemmoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29292076&form=6&db=m Local Regulation of Thrombin Activity by Factor Xa in Peripheral Nerve Schwann Cells. ongoing research,unassigned 4,0 3.4.21.5 Neuritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30662428&form=6&db=m Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Neuritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neuritis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30662428&form=6&db=m Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Neuritis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=438177&form=6&db=m Binding of human thrombin to cultured human endothelial cells. unassigned - 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1310864&form=6&db=m Thrombin causes neurite retraction in neuronal cells through activation of cell surface receptors. ongoing research,unassigned 2,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1323475&form=6&db=m Thrombin is the major serum factor stimulating phosphoinositide turnover, but not DNA synthesis in human neuroblastoma SH-EP cells. causal interaction,unassigned 1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1913850&form=6&db=m Transient neuritogenesis in NB2a/d1 neuroblastoma cells induced by glial-derived protease inhibitors. therapeutic application,unassigned 1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1917984&form=6&db=m Modulation of neurite outgrowth in neuroblastoma cells by protein kinase C and platelet-activating factor. ongoing research,unassigned 4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1973084&form=6&db=m Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro. ongoing research,unassigned 2,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2055967&form=6&db=m Addition of protease inhibitors to culture medium of neuroblastoma cells induces both neurite outgrowth and phosphorylation of microtubule-associated protein MAP-1B. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2298818&form=6&db=m Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2337608&form=6&db=m Functional sites of glia-derived nexin (GDN): importance of the site reacting with the protease. therapeutic application,unassigned 1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2654147&form=6&db=m Proteolytic regulation of neurite outgrowth from neuroblastoma cells by thrombin and protease nexin-1. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2792085&form=6&db=m Modulation of morphological differentiation of human neuroepithelial cells by serine proteases: independence from blood coagulation. ongoing research,unassigned 4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2835773&form=6&db=m Thrombin modulates and reverses neuroblastoma neurite outgrowth. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2992771&form=6&db=m Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines. ongoing research,unassigned 3,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3022385&form=6&db=m Thrombin binding and stimulation of cyclic guanosine monophosphate formation in neuroblastoma cells. ongoing research,unassigned 2,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3829002&form=6&db=m Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6086621&form=6&db=m Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6306770&form=6&db=m Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115). causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6645628&form=6&db=m Thrombin binding to human brain and spinal cord. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7518511&form=6&db=m Characterization of platelet activity in neuroblastoma. causal interaction,unassigned 4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7552363&form=6&db=m Exogenous thrombin inhibits neuritogenesis in cultured neuroblastoma cells but not in rat hippocampal neurons. ongoing research,unassigned 3,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8982657&form=6&db=m Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9247061&form=6&db=m Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses. ongoing research,unassigned 1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9619630&form=6&db=m Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. ongoing research,unassigned 2,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9666159&form=6&db=m Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons. unassigned - 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9712658&form=6&db=m Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10085414&form=6&db=m Plasticity-related serine proteases in the brain (review). diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10494766&form=6&db=m Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10895075&form=6&db=m Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15245911&form=6&db=m Characterization of the prothrombin gene expression during nerve differentiation. ongoing research,unassigned 3,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16293985&form=6&db=m Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20118812&form=6&db=m Venous thrombosis and procoagulant factors in high-risk neuroblastoma. unassigned - 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21336167&form=6&db=m Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30562971&form=6&db=m Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8296393&form=6&db=m Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. causal interaction,unassigned 4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9204916&form=6&db=m Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9423797&form=6&db=m Thrombin and its precursor in human cerebrospinal fluid. causal interaction,unassigned 4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9699152&form=6&db=m Quantitative reverse transcriptase PCR to gauge increased protease-activated receptor 1 (PAR-1) mRNA copy numbers in the Wobbler mutant mouse. unassigned - 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11438939&form=6&db=m Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15032647&form=6&db=m Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15843610&form=6&db=m Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16410745&form=6&db=m Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18183616&form=6&db=m Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18841278&form=6&db=m Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20028220&form=6&db=m Specific fibrinogen and thrombin concentrations promote neuronal rather than glial growth when primary neural cells are seeded within plasma-derived fibrin gels. unassigned - 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20150433&form=6&db=m Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24912033&form=6&db=m Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection. therapeutic application,unassigned 1,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27138068&form=6&db=m Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1. causal interaction,unassigned 3,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27458694&form=6&db=m Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30804878&form=6&db=m Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders. therapeutic application,unassigned 1,0 3.4.21.5 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Neuroectodermal Tumors, Primitive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8296204&form=6&db=m [Study on the mechanisms of thrombin to inhibit neurite outgrowth] ongoing research,unassigned 4,0 3.4.21.5 Neurogenic Inflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11949877&form=6&db=m Cerebrovascular inflammation following subarachnoid hemorrhage. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18502312&form=6&db=m Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes. causal interaction,unassigned 3,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19527794&form=6&db=m Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes. unassigned - 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19931359&form=6&db=m Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24740641&form=6&db=m Early detection of thrombin activity in neuroinflammatory disease. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27181591&form=6&db=m Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27397090&form=6&db=m Differential effects on glial activation by a direct versus an indirect thrombin inhibitor. therapeutic application,unassigned 4,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27553758&form=6&db=m HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29404650&form=6&db=m [Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30562971&form=6&db=m Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31440383&form=6&db=m Deficiency of tPA Exacerbates White Matter Damage, Neuroinflammation, Glymphatic Dysfunction and Cognitive Dysfunction in Aging Mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31601371&form=6&db=m Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32423817&form=6&db=m Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32792902&form=6&db=m Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33252072&form=6&db=m Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells. unassigned - 3.4.21.5 Neurologic Manifestations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15975137&form=6&db=m The role of thrombin in gliomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Neurologic Manifestations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32356674&form=6&db=m Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population. diagnostic usage,unassigned 2,0 3.4.21.5 Neutropenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929114&form=6&db=m Thrombin generation in children with febrile neutropenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21907177&form=6&db=m Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22841818&form=6&db=m Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138021&form=6&db=m Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27613713&form=6&db=m Coagulation-driven hepatic fibrosis requires protease activated receptor-1 (PAR-1) in a mouse model of TCDD-elicited steatohepatitis. ongoing research,unassigned 2,0 3.4.21.5 Non-ST Elevated Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20390444&form=6&db=m Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Non-ST Elevated Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22234385&form=6&db=m Contemporary use of glycoprotein IIb/IIIa inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Non-ST Elevated Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24337310&form=6&db=m Anticoagulation during and after acute coronary syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Non-ST Elevated Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31754904&form=6&db=m Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Noonan Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12754583&form=6&db=m Hematological findings in Noonan syndrome. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Nose Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21711961&form=6&db=m Role of thrombin in chronic rhinosinusitis-associated tissue remodeling. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8969783&form=6&db=m alpha-Thrombin upregulates G alpha i3 in human vascular endothelial cells. unassigned - 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12739986&form=6&db=m No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228864&form=6&db=m Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19267924&form=6&db=m Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro. causal interaction,unassigned 4,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22035573&form=6&db=m Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation. causal interaction,unassigned 3,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22841818&form=6&db=m Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23340049&form=6&db=m Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23470648&form=6&db=m Obesity and thrombin-generation profiles in women with venous thromboembolism. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184172&form=6&db=m Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28737512&form=6&db=m Thrombin promotes diet-induced obesity through fibrin-driven inflammation. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31233979&form=6&db=m Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31560950&form=6&db=m The repertoire of family A-peptide GPCRs in archaic hominins. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31806688&form=6&db=m Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32920297&form=6&db=m Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity. causal interaction,unassigned 3,0 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33054057&form=6&db=m Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34117131&form=6&db=m Maternal thrombin generation and D-dimer levels in obesity and pregnancy: results from the maternal thrombin generation in obesity and pregnancy (MaTOPs) study. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Obesity, Morbid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20102484&form=6&db=m Thrombin generation in morbid obesity: significant reduction after weight loss. therapeutic application,unassigned 2,0 3.4.21.5 Obesity, Morbid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22393929&form=6&db=m Staple-Line Reinforcement with a Thrombin Matrix During Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Case Series. unassigned - 3.4.21.5 Obesity, Morbid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31249920&form=6&db=m Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity. unassigned - 3.4.21.5 Obesity, Morbid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32920297&form=6&db=m Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity. causal interaction,unassigned 3,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4002923&form=6&db=m [Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11717633&form=6&db=m The role of thrombin in preterm parturition. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12389650&form=6&db=m Activation of coagulation system in preterm labor and preterm premature rupture of membranes. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16551735&form=6&db=m Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidual cells: implications for preterm labor. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17403427&form=6&db=m Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition. causal interaction,unassigned 2,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17901076&form=6&db=m Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19591075&form=6&db=m Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: Evidence of an increased thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19883261&form=6&db=m High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19900035&form=6&db=m Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23008015&form=6&db=m Early second trimester maternal plasma levels of thrombin-inhibitor complexes and subsequent spontaneous preterm delivery. diagnostic usage,unassigned 1,0 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25854178&form=6&db=m The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications. unassigned - 3.4.21.5 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Oliguria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23640650&form=6&db=m Renal involvement in sepsis: a prospective single-center study of 136 cases. causal interaction,unassigned 3,0 3.4.21.5 Optic Nerve Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12888064&form=6&db=m Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child. therapeutic application,unassigned 1,0 3.4.21.5 Oral Submucous Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22965839&form=6&db=m Regulation of protease-activated receptor-1 expression in human buccal fibroblasts stimulated with arecoline. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Oral Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14798567&form=6&db=m [Thrombin therapy of severe mouth ulcers.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Osteitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14898085&form=6&db=m Management of chronic osteitis and osteomyelitis with a coagulum of autogenous blood + penicillin + thrombin; (on the base of 56 cases results). therapeutic application,unassigned 1,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7554443&form=6&db=m Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7573004&form=6&db=m Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8877916&form=6&db=m Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976643&form=6&db=m Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9640132&form=6&db=m Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15229942&form=6&db=m Relationship between cathepsin B and thrombin in rheumatoid arthritis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.5 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27262798&form=6&db=m Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Osteoma, Osteoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015326&form=6&db=m Percutaneous thrombin injection treatment of a gluteal pseudoaneurysm following radiofrequency ablation of a hip osteoid osteoma in a 6-year-old boy. therapeutic application,unassigned 4,0 3.4.21.5 Osteomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9427055&form=6&db=m The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Osteomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14898085&form=6&db=m Management of chronic osteitis and osteomyelitis with a coagulum of autogenous blood + penicillin + thrombin; (on the base of 56 cases results). therapeutic application,unassigned 1,0 3.4.21.5 Osteonecrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23313282&form=6&db=m Preventive effects of the anti-vasospasm agent via the regulation of the Rho-kinase pathway on the development of steroid-induced osteonecrosis in rabbits. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Osteoporosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15229714&form=6&db=m [Biological effects of vitamin K and concentration of vitamin K in Norwegian food] causal interaction,unassigned 4,0 3.4.21.5 Osteoporosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16893408&form=6&db=m The safety of heparins in end-stage renal disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Osteoporosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441362&form=6&db=m PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1846537&form=6&db=m Thrombin effects on osteoblastic cells. II. Structure-function relationships. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1874183&form=6&db=m Thrombin and parathyroid hormone mobilize intracellular calcium in rat osteosarcoma cells by distinct pathways. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153536&form=6&db=m Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2553011&form=6&db=m Thrombin's effects on osteoblastic cells. I. Cytosolic calcium and phosphoinositides. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7565635&form=6&db=m Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8169821&form=6&db=m A novel phospholipase C inhibitor and phorbol esters reveal selective regulation of thrombin- and parathyroid hormone-stimulated signaling pathways in rat osteosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,3,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8213257&form=6&db=m Endothelin-1 modulates calcium signaling by epidermal growth factor, alpha-thrombin, and prostaglandin E1 in UMR-106 osteoblastic cells. ongoing research,unassigned 4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10568828&form=6&db=m The zymogen prothrombin stimulates cell locomotion and calcium influx in murine osteosarcoma cells by different mechanism from thrombin. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12408470&form=6&db=m Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16051297&form=6&db=m Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin. ongoing research,unassigned 4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18048360&form=6&db=m Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19487525&form=6&db=m The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21953059&form=6&db=m Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,2 3.4.21.5 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29949655&form=6&db=m Platelet-Derived TGF-? Induces Tissue Factor Expression via the Smad3 Pathway in Osteosarcoma Cells. therapeutic application,unassigned 4,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3422589&form=6&db=m A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8118270&form=6&db=m [Expression of the cell surface receptor for thrombin, thrombomodulin, in human ovarian cancer cells] diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065993&form=6&db=m Blood coagulation and thrombosis in patients with ovarian malignancy. causal interaction,unassigned 4,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9735390&form=6&db=m Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15684253&form=6&db=m Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20352429&form=6&db=m Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells. causal interaction,unassigned 1,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23875077&form=6&db=m Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25502723&form=6&db=m Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161714&form=6&db=m PO-24 - Determinants of thrombin generation in gynaecological malignancies. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27609342&form=6&db=m The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27852034&form=6&db=m Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33571724&form=6&db=m Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20619835&form=6&db=m Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21334626&form=6&db=m Normalization of haemostatic alterations in overweight children with weight loss due to lifestyle intervention. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23415973&form=6&db=m Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25318550&form=6&db=m Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25618791&form=6&db=m Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26595150&form=6&db=m Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184172&form=6&db=m Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29887998&form=6&db=m Effects of 6 Months of Active Commuting and Leisure-Time Exercise on Fibrin Turnover in Sedentary Individuals with Overweight and Obesity: A Randomised Controlled Trial. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Pancreatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21148289&form=6&db=m Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8854822&form=6&db=m [A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin] therapeutic application,unassigned 4,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9510143&form=6&db=m Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2). causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11504518&form=6&db=m Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11964083&form=6&db=m Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22683980&form=6&db=m Thrombin stimulates integrin ?1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-activated receptor (PAR)-1. ongoing research,unassigned 4,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22724467&form=6&db=m Effect of Low Molecular Weight Heparins and Fondaparinux upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26023170&form=6&db=m Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161715&form=6&db=m PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28182192&form=6&db=m Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692431&form=6&db=m Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28910348&form=6&db=m The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075790&form=6&db=m Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33385797&form=6&db=m Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33805059&form=6&db=m A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Pancreatic Pseudocyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29905310&form=6&db=m Endoscopic use of oxidized regenerated cellulose and topical thrombin: a novel approach for control of bleeding pancreatic pseudocyst wall after endoscopic cystgastrostomy. therapeutic application,unassigned 2,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=850868&form=6&db=m The relationship of coagulation factors to clinical complications of acute pancreatitis. diagnostic usage,unassigned 4,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1909634&form=6&db=m Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3104578&form=6&db=m Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis. therapeutic application,unassigned 3,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12003423&form=6&db=m Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12657945&form=6&db=m Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14562987&form=6&db=m Ultrasonic-guided percutaneous injection of pancreatic pseudoaneurysm with thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15552880&form=6&db=m [Role of increase in permeability and circulatory failure in the development of organ dysfunction in severe acute pancreatitis] causal interaction,unassigned 3,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15796165&form=6&db=m Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan). unassigned - 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17131209&form=6&db=m Percutaneous ultrasound-guided thrombin injection as first-line treatment of pancreatic pseudoaneurysm. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17171306&form=6&db=m Treatment of a splenic artery pseudoaneurysm by endoscopic ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22213026&form=6&db=m Thrombin Generation in vitro and in vivo, and Disturbed Tissue Factor Regulation in Patients with Acute Pancreatitis. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.5 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26421108&form=6&db=m Endoscopic ultrasound guided thrombin injection of angiographically occult pancreatitis associated visceral artery pseudoaneurysms: Case series. therapeutic application,unassigned 2,0 3.4.21.5 Pancreatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14512011&form=6&db=m Ultrasound guided thrombin injection to treat a pseudoaneurysm secondary to chronic pancreatitis. therapeutic application,unassigned 3,0 3.4.21.5 Pancreatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15018170&form=6&db=m Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Pancreatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21944714&form=6&db=m Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Pancreatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25121631&form=6&db=m Endoscopic ultrasound-guided thrombin injection in a large splenic artery aneurysm: first report in a patient with tropical chronic pancreatitis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3704722&form=6&db=m Hyperfibrinogenemia as a cause of prolonged thrombin clotting time. diagnostic usage,unassigned 3,0 3.4.21.5 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10517116&form=6&db=m [Increased thrombin time in a patient with multiple myeloma] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26626040&form=6&db=m Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab. causal interaction,unassigned 4,0 3.4.21.5 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26759370&form=6&db=m Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Paratuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7881551&form=6&db=m Cloning and expression in Escherichia coli of DNA encoding a 60 kDa stress protein of Mycobacterium paratuberculosis, the causative agent of Johne's disease. ongoing research,unassigned 4,0 3.4.21.5 Paresthesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737712&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12843292&form=6&db=m Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619541&form=6&db=m Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15789435&form=6&db=m Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. causal interaction,unassigned 4,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16410750&form=6&db=m Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16934779&form=6&db=m Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease. ongoing research,unassigned 2,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17629581&form=6&db=m The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27458694&form=6&db=m Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28344073&form=6&db=m Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. causal interaction,unassigned 4,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28585189&form=6&db=m Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32423817&form=6&db=m Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Pelvic Floor Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15735538&form=6&db=m The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22272909&form=6&db=m Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases. causal interaction,unassigned 2,0 3.4.21.5 Penile Induration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32830078&form=6&db=m Multicenter Prospective Study of Grafting With Collagen Fleece TachoSil in Patients With Peyronie's Disease. therapeutic application,unassigned 1,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2209496&form=6&db=m Injection therapy of bleeding peptic ulcer. A prospective, randomized trial using epinephrine and thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2408191&form=6&db=m [Endoscopic hemostasis in hemorrhagic peptic ulcer. A review and pilot study of local thrombin injection combined with systemic fibrinolysis inhibition (with tranexamic acid)] causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2685540&form=6&db=m [Endoscopic hemostasis against hemorrhage from the upper gastrointestinal tract: its indication and limitation] therapeutic application,unassigned 3,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2864663&form=6&db=m [Somatostatin in severe peptic ulcer hemorrhage] ongoing research,unassigned 3,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3578266&form=6&db=m Spontaneous antithrombin in a patient with benign paraprotein. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8780566&form=6&db=m Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112916&form=6&db=m Experimental studies of injection therapy for ulcer haemorrhage in rabbits. therapeutic application,unassigned 4,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9365313&form=6&db=m Adding heat probe treatment to adrenaline injection for spurting haemorrhage of peptic ulcers. Injection of adrenaline and human thrombin is best option. therapeutic application,unassigned 4,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783357&form=6&db=m Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12891541&form=6&db=m A randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14988862&form=6&db=m Discussion on a randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer. therapeutic application,unassigned 2,0 3.4.21.5 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25440919&form=6&db=m Endoscopic management of acute peptic ulcer bleeding. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Peptic Ulcer Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8780566&form=6&db=m Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Pericarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Pericarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32356674&form=6&db=m Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population. diagnostic usage,unassigned 2,0 3.4.21.5 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3126818&form=6&db=m Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9689616&form=6&db=m Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts. causal interaction,unassigned 4,0 3.4.21.5 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10929869&form=6&db=m Expression and activity of thrombomodulin in human gingival epithelium: in vivo and in vitro studies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2671341&form=6&db=m Thrombin and bradykinin enhance prostaglandin production in human peripheral blood monocytes. unassigned - 3.4.21.5 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9188512&form=6&db=m Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10929869&form=6&db=m Expression and activity of thrombomodulin in human gingival epithelium: in vivo and in vitro studies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11139397&form=6&db=m Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11278315&form=6&db=m Activation of human prothrombin by arginine-specific cysteine proteinases (Gingipains R) from porphyromonas gingivalis. causal interaction,unassigned 4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246539&form=6&db=m Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16149016&form=6&db=m Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598112&form=6&db=m Use of Bivalirudin as the Foundation Anticoagulant during Percutaneous Peripheral Interventions. causal interaction,unassigned 3,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24382127&form=6&db=m Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. causal interaction,unassigned 3,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25262270&form=6&db=m Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26609688&form=6&db=m Vorapaxar and optimal aspirin dose: The FDA outlook. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26860124&form=6&db=m Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27128545&form=6&db=m Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28062625&form=6&db=m High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28267691&form=6&db=m Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28473975&form=6&db=m Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case-Control Study. diagnostic usage,unassigned 3,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28854808&form=6&db=m Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease. diagnostic usage,unassigned 3,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30702990&form=6&db=m Antithrombotic Agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32252612&form=6&db=m Altered coagulation profile in peripheral artery disease patients. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Peripheral Nerve Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8863530&form=6&db=m Neural thrombin and protease nexin I kinetics after murine peripheral nerve injury. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.5 Peripheral Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9423797&form=6&db=m Thrombin and its precursor in human cerebrospinal fluid. causal interaction,unassigned 4,0 3.4.21.5 Peripheral Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26851772&form=6&db=m A novel histochemical method for the visualization of thrombin activity in the nervous system. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.5 Peripheral Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32416186&form=6&db=m Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1155713&form=6&db=m Hypercoagulability in patients with peripheral vascular disease. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12917829&form=6&db=m Exercise in claudicants is accompanied by excessive thrombin generation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16079449&form=6&db=m A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21614411&form=6&db=m Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,1 3.4.21.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11816285&form=6&db=m [The role of PAR family receptors in activation of mast cells in the norm and in acute inflammation in rats] ongoing research,unassigned 2,0 3.4.21.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17415421&form=6&db=m Effect of activated protein C on secretory activity of rat peritoneal mast cells. ongoing research,unassigned 3,0 3.4.21.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18927430&form=6&db=m Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26450485&form=6&db=m Human Neutrophils Support Thrombin Generation in Peritonitis. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Peroneal Neuropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19078621&form=6&db=m Calf compartment syndrome and lumbar plexopathy following topical bovine thrombin-induced coagulopathy. therapeutic application,unassigned 3,0 3.4.21.5 Persistent Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29169300&form=6&db=m Arterio-biliary fistulas: What to choose as endovascular treatment? therapeutic application,unassigned 3,0 3.4.21.5 Pilonidal Sinus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27384096&form=6&db=m Novel Approach of Treatment of Pilonidal Sinus Disease With Thrombin Gelatin Matrix as a Sealant. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Pilonidal Sinus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31095861&form=6&db=m Treatment of pilonidal sinus disease with thrombin gelatin matrix - a video vignette. therapeutic application,unassigned 4,0 3.4.21.5 Pituitary ACTH Hypersecretion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27448294&form=6&db=m Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. diagnostic usage,unassigned 2,0 3.4.21.5 Placental Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12738160&form=6&db=m Placental insufficiency is characterized by platelet activation in the fetus. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11312613&form=6&db=m Structure-function analysis of Yersinia pestis YopM's interaction with alpha-thrombin to rule on its significance in systemic plague and to model YopM's mechanism of binding host proteins. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 plasma kallikrein deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27380557&form=6&db=m Antithrombotic potential of the contact activation pathway. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19373890&form=6&db=m The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.5 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31469483&form=6&db=m Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Platelet Storage Pool Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6401213&form=6&db=m Thrombin and ionophore A23187-induced dense granule secretion in storage pool deficient platelets: evidence for impaired nucleotide storage as the primary dense granule defect. unassigned - 3.4.21.5 Platelet Storage Pool Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9057642&form=6&db=m Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,1,0 3.4.21.5 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1431501&form=6&db=m The contribution of factor V to the coagulant property of pleural fluid. causal interaction,unassigned 1,0 3.4.21.5 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31614900&form=6&db=m Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis. diagnostic usage,unassigned 4,0 3.4.21.5 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31892546&form=6&db=m Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Pleurisy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10678641&form=6&db=m Release of endothelins and platelet-activating factor by a rat pleural mesothelial cell line. causal interaction,unassigned 1,0 3.4.21.5 Pleurisy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15438045&form=6&db=m [Action of thrombin on the serofibrinous pleurisies of substitution of therapeutic pneumothorax.] therapeutic application,unassigned 2,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9646165&form=6&db=m A case of delayed death after accidental intravenous injection of thrombin. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11418072&form=6&db=m Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12699352&form=6&db=m Anticoagulant therapy for acute lung injury or pneumonia. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14760153&form=6&db=m Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18706698&form=6&db=m Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19025114&form=6&db=m Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20004361&form=6&db=m Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling. causal interaction,unassigned 1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20854735&form=6&db=m [The DNA binding activity of nuclear factor-?B in patients with severe pneumonia and the intervention effects of Xuebijing injection.] diagnostic usage,unassigned 2,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22646857&form=6&db=m Enhanced thrombin generation and depressed anticoagulant function in children with pneumonia. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23357535&form=6&db=m Thrombin-induced NF-?B activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells. causal interaction,unassigned 4,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24277696&form=6&db=m Thrombin-induced CCAAT/enhancer-binding protein ? activation and IL-8/CXCL8 expression via MEKK1, ERK, and p90 ribosomal S6 kinase 1 in lung epithelial cells. causal interaction,unassigned 4,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24469066&form=6&db=m Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25200038&form=6&db=m [Coagulopathy correlates with outcomes in patients with community- acquired pneumonia]. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25518936&form=6&db=m Asef controls vascular endothelial permeability and barrier recovery in the lung. unassigned - 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25799829&form=6&db=m [Peculiarities of thrombin generation and prognosis of unfavourable outcome in patients with severe pneumonia and pneumogenic sepsis]. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25948816&form=6&db=m Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26320153&form=6&db=m Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463037&form=6&db=m Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-?B pathways in human lung epithelial cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26640170&form=6&db=m Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28092405&form=6&db=m Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,3 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28428115&form=6&db=m p300 and C/EBP?-regulated IKK? expression are involved in thrombin-induced IL-8/CXCL8 expression in human lung epithelial cells. unassigned - 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29514266&form=6&db=m SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. unassigned - 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31863766&form=6&db=m Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32360484&form=6&db=m Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study. therapeutic application,unassigned 1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33834977&form=6&db=m [The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward]. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.5 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34110529&form=6&db=m Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Pneumonia, Bacterial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32548551&form=6&db=m COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pneumoperitoneum http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31593122&form=6&db=m Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1914610&form=6&db=m Comparative studies using a rigid thoracoscope and fiberoptic bronchoscope to treat spontaneous pneumothorax. therapeutic application,unassigned 4,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2615097&form=6&db=m [Chemical pleurodesis induced with fibrin glue in the treatment of inoperable spontaneous pneumothorax] diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14866241&form=6&db=m [Intramuscular injections of thrombase can absorb the sero-fibrinous effusions of therapeutic pneumothorax.] therapeutic application,unassigned 1,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15438045&form=6&db=m [Action of thrombin on the serofibrinous pleurisies of substitution of therapeutic pneumothorax.] therapeutic application,unassigned 2,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27454474&form=6&db=m Intrabronchial Infusion of Autologous Blood Plus Thrombin for Intractable Pneumothorax After Bronchial Occlusion Using Silicon Spigots: A Case Series of 9 Patients With Emphysema. therapeutic application,unassigned 2,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29880183&form=6&db=m Chemical pleurodesis with autologous blood and freeze-dried concentrated human thrombin improved spontaneous pneumothorax and thoracic endometriosis: The first case involving a pregnant woman. therapeutic application,unassigned 1,0 3.4.21.5 Pneumothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34256448&form=6&db=m [Efficacy and safety of position selection combined with intra-pleural thrombin injection in the treatment of postoperative persistent air leakage in bullous pulmonary-pleural diseases]. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Polyarteritis Nodosa http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14253131&form=6&db=m WIDELY DISTRIBUTED NECROTIZING ARTERITIS INDUCED IN RABBITS BY EXPERIMENTAL RENAL ALTERATIONS. IV. DEMONSTRATION OF DECREASED AMOUNT OF THROMBIN CLOTTABLE PLASMA PROTEIN DURING DEVELOPMENT OF THE ARTERIAL LESIONS. ongoing research,unassigned 3,0 3.4.21.5 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23415973&form=6&db=m Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.5 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26194691&form=6&db=m Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26291802&form=6&db=m Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.5 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3322525&form=6&db=m Use of clinical pathology in evaluation of horses with colic. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5994646&form=6&db=m [Inhibition of thrombin in the plasma of patients with polycythemia vera] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18325302&form=6&db=m Identification and treatment of arterial thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18768782&form=6&db=m Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21442635&form=6&db=m Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. diagnostic usage,unassigned 3,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23233637&form=6&db=m Thrombotic disease in the myeloproliferative neoplasms. causal interaction,unassigned 1,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23735588&form=6&db=m ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. causal interaction,unassigned 4,0 3.4.21.5 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23941968&form=6&db=m Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Polyneuropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27295570&form=6&db=m An electrochemical aptasensor based on TiO2/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Polyneuropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343583&form=6&db=m Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Postpartum Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16527789&form=6&db=m Hematome peridural chez une parturiente au decours d'un choc hemorragique: [Epidural hematoma after hemorrhagic shock in a parturient]. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Postpartum Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17899575&form=6&db=m Pelvic arterial pseudoaneurysm-a rare complication of Cesarean section: diagnosis and novel treatment. therapeutic application,unassigned 2,0 3.4.21.5 Postthrombotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18372264&form=6&db=m Current treatment of acute lower extremity deep venous thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=588503&form=6&db=m Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy. causal interaction,unassigned 3,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1005056&form=6&db=m The role of coagulation and fibrinolysis in preeclampsia. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1138817&form=6&db=m Blood coagulation profile in Indian patients with pre-eclampsia and eclampsia. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1837248&form=6&db=m Preeclampsia-eclampsia syndrome and coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1852102&form=6&db=m Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3627580&form=6&db=m A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. unassigned - 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6176042&form=6&db=m Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8821879&form=6&db=m Hemostatic abnormalities may predict chronic hypertension after preeclampsia. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9360180&form=6&db=m Effects of serum from preeclamptic women on prostacyclin production by human endothelial cells. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9423760&form=6&db=m The procoagulant activity of red blood cells from patients with severe preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9882986&form=6&db=m [Endothelial damage and blood coagulation activation in preeclampsia] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10625202&form=6&db=m Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth. causal interaction,unassigned 4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12353069&form=6&db=m Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12389649&form=6&db=m Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118653&form=6&db=m Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15730558&form=6&db=m Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro. causal interaction,unassigned 4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16244774&form=6&db=m Coagulation and fibrinolysis in preeclampsia and neonates. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16788310&form=6&db=m Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia. causal interaction,unassigned 4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17346550&form=6&db=m Thrombin regulates monocyte chemoattractant protein-1 expression in human first trimester and term decidual cells. causal interaction,unassigned 1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17392178&form=6&db=m Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18443332&form=6&db=m Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18501408&form=6&db=m Increased thrombin generation in women with a history of preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,1 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18570113&form=6&db=m Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. causal interaction,unassigned 3,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19822350&form=6&db=m Platelet activation and endogenous thrombin potential in pre-eclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,2 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21868071&form=6&db=m Alterations of profibrinolytic receptor annexin A2 in pre-eclampsia: A possible role in placental thrombin formation. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21979881&form=6&db=m Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22819145&form=6&db=m Thrombin enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts; possible involvement in the pathogenesis of preeclampsia. causal interaction,unassigned 3,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24313434&form=6&db=m [Preeclampsia and thrombin generation test]. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25003615&form=6&db=m Pre-eclampsia part 1: current understanding of its pathophysiology. causal interaction,unassigned 3,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25824463&form=6&db=m Activation of PAR-1/NADPH oxidase/ROS signaling pathways is crucial for the thrombin-induced sFlt-1 production in extravillous trophoblasts: possible involvement in the pathogenesis of preeclampsia. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26527498&form=6&db=m A suggestion about the cause of inflammation in acute atherosis complicating poor placentation in preeclampsia. causal interaction,unassigned 4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28164533&form=6&db=m Possibility of Coagulation System Activation Determination with Tissue Factor in Pregnancy Complications. ongoing research,unassigned 3,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28438061&form=6&db=m The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28521572&form=6&db=m Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28569919&form=6&db=m Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29296764&form=6&db=m Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins. causal interaction,unassigned 4,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29325127&form=6&db=m Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31862363&form=6&db=m Identification of unexplored substrates of the serine protease, thrombin, using N-terminomics strategy. unassigned - 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32190981&form=6&db=m Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34058707&form=6&db=m Thrombin impairs the angiogenic activity of extravillous trophoblast cells via monocyte chemotactic protein-1 (MCP-1): A possible link with preeclampsia. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34190173&form=6&db=m Analysis of perinatal coagulation function in preeclampsia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3525766&form=6&db=m The clinical and biological correlates of coagulopathy in children with acute leukemia. diagnostic usage,unassigned 2,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6571789&form=6&db=m Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6573546&form=6&db=m Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8286739&form=6&db=m Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. causal interaction,unassigned 3,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127398&form=6&db=m Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11208295&form=6&db=m Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14693164&form=6&db=m Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20405515&form=6&db=m von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22227959&form=6&db=m Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31556233&form=6&db=m Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia. causal interaction,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929114&form=6&db=m Thrombin generation in children with febrile neutropenia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Pregnancy Complications http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28164533&form=6&db=m Possibility of Coagulation System Activation Determination with Tissue Factor in Pregnancy Complications. ongoing research,unassigned 3,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19591075&form=6&db=m Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: Evidence of an increased thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19900035&form=6&db=m Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22464077&form=6&db=m Prospective investigation of second-trimester thrombin activation and preterm birth. therapeutic application,unassigned 1,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22598484&form=6&db=m Phospholipid Scramblase Expression in the Pregnant Mouse Uterus in LPS-Induced Preterm Delivery. causal interaction,unassigned 3,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23008015&form=6&db=m Early second trimester maternal plasma levels of thrombin-inhibitor complexes and subsequent spontaneous preterm delivery. diagnostic usage,unassigned 1,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24652285&form=6&db=m Effect of Thrombin on Human Amnion Mesenchymal Cells, Mouse Fetal Membranes, and Preterm Birth. ongoing research,unassigned 4,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27050800&form=6&db=m Nrf2 Activation Inhibits Effects of Thrombin in Human Amnion Cells and Thrombin-induced Preterm Birth in Mice. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Premature Birth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27108773&form=6&db=m Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Priapism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17445680&form=6&db=m Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Priapism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24343090&form=6&db=m [Strategies for the treatment and prevention of priapism in children]. therapeutic application,unassigned 4,0 3.4.21.5 Primary Myelofibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30274004&form=6&db=m Thrombin Generation Testing in Patients with Myelofibrosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.5 Prion Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673270&form=6&db=m Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Prolactinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21993601&form=6&db=m Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2448891&form=6&db=m Effect of urokinase on the proliferation of primary cultures of human prostatic cells. ongoing research,unassigned 4,0 3.4.21.5 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2454021&form=6&db=m [Effect of thrombin on hematuria after operation for benign prostatic hyperplasia] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,4 3.4.21.5 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30985725&form=6&db=m Transurethral resection versus holmium laser enucleation of the prostate: A prospective randomized trial comparing perioperative thrombin generation and fibrinolysis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8205553&form=6&db=m Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023846&form=6&db=m Mechanism of thrombin-induced angiogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12429291&form=6&db=m A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12540969&form=6&db=m Correlates of thrombin generation in patients with advanced prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12883880&form=6&db=m Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15034798&form=6&db=m Role of thrombin in angiogenesis and tumor progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15143072&form=6&db=m Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15527781&form=6&db=m Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16052512&form=6&db=m PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16245281&form=6&db=m Thrombin receptor expression is upregulated in prostate cancer. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16472687&form=6&db=m Rational design and applications of a Rac GTPase-specific small molecule inhibitor. ongoing research,unassigned 4,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16530725&form=6&db=m Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17492768&form=6&db=m PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17880464&form=6&db=m Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18297239&form=6&db=m Effect of thrombin tube on PSA determination, a clue for false negative in screening for prostate cancer. diagnostic usage,unassigned 1,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19351827&form=6&db=m Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20190559&form=6&db=m Role of thrombin as a tumor growth factor. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20886199&form=6&db=m Oral thrombostatin FM19 inhibits prostate cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23236465&form=6&db=m Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27207422&form=6&db=m The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,1 3.4.21.5 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34298537&form=6&db=m A SERS-LFA biosensor combined with aptamer recognition for simultaneous detection of thrombin and PDGF-BB in prostate cancer plasma. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8427961&form=6&db=m Increased thrombin generation in a child with a combined factor IX and protein C deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073268&form=6&db=m Heparin-induced thrombocytopenia: a ten-year retrospective. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11007197&form=6&db=m The protein C pathway. causal interaction,unassigned 1,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17849065&form=6&db=m Protein C deficiency screening using a thrombin generation assay - an upgrade. diagnostic usage,unassigned 3,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22984498&form=6&db=m The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation. causal interaction,unassigned 2,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26785615&form=6&db=m Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association? causal interaction,unassigned 1,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27734187&form=6&db=m The use of direct oral anticoagulants in inherited thrombophilia. causal interaction,unassigned 4,0 3.4.21.5 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29365322&form=6&db=m Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. therapeutic application,unassigned 1,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7709951&form=6&db=m Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8029798&form=6&db=m A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. diagnostic usage,unassigned 3,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8815575&form=6&db=m Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12152677&form=6&db=m Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469858&form=6&db=m Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18695379&form=6&db=m Regulation of coagulation by protein S. unassigned - 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23841464&form=6&db=m Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. causal interaction,unassigned 4,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26586461&form=6&db=m Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27421039&form=6&db=m Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27734187&form=6&db=m The use of direct oral anticoagulants in inherited thrombophilia. causal interaction,unassigned 4,0 3.4.21.5 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32347013&form=6&db=m Sequential multiple retinal vein occlusions and transient ischemic attack in MTHFR polymorphism and protein S deficiency. causal interaction,unassigned 4,0 3.4.21.5 Protein-Energy Malnutrition http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6419685&form=6&db=m [Prolonged thrombin time observed in protein-energy malnutrition] unassigned - 3.4.21.5 protein-glutamine gamma-glutamyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18277134&form=6&db=m Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 protein-glutamine gamma-glutamyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27902939&form=6&db=m Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement. causal interaction,unassigned 2,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836241&form=6&db=m [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2465224&form=6&db=m Mechanisms of the development of acquired antithrombin III deficiency in the experimental nephrotic syndromes. causal interaction,unassigned 3,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7772198&form=6&db=m Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11503969&form=6&db=m Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells. diagnostic usage,unassigned 3,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439147&form=6&db=m Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20964615&form=6&db=m Favorable Maternal and Fetal Effects of Danshensu in an Experimental Mice Model of Preeclampsia. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25855774&form=6&db=m Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome. unassigned - 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28424276&form=6&db=m Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441513&form=6&db=m Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33636573&form=6&db=m Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33929117&form=6&db=m The assesment of prothrombotic potential using thrombin generation assay in pediatric patients with nephrotic syndrome: preliminary study. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15199637&form=6&db=m [Relationship between syndrome pattern of psoriasis and platelet thrombin sensitive protein and CD36 molecular expression] diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14555559&form=6&db=m Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34404541&form=6&db=m The dynamics of thrombin formation in patients with pulmonary arterial hypertension. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Pulmonary Atresia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1570710&form=6&db=m [Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue] therapeutic application,unassigned 4,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7855781&form=6&db=m Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11929177&form=6&db=m Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19776082&form=6&db=m Air-leak management after upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a pilot trial comparing sealant and standard treatment. therapeutic application,unassigned 4,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21043642&form=6&db=m In vivo thrombin generation and platelet hyperactivity in patients with chronic obstructive pulmonary disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21236471&form=6&db=m Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21624643&form=6&db=m Thrombin generation in chronic obstructive pulmonary disease: Dependence on plasma factor composition. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25922720&form=6&db=m Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26369819&form=6&db=m Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales. causal interaction,unassigned 4,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26908183&form=6&db=m Ultrasensitive electrochemical aptasensor for the detection of thrombin based on dual signal amplification strategy of Au@GS and DNA-CoPd NPs conjugates. unassigned - 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29020675&form=6&db=m Increased Platelet-Monocyte Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31863766&form=6&db=m Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32758992&form=6&db=m Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2077021&form=6&db=m Role of hemodynamics and vagus nerves in development of fibrin-induced pulmonary edema. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2476955&form=6&db=m Capsaicin-sensitive nerves exert an inhibitory effect on the development of fibrin-induced pulmonary edema in rats. ongoing research,unassigned 4,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3379836&form=6&db=m Factors influencing fibrin-induced pulmonary edema. ongoing research,unassigned 4,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3693233&form=6&db=m Alpha-thrombin-induced pulmonary vasoconstriction. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3836350&form=6&db=m Blockade of histamine receptors and thrombin-induced microembolic pulmonary edema in the rat. therapeutic application,unassigned 3,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7549227&form=6&db=m Effect of ibuprofen on thrombin-induced pulmonary edema in the rat. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8821125&form=6&db=m Beneficial effects of a leukotriene receptor antagonist on thrombin-induced pulmonary edema in the rat. causal interaction,unassigned 3,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10813087&form=6&db=m Presence and quantification of neuropeptide Y in pulmonary edema fluids in rats. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395608&form=6&db=m Role of central nervous system nitric oxide in the development of neurogenic pulmonary edema in rats. unassigned - 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15915031&form=6&db=m Opposing effects of isoflurane and sevoflurane on neurogenic pulmonary edema development in an animal model. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23729486&form=6&db=m Ezrin/radixin/moesin proteins differentially regulate endothelial hyperpermeability after thrombin. causal interaction,unassigned 1,0 3.4.21.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28921146&form=6&db=m Effects of vasodilators on fibrin-induced pulmonary edema, so-called neurogenic pulmonary edema, in the rat. ongoing research,unassigned 1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=993337&form=6&db=m The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1576116&form=6&db=m Persistent generation of thrombin after acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2958657&form=6&db=m [Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin] diagnostic usage,unassigned 4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6727275&form=6&db=m [Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma] causal interaction,unassigned 1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7431104&form=6&db=m Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-111-labeled platelets. ongoing research,unassigned 1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7813328&form=6&db=m Anticoagulation in the prevention and treatment of pulmonary embolism. therapeutic application,unassigned 4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8899954&form=6&db=m Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. causal interaction,unassigned 3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9199818&form=6&db=m Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9647415&form=6&db=m Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10847425&form=6&db=m The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. diagnostic usage,unassigned 3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11255277&form=6&db=m Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11441979&form=6&db=m Anticoagulation: the present and future. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431473&form=6&db=m Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12524220&form=6&db=m The dynamics of thrombin formation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14555559&form=6&db=m Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992034&form=6&db=m Low molecular weight heparin in acute stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16026408&form=6&db=m Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16283976&form=6&db=m Pulmonary embolism: current treatment options. therapeutic application,unassigned 4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16547433&form=6&db=m Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16675723&form=6&db=m Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. ongoing research,unassigned 2,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16707920&form=6&db=m Bothrojaracin, a Bothrops jararaca snake venom-derived (pro)thrombin inhibitor, as an anti-thrombotic molecule. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17658944&form=6&db=m Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737712&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20208970&form=6&db=m Retrieval of "Recovery IVC Filter" after 383 days. unassigned - 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20435232&form=6&db=m Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21538731&form=6&db=m Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23182978&form=6&db=m Oral antithrombotic effects of acylhydrazone derivatives. therapeutic application,unassigned 1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23818798&form=6&db=m Transitions of care in anticoagulated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24624626&form=6&db=m [Management of major bleeding complications in patients on long-term treatment with oral anticoagulants]. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26423607&form=6&db=m Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26636644&form=6&db=m Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26674596&form=6&db=m Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26846610&form=6&db=m Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26875179&form=6&db=m Direct oral anticoagulants in rare venous thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27045032&form=6&db=m Development and Characterization of an Inducible Rat Model of Chronic Thromboembolic Pulmonary Hypertension. ongoing research,unassigned 2,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27138487&form=6&db=m Molecular Imaging of Activated Platelets Allows the Detection of Pulmonary Embolism with Magnetic Resonance Imaging. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27670677&form=6&db=m 14-3-3? regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27796581&form=6&db=m Treatment of accidental perianal injection of topical thrombin with intravenous antithrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28528289&form=6&db=m Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism. causal interaction,unassigned 3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28594794&form=6&db=m [Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29212130&form=6&db=m Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30685261&form=6&db=m Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31002695&form=6&db=m Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31850760&form=6&db=m Anticoagulant Decapeptide Interacts with Thrombin at the Active Site and Exosite-I. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32586214&form=6&db=m The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. causal interaction,unassigned 3,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33707842&form=6&db=m Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34491753&form=6&db=m Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1701928&form=6&db=m Significance of thrombin in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1709710&form=6&db=m [The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder] ongoing research,unassigned 3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1715176&form=6&db=m Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510986&form=6&db=m Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7564789&form=6&db=m Role of thrombin in pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395719&form=6&db=m Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9695019&form=6&db=m Thrombin. causal interaction,unassigned 4,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11583966&form=6&db=m Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023853&form=6&db=m Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12461737&form=6&db=m Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15344597&form=6&db=m Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma). causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16207402&form=6&db=m [The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16338226&form=6&db=m Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19060230&form=6&db=m Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. therapeutic application,unassigned 3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21168185&form=6&db=m Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease. causal interaction,unassigned 4,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21312187&form=6&db=m Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23583295&form=6&db=m Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-?B and activator protein-1. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23919450&form=6&db=m Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27549302&form=6&db=m Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28407300&form=6&db=m Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28469072&form=6&db=m Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. causal interaction,unassigned 3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29212801&form=6&db=m Roles of high-mobility group box 1 and thrombin in murine pulmonary fibrosis and the therapeutic potential of thrombomodulin. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29902535&form=6&db=m ADAM17/EGFR-dependent ERK activation mediates thrombin-induced CTGF expression in human lung fibroblasts. causal interaction,unassigned 4,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30831079&form=6&db=m Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice. therapeutic application,unassigned 1,0 3.4.21.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31831767&form=6&db=m Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Purpura, Thrombocytopenic, Idiopathic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2595658&form=6&db=m Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Purpura, Thrombocytopenic, Idiopathic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9777138&form=6&db=m Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. therapeutic application,unassigned 2,0 3.4.21.5 Purpura, Thrombocytopenic, Idiopathic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18458557&form=6&db=m Anaesthetic management of a patient with thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Purpura, Thrombocytopenic, Idiopathic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31280643&form=6&db=m Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. therapeutic application,unassigned 1,0 3.4.21.5 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1514182&form=6&db=m Thrombin generation in thrombotic thrombocytopenic purpura. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1803613&form=6&db=m Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2479264&form=6&db=m Thrombin generation in patients with thrombotic thrombocytopenic purpura. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8266913&form=6&db=m Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18325302&form=6&db=m Identification and treatment of arterial thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Quadriplegia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26202881&form=6&db=m Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Radiation Pneumonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11418072&form=6&db=m Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Radiculopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21944723&form=6&db=m The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,2 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2670794&form=6&db=m Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230118&form=6&db=m Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7033809&form=6&db=m Protective effect of angiotensin II inhibition on acute renal failure after intravascular coagulation in the rat. therapeutic application,unassigned 1,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7540878&form=6&db=m Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610957&form=6&db=m Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9674202&form=6&db=m [Markers of thrombin generation in kidney failure of children with epidemic hemolytic uremic syndrome] diagnostic usage,unassigned 2,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11533507&form=6&db=m Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12420243&form=6&db=m Hirudin in renal insufficiency. therapeutic application,unassigned 4,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12679753&form=6&db=m Anticoagulation in acute cardiac care in patients with chronic kidney disease. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12921505&form=6&db=m Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16562602&form=6&db=m [Anticoagulation in patients with chronic renal failure] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19804226&form=6&db=m Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22504623&form=6&db=m [Novel oral anticoagulants and their use in the perioperative setting]. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33359501&form=6&db=m A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7064128&form=6&db=m Evaluation of a heparin assay method using a fluorogenic synthetic peptide substrate for thrombin. diagnostic usage,unassigned 4,0 3.4.21.5 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20727512&form=6&db=m Systemic anticoagulation considerations in chronic kidney disease. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30785941&form=6&db=m Evaluation of hemostasis in patients with end-stage renal disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8902880&form=6&db=m Recovery of endothelium-dependent relaxations four weeks after ischemia and progressive reperfusion in canine coronary arteries. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,2 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9662465&form=6&db=m Antithrombin and ischemia/reperfusion. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10385784&form=6&db=m Potential non-glycoprotein IIb/IIIa effects of abciximab. causal interaction,unassigned 4,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246985&form=6&db=m [Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung] causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12169361&form=6&db=m Antithrombin III prevents deleterious effects of remote ischemia-reperfusion injury on healing of colonic anastomoses. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12607707&form=6&db=m Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. causal interaction,unassigned 3,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16168073&form=6&db=m Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. therapeutic application,unassigned 4,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16488723&form=6&db=m Crosstalk between thrombosis and inflammation in lung reperfusion injury. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16839349&form=6&db=m Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage. causal interaction,unassigned 3,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17418736&form=6&db=m Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18332863&form=6&db=m Sodium/hydrogen exchange inhibition with cariporide reduces leukocyte adhesion via P-selectin suppression during inflammation. unassigned - 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19231390&form=6&db=m Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19372304&form=6&db=m The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs. ongoing research,unassigned 2,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19559265&form=6&db=m Thrombin in myocardial ischemia-reperfusion during cardiac surgery. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20008957&form=6&db=m Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury. unassigned - 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460385&form=6&db=m Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20494024&form=6&db=m Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20542424&form=6&db=m Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20837908&form=6&db=m Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus. ongoing research,unassigned 4,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29148253&form=6&db=m Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29315844&form=6&db=m Local and systemic coagulation marker response to musculocutaneous flap ischemia-reperfusion injury and remote ischemic conditioning: An experimental study in a porcine model. diagnostic usage,unassigned 1,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5832152&form=6&db=m Fibrinolytic activity, thrombin inhibitor and kinetics of clot formation in premature infants with respiratory distress syndrome. causal interaction,unassigned 2,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6369911&form=6&db=m Adult respiratory distress syndrome (ARDS): experimental models with elastase and thrombin infusion in pigs. unassigned - 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9267673&form=6&db=m Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters. causal interaction,unassigned 2,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22491592&form=6&db=m Fresh frozen plasma/red blood cell resuscitation regimen that restores procoagulants without causing adult respiratory distress syndrome. diagnostic usage,unassigned 2,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23555849&form=6&db=m Critical role of non-muscle myosin light chain kinase in thrombin-induced endothelial cell inflammation and lung PMN infiltration. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24469066&form=6&db=m Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25057925&form=6&db=m Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25214765&form=6&db=m Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33302737&form=6&db=m Protease-activated receptor 1 as a potential therapeutic target for COVID-19. causal interaction,unassigned 4,0 3.4.21.5 Respiratory Distress Syndrome, Newborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1554199&form=6&db=m Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Respiratory Distress Syndrome, Newborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9700123&form=6&db=m A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Respiratory Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3938413&form=6&db=m Experimental studies on the adult respiratory distress syndrome: effects of induced DIC; granulocytes and elastase in mini pigs. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Respiratory Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4790359&form=6&db=m Effect of reptilase on respiratory insufficiency induced by intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Respiratory Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18294351&form=6&db=m Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery. diagnostic usage,unassigned 2,0 3.4.21.5 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3347459&form=6&db=m Use of fibrin glue in ocular surgery. diagnostic usage,unassigned 3,0 3.4.21.5 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11291298&form=6&db=m [Thrombin-antithrombin III complexes in plasma and subretinal fluid in patients with perforated retinal detachment] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29617690&form=6&db=m Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment. diagnostic usage,unassigned 3,0 3.4.21.5 Retinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11549610&form=6&db=m Thrombin regulates chemokine induction during human retinal pigment epithelial cell/monocyte interaction. causal interaction,unassigned 3,0 3.4.21.5 Retinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20672289&form=6&db=m Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation. diagnostic usage,unassigned 1,0 3.4.21.5 Retinal Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2603849&form=6&db=m [Experimental retinal vein obstruction induced by transadventitial administration of thrombin in the rabbit] diagnostic usage,unassigned 1,0 3.4.21.5 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8610806&form=6&db=m Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9002129&form=6&db=m Thrombin in the management of full thickness macular holes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.5 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20435588&form=6&db=m High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment. unassigned - 3.4.21.5 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32338531&form=6&db=m Broad internal limiting membrane peeling with adjunctive plasma-thrombin for repair of large macular holes: A retrospective case series. unassigned - 3.4.21.5 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19660790&form=6&db=m In retinal vein occlusion platelet response to thrombin is increased. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.5 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24625582&form=6&db=m Intravitreal thrombin activity is elevated in retinal vein occlusion. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Retinopathy of Prematurity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3813950&form=6&db=m Thrombin infusion to control bleeding during vitrectomy for stage V retinopathy of prematurity. diagnostic usage,unassigned 2,0 3.4.21.5 Rhabdomyolysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31857822&form=6&db=m New considerations on pathways involved in acute traumatic coagulopathy: the thrombin generation paradox. unassigned - 3.4.21.5 Rhabdomyosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1839080&form=6&db=m Stimulation of cell surface plasminogen activation by heparin and related polyionic substances. causal interaction,unassigned 1,0 3.4.21.5 Rhabdomyosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3350846&form=6&db=m Thrombin: implications for intratumor therapy against metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Rhabdomyosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20442298&form=6&db=m Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25890027&form=6&db=m Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Rhinitis, Allergic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18789772&form=6&db=m Role of the coagulation system in allergic inflammation in the upper airways. causal interaction,unassigned 3,0 3.4.21.5 Rhinitis, Allergic, Seasonal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1913263&form=6&db=m Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,1 3.4.21.5 Sagittal Sinus Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29061392&form=6&db=m A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Sarcoidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7564789&form=6&db=m Role of thrombin in pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6341911&form=6&db=m [Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells] causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6571789&form=6&db=m Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6573546&form=6&db=m Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12231573&form=6&db=m Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=165484&form=6&db=m Plasminogen-independent fibrinolysis by proteases produced by transformed chick embryo fibroblasts. ongoing research,unassigned 3,0 3.4.21.5 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=191817&form=6&db=m Binding and internalization of thrombin by normal and transformed chick cells. ongoing research,unassigned 3,0 3.4.21.5 Schistosomiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489960&form=6&db=m Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Schistosomiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665393&form=6&db=m Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. unassigned - 3.4.21.5 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7564789&form=6&db=m Role of thrombin in pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.5 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21312187&form=6&db=m Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21834070&form=6&db=m Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through endothelin-1 receptor A up-regulation. ongoing research,unassigned 2,0 3.4.21.5 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33769265&form=6&db=m Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers. causal interaction,unassigned 3,0 3.4.21.5 Scoliosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12780956&form=6&db=m Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients. diagnostic usage,unassigned 2,0 3.4.21.5 Scoliosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26920966&form=6&db=m Gelatine matrix with human thrombin decreases blood loss in adolescents undergoing posterior spinal fusion for idiopathic scoliosis: a multicentre, randomised clinical trial. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7772198&form=6&db=m Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8660379&form=6&db=m Platelet-derived growth factor B-chain homodimer suppressing a convulsion of epilepsy model mouse El. therapeutic application,unassigned 1,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9202268&form=6&db=m Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,3 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10844028&form=6&db=m Potentiation of NMDA receptor function by the serine protease thrombin. causal interaction,unassigned 1,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12485396&form=6&db=m The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12581058&form=6&db=m Thrombin injection for repair of pseudoaneurysms: a case for caution. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14378265&form=6&db=m [Blood fibrinogenase in insulin shock, in electroshock, and in epileptic seizure.] therapeutic application,unassigned 1,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18199772&form=6&db=m Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults. ongoing research,unassigned 4,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18596881&form=6&db=m Thrombin: is it on a par with seizures and epilepsy? ongoing research,unassigned 3,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22926852&form=6&db=m Thrombin facilitates seizures through activation of persistent sodium current. causal interaction,unassigned 2,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23103417&form=6&db=m Thrombin regulation of synaptic transmission: implications for seizure onset. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23467310&form=6&db=m Treating seizures and epilepsy with anticoagulants? causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26537880&form=6&db=m Minimal Traumatic Brain Injury in Mice: Protease-Activated Receptor 1 and Thrombin-Related Changes. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26717112&form=6&db=m Prolonged Localized Mild Hypothermia Does Not Affect Seizure Activity After Intracerebral Hemorrhage in Rats. unassigned - 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30515700&form=6&db=m Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31667526&form=6&db=m Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32009953&form=6&db=m Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32850552&form=6&db=m The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children. diagnostic usage,unassigned 3,0 3.4.21.5 Seizures, Febrile http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32850552&form=6&db=m The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children. diagnostic usage,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=946230&form=6&db=m Platelet aggregation as a sign of septicemia in thermal injury. A prospective study. diagnostic usage,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1627018&form=6&db=m Modulators of coagulation. A critical appraisal of their role in sepsis. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1872494&form=6&db=m The pathogenesis of sepsis. causal interaction,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2670794&form=6&db=m Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2759692&form=6&db=m Hemostatic changes in neonates with anoxia and sepsis. diagnostic usage,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3061681&form=6&db=m Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6446336&form=6&db=m Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. causal interaction,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7974345&form=6&db=m Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis. therapeutic application,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8846045&form=6&db=m Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8902937&form=6&db=m Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8940690&form=6&db=m [Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults] unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9267673&form=6&db=m Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters. causal interaction,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366764&form=6&db=m Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9657433&form=6&db=m Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819023&form=6&db=m Tissue factor expression by monocytes: regulation and pathophysiological roles. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9875912&form=6&db=m Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. diagnostic usage,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10613651&form=6&db=m Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10688831&form=6&db=m Lepirudin blunts endotoxin-induced coagulation activation. therapeutic application,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10993801&form=6&db=m Thrombin and leukocyte recruitment in endotoxemia. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11007197&form=6&db=m The protein C pathway. causal interaction,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11035210&form=6&db=m Unlike thrombin, protein C and activated protein C do not affect vascular tone. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060733&form=6&db=m Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11312618&form=6&db=m Thrombin generation and mortality during Staphylococcus aureus sepsis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11372673&form=6&db=m Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. ongoing research,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11557600&form=6&db=m Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability. ongoing research,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740686&form=6&db=m Fibrinolysis in disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740690&form=6&db=m Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12004254&form=6&db=m Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12010802&form=6&db=m Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. therapeutic application,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12052963&form=6&db=m Activation of endothelial cell protease activated receptor 1 by the protein C pathway. causal interaction,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12463764&form=6&db=m Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483072&form=6&db=m Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12606553&form=6&db=m Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation. unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12745654&form=6&db=m Current clinical practice. DIC 2002: a review of disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12831462&form=6&db=m Coagulation and inflammation. therapeutic application,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14749872&form=6&db=m [Role of the innate immune response in sepsis] unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961149&form=6&db=m Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium. causal interaction,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15002397&form=6&db=m Coagulation disorders in patients with cirrhosis and severe sepsis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15063484&form=6&db=m Crosstalk between inflammation and thrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15181414&form=6&db=m [Protein C and coagulation in sepsis] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201277&form=6&db=m Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15349131&form=6&db=m Drotrecogin alfa. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15650061&form=6&db=m Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. ongoing research,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16168073&form=6&db=m Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. therapeutic application,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16188810&form=6&db=m Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16277710&form=6&db=m Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387470&form=6&db=m [Activated proteine C] causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16909370&form=6&db=m The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17010048&form=6&db=m Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17562127&form=6&db=m A case of disseminated intravascular coagulation caused by Brucella melitensis. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18067862&form=6&db=m Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria. causal interaction,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18089851&form=6&db=m Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18634754&form=6&db=m Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-alpha. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19334478&form=6&db=m [Approbation of a new test system determining the activity of a plasmin inhibitor in patients with sepsis] diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19423468&form=6&db=m A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19437587&form=6&db=m Crosstalk between inflammation and thrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630782&form=6&db=m Vascular and dendritic cell coagulation signaling in sepsis progression. unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630786&form=6&db=m The many faces of tissue factor. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19689998&form=6&db=m Tissue Factor Pathway Inhibitor and P-Selectin as Markers of Sepsis-Induced Non-overt Disseminated Intravascular Coagulopathy. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19691582&form=6&db=m Thrombin physiology and pathophysiology. causal interaction,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20079161&form=6&db=m Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21193113&form=6&db=m Inflammation and coagulation. An overview. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21253429&form=6&db=m Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21415977&form=6&db=m Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. causal interaction,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21526108&form=6&db=m Review of cellular and molecular pathways linking thrombosis and innate immune system during sepsis. unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21849480&form=6&db=m Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21872299&form=6&db=m Thrombin generation in severe sepsis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21972970&form=6&db=m Pathophysiology, staging and therapy of severe sepsis in baboon models. causal interaction,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22012337&form=6&db=m [Thrombin generation in critical illnesses]. therapeutic application,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22028651&form=6&db=m Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22143469&form=6&db=m Heparin-induced thrombocytopenia in the cardiac patient: 10 points to help the physician. unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22154246&form=6&db=m The protein C pathway and sepsis. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22252818&form=6&db=m Antimicrobial and Anticoagulant Activity of N-chlorotaurine (NCT), N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-monochloro-2,2-dimethyltaurine (NVC-612) in Human Blood. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22842493&form=6&db=m Regulation of RelA/p65 and Endothelial Cell Inflammation by Proline-Rich Tyrosine Kinase 2. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22923022&form=6&db=m The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23096108&form=6&db=m Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure. diagnostic usage,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23272096&form=6&db=m Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23804232&form=6&db=m Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin. causal interaction,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24075296&form=6&db=m Impairment of thrombin generation in the early phases of the host response of sepsis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24640752&form=6&db=m [Use of thrombin generation assay for the evaluation of coagulation and anticoagulant activity of hemostasis system in patients with abdominal sepsis]. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24978891&form=6&db=m Dynamic changes in thrombin generation in abdominal sepsis in mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25012129&form=6&db=m Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25057925&form=6&db=m Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25338593&form=6&db=m [Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies]. diagnostic usage,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25813486&form=6&db=m Thrombin generation in abdominal sepsis is Rho-kinase-dependent. causal interaction,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25938026&form=6&db=m Anticoagulant modulation of inflammation in severe sepsis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26232351&form=6&db=m Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26414883&form=6&db=m A Double-Chambered Protein Nanocage Loaded with Thrombin Receptor Agonist Peptide (TRAP) and ?-Carboxyglutamic Acid of Protein C (PC-Gla) for Sepsis Treatment. therapeutic application,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26476743&form=6&db=m Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-?B and AP-1. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26939619&form=6&db=m Histones as mediators of host defense, inflammation and thrombosis. causal interaction,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27458694&form=6&db=m Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28073784&form=6&db=m Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. ongoing research,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28092405&form=6&db=m Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,3 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28166112&form=6&db=m Endogenous thrombin potential as marker of procoagulant response that can be useful in early stage of sepsis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28288667&form=6&db=m Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28409836&form=6&db=m Platelet-derived microparticles regulates thrombin generation via phophatidylserine in abdominal sepsis. unassigned - 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28465231&form=6&db=m Rac1 regulates sepsis-induced formation of platelet-derived microparticles and thrombin generation. ongoing research,unassigned 2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28802974&form=6&db=m Characteristics of thrombin generation in a fulminant porcine sepsis model. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28846570&form=6&db=m Macrophage Migration Inhibitory Factor-Induced Autophagy Contributes to Thrombin-Triggered Endothelial Hyperpermeability in Sepsis. causal interaction,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31054328&form=6&db=m Critical role of autophagy regulator Beclin1 in endothelial cell inflammation and barrier disruption. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31091226&form=6&db=m Thrombin-cleaved syndecan-3/-4 ectodomain fragments mediate endothelial barrier dysfunction. causal interaction,unassigned 3,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31175488&form=6&db=m Lipopolysaccharide-Induced Hemolysis Is Abolished by Inhibition of Thrombin Generation but Not Inhibition of Platelet Aggregation. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,1,1 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31855152&form=6&db=m D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis. therapeutic application,unassigned 1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33120488&form=6&db=m [Predictive value of complement and coagulation indicators in sepsis related acute kidney injury]. diagnostic usage,unassigned 4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33196292&form=6&db=m COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33821229&form=6&db=m COVID-19 and cardiovascular problems in elderly patients: Food for thought. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33837227&form=6&db=m Role of a thrombin generation assay in the prediction of infection severity. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34369427&form=6&db=m Dielectric Blood Coagulometry for the Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Prospective Observational Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2020936&form=6&db=m A purified antithrombin III--heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2788582&form=6&db=m The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. ongoing research,unassigned 3,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2977523&form=6&db=m Neutrophil elastase, thrombin and plasmin in septic shock. unassigned - 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7073057&form=6&db=m Effects of dexamethasone on endotoxin shock in the anesthetized pony: hematologic, blood gas, and coagulation changes. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7720338&form=6&db=m Thrombin does not alter vascular hyporeactivity in models of endotoxin-induced septic shock in rats. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8704245&form=6&db=m Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8902937&form=6&db=m Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9843177&form=6&db=m Recombinant antitrypsin Pittsburgh undergoes proteolytic cleavage during E. coli sepsis and fails to prevent the associated coagulopathy in a primate model. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9869178&form=6&db=m Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9875912&form=6&db=m Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. diagnostic usage,unassigned 4,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10364091&form=6&db=m Influence of antithrombin III on coagulation and inflammation in porcine septic shock. ongoing research,unassigned 3,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669267&form=6&db=m Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs. causal interaction,unassigned 3,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060733&form=6&db=m Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11581572&form=6&db=m Porins from Salmonella typhimurium accelerate human blood coagulation in vitro by selective stimulation of thrombin activity: implications in septic shock DIC pathogenesis. ongoing research,unassigned 2,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12010802&form=6&db=m Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. therapeutic application,unassigned 4,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17894858&form=6&db=m Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction. causal interaction,unassigned 3,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18636042&form=6&db=m The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock. ongoing research,unassigned 4,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22735856&form=6&db=m Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25255379&form=6&db=m Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29197958&form=6&db=m Immunohaemostasis: a new view on haemostasis during sepsis. causal interaction,unassigned 1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30907672&form=6&db=m Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31722081&form=6&db=m Characterization of circulating thrombin in patients with septic shock: a prospective observational study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34221069&form=6&db=m Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Shoulder Dislocation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29528838&form=6&db=m A Rare Case of Axillary Artery Pseudoaneurysm Due to Shoulder Dislocation Treated With Percutaneous Thrombin Injection. therapeutic application,unassigned 2,0 3.4.21.5 Shwartzman Phenomenon http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1188709&form=6&db=m The effects of infusion of thrombin or endotoxin in rabbits treated with cortisone. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Shwartzman Phenomenon http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5662752&form=6&db=m Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Shwartzman Phenomenon http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6023410&form=6&db=m Failure to provoke the local Shwartzman reaction with thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Shwartzman Phenomenon http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6522106&form=6&db=m Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits. therapeutic application,unassigned 3,0 3.4.21.5 Shwartzman Phenomenon http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14190734&form=6&db=m PRODUCTION OF THE GENERALIZED SHWARTZMAN REACTION IN PREGNANT RATS BY INTRAVENOUS INFUSION OF THROMBIN. unassigned - 3.4.21.5 Sinus Thrombosis, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20124931&form=6&db=m Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. unassigned - 3.4.21.5 Sinus Thrombosis, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26297898&form=6&db=m Photothrombosis combined with thrombin injection establishes a rat model of cerebral venous sinus thrombosis. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Sinus Thrombosis, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29061392&form=6&db=m A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30353092&form=6&db=m Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Skin Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608016&form=6&db=m Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 3.4.21.5 Skin Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23607097&form=6&db=m Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series. diagnostic usage,unassigned 4,0 3.4.21.5 Sleep Apnea Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15588038&form=6&db=m Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Sleep Apnea, Central http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Sleep Apnea, Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15588038&form=6&db=m Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Sleep Apnea, Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33761732&form=6&db=m Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Sleep Deprivation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20418241&form=6&db=m Chronic sleep deprivation markedly reduces coagulation factor VII expression. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2467397&form=6&db=m Abnormal haemostasis in small cell lung cancer. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=847788&form=6&db=m Pleocytosis and elevation of prostaglandins F2a and E2 in cerebrospinal fluid following intracisternal injection of thrombin. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2146992&form=6&db=m Fibrinopeptide A is released into the coronary circulation after coronary spasm. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2525582&form=6&db=m Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6476135&form=6&db=m Endothelium and asymmetrical responses of the coronary arterial wall. unassigned - 3.4.21.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7511130&form=6&db=m Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8107282&form=6&db=m [Blood coagulation and fibrinolysis in ischemic heart disease] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8552614&form=6&db=m Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9187610&form=6&db=m Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15307903&form=6&db=m Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23647384&form=6&db=m Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25061982&form=6&db=m Thrombin enhances NGF-mediated neurite extension via increased and sustained activation of p44/42 MAPK and p38 MAPK. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27145117&form=6&db=m Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33549720&form=6&db=m The thrombin receptor links brain derived neurotrophic factor to neuron cholesterol production, resiliency and repair after spinal cord injury. unassigned - 3.4.21.5 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33887067&form=6&db=m The thrombin receptor modulates astroglia-neuron trophic coupling and neural repair after spinal cord injury. therapeutic application,unassigned 2,0 3.4.21.5 Spondylitis, Ankylosing http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20714763&form=6&db=m Thrombin generation in ankylosing spondylitis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15049722&form=6&db=m Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16331363&form=6&db=m [Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.] therapeutic application,unassigned 3,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17696566&form=6&db=m Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17912165&form=6&db=m Emergency Percutaneous Coronary Interven-tion (PCI) for the care of patients with ST-Elevation Myocardial Infarction (STEMI). therapeutic application,unassigned 1,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18561506&form=6&db=m New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications. therapeutic application,unassigned 4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371202&form=6&db=m Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552570&form=6&db=m Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19631970&form=6&db=m Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20384472&form=6&db=m Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20390444&form=6&db=m Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23344994&form=6&db=m Platelet Reactivity and Intramyocardial Hemorrhage in Patients With ST-Segment Elevation Myocardial Infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24337310&form=6&db=m Anticoagulation during and after acute coronary syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24514756&form=6&db=m Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28581998&form=6&db=m Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29695176&form=6&db=m Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30716426&form=6&db=m Platelet dysfunction after Out of Hospital Cardiac Arrest. Results from POHCAR: A prospective observational, cohort study. diagnostic usage,unassigned 2,0 3.4.21.5 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32184977&form=6&db=m Plaque herniation after stenting the culprit lesion with myocardial bridging in ST elevation myocardial infarction: A case report. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3005046&form=6&db=m EGF and insulin action in fibroblasts. Evidence that phosphoinositide hydrolysis is not an essential mitogenic signalling pathway. ongoing research,unassigned 1,0 3.4.21.5 Status Epilepticus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25843668&form=6&db=m Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis. causal interaction,unassigned 4,0 3.4.21.5 Status Epilepticus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30391321&form=6&db=m Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Status Epilepticus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30515700&form=6&db=m Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Status Epilepticus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31667526&form=6&db=m Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Status Epilepticus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32009953&form=6&db=m Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11816542&form=6&db=m Alteration of haemostasis in non-metastatic gastric cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15822938&form=6&db=m Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25231630&form=6&db=m Thrombin conducts epithelial?mesenchymal transition via protease?activated receptor?1 in human gastric cancer. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28833193&form=6&db=m Coagulation and fibrinolysis in gastric cancer. unassigned - 3.4.21.5 Stomach Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=467921&form=6&db=m Control of upper gastrointestinal hemorrhage by endoscopic spraying of clotting factors. causal interaction,unassigned 3,0 3.4.21.5 Stomach Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783357&form=6&db=m Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Stomach Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14878403&form=6&db=m Hemostatic effects of powdered gelfoam thrombin solution and blood transfusions in an instance of recurring massive hemorrhage from a large chronic gastric ulcer: report of a case. ongoing research,unassigned 2,0 3.4.21.5 Stomach Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17369897&form=6&db=m Thrombin receptor agonist Peptide immobilized in microspheres stimulates reparative processes in rats with gastric ulcer. unassigned - 3.4.21.5 Stomach Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32289853&form=6&db=m A prospective, randomized trial of thrombin versus cyanoacrylate injection in the control of acute gastric variceal hemorrhage. unassigned - 3.4.21.5 Strabismus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3347459&form=6&db=m Use of fibrin glue in ocular surgery. diagnostic usage,unassigned 3,0 3.4.21.5 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19056689&form=6&db=m Reduced thrombin generation increases host susceptibility to group A streptococcal infection. causal interaction,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=580508&form=6&db=m Blood coagulation and fibrinolysis in haemorrhagic stroke. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1284251&form=6&db=m Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1829631&form=6&db=m A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen). therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2582596&form=6&db=m A plasmatic factor may cause platelet activation in acute ischemic stroke. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7773734&form=6&db=m Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7865679&form=6&db=m The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8568564&form=6&db=m Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin. diagnostic usage,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8568567&form=6&db=m Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9005443&form=6&db=m Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9445356&form=6&db=m Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9471097&form=6&db=m Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9540779&form=6&db=m Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9647415&form=6&db=m Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10582976&form=6&db=m Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10775022&form=6&db=m Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11214426&form=6&db=m Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11253464&form=6&db=m Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering. causal interaction,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12020054&form=6&db=m Ximelagatran (AstraZeneca). causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12235794&form=6&db=m [Strategy for circulatory disturbance] therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12373680&form=6&db=m [Inflammatory mechanisms, arteriosclerosis and ischemic stroke: clinical data and perspectives] unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12524220&form=6&db=m The dynamics of thrombin formation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12529741&form=6&db=m Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12660663&form=6&db=m Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12769712&form=6&db=m G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12811011&form=6&db=m Argatroban in thrombotic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853713&form=6&db=m Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14607082&form=6&db=m Targeting thrombin--rational drug design from natural mechanisms. causal interaction,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14643116&form=6&db=m Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14663340&form=6&db=m Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14688636&form=6&db=m Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14747742&form=6&db=m Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753434&form=6&db=m Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961162&form=6&db=m Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15028346&form=6&db=m Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15075048&form=6&db=m Stroke prevention using an oral thrombin inhibitor in atrial fibrillation. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102593&form=6&db=m American Heart Association scientific sessions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15143301&form=6&db=m Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15151465&form=6&db=m Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15253941&form=6&db=m Will oral antithrombin agents replace warfarin? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15306086&form=6&db=m Direct thrombin inhibition to prevent stroke in atrial fibrillation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15334192&form=6&db=m New developments in the treatment of neurological diseases. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15341703&form=6&db=m New anticoagulants and their potential impact on the treatment of thromboembolic disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15365123&form=6&db=m Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15566318&form=6&db=m Novel therapies for the prevention of stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15610639&form=6&db=m SPORTIF III and SPORTIF V: Stroke Prevention Using the Direct Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619541&form=6&db=m Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619612&form=6&db=m Changing the guard in long-term anticoagulation: clinical and economic implications. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15619614&form=6&db=m Reducing cardiac events after acute coronary syndromes. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15644791&form=6&db=m Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15660523&form=6&db=m Atrial fibrillation: modern concepts and management. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15692116&form=6&db=m Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15696910&form=6&db=m Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15701910&form=6&db=m Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15785149&form=6&db=m Anticoagulation for atrial fibrillation in the elderly. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15812201&form=6&db=m Preventing stroke in atrial fibrillation: the SPORTIF programme. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15968399&form=6&db=m Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16025234&form=6&db=m Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16076267&form=6&db=m Ximelagatran for stroke prevention in atrial fibrillation. ongoing research,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16123916&form=6&db=m Prevention of stroke in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16144513&form=6&db=m Ximelagatran--recent comparisons with warfarin. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16449807&form=6&db=m Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. Pooled Analysis from the SPORTIF III and V Studies. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16475045&form=6&db=m New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16511607&form=6&db=m Ximelagatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16636210&form=6&db=m Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16749907&form=6&db=m Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757126&form=6&db=m Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16774980&form=6&db=m Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16908730&form=6&db=m Argatroban tPA stroke study: study design and results in the first treated cohort. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16959740&form=6&db=m Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070169&form=6&db=m Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17124098&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17289744&form=6&db=m Effect of hypertension on anticoagulated patients with atrial fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296878&form=6&db=m Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296916&form=6&db=m Protective effects of beta-blockers in cerebrovascular disease. causal interaction,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17483128&form=6&db=m Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17547713&form=6&db=m Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17629581&form=6&db=m The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17673721&form=6&db=m Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17729188&form=6&db=m Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17885258&form=6&db=m Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17975103&form=6&db=m Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia. causal interaction,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18199772&form=6&db=m Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults. ongoing research,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18215612&form=6&db=m Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18266660&form=6&db=m Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18574928&form=6&db=m Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18596881&form=6&db=m Thrombin: is it on a par with seizures and epilepsy? ongoing research,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18598697&form=6&db=m Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18755350&form=6&db=m Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. diagnostic usage,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19018807&form=6&db=m DYSREGULATION OF Ca(2+) MOVEMENT IN PLATELETS FROM PATIENTS WITH ACUTE ISCHAEMIC STROKE. causal interaction,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19178132&form=6&db=m Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19445805&form=6&db=m Stroke management. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19690349&form=6&db=m Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20076850&form=6&db=m Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20076857&form=6&db=m Another oral thrombin inhibitor for stroke preventionin atrial fibrillation? therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20170696&form=6&db=m Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20345495&form=6&db=m New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20446854&form=6&db=m Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20594045&form=6&db=m Smoking and coagulation: the sticky fibrin phenomenon. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20617417&form=6&db=m Novel anticoagulant therapy: principle and practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20655037&form=6&db=m Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20709367&form=6&db=m Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. causal interaction,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20716144&form=6&db=m Cutting through the statistical fog: understanding and evaluating non-inferiority trials. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20723798&form=6&db=m Stroke prevention and treatment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20809275&form=6&db=m [New oral anticoagulants : Better than vitamin K antagonists?] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20842548&form=6&db=m Thrombi of different pathologies: implications for diagnosis and treatment. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20966414&form=6&db=m Functional Occurrence of the Interaction of Tissue Plasminogen Activator With the NR1 Subunit of N-Methyl-D-Aspartate Receptors During Stroke. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21068702&form=6&db=m Dabigatran etexilate (Pradaxa)--a new oral anticoagulant. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21144965&form=6&db=m Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21172721&form=6&db=m Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21221717&form=6&db=m A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21239798&form=6&db=m Warfarin versus new agents: interpreting the data. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21291575&form=6&db=m [New antithrombotics for atrial fibrillation.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21352091&form=6&db=m Treating arrhythmias: an expert opinion. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21421599&form=6&db=m Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21429525&form=6&db=m Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21481181&form=6&db=m S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21517644&form=6&db=m New options for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533567&form=6&db=m Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21537165&form=6&db=m Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21538731&form=6&db=m Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21577333&form=6&db=m Thrombin antithrombin complex and IL-18 serum levels in stroke patients. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21654569&form=6&db=m Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation? causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21663525&form=6&db=m Clopidogrel hydrogen sulphate for atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21694684&form=6&db=m What's new in stroke? The top 10 studies of 2009-2011: part II. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21740079&form=6&db=m Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21748501&form=6&db=m Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21769985&form=6&db=m Chemical shift sodium imaging in a mouse model of thromboembolic stroke at 9.4 T. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21788545&form=6&db=m The use of dabigatran in elderly patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21788962&form=6&db=m The role of aspirin for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21816811&form=6&db=m Update on anti-coagulation in atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21822469&form=6&db=m Antithrombotic medication for cardioembolic stroke prevention. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21881389&form=6&db=m Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21956604&form=6&db=m Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21960064&form=6&db=m Preventing cardioembolic stroke in atrial fibrillation with dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21995885&form=6&db=m Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22001525&form=6&db=m Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22012548&form=6&db=m [Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22080642&form=6&db=m Tissue factor/factor VIIa pathway mediates coagulation activation in induced-heat stroke in the baboon. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22122184&form=6&db=m Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22193838&form=6&db=m Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22223235&form=6&db=m The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22252796&form=6&db=m Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22298812&form=6&db=m The Pharmacology and Therapeutic Use of Dabigatran Etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22306274&form=6&db=m Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22353706&form=6&db=m A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22367842&form=6&db=m Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22370770&form=6&db=m Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22417716&form=6&db=m New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22431533&form=6&db=m Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22432811&form=6&db=m Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22458577&form=6&db=m Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22564122&form=6&db=m Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22565859&form=6&db=m [Pharmacology of the new oral anticoagulants]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22577900&form=6&db=m Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22595814&form=6&db=m Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22645678&form=6&db=m Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22668618&form=6&db=m New oral anticoagulants: will they replace warfarin? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682209&form=6&db=m [Dabigatran: a new therapeutic alternative in the prevention of stroke]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22683118&form=6&db=m Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22684583&form=6&db=m Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22730480&form=6&db=m New anticoagulant treatments to protect against stroke in atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22739760&form=6&db=m Dabigatran for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22787066&form=6&db=m Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22826692&form=6&db=m An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22828994&form=6&db=m [New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22839715&form=6&db=m [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22869389&form=6&db=m A comparison of bleeding complications post-ablation between warfarin and dabigatran. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22910132&form=6&db=m Evaluating and assessing dabigatran drug interactions. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22921458&form=6&db=m Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22952215&form=6&db=m Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22955200&form=6&db=m Vitamin K antagonists. Ready to be replaced? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22958146&form=6&db=m Gastrointestinal disorders and dabigatran. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23026659&form=6&db=m What did we learn from new oral anticoagulant treatment? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23031622&form=6&db=m Dabigatran in clinical practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23058974&form=6&db=m Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23108916&form=6&db=m Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23114798&form=6&db=m [Dabigatran therapy--perioperative management and interpretation of coagulation tests]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23160166&form=6&db=m An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. therapeutic application,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23166825&form=6&db=m Spontaneous reperfusion after in situ thromboembolic stroke in mice. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23212788&form=6&db=m Positive Outcome After Intentional Overdose of Dabigatran. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23213626&form=6&db=m Stroke prevention: managing modifiable risk factors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23219111&form=6&db=m Removal of dabigatran by hemodialysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23221509&form=6&db=m Dabigatran, a Cause of Hematologic Emergency. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23224686&form=6&db=m Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23258203&form=6&db=m [Waiting for the new oral anticoagulants: questions and answers about dabigatran]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389759&form=6&db=m Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. therapeutic application,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389892&form=6&db=m Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23391669&form=6&db=m Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23397554&form=6&db=m Anticoagulation therapy for atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23400738&form=6&db=m The pharmacology and therapeutic use of dabigatran etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23423463&form=6&db=m t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23435652&form=6&db=m The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23466965&form=6&db=m Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23466966&form=6&db=m Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23466967&form=6&db=m Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23522810&form=6&db=m Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23547700&form=6&db=m Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23577951&form=6&db=m Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23631181&form=6&db=m [Direct oral thrombin inhibitor, "dabigatran"]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23632424&form=6&db=m [Stroke prevention in atrial fibrillation : old and new anticoagulants]. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23670031&form=6&db=m Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23704302&form=6&db=m Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23803980&form=6&db=m Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23818798&form=6&db=m Transitions of care in anticoagulated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23841763&form=6&db=m Stroke thrombolysis in patients taking dabigatran. diagnostic usage,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23860880&form=6&db=m The pharmacology of novel oral anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23900720&form=6&db=m Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23909016&form=6&db=m [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23997448&form=6&db=m Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24015809&form=6&db=m Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24029592&form=6&db=m The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24063505&form=6&db=m Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24117111&form=6&db=m Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24138517&form=6&db=m Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24151507&form=6&db=m Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24182477&form=6&db=m Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24183214&form=6&db=m The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24231693&form=6&db=m Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24288086&form=6&db=m Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24291856&form=6&db=m [Evidence of novel oral anticoagulants (NOAC)]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24319080&form=6&db=m Dabigatran Use in the Real World A Multihospital System Experience. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24339381&form=6&db=m Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24347404&form=6&db=m Characterization of a New Model of Thromboembolic Stroke in C57 black/6J mice. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24373340&form=6&db=m Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24378048&form=6&db=m [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385325&form=6&db=m Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24400656&form=6&db=m The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24432039&form=6&db=m Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24473182&form=6&db=m Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24492353&form=6&db=m Increased risk of myocardial infarction with dabigatran: fact or fiction? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24508114&form=6&db=m Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24509332&form=6&db=m Impaired renal function and bleeding in elderly treated with dabigatran. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24556890&form=6&db=m Practical aspects of new oral anticoagulant use in atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24605405&form=6&db=m [New treatments for stroke and thromboembolism prevention in atrial fibrillation]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24614113&form=6&db=m Oral anticoagulants for Asian patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24668159&form=6&db=m A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24683059&form=6&db=m Benefit-Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24711240&form=6&db=m [Perioperative management and therapy of bleeding complications]. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24803917&form=6&db=m Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24813481&form=6&db=m [Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24814537&form=6&db=m Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24815541&form=6&db=m ?T -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24846226&form=6&db=m Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24963788&form=6&db=m Analysis of the influence of dabigatran on coagulation factors and inhibitors. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24973113&form=6&db=m Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25033981&form=6&db=m Increased thrombin generation potential in symptomatic versus asymptomatic moderate or severe carotid stenosis and relationship with cerebral microemboli. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25046150&form=6&db=m Antithrombotics in atrial fibrillation and coronary disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25084117&form=6&db=m Continuation of dabigatran therapy in "real-world" practice in Hong Kong. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138549&form=6&db=m Dabigatran: patient management in specific clinical settings. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25172669&form=6&db=m On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25215263&form=6&db=m Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25261684&form=6&db=m Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models. therapeutic application,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25278289&form=6&db=m Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25440361&form=6&db=m Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25490355&form=6&db=m [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25604482&form=6&db=m Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25615590&form=6&db=m Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25633777&form=6&db=m Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25682085&form=6&db=m Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25762815&form=6&db=m Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25793127&form=6&db=m Thrombus formation in left atrium on dabigatran therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25830002&form=6&db=m Acute myocardial infarction after switching from warfarin to dabigatran. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25918026&form=6&db=m Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25978611&form=6&db=m Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26019695&form=6&db=m An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26048605&form=6&db=m Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26162958&form=6&db=m Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26219486&form=6&db=m Impact of dabigatran on platelet function and fibrinolysis. ongoing research,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26270886&form=6&db=m Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26286125&form=6&db=m Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26305570&form=6&db=m Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26356074&form=6&db=m Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26370208&form=6&db=m Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26420134&form=6&db=m Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26425251&form=6&db=m Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26452739&form=6&db=m Pradaxa-induced esophageal ulcer. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26458452&form=6&db=m [Novel oral anticoagulants (NOAC)]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26596056&form=6&db=m [COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION]. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26670085&form=6&db=m Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26835091&form=6&db=m Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26846610&form=6&db=m Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26905070&form=6&db=m Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26994821&form=6&db=m Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27023335&form=6&db=m The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27032444&form=6&db=m Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27115860&form=6&db=m Clinical and laboratory predictors of deep vein thrombosis after acute stroke. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27138068&form=6&db=m Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1. causal interaction,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184031&form=6&db=m Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184172&form=6&db=m Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27342651&form=6&db=m Apixaban to prevent stroke in patients with atrial fibrillation: a review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27347226&form=6&db=m Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27364823&form=6&db=m The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27431453&form=6&db=m Thrombin preferentially induces autophagy in glia cells in the rat central nervous system. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27526541&form=6&db=m [Monitoring of Oral Thrombin Inhibitor]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27734642&form=6&db=m Current Perspective on Use of NOAC in Clinical Practice in India. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27797449&form=6&db=m Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27910004&form=6&db=m Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27957046&form=6&db=m Efficacy And Safety of Dabigatran Etexilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial Fibrillation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27998795&form=6&db=m Mechanisms of modulation of brain microvascular endothelial cells function by thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28060970&form=6&db=m [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation]. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116215&form=6&db=m Thrombin Generation in Acute Ischaemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28294796&form=6&db=m [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28382369&form=6&db=m Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28416406&form=6&db=m Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28419510&form=6&db=m Increase of aquaporin 9 expression in astrocytes participates in astrogliosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28443061&form=6&db=m A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28493056&form=6&db=m Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28496710&form=6&db=m Prevention of Stroke in Patients With Atrial Fibrillation. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28592454&form=6&db=m Coated-platelets predict stroke at 30 days following TIA. therapeutic application,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28805310&form=6&db=m Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28883845&form=6&db=m The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke. diagnostic usage,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29105079&form=6&db=m Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29239808&form=6&db=m Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. causal interaction,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29299952&form=6&db=m The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29335786&form=6&db=m Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29488150&form=6&db=m Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29633066&form=6&db=m Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29651748&form=6&db=m Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29849330&form=6&db=m Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29867495&form=6&db=m Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29904298&form=6&db=m Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29972860&form=6&db=m No Association between Thrombin Generation and Intra-Plaque Haemorrhage in Symptomatic Carotid Atherosclerotic Plaques: The Plaque at RISK (PARISK) Study. unassigned - 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29975925&form=6&db=m Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30209126&form=6&db=m Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30264130&form=6&db=m Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. ongoing research,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30564010&form=6&db=m The role of thrombin in central nervous system activity and stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30742307&form=6&db=m Statins and the risk of bleeding in patients taking dabigatran. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30864392&form=6&db=m Enhancing the anticoagulant profile of meizothrombin. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30936131&form=6&db=m Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. therapeutic application,unassigned 1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30955928&form=6&db=m Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex). causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31005062&form=6&db=m The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31537027&form=6&db=m Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31607864&form=6&db=m Post Stroke Seizures and Epilepsy: From Proteases to Maladaptive Plasticity. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31886279&form=6&db=m Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32027788&form=6&db=m Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32048978&form=6&db=m A Rare Case Report Of Dabigatran Induced Oral Ulcers. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32227212&form=6&db=m A murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32247819&form=6&db=m Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity? therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32312069&form=6&db=m Stratification of venous thromboembolism risk in stroke patients by Caprini score. diagnostic usage,unassigned 2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32404035&form=6&db=m Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. therapeutic application,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32586214&form=6&db=m The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. causal interaction,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32617467&form=6&db=m Left atrial appendage thrombus on full-dose dabigatran treatment: a case report. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32689602&form=6&db=m Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32699371&form=6&db=m Validation of a stroke model in rat compatible with rt-PA-induced thrombolysis: new hope for successful translation to the clinic. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32758579&form=6&db=m Ctnnb1 transcriptional upregulation compensates for Mdm2/p53-mediated ?-catenin degradation in neutrophils following cardioembolic stroke. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33055222&form=6&db=m In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke. diagnostic usage,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33132228&form=6&db=m Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source?- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial. therapeutic application,unassigned 4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33504190&form=6&db=m Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33588594&form=6&db=m Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33593994&form=6&db=m Comparative effectiveness of oral anticoagulants in everyday practice. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33612323&form=6&db=m Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR). causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34221069&form=6&db=m Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34233467&form=6&db=m Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34374256&form=6&db=m [Characteristics of circulation and microcirculation in healthy people of Han nationality at different altitudes]. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34398251&form=6&db=m The role of leukocytes in acute ischemic stroke-related thrombosis: a notable but neglected topic. causal interaction,unassigned 3,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34401468&form=6&db=m Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34495626&form=6&db=m Embolic Stroke Model with Magnetic Nanoparticles. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Stroke, Lacunar http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8248977&form=6&db=m Hematologic abnormalities occur in both cortical and lacunar infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Stroke, Lacunar http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10689930&form=6&db=m [Coagulation and fibrinolytic activation in lacunar infarct patients] unassigned - 3.4.21.5 Stroke, Lacunar http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26373290&form=6&db=m Chronic Systemic Immune Dysfunction in African-Americans with Small Vessel-Type Ischemic Stroke. diagnostic usage,unassigned 1,0 3.4.21.5 Stupor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=687073&form=6&db=m [Narcosis, platelet aggregation and arousing drugs] therapeutic application,unassigned 1,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1636187&form=6&db=m Impairment of endothelium-dependent relaxation in human basilar artery after subarachnoid hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1636198&form=6&db=m Thrombin activity in cerebrospinal fluid after subarachnoid hemorrhage. diagnostic usage,unassigned 2,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2579347&form=6&db=m Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6998061&form=6&db=m Cerebral arterial contractions induced by human and bovine thrombin. causal interaction,unassigned 4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10069585&form=6&db=m Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10978044&form=6&db=m Thrombin reduces cerebral arterial contractions caused by cerebrospinal fluid from patients with subarachnoid hemorrhage. causal interaction,unassigned 4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11070371&form=6&db=m Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11441217&form=6&db=m Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12764230&form=6&db=m Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17962603&form=6&db=m Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. therapeutic application,unassigned 1,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19098389&form=6&db=m Basic and translational research on proteinase-activated receptors: the role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage. ongoing research,unassigned 4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19228846&form=6&db=m Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,4 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19934959&form=6&db=m Thrombin inhibition in subarachnoid hemorrhage. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20859063&form=6&db=m Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21564089&form=6&db=m Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid hemorrhage. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23539525&form=6&db=m Role of SCH79797 in Maintaining Vascular Integrity in Rat Model of Subarachnoid Hemorrhage. causal interaction,unassigned 4,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31179838&form=6&db=m Effect of thrombin injection on cerebral vascular in rats with subarachnoid hemorrhage. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31433571&form=6&db=m Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Surgical Wound Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26975606&form=6&db=m Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Surgical Wound Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31593122&form=6&db=m Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1372297&form=6&db=m Analysis of the N-terminal region of the 47-kilodalton integral membrane lipoprotein of Treponema pallidum. diagnostic usage,unassigned 1,0 3.4.21.5 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17144492&form=6&db=m [Study the safty and effectivity of human thrombin after tonsillectomy] diagnostic usage,unassigned 3,0 3.4.21.5 Systemic Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21733119&form=6&db=m Thromboembolic disease in systemic vasculitis is associated with enhanced microparticle-mediated thrombin generation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Tangier Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524709&form=6&db=m Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Tauopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12821672&form=6&db=m Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling. causal interaction,unassigned 2,0 3.4.21.5 Telangiectasia, Hereditary Hemorrhagic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18145569&form=6&db=m Hereditary hemorrhagic telangiectasia with intestinal bleeding; case report and therapy with tropical thrombin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Telangiectasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18145569&form=6&db=m Hereditary hemorrhagic telangiectasia with intestinal bleeding; case report and therapy with tropical thrombin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Tetanus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1335019&form=6&db=m Effects of tetanus toxin, Salmonella typhimurium porin, and bacterial lipopolysaccharide on platelet aggregation. ongoing research,unassigned 4,0 3.4.21.5 Tetanus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24753100&form=6&db=m The anticoagulant activated protein C (aPC) promotes metaplasticity in the hippocampus through an EPCR-PAR1-S1P1 receptors dependent mechanism. unassigned - 3.4.21.5 Thalassemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19648162&form=6&db=m Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1660876&form=6&db=m Involvement of platelet glycoprotein IIb-IIIa (alpha IIb-beta 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3',4'-bisphosphate. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2117306&form=6&db=m Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. ongoing research,unassigned 2,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2588948&form=6&db=m [Analysis of platelet surface conformation in thrombin-induced aggregation] ongoing research,unassigned 2,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6457625&form=6&db=m Antibodies against platelet membrane glycoproteins. II. Influence on ADP- and collagen-induced platelet aggregation, crossed immunoelectrophoresis studies and relevance to Glanzmann's thrombasthenia. causal interaction,unassigned 3,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7680100&form=6&db=m Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets. unassigned - 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7687438&form=6&db=m Involvement of GPIIb-IIIa on human platelets in phosphotyrosine-specific dephosphorylation. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8698879&form=6&db=m Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9057642&form=6&db=m Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,1,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12761479&form=6&db=m Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma. unassigned - 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17572261&form=6&db=m The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18544417&form=6&db=m Tissue factor-independent effects of recombinant factor VIIa on hemostasis. causal interaction,unassigned 3,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012175&form=6&db=m Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19408196&form=6&db=m Impaired platelet procoagulant mechanisms in patients with bleeding disorders. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20632246&form=6&db=m Recombinant activated factor VII: mechanisms of action and current indications. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015059&form=6&db=m Recombinant activated factor VII in clinical practice: a 2014 update. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26073368&form=6&db=m Recombinant activated factor VII: 30 years of research and innovation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26290457&form=6&db=m Association of Factor V Secretion with Protein Kinase B Signaling in Platelets from Horses with Atypical Equine Thrombasthenia. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30597506&form=6&db=m Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 thrombin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25424451&form=6&db=m Warfarin pretreatment reduces cell death and mmp-9 activity in experimental intracerebral hemorrhage. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.5 thrombin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29654769&form=6&db=m Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 thrombin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31164248&form=6&db=m The central role of thrombin in bleeding disorders. causal interaction,unassigned 3,0 3.4.21.5 thrombin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33481255&form=6&db=m A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8387942&form=6&db=m Cytoskeleton protein composition upon platelet stimulation with thrombin in essential thrombocythemia. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883266&form=6&db=m Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16256174&form=6&db=m Lactate production by thrombin-activated platelets of patients with primary thrombocythemia. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18768782&form=6&db=m Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19508974&form=6&db=m Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,4,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21442635&form=6&db=m Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23233637&form=6&db=m Thrombotic disease in the myeloproliferative neoplasms. causal interaction,unassigned 1,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23735588&form=6&db=m ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. causal interaction,unassigned 4,0 3.4.21.5 Thrombocythemia, Essential http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23873831&form=6&db=m Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,1 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4041&form=6&db=m Platelet aggregation in portal cirrhosis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=861835&form=6&db=m The pathogenesis of leptospirosis I. Hemorrhages in experimental leptospirosis in guinea pigs. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1008076&form=6&db=m Coagulation studies of viral hepatitis occurring during pregnancy. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1091153&form=6&db=m Effects of intravascular clotting on the activation of the complement system: The role of the platelet. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1147670&form=6&db=m Disseminated intravascular clotting in kwashiorkor. causal interaction,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1244923&form=6&db=m Infectious canine hepatitis: animal model for viral-induced disseminated intravascular coagulation. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1258926&form=6&db=m Abnormal coagulation and fibrinolysis in eclampsia. A clinical and laboratory correlation study. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1258945&form=6&db=m Coagulation changes in eclampsia: their frequency and pathogenesis. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1266538&form=6&db=m Induction of endogenous fibrinolysis inhibition in the dog. Effect of intravascular coagulation and release of free fatty acids. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1486048&form=6&db=m Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1601644&form=6&db=m Massive pulmonary embolism presenting as disseminated intravascular coagulation. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1703455&form=6&db=m Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901342&form=6&db=m Thrombin-induced leukopenia and thrombocytopenia are attenuated by PAF antagonist WEB 2086. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3194891&form=6&db=m Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3627580&form=6&db=m A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3775692&form=6&db=m Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3787568&form=6&db=m A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5639161&form=6&db=m Inhibition by adenosine diphosphate of the thrombocytopenia induced in rabbits by collagen or thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5838404&form=6&db=m Thrombocytopenia and release of platelet amines induced by thrombin and bacterial lipopolysaccharide. Observations after infusion of low molecular weight dextran. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230118&form=6&db=m Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6446336&form=6&db=m Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. causal interaction,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6481187&form=6&db=m Hematologic changes in brucellosis. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6727275&form=6&db=m [Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma] causal interaction,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6813969&form=6&db=m Thrombocytopenia in preeclampsia and eclampsia. causal interaction,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6943979&form=6&db=m Disseminated intravascular coagulation: a clinical/laboratory study of 48 patients. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7474966&form=6&db=m Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489960&form=6&db=m Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7833251&form=6&db=m Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7918038&form=6&db=m Procoagulant activity of the MC28 fibrosarcoma cell line in vitro and in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7957610&form=6&db=m Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,4,4 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8266156&form=6&db=m Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9266927&form=6&db=m Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9288875&form=6&db=m Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9382401&form=6&db=m The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9622218&form=6&db=m The coagulation profile in hepatosplenic schistosomiasis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9690602&form=6&db=m Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs. causal interaction,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819030&form=6&db=m Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9855181&form=6&db=m New treatment options for heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9930560&form=6&db=m Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. therapeutic application,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9930564&form=6&db=m Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10560805&form=6&db=m Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10570098&form=6&db=m In vitro study of r-hirudin permeability through membranes of different haemodialysers. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10577463&form=6&db=m Newer antithrombin agents in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10581995&form=6&db=m [Indications for anticoagulants] therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10671997&form=6&db=m Systemic lupus erythematosus presenting with haemorrhagic manifestation. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10702817&form=6&db=m Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10725984&form=6&db=m Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726035&form=6&db=m Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726037&form=6&db=m Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. therapeutic application,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10972630&form=6&db=m Use of direct thrombin inhibitors in acute coronary syndrome. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10999507&form=6&db=m Lepirudin dosing in dialysis-dependent renal failure. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11030460&form=6&db=m Characterization and quantitation by flow cytometry of membranous microparticles formed during activation of platelet suspensions with ionophore or thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11269422&form=6&db=m Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and thrombosis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11285600&form=6&db=m From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11434701&form=6&db=m A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11437595&form=6&db=m Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11533507&form=6&db=m Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11692908&form=6&db=m [Calcium heparin-induced immunologic thrombocytopenia complicated with venous gangrene of the legs. Report of a clinical case] therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11704218&form=6&db=m Anticoagulation with a selective thrombin inhibitor in a woman with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11729365&form=6&db=m A synopsis of the clinical uses of argatroban. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11840659&form=6&db=m [Intraoperative management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor] therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11899844&form=6&db=m [Autoimmune thrombocytopenia in chronic liver disease] causal interaction,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11939684&form=6&db=m Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11975790&form=6&db=m Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12211410&form=6&db=m Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214146&form=6&db=m Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214148&form=6&db=m To general haemostasis--the evidence-based route. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12221676&form=6&db=m Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12393117&form=6&db=m Monitoring of hirudin therapy with the Thrombelastograph. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12401853&form=6&db=m In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12404091&form=6&db=m Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12420243&form=6&db=m Hirudin in renal insufficiency. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12508198&form=6&db=m Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12533066&form=6&db=m Argatroban in adult extracorporeal membrane oxygenation. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12546000&form=6&db=m Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12556751&form=6&db=m Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12579101&form=6&db=m Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12643418&form=6&db=m Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12842558&form=6&db=m Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected]. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12901145&form=6&db=m Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12912723&form=6&db=m Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13034911&form=6&db=m A thrombin generation test; the application in haemophilia and thrombocytopenia. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14568897&form=6&db=m Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14633796&form=6&db=m Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14695634&form=6&db=m Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14742788&form=6&db=m Effect of renal function on the pharmacodynamics of argatroban. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15107981&form=6&db=m [Modern anticoagulation. Problems of the proven, hope for the new] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15114601&form=6&db=m Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15116259&form=6&db=m The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15122174&form=6&db=m A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15151481&form=6&db=m Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15155316&form=6&db=m Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15164386&form=6&db=m Warfarin-induced limb gangrene in the setting of lung adenocarcinoma. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15238620&form=6&db=m Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15282649&form=6&db=m An overview of the heparin-induced thrombocytopenia syndrome. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15282652&form=6&db=m Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15282654&form=6&db=m The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15283365&form=6&db=m Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15318856&form=6&db=m Transfusion medicine service policies for recombinant factor VIIa administration. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15534737&form=6&db=m Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15632219&form=6&db=m Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15673409&form=6&db=m Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15701441&form=6&db=m Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15706030&form=6&db=m Thrombocytopenia in cardiovascular patients: diagnosis and management. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719581&form=6&db=m Direct thrombin inhibitors in heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15720249&form=6&db=m Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15870544&form=6&db=m Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15902370&form=6&db=m [Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15918449&form=6&db=m Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: a case report. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15981562&form=6&db=m Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16015413&form=6&db=m Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16082605&form=6&db=m Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16119279&form=6&db=m The paradox of heparin-induced thrombocytopenia: future anticoagulation. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16125511&form=6&db=m Heparin-induced thrombocytopenia: clinical manifestations and management strategies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16131539&form=6&db=m Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16276136&form=6&db=m Thrombocytopenia following heparin flush. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305293&form=6&db=m Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305522&form=6&db=m Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16350384&form=6&db=m Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16371760&form=6&db=m The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16377466&form=6&db=m New anticoagulant agents: direct thrombin inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16394885&form=6&db=m Argatroban anticoagulation in pediatric patients: a literature analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16427387&form=6&db=m Massive transfusion coagulopathy. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16434493&form=6&db=m Roles of protease-activated receptors in a mouse model of endotoxemia. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16449547&form=6&db=m Successful recovery after an overdose of argatroban. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16475045&form=6&db=m New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16553503&form=6&db=m Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16562602&form=6&db=m [Anticoagulation in patients with chronic renal failure] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16676057&form=6&db=m [Acute coronary syndrome: peri-interventional antithrombotic therapy] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16767070&form=6&db=m Anticoagulation options for intermittent haemodialysis. causal interaction,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16778256&form=6&db=m Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16801109&form=6&db=m Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16871542&form=6&db=m Thrombin generation in patients with cirrhosis: the role of platelets. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16893408&form=6&db=m The safety of heparins in end-stage renal disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16961586&form=6&db=m Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17016394&form=6&db=m Anticoagulation for continuous renal replacement therapy. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17109386&form=6&db=m Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17124098&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17176266&form=6&db=m Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17179827&form=6&db=m Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17187457&form=6&db=m Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17252251&form=6&db=m [Two surgical case reports showing atypical heparin-induced thrombocytopenia] causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17374738&form=6&db=m Diverging signaling events control the pathway of GPVI down-regulation in vivo. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17424791&form=6&db=m Anticoagulation in CRRT: agents and strategies in Australian ICUs. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17530465&form=6&db=m Effect of body mass index on Argatroban therapy during percutaneous coronary intervention. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17537058&form=6&db=m Argatroban in extracorporeal membrane oxygenation. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17546553&form=6&db=m Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17571914&form=6&db=m Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17667231&form=6&db=m A case series describing the use of argatroban in patients on extracorporeal circulation. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17699453&form=6&db=m Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17726318&form=6&db=m Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17886208&form=6&db=m [Anticoagulation and chronic hemodialysis.] causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17910040&form=6&db=m Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18217128&form=6&db=m Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18303934&form=6&db=m Low-Molecular-Weight Heparins : Mechanisms, Trials, and Role in Contemporary Interventional Medicine. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18325302&form=6&db=m Identification and treatment of arterial thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18406993&form=6&db=m New anticoagulant agents: direct thrombin inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18458557&form=6&db=m Anaesthetic management of a patient with thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18560242&form=6&db=m Argatroban anticoagulation in renal dysfunction: a literature analysis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18664968&form=6&db=m Usefulness of pretest clinical score (4Ts) combined with immunoassay for the diagnosis of heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18685428&form=6&db=m Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18827868&form=6&db=m Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18827975&form=6&db=m A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18956996&form=6&db=m Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18971611&form=6&db=m [Heparin-induced thrombocytopenia] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012175&form=6&db=m Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19016728&form=6&db=m Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,2 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19025434&form=6&db=m Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19050602&form=6&db=m Argatroban for anticoagulation in continuous renal replacement therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19054792&form=6&db=m Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19059879&form=6&db=m Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19126942&form=6&db=m Heparin induced thrombocytopenia management with bivalirudin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19129243&form=6&db=m Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19191676&form=6&db=m Pharmacotherapy of acute coronary syndrome: the ACUITY trial. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19338378&form=6&db=m Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19379358&form=6&db=m Anticoagulation options for pediatric hemodialysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19504050&form=6&db=m Impact of renal function on argatroban therapy during percutaneous coronary intervention. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19539510&form=6&db=m Concentration of D-dimers in healthy cats and sick cats with and without disseminated intravascular coagulation (DIC). diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19549276&form=6&db=m Thrombin generation and heparin-induced thrombocytopenia. therapeutic application,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19655821&form=6&db=m Argatroban: a review of its use in the management of heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19764444&form=6&db=m [Anesthetic management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor] therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19795099&form=6&db=m [Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.] causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19950764&form=6&db=m [Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20003049&form=6&db=m Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20083913&form=6&db=m Acquired thrombotic risk factors in the critical care setting. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20186683&form=6&db=m Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20579693&form=6&db=m Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20686010&form=6&db=m Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20812431&form=6&db=m Bivalirudin use during radiofrequency catheter ablation procedures in two patients with a history of heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21039876&form=6&db=m Unfractionated heparin for hemodialysis: still the best option. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21083469&form=6&db=m Pharmacology of argatroban. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21241354&form=6&db=m Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21303963&form=6&db=m Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21328434&form=6&db=m Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21698505&form=6&db=m Antiplatelet and Anticoagulant Drugs in Interventional Radiology. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21727925&form=6&db=m What are the anticoagulation options for intermittent hemodialysis? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21740395&form=6&db=m [Fondaparinux treatment in heparin induced thrombocytopenia:a case report]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21863223&form=6&db=m Natural language processor as a tool to assess heparin induced thrombocytopenia awareness. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21881032&form=6&db=m Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21892362&form=6&db=m The proof for new oral anticoagulants: clinical trial evidence. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21950643&form=6&db=m New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21986355&form=6&db=m Clinical picture and laboratorial evaluation in human loxoscelism. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22031688&form=6&db=m [News on antithrombotic therapy and pregnancy]. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22254265&form=6&db=m Modeling the effects of bivalirudin in cardiac surgical patients. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22261947&form=6&db=m Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22271374&form=6&db=m Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22329977&form=6&db=m Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22475438&form=6&db=m Management of heparin-induced thrombocytopenia. therapeutic application,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22477834&form=6&db=m Bivalirudin use in an infant with persistent clotting on unfractionated heparin. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22478907&form=6&db=m Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22542931&form=6&db=m Interference of thrombin in immunological assays for hirudin specific antibodies. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22642260&form=6&db=m Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation. causal interaction,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22671287&form=6&db=m Mammary gland carcinoma in a dog with peripheral blood and bone marrow involvement associated with disseminated intravascular coagulation. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22743780&form=6&db=m Bleeding risk factors associated with argatroban therapy in the critically ill. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22841202&form=6&db=m Coagulopathy management in liver transplantation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22935938&form=6&db=m Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22939359&form=6&db=m Incidence of Thrombocytopenia among Patients Receiving Heparin Venous Thromboembolism Prophylaxis. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22970706&form=6&db=m Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22988498&form=6&db=m Reversible crystallization of argatroban after subcutaneous application in pigs. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23118656&form=6&db=m Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23328916&form=6&db=m Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin - induced thrombocytopenia. ongoing research,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389318&form=6&db=m [Optimal dose of bivalirudin in dialysis patients at high risk of heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case report]. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23407717&form=6&db=m Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23482736&form=6&db=m Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April). therapeutic application,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23690810&form=6&db=m Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23813781&form=6&db=m Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23966356&form=6&db=m Crystallographic, Spectroscopic, and Theoretical Investigation of the Efficiently Separated 21R and 21S-Diastereoisomers of Argatroban. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24013828&form=6&db=m Predicting and Evaluating the Effect of Bivalirudin in Cardiac Surgical Patients. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24161661&form=6&db=m Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia. causal interaction,ongoing research,therapeutic application,unassigned 2,3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24247801&form=6&db=m Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24422691&form=6&db=m Argatroban therapy in heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24781880&form=6&db=m A Predictive Model for the Anticoagulant Bivalirudin Administered to Cardiac Surgical Patients. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25171706&form=6&db=m Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25314695&form=6&db=m Adaptive control of bivalirudin in the cardiac intensive care unit. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25590527&form=6&db=m Hemostatic and thrombotic issues in cardiac surgery. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25804370&form=6&db=m Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25913754&form=6&db=m Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25979950&form=6&db=m Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26080462&form=6&db=m Bothrops jararaca envenomation: Pathogenesis of hemostatic disturbances and intravascular hemolysis. causal interaction,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26939619&form=6&db=m Histones as mediators of host defense, inflammation and thrombosis. causal interaction,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27015137&form=6&db=m Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27102287&form=6&db=m Novel oral anticoagulants for heparin-induced thrombocytopenia. therapeutic application,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27134308&form=6&db=m Bivalirudin Anticoagulation for a Pediatric Patient with Heparin-Induced Thrombocytopenia and Thrombosis Requiring Cardiopulmonary Bypass for Ventricular Assist Device Placement. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27356945&form=6&db=m Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27424316&form=6&db=m TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia. unassigned - 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27501998&form=6&db=m Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27956417&form=6&db=m Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28052306&form=6&db=m Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28057952&form=6&db=m Direct Thrombin Inhibitor Resistance and Possible Mechanisms. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28092405&form=6&db=m Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,3 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28103832&form=6&db=m Thromboelastometry analysis of thrombocytopenic dengue patients: a cross-sectional study. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28320219&form=6&db=m Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"? therapeutic application,unassigned 2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28662704&form=6&db=m Thrombocytopenia induced by dabigatran: two case reports. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28771917&form=6&db=m 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28839178&form=6&db=m Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28840985&form=6&db=m Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29461391&form=6&db=m Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29574610&form=6&db=m Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29622761&form=6&db=m Simultaneous Pancreas-Kidney Transplantation in a Patient with Heparin-Induced Thrombocytopenia on Dabigatran Therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29707901&form=6&db=m Argatroban is stable in citrated whole blood for 24 hours. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29744595&form=6&db=m Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29945285&form=6&db=m [Point-of-Care Testing in Trauma Patients - Methods and Evidence]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29985837&form=6&db=m Epoprostenol Therapy for a Pediatric Patient With Subacute Heparin-Induced Thrombocytopenia and a Ventricular Assist Device Undergoing Heart Transplant: A Case Report. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30407650&form=6&db=m Plasma exchange for heparin-induced thrombocytopenia in patients on extracorporeal circuits: A challenging case and a survey of the field. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30907752&form=6&db=m Titration of Bivalirudin Infusion in the Pediatric Cardiac Catheterization Laboratory: A Case Report. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31142810&form=6&db=m Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31249965&form=6&db=m Antithrombotic Management during Percutaneous Mitral Valve Repair with the Mitraclip System in a Patient with Heparin-Induced Thrombocytopenia. therapeutic application,unassigned 3,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31559512&form=6&db=m Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31587337&form=6&db=m Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31645190&form=6&db=m Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31694454&form=6&db=m Early Identification of Argatroban Resistance and the Consideration of Factor VIII. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31881749&form=6&db=m Application of Piezo-Based Measuring System for Evaluation of Nucleic Acid-Based Drugs Influencing the Coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32110765&form=6&db=m Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32905282&form=6&db=m SARS-CoV-2 and pulmonary embolism: who stole the platelets? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33013402&form=6&db=m Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review. therapeutic application,unassigned 4,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33618796&form=6&db=m Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34278315&form=6&db=m Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombocytopenia, Neonatal Alloimmune http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31142810&form=6&db=m Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4084660&form=6&db=m Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7777905&form=6&db=m Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7833251&form=6&db=m Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15095037&form=6&db=m Exercise-induced platelet and leucocyte activation is not enhanced in well-controlled Type 1 diabetes, despite increased activity at rest. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18325302&form=6&db=m Identification and treatment of arterial thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23873831&form=6&db=m Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,1 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29240268&form=6&db=m Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30274004&form=6&db=m Thrombin Generation Testing in Patients with Myelofibrosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1090031&form=6&db=m The effect of major surgery, low doses of heparin and thromboembolism on plasma antithrombin. Comparison of immediate thrombin inhibiting capacity and the antithrombin III content. therapeutic application,unassigned 2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1333021&form=6&db=m [Therapeutic evaluation of recombinant thrombomodulin] unassigned - 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1457938&form=6&db=m Thrombin activity resides on LVAD Dacron inflow and outflow grafts. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836241&form=6&db=m [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2057920&form=6&db=m Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2156578&form=6&db=m Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2166971&form=6&db=m Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2830928&form=6&db=m A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6417868&form=6&db=m Further simplification of cryoprecipitate coagulum pyelolithotomy without thrombin. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6779400&form=6&db=m Increased fibrinopeptide A after prothrombin complex concentrates. causal interaction,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7843647&form=6&db=m Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7851481&form=6&db=m Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8306102&form=6&db=m The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. therapeutic application,unassigned 2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8734083&form=6&db=m [Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8889359&form=6&db=m Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9020374&form=6&db=m Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene. ongoing research,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9449701&form=6&db=m Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10631865&form=6&db=m Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11192373&form=6&db=m Mouse models of focal arterial and venous thrombosis. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11228339&form=6&db=m Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11302409&form=6&db=m Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11340145&form=6&db=m Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11858482&form=6&db=m A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12003722&form=6&db=m Pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023846&form=6&db=m Mechanism of thrombin-induced angiogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12195697&form=6&db=m Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). causal interaction,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12211414&form=6&db=m ART-123 Asahi Kasei. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12784754&form=6&db=m [Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives] therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12933533&form=6&db=m Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. causal interaction,unassigned 1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12947359&form=6&db=m Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15060420&form=6&db=m The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15151465&form=6&db=m Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15317834&form=6&db=m A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15383641&form=6&db=m Ximelagatran: an oral direct thrombin inhibitor. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15650548&form=6&db=m Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15696910&form=6&db=m Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16253651&form=6&db=m Antithrombotic therapy for stroke prevention in atrial fibrillation. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305293&form=6&db=m Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16372822&form=6&db=m Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16430312&form=6&db=m Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17080212&form=6&db=m Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17347079&form=6&db=m [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17454672&form=6&db=m Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17483128&form=6&db=m Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17512549&form=6&db=m A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17627564&form=6&db=m New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation. therapeutic application,unassigned 3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17662773&form=6&db=m Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model. therapeutic application,unassigned 3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17985858&form=6&db=m Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17989864&form=6&db=m [Update on the prevention of thromboembolic phenomena in atrial fibrillation] causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18632433&form=6&db=m Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19178132&form=6&db=m Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19232683&form=6&db=m Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19438723&form=6&db=m Thrombin-mediated impairment of fibroblast growth factor-2 activity. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19521017&form=6&db=m Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period. Comparison with chronic atrial fibrillation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19553827&form=6&db=m What can ongoing clinical trials of anticoagulants demonstrate? ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19656279&form=6&db=m Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20234784&form=6&db=m Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20362347&form=6&db=m Should all patients with non-valvular atrial fibrillation be anticoagulated? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20858184&form=6&db=m New Anticoagulants for the Prevention of Thromboembolism. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21068702&form=6&db=m Dabigatran etexilate (Pradaxa)--a new oral anticoagulant. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21143166&form=6&db=m Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer? therapeutic application,unassigned 1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21211621&form=6&db=m [Focus on managing AF and preventing stroke]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21226611&form=6&db=m Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21291575&form=6&db=m [New antithrombotics for atrial fibrillation.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21430357&form=6&db=m Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients. causal interaction,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21527535&form=6&db=m The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds. ongoing research,unassigned 2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22035573&form=6&db=m Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation. causal interaction,unassigned 3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22234363&form=6&db=m The thrombin inhibitors hirudin and Refludan® activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22289207&form=6&db=m Continuous thrombin infusion leads to a bleeding phenotype in sheep. unassigned - 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22459904&form=6&db=m Use of Direct Thrombin Inhibitor for Treatment of Cerebral Venous Thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22970730&form=6&db=m Hemorrhagic complications associated with dabigatran use. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23129871&form=6&db=m Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation? causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23220847&form=6&db=m Acute management of bleeding in patients on novel oral anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389753&form=6&db=m Reversal of novel oral anticoagulants in patients with major bleeding. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23597859&form=6&db=m Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23631182&form=6&db=m [Factor Xa inhibitor (rivaroxaban and drugs under investigation)]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23713461&form=6&db=m Pharmacophore Design, Virtual Screening, Molecular Docking and Optimization Approaches to Discover Potent Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23803980&form=6&db=m Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy. therapeutic application,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24411286&form=6&db=m Comparison between ultrasound-guided compression and para-aneurysmal saline injection in the treatment of postcatheterization femoral artery pseudoaneurysms. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25254608&form=6&db=m The association of direct thrombin inhibitor anticoagulants with cardiac thromboses. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25490355&form=6&db=m [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25565675&form=6&db=m Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25597592&form=6&db=m Individualized antithrombotic therapy. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25793127&form=6&db=m Thrombus formation in left atrium on dabigatran therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25815177&form=6&db=m Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26214205&form=6&db=m Perioperative Management of Anticoagulation-Review of Latest Evidence. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26492202&form=6&db=m Laboratory measurement of the direct oral anticoagulants. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27571947&form=6&db=m Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27988438&form=6&db=m Detection of lupus anticoagulant in the era of direct oral anticoagulants. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28060970&form=6&db=m [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation]. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28662704&form=6&db=m Thrombocytopenia induced by dabigatran: two case reports. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28725494&form=6&db=m Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. causal interaction,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29153864&form=6&db=m Changes in Markers of Thrombin Generation and Interleukin-6 During Unicondylar Knee and Total Knee Arthroplasty. diagnostic usage,unassigned 2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29692734&form=6&db=m Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30809772&form=6&db=m Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32347013&form=6&db=m Sequential multiple retinal vein occlusions and transient ischemic attack in MTHFR polymorphism and protein S deficiency. causal interaction,unassigned 4,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33294754&form=6&db=m Salvage of autogenous dialysis access with balloon-assisted thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33946588&form=6&db=m Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27589692&form=6&db=m Histones link inflammation and thrombosis through the induction of Weibel-Palade Body exocytosis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27634832&form=6&db=m TMEM16F-Mediated Platelet Membrane Phospholipid Scrambling Is Critical for Hemostasis and Thrombosis but not Thromboinflammation in Mice. diagnostic usage,unassigned 4,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29044290&form=6&db=m Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation? unassigned - 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32586214&form=6&db=m The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. causal interaction,unassigned 3,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32945081&form=6&db=m COVID-19 patients exhibit reduced procoagulant platelet responses. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33124941&form=6&db=m Inflammation and thrombosis in COVID-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. causal interaction,unassigned 3,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34177896&form=6&db=m Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thromboinflammation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34336711&form=6&db=m Tissue Factor-Enriched Neutrophil Extracellular Traps Promote Immunothrombosis and Disease Progression in Sepsis-Induced Lung Injury. ongoing research,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=505379&form=6&db=m Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=645319&form=6&db=m [Changes in the blood clotting system of patients with atherosclerotic and senile dementias] unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1037155&form=6&db=m Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1155713&form=6&db=m Hypercoagulability in patients with peripheral vascular disease. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1634610&form=6&db=m Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2122227&form=6&db=m [Effects of the synthetic proteinase inhibitor, FOY, on hypercoagulability after surgery for esophageal carcinoma] unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2783675&form=6&db=m Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4084660&form=6&db=m Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4655614&form=6&db=m [Usefulness of a modified thrombin generation test in the diagnosis of chronometric hypercoagulability] diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6165217&form=6&db=m Thrombin inhibitors in women on oral contraceptives. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6464012&form=6&db=m Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia. causal interaction,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7667836&form=6&db=m Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. therapeutic application,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7967434&form=6&db=m Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8089219&form=6&db=m Markers of thrombin and plasmin generation in patients with inherited thrombophilia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8314016&form=6&db=m Fibrinogen plasma levels as a marker of thrombin activation in diabetes. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8331683&form=6&db=m Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8624369&form=6&db=m Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8839395&form=6&db=m Activated protein C resistance: from phenotype to genotype and clinical practice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134633&form=6&db=m The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9296472&form=6&db=m Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9394323&form=6&db=m Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9540779&form=6&db=m Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9622218&form=6&db=m The coagulation profile in hepatosplenic schistosomiasis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9831087&form=6&db=m Cardiopulmonary bypass pumps and thrombin generation: what goes around comes around. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10064000&form=6&db=m Recombinant factor VIIa does not induce hypercoagulability in vitro. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10070829&form=6&db=m Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10544904&form=6&db=m Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10775022&form=6&db=m Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10795781&form=6&db=m Blood hemostasis in exercise and training. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11422096&form=6&db=m Evidence for activation of the coagulation system in migraine with aura. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11736955&form=6&db=m Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740417&form=6&db=m Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11921015&form=6&db=m Abnormalities in hemostasis in acute promyelocytic leukemia. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12195697&form=6&db=m Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). causal interaction,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12479881&form=6&db=m Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets: a potential correlation with caspase activation. causal interaction,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12680634&form=6&db=m Screening for thrombophilia: a laboratory perspective. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853709&form=6&db=m Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853713&form=6&db=m Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871277&form=6&db=m Management of thrombophilia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12941039&form=6&db=m Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15735792&form=6&db=m Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15761339&form=6&db=m Hypercoagulability is most prevalent early after injury and in female patients. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15978105&form=6&db=m The plasma hemostatic proteome: thrombin generation in healthy individuals. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16026408&form=6&db=m Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16241948&form=6&db=m Thrombin generation profiles in deep venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17018385&form=6&db=m The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17024597&form=6&db=m Inherited thrombophilia and venous thromboembolism. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17124091&form=6&db=m Think of HIT. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17253197&form=6&db=m The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. causal interaction,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17346550&form=6&db=m Thrombin regulates monocyte chemoattractant protein-1 expression in human first trimester and term decidual cells. causal interaction,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17392178&form=6&db=m Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17565236&form=6&db=m Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17635710&form=6&db=m Factor Xa or thrombin: is factor Xa a better target? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17938814&form=6&db=m A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. therapeutic application,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17958739&form=6&db=m Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18160569&form=6&db=m Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18217158&form=6&db=m Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18222259&form=6&db=m Thrombophilic variables do not increase the generation or procoagulant activity of thrombin during cardiopulmonary bypass. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,2 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18302088&form=6&db=m The approach to heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18443332&form=6&db=m Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18466239&form=6&db=m Hypercoagulability in cats with cardiomyopathy. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18479738&form=6&db=m Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18501098&form=6&db=m Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18501408&form=6&db=m Increased thrombin generation in women with a history of preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18796458&form=6&db=m D-Dimers, Thrombin-Antithrombin Complexes, and Risk Factors for Thromboembolism in Hospitalized Patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18983497&form=6&db=m Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19195685&form=6&db=m Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19454584&form=6&db=m Hypercoagulable state in Cushing's syndrome: a systematic review. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19519581&form=6&db=m Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19648162&form=6&db=m Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19687358&form=6&db=m Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20029948&form=6&db=m Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus. therapeutic application,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20062673&form=6&db=m Idiopathic pulmonary fibrosis associated with pulmonary vein thrombosis: a case report. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20229688&form=6&db=m Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis. causal interaction,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20553380&form=6&db=m The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20605586&form=6&db=m Differentiation of enzymatic from platelet hypercoagulability using the novel thrombelastography parameter delta (delta). diagnostic usage,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20640482&form=6&db=m Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20714763&form=6&db=m Thrombin generation in ankylosing spondylitis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20843543&form=6&db=m Monitoring platelet dependent thrombin generation in mice. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20888030&form=6&db=m Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21127274&form=6&db=m Enhanced thrombin generation after cardiopulmonary bypass surgery. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21287673&form=6&db=m Thrombin generation in pediatric patients with Crohn's disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21370218&form=6&db=m Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. causal interaction,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21537160&form=6&db=m Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21593025&form=6&db=m Evaluation of Hypercoagulability in Obese Children With Thrombin Generation Test and Microparticle Release: Effect of Metabolic Parameters. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21692994&form=6&db=m Using the laboratory to predict recurrent venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22079443&form=6&db=m Thrombin generation in clinical conditions. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22154243&form=6&db=m The APC-PCI concentration as an early marker of activation of blood coagulation A study of women on combined oral contraceptives. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22429019&form=6&db=m Computational analysis of intersubject variability and thrombin generation in dilutional coagulopathy. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22475311&form=6&db=m Clinical and biological factors that contribute to thrombin generation in prothrombin G20210A carriers: a case-control study in a single Thrombophilia Center. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23236465&form=6&db=m Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23415973&form=6&db=m Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23419411&form=6&db=m A novel approach for detecting hypercoagulability utilizing thromboelastography. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23555099&form=6&db=m Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23962423&form=6&db=m Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23971903&form=6&db=m Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. therapeutic application,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24060191&form=6&db=m Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24123221&form=6&db=m Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24241912&form=6&db=m Thrombin generation and atherosclerosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385341&form=6&db=m Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24403961&form=6&db=m Grave's disease with transverse and sigmoid sinus thrombosis needing surgical intervention. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24593861&form=6&db=m The Northwick Park Heart Study: Evidence from the Laboratory. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24614609&form=6&db=m Age-Based Difference in Activation Markers of Coagulation and Fibrinolysis in Extracorporeal Membrane Oxygenation. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24667614&form=6&db=m Establishment of Methods for Performing Thrombelastography and Calibrated Automated Thrombography in Rats. therapeutic application,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24759144&form=6&db=m Red blood cells and thrombin generation in sickle cell disease. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24766850&form=6&db=m Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25068444&form=6&db=m Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25069814&form=6&db=m Short-term venous stasis induces fibrinolytic activation but not thrombin formation. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25114412&form=6&db=m Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25121606&form=6&db=m Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25255379&form=6&db=m Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25303721&form=6&db=m Prominent protein Z-induced thrombin inhibition in cirrhosis: A new functional assay for hypercoagulability assessment. therapeutic application,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25318550&form=6&db=m Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25382796&form=6&db=m Hypercoagulability following major partial liver resection - detected by thrombomodulin-modified thrombin generation testing. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25392852&form=6&db=m Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25793906&form=6&db=m Onset of Thrombin Generation Occurs More Rapidly in Pediatric Patients With Celiac Disease. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25907422&form=6&db=m Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25966640&form=6&db=m Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG). causal interaction,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26028157&form=6&db=m [Thrombin generation test]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26178257&form=6&db=m The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26493603&form=6&db=m Thrombin generation and international normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26529664&form=6&db=m PLASMA RESUSCITATION PROMOTES COAGULATION HOMEOSTASIS FOLLOWING SHOCK-INDUCED HYPERCOAGULABILITY. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26742564&form=6&db=m Thrombin stimulates insulin secretion via protease-activated receptor-3. causal interaction,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26784699&form=6&db=m Genetic Determinants of Thrombin Generation and Their Relation to Venous Thrombosis: Results from the GAIT-2 Project. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26825627&form=6&db=m Activity levels of natural anticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment. causal interaction,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27071821&form=6&db=m Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. ongoing research,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27085896&form=6&db=m Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27396242&form=6&db=m Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27430959&form=6&db=m Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27448294&form=6&db=m Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28075532&form=6&db=m Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116215&form=6&db=m Thrombin Generation in Acute Ischaemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28195091&form=6&db=m Coagulation profile during induction chemotherapy in childhood acute lymphoblastic leukemia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28259966&form=6&db=m A genetic risk factor for thrombophilia in a Han Chinese family. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28503774&form=6&db=m Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28802974&form=6&db=m Characteristics of thrombin generation in a fulminant porcine sepsis model. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29104003&form=6&db=m Assessment of the procoagulant potential after laparoscopic sleeve gastrectomy: a potential role for extended thromboprophylaxis. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29174034&form=6&db=m Panax notoginseng saponins reduce high-risk factors for thrombosis through peroxisome proliferator-activated receptor -? pathway. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29573340&form=6&db=m The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29577605&form=6&db=m Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. ongoing research,unassigned 2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29669440&form=6&db=m Thrombin Generation Assay Detects Moderate-Intensity Statin-Induced Reduction of Hypercoagulability in Diabetes. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29738632&form=6&db=m Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29971544&form=6&db=m Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30038462&form=6&db=m Perioperative thromboprophylaxis in liver transplant patients. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30104289&form=6&db=m Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30244327&form=6&db=m Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30327230&form=6&db=m Thrombin generation in patients with severe thermal injury. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30486664&form=6&db=m Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30547189&form=6&db=m Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia. ongoing research,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30881084&form=6&db=m c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30933373&form=6&db=m Warfarin dose requirement in patients having severe thrombosis or thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31085150&form=6&db=m Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31249920&form=6&db=m Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31249940&form=6&db=m Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA). causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31276565&form=6&db=m The role of thrombin in the pathogenesis of diabetic neuropathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31599511&form=6&db=m Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31915751&form=6&db=m Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31918352&form=6&db=m Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31948350&form=6&db=m Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31994012&form=6&db=m The haemostatic system in acromegaly: a single-centre case-control study. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32450779&form=6&db=m Iron-Deficiency and Estrogen Are Associated With Ischemic Stroke by Up-Regulating Transferrin to Induce Hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32551814&form=6&db=m Coagulation Dysfunction. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32558351&form=6&db=m Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32576489&form=6&db=m Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33080636&form=6&db=m Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk. causal interaction,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33243453&form=6&db=m Presence of nucleosomes in plasma and increased thrombin generation in dogs with acute and chronic gastroenteropathies. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33359501&form=6&db=m A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33450154&form=6&db=m Light Chain Mutation Effects on the Dynamics of Thrombin. therapeutic application,unassigned 3,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33560006&form=6&db=m Microparticles: a link to increased thrombin generation. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33819778&form=6&db=m Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. unassigned - 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34205545&form=6&db=m Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34246010&form=6&db=m Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. therapeutic application,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34288927&form=6&db=m Increased activity of procoagulant factors in patients with small cell lung cancer. ongoing research,unassigned 1,0 3.4.21.5 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34509666&form=6&db=m Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9914994&form=6&db=m [Morphologic changes in the thrombus and venous wall in experimental phleobothrombosis and thrombophlebitis] diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=65798&form=6&db=m Inactivation of alpha- and beta- thrombin by antithrombin-III and heparin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=150066&form=6&db=m [Replacement of the thoracic aorta by sealed dacron prostheses (author's transl)] diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=308066&form=6&db=m Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=353660&form=6&db=m [Thrombin, enzyme of hemostasis and thrombosis: a model of enzymatic autoregulation] ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=434223&form=6&db=m Lack of fibrin formation in exercise-induced activation of coagulation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=449250&form=6&db=m Thrombin and fibrin-induced growth of fibroblasts: role in wound repair and thrombus organization. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=505379&form=6&db=m Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=505392&form=6&db=m Thrombus weight as a measure of hypercoagulability induced by drugs. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=541980&form=6&db=m [The importance of the plasmatic blood clotting system in the early stages of arterial thrombogenesis (author's transl)] unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=640489&form=6&db=m The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=805207&form=6&db=m Enhancement of blood coagulation by soluble fibrin complexes. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=932879&form=6&db=m Venous infarction of the adrenal glands. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1037155&form=6&db=m Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1099336&form=6&db=m Endothelial injury induced by thrombin or thrombi. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1101695&form=6&db=m Orthodontics and dentistry for the hemophilic patient. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1126910&form=6&db=m Cerebral hemodynamics following internal maxillary artery ligation in the goat. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1237945&form=6&db=m Standard for human thrombin. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1290382&form=6&db=m [Thrombosis and thrombin] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1300540&form=6&db=m Direct thrombin inhibitors. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1309058&form=6&db=m Principles underlying the use of conjunctive agents with plasminogen activators. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1310695&form=6&db=m "Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1311947&form=6&db=m Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1312651&form=6&db=m Thrombomodulin, an endothelial anticoagulant; its structure, function and expression. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1313452&form=6&db=m Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1320300&form=6&db=m Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1333021&form=6&db=m [Therapeutic evaluation of recombinant thrombomodulin] unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1373886&form=6&db=m Thrombin inhibition is impaired in plasma of sick neonates. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1400076&form=6&db=m Leeches to hirulogs and other thrombin-directed antithrombotics. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1400080&form=6&db=m Fibrinogen anomalies and disease. A clinical update. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1412156&form=6&db=m Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1420824&form=6&db=m Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423816&form=6&db=m Hemostatic alterations in cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1424043&form=6&db=m Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1424053&form=6&db=m Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1426157&form=6&db=m Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1440501&form=6&db=m Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1448349&form=6&db=m Molecular abnormalities responsible for thrombosis. Genetic aspects. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1448774&form=6&db=m Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1450317&form=6&db=m Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1451271&form=6&db=m Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1466485&form=6&db=m Failure of thrombin-antithrombin III complexes in the diagnosis of deep vein thrombosis. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1473925&form=6&db=m Arteriosclerosis obliterans in a rabbit model. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1475778&form=6&db=m Thrombin inhibition compared with other antithrombotic drugs in rats. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1498336&form=6&db=m Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1498339&form=6&db=m Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1511773&form=6&db=m Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1516190&form=6&db=m Transient intermittent lymphocyte activation is responsible for the instability of angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1560563&form=6&db=m The effect of thrombin on low-density lipoprotein permeability and uptake by an arterial endothelial smooth muscle cell bilayer. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1574718&form=6&db=m Thrombin regulation in mother and fetus during pregnancy. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1578372&form=6&db=m Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1602394&form=6&db=m Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1606287&form=6&db=m A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1608039&form=6&db=m Early thrombolysis by recombinant tissue-plasminogen activator is beneficial to the ischemic myocardium. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1613330&form=6&db=m Some antiphospholipid antibodies inhibit phospholipase A2 activity. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1631789&form=6&db=m A collaborative study to establish an international standard for alpha-thrombin. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1693353&form=6&db=m Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1698774&form=6&db=m Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and -independent pathways. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1717851&form=6&db=m Domains specifying thrombin-receptor interaction. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1725498&form=6&db=m [Application of a monoclonal antibody SZ-51 specific for activated human platelets in canine thrombosis imaging] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1726211&form=6&db=m Vessel wall-related risk factors in acute vascular events. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1735171&form=6&db=m Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1763035&form=6&db=m The 29-kDa proteins phosphorylated in thrombin-activated human platelets are forms of the estrogen receptor-related 27-kDa heat shock protein. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1764746&form=6&db=m Thrombolysis by rotational thrombectomy followed by tissue plasminogen activator: evaluation by angioscopy. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1788827&form=6&db=m The effect of thrombin inhibition in a rat arterial thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1798957&form=6&db=m Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1799748&form=6&db=m Thrombin-soaked coils: estimation of thrombin dose. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1829631&form=6&db=m A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen). therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1830520&form=6&db=m Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1832095&form=6&db=m Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1833089&form=6&db=m Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1849931&form=6&db=m Importance of antithrombin therapy during coronary angioplasty. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1861092&form=6&db=m Heparin, heparin plus ASA and dipyridamole, and arteriovenous fistula as adjuvant methods to prevent rethrombosis after venous thrombectomy. Experimental study in rabbits. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1892063&form=6&db=m Pathogenesis of thrombosis in unstable angina. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1894862&form=6&db=m Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1895868&form=6&db=m Experimental treatment of thrombotic vascular occlusion. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1898838&form=6&db=m Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901445&form=6&db=m Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1904936&form=6&db=m Action of gold sodium thiomalate on experimental thrombosis in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1914107&form=6&db=m Dissolution of peripheral arterial thrombi by ultrasound. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1926039&form=6&db=m Role of thrombin in arterial thrombosis: implications for therapy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1926061&form=6&db=m Antithrombin III modulates the effect of thrombin on the metabolism of glycosaminoglycans in cultured endothelial cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1990783&form=6&db=m Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1996320&form=6&db=m Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2019790&form=6&db=m Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2024237&form=6&db=m D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2070078&form=6&db=m Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2104522&form=6&db=m Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen in heparinized blood. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2117620&form=6&db=m Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2123135&form=6&db=m In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2128137&form=6&db=m Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2146992&form=6&db=m Fibrinopeptide A is released into the coronary circulation after coronary spasm. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2151728&form=6&db=m Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2179212&form=6&db=m Platelet inhibitor therapy. Agents and clinical implications. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2206376&form=6&db=m [Effects of tetrandrine on platelet aggregation, platelet adhesion and coagulation] causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2246559&form=6&db=m Production of thrombi on intact endothelium by use of antiheparin agents in vivo. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2257931&form=6&db=m The relation among vessel injury, thrombus formation, and platelet survival in rabbits. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2291954&form=6&db=m [Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2295636&form=6&db=m Alpha-thrombin-catalyzed hydrolysis of fibrin I. Alternative binding modes and the accessibility of the active site in fibrin I-bound alpha-thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2297828&form=6&db=m Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2298753&form=6&db=m Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2363121&form=6&db=m The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2363124&form=6&db=m Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2369370&form=6&db=m Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2401076&form=6&db=m Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2405621&form=6&db=m New approaches to treatment of myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2459030&form=6&db=m Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2473288&form=6&db=m The possible role of endothelin-1 in the pathogenesis of coronary vasospasm. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2473537&form=6&db=m Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2480655&form=6&db=m Thrombin stimulated platelet accumulation on protein coated glass capillaries: role of adhesive platelet alpha-granule proteins. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2492455&form=6&db=m Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis. causal interaction,ongoing research,therapeutic application,unassigned 2,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2494006&form=6&db=m Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2495318&form=6&db=m A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2507583&form=6&db=m Intravascular thrombosis: definitive detection by quantitative tissue characterization in vitro. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2508792&form=6&db=m Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521125&form=6&db=m A canine model of controlled thrombotic vascular occlusion. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521276&form=6&db=m Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2525582&form=6&db=m Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2528202&form=6&db=m Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2533138&form=6&db=m Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2546282&form=6&db=m The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2595216&form=6&db=m [Role of platelets in atherosclerosis and arterial thrombosis] therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2595658&form=6&db=m Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2603849&form=6&db=m [Experimental retinal vein obstruction induced by transadventitial administration of thrombin in the rabbit] diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2611327&form=6&db=m Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2612444&form=6&db=m Kinetics of pulmonary platelet deposition and clearance during thrombin-induced microembolism in rabbits. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2617925&form=6&db=m [The effect of thymoptin on enzymatic fibrinolysis] ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2678451&form=6&db=m [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?] diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2731778&form=6&db=m Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2735661&form=6&db=m Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2735662&form=6&db=m Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2832448&form=6&db=m Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2905842&form=6&db=m Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2930939&form=6&db=m Nephrotic syndrome: a platelet hyperaggregability state. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2937472&form=6&db=m The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2956836&form=6&db=m Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2958657&form=6&db=m [Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin] diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3047669&form=6&db=m Pharmacology of selective thrombin inhibitors. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3051386&form=6&db=m Regulation of thrombin generation at cell surfaces. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3057038&form=6&db=m Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3111693&form=6&db=m Embolization of a subclavian artery aneurysm with steel coils and thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3146820&form=6&db=m Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3158094&form=6&db=m Effects of plasmin on rabbit platelets. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3159207&form=6&db=m Platelets, endothelium, and vessel injury. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3166242&form=6&db=m The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3168184&form=6&db=m 111In-labeled platelet scintigraphy and two-dimensional echocardiography for detection of left atrial appendage thrombi. Studies in a new canine model. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3223777&form=6&db=m The role of intravascular coagulation in pregnancy related acute renal failure. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3252043&form=6&db=m Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3286116&form=6&db=m Human fibrinogen. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3298621&form=6&db=m Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits. causal interaction,ongoing research,therapeutic application,unassigned 2,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3362867&form=6&db=m Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3380865&form=6&db=m Pharmacological survey of recombinant hirudin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3456576&form=6&db=m Identification of a thrombin sequence with growth factor activity on macrophages. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3537068&form=6&db=m Disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3537069&form=6&db=m Role of platelet activation and fibrin formation in thrombogenesis. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3571745&form=6&db=m Indium-111 platelet scintigraphy and two-dimensional echocardiography for detection of left ventricular thrombus: influence of clot size and age. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3604141&form=6&db=m [Formation of streptokinase-heparin complexes and their properties] diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3663509&form=6&db=m Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3711137&form=6&db=m A model of thrombin inactivation in heparinized and nonheparinized tubes with consequences for thrombus formation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3718412&form=6&db=m [Biochemistry of tumor cell thrombosis: thrombin as growth hormone] causal interaction,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3750276&form=6&db=m Adhesion and aggregation of thrombin prestimulated human platelets: evaluation of surface-bound fibrinogen and surface-bound albumin. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3810564&form=6&db=m Anticoagulant and antithrombotic properties of a gamma-carboxyglutamic acid-rich peptide derived from the light chain of blood coagulation factor X. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3814237&form=6&db=m Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3878349&form=6&db=m [New aspects in the treatment of hemangioma] therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3918416&form=6&db=m Experimental production of superior sagittal sinus thrombosis in the dog. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3918615&form=6&db=m Epidemiological characteristics of platelet aggregability. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3931291&form=6&db=m Protraction of whole blood and plasma clot lysis in patients with high levels of an inhibitor of tissue-type plasminogen activator. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3972001&form=6&db=m Uptake and inactivation of thrombin on aortic endothelium and neo-intima. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4010439&form=6&db=m Absence of distal emboli during in vivo laser recanalization. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4069759&form=6&db=m Vasoactive agents and production of thrombosis during intravascular coagulation. 2. alpha-Adrenergic stimulation: effects and mechanisms. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4089838&form=6&db=m Thrombus formation by the application of thrombin to the outer surface of mouse mesenteric vein: comparison with the application of ADP. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4439839&form=6&db=m [Artificial arterial thrombosis using solutions of fibrinogen and thrombin (preliminary report)] ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4454034&form=6&db=m Anti-thormbin III and heparin clotting times in thrombosis and atherosclerosis. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4771119&form=6&db=m A mechanism of thrombosis requiring neither platelets nor thrombin. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4783883&form=6&db=m [Thrombocytes, thrombin, thrombosis and heart infarct] therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5590242&form=6&db=m Comparative effects o ADP and thrombin in producing stasis thrombosis. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5662752&form=6&db=m Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5784961&form=6&db=m Thrombin adsorption and possible relations to thrombus formation. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6126613&form=6&db=m [Morphological composition and functions of the human blood coagulating and anticoagulating systems in prolonged exposure to low ammonia concentrations in a sealed environment] diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6222508&form=6&db=m The release of B beta 1-42 from fibrinogen and fibrin by plasmin. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6241562&form=6&db=m Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6259408&form=6&db=m Growth regulation of fibroblasts by thrombin, factor XIII and fibronectin. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6309278&form=6&db=m Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6334102&form=6&db=m Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6380814&form=6&db=m Application of enzyme immunoassays to coagulation testing. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6407310&form=6&db=m Aspirin in the treatment of cardiovascular disease: a review. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6434594&form=6&db=m Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6453297&form=6&db=m Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6476135&form=6&db=m Endothelium and asymmetrical responses of the coronary arterial wall. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6496186&form=6&db=m The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6522106&form=6&db=m Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6530485&form=6&db=m Evaluation of a commercial kit for the radioimmunoassay of fibrinopeptide A. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6713090&form=6&db=m Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6742497&form=6&db=m [Relation of the formation of the fibrin network of a blood clot to the amount of thrombin in complexes with endogenous heparin] diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6821701&form=6&db=m Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7010497&form=6&db=m [The formation of paradoxical thrombin and emboli by an interauricular shunt. Comments on F. Wilh, Zahn's articles: Thrombus formation, current status of this problem. Thrombosis of several branches of the inferior vena cava with consecutive emboli in the pulmonary, splenic, renal and right iliac arteries] causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7129817&form=6&db=m 1982 George Simon Memorial Fellowship Award. Experimental studies with 111indium-labeled platelets in pulmonary embolism. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7347422&form=6&db=m Scanning electron microscopy of experimental thrombus formation in canine lateral saphena vein. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7392548&form=6&db=m Effect of a potent thrombin inhibitor, No. 407, on novel experimental thrombosis generated by acetic acid. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7431104&form=6&db=m Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-111-labeled platelets. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7441181&form=6&db=m Thromboplastic activity of human arterial walls and its interaction with the plasmatic coagulation system. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7487761&form=6&db=m Embolization of hepatic artery pseudo-aneurysm facilitated by selective injection of thrombin and thrombin-soaked coils. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7495072&form=6&db=m Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7511748&form=6&db=m Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7529534&form=6&db=m Thrombin binding to platelets and their activation in plasma. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7529817&form=6&db=m Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7545318&form=6&db=m Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7557657&form=6&db=m Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7578891&form=6&db=m Challenges in the development of orally bioavailable thrombin active site inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7596132&form=6&db=m Cardioprotection and thrombolysis by anistreplase in anesthetized dogs. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7630043&form=6&db=m Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7634317&form=6&db=m [Antithrombin therapy in acute coronary syndromes] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641380&form=6&db=m Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7678021&form=6&db=m Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7681904&form=6&db=m Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683662&form=6&db=m Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7703589&form=6&db=m Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7708874&form=6&db=m Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7719525&form=6&db=m Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7740451&form=6&db=m Thrombin regulation in children differs from adults in the absence and presence of heparin. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7740487&form=6&db=m Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7789679&form=6&db=m Evaluation of the effects of esophageal varicosclerosants on local vascular occlusion and systemic blood coagulation. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7790755&form=6&db=m Intraoperative thrombolytic therapy as a treatment of small vessel thrombosis: an experimental study. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7796507&form=6&db=m An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7805084&form=6&db=m Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7823899&form=6&db=m [An experimental study of arterial graft implantation--the effects of an anti-thrombin agent, argatroban, and an anti-platelet agent, clopidogrel (SR 25990 C) on the inner capsule] causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841312&form=6&db=m alpha-thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7856278&form=6&db=m [Mechanisms of re-stenosis after angioplasty] ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863479&form=6&db=m Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863965&form=6&db=m Thrombin hypothesis of thrombus generation and vascular lesion formation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863966&form=6&db=m Activation of blood coagulation by plaque rupture: mechanisms and prevention. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7867200&form=6&db=m Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7878625&form=6&db=m Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7884545&form=6&db=m Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7889274&form=6&db=m Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7919337&form=6&db=m Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923684&form=6&db=m Local delivery of an antithrombin inhibits platelet-dependent thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7923685&form=6&db=m Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7949091&form=6&db=m Reduced thrombus formation in native blood of homozygous factor VII-deficient patients at high arterial wall shear rate. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7955198&form=6&db=m Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7955200&form=6&db=m Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7955205&form=6&db=m Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7957610&form=6&db=m Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,4,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7959358&form=6&db=m Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7959365&form=6&db=m Thrombin in arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7994858&form=6&db=m Suppression of thrombolysis in a canine model of pulmonary embolism. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8013531&form=6&db=m Platelet thromboembolism. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8022782&form=6&db=m High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8029801&form=6&db=m A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8029802&form=6&db=m Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8042187&form=6&db=m Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8052972&form=6&db=m Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8065613&form=6&db=m The scientific basis for selection of measures of thrombogenicity. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8068609&form=6&db=m Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8073391&form=6&db=m Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8078383&form=6&db=m Effects of thermal exposure on binding of heparin in vitro to the arterial wall and to clot and on the chronic angiographic luminal response to local application of a heparin film during angioplasty in an in vivo rabbit model. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8080990&form=6&db=m An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells, and protein C activation. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8085239&form=6&db=m Effect of monomethylmethacrylate on procoagulant activities of human monocytes and umbilical vein endothelial cells in vitro. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8085247&form=6&db=m Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8085294&form=6&db=m Enhancement of thrombolysis by ultrasound. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8087958&form=6&db=m Direct thrombin inhibitors in cardiovascular medicine. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8091383&form=6&db=m Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8091405&form=6&db=m Flow mediated fibrin thrombus formation in an endothelium-lined model of arterial branching. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8107282&form=6&db=m [Blood coagulation and fibrinolysis in ischemic heart disease] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8128426&form=6&db=m Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8132848&form=6&db=m New antithrombotic strategies for resistant thrombotic processes. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140759&form=6&db=m [Coronary thrombosis--pathogenic basis of acute coronary syndromes] causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8141448&form=6&db=m Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8149517&form=6&db=m Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8149521&form=6&db=m Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8149546&form=6&db=m Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8154338&form=6&db=m Mechanisms for the anticoagulant effects of synthetic antithrombins. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8165634&form=6&db=m Thrombogenicity of the injured vessel wall--role of antithrombin and heparin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8175045&form=6&db=m Comparison of in vitro and in vivo properties of rhirudin (HBW 023) and a synthetic analogous peptide. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8186356&form=6&db=m Strategies for inhibiting the effects of thrombin. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8195517&form=6&db=m Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8198374&form=6&db=m Hirudin: clinical potential of a thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8206894&form=6&db=m Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8213576&form=6&db=m Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8218859&form=6&db=m Mechanisms of thromboembolism at arterial plaques. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8236149&form=6&db=m Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8236160&form=6&db=m Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8263785&form=6&db=m Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8267061&form=6&db=m Thrombosis and hormone replacement therapy in postmenopausal women. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8269108&form=6&db=m Hypercoagulability in the left atrium: Part II: Coagulation factors. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8279364&form=6&db=m Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8281671&form=6&db=m Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8282198&form=6&db=m The discovery and characterization of a novel nucleotide-based thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8292726&form=6&db=m Thrombin interactions with cells of the megakaryocytic lineage. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8294310&form=6&db=m Understanding thrombin and hemostasis. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8298130&form=6&db=m A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8303681&form=6&db=m Shear dependence of the fibrin coagulation kinetics in vitro. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8322273&form=6&db=m Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8322274&form=6&db=m Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8324216&form=6&db=m Artificial microvascular graft thrombosis: the consequences of platelet membrane glycoprotein Ib inhibition and thrombin inhibition. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8328214&form=6&db=m Inhibition of platelets and thrombin: implications for treatment of coronary artery thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8329574&form=6&db=m Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8343496&form=6&db=m Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8348763&form=6&db=m Plasma level changes of fibrinopeptide A after uncomplicated coronary angioplasty. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8367461&form=6&db=m Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8388358&form=6&db=m Antithrombotic activity and its relationship to in vitro anticoagulant effects. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8408654&form=6&db=m Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8409044&form=6&db=m Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8436751&form=6&db=m Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8446935&form=6&db=m Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8452516&form=6&db=m Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8459055&form=6&db=m Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8461462&form=6&db=m Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8465278&form=6&db=m The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8485052&form=6&db=m Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8499564&form=6&db=m A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8525667&form=6&db=m [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)] unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8562832&form=6&db=m Vascular endothelial cell activation and permeability responses to thrombin. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8571315&form=6&db=m Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8571329&form=6&db=m Prolonged expression of procoagulant activity of human platelets degranulated by thrombin. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8574461&form=6&db=m A closed-chest porcine model of coronary dissection and thrombosis. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578443&form=6&db=m Flow-related platelet deposition on subendothelium. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578446&form=6&db=m Thrombin generation in plasma: its assessment via the endogenous thrombin potential. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578525&form=6&db=m Advances in antithrombotic therapy: novel agents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8588204&form=6&db=m The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8592407&form=6&db=m Antithrombotic effects of hirulog in a rat carotid endarterectomy model. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8603017&form=6&db=m Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8605614&form=6&db=m Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8613842&form=6&db=m Edema from intracerebral hemorrhage: the role of thrombin. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8613969&form=6&db=m Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8616093&form=6&db=m Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8616922&form=6&db=m Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8623150&form=6&db=m Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8626947&form=6&db=m A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632823&form=6&db=m Role of the thrombin receptor in development and evidence for a second receptor. causal interaction,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8639834&form=6&db=m Platelet-derived microparticles associate with fibrin during thrombosis. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8641009&form=6&db=m Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8665773&form=6&db=m Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8667188&form=6&db=m Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8680743&form=6&db=m Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683388&form=6&db=m Tissue plasminogen activator production by monocytes in venous thrombolysis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8690050&form=6&db=m A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8698879&form=6&db=m Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8723593&form=6&db=m Antiplatelet and anticoagulant use after myocardial infarction. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8732754&form=6&db=m Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8735626&form=6&db=m Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8756006&form=6&db=m Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8759906&form=6&db=m Age-related changes in factor VII proteolysis in vivo. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8790994&form=6&db=m Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8796119&form=6&db=m Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8798478&form=6&db=m An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807710&form=6&db=m Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807714&form=6&db=m Thrombin regulation by physiological inhibitors: the role of vitronectin. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807728&form=6&db=m Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8836007&form=6&db=m Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8839997&form=6&db=m Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8840864&form=6&db=m Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8841738&form=6&db=m Recognition and treatment of unstable angina. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8845466&form=6&db=m Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8857926&form=6&db=m Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8867650&form=6&db=m Effect of argatroban on the formation of artificial thrombus on dogs. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883275&form=6&db=m Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8889355&form=6&db=m The role of thrombin in coronary artery thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8900278&form=6&db=m Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8901652&form=6&db=m Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8911411&form=6&db=m Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8917566&form=6&db=m Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8944417&form=6&db=m The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8968361&form=6&db=m Cardiovascular actions of thrombin receptor activation in vivo. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8969783&form=6&db=m alpha-Thrombin upregulates G alpha i3 in human vascular endothelial cells. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8979133&form=6&db=m Plaque rupture, thrombosis, and therapeutic implications. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9031448&form=6&db=m Thrombin activity associated with indwelling central venous catheters. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9040491&form=6&db=m A new rat model of thrombotic focal cerebral ischemia. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9042689&form=6&db=m Antithrombotic effect in vivo of thrombotic substances adsorbed on a platinum surface. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9054733&form=6&db=m Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9057074&form=6&db=m CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065993&form=6&db=m Blood coagulation and thrombosis in patients with ovarian malignancy. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9066013&form=6&db=m Thrombin augments vascular cell-dependent migration of human mast cells: role of MGF. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9092407&form=6&db=m [Hirudin: the relative failure of a very promising molecule] causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9107158&form=6&db=m Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9129631&form=6&db=m Thrombogenicity of small-diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134653&form=6&db=m Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9156415&form=6&db=m Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9158859&form=6&db=m Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9160347&form=6&db=m [A novel photochemical model of the middle cerebral artery for thrombosis research and evaluation of anti-thrombotic agents] causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9173723&form=6&db=m [Significance of coronary thrombosis for chronic myocardial ischemia] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9175244&form=6&db=m Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178727&form=6&db=m Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186599&form=6&db=m Human lesion studies. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9195869&form=6&db=m Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9198248&form=6&db=m Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9212208&form=6&db=m Ultrasound enhancement of rabbit femoral artery thrombolysis. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9231027&form=6&db=m Reactive oxygen metabolites and arterial thrombosis. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9240316&form=6&db=m Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9263656&form=6&db=m Antiplatelet and antithrombin therapies in the acute coronary syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9294322&form=6&db=m [Hypercoagulable state in Duchenne muscular dystrophy] diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9296465&form=6&db=m New frontiers in the management of unstable coronary artery disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9308768&form=6&db=m Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9340367&form=6&db=m [Thrombin receptor in thrombosis] causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9341161&form=6&db=m Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9364998&form=6&db=m Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9364999&form=6&db=m The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9372020&form=6&db=m Resistance to activated protein C caused by a factor V gene mutation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9372023&form=6&db=m Hirudin and hirudin analogues as new anticoagulant agents. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9408013&form=6&db=m Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9408021&form=6&db=m Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9408027&form=6&db=m Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9409233&form=6&db=m Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9414275&form=6&db=m Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9432025&form=6&db=m Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9439754&form=6&db=m Low-molecular-weight heparins and unstable angina--current perspectives. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9458447&form=6&db=m A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9471327&form=6&db=m [Unstable atherosclerotic plaque and acute coronary syndromes] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9484990&form=6&db=m Prolonged activation of prothrombin on the vascular wall after arterial injury. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493595&form=6&db=m Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493602&form=6&db=m Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493603&form=6&db=m BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9494029&form=6&db=m Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9495304&form=6&db=m Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9514177&form=6&db=m Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531030&form=6&db=m Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531058&form=6&db=m Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9555855&form=6&db=m Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9556230&form=6&db=m Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9589189&form=6&db=m Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610746&form=6&db=m Expression of the thrombin receptor in developing bone and associated tissues. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9615911&form=6&db=m The response of smooth muscle cells to alpha-thrombin depends on its arterial origin: comparison among different species. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9620151&form=6&db=m Thrombin activates MAPKAP2 kinase in vascular smooth muscle. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9647415&form=6&db=m Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9652465&form=6&db=m Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9662465&form=6&db=m Antithrombin and ischemia/reperfusion. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9667850&form=6&db=m New thrombin inhibitors in cardiovascular disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9688802&form=6&db=m Animal model of acute deep vein thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9690479&form=6&db=m Laboratory assessment of antithrombotic therapy: what tests and if so why? causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9694241&form=6&db=m The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9702317&form=6&db=m Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9712290&form=6&db=m The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9712658&form=6&db=m Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9714116&form=6&db=m Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9714136&form=6&db=m Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9716134&form=6&db=m A dual thrombin receptor system for platelet activation. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9716151&form=6&db=m Effects of radiographic contrast agents on thrombin formation and activity. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9736918&form=6&db=m Cardiovascular chemotherapy: anticoagulants. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9737460&form=6&db=m In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9737474&form=6&db=m Clinical potential of antithrombotic drugs in coronary syndromes. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9765662&form=6&db=m [Thrombin and its pharmacologic regulation] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9788223&form=6&db=m Acute thrombogenic effects of fibrin sealant on microvascular anastomoses in a rat model. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9792431&form=6&db=m Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9796835&form=6&db=m Endothelial dysfunction and inhibition of converting enzyme. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9804454&form=6&db=m Quantification of device adherent, circulating, and organ pool of thrombin and fibrinogen after cardiopulmonary bypass in a pig model. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9809887&form=6&db=m Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819023&form=6&db=m Tissue factor expression by monocytes: regulation and pathophysiological roles. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9820166&form=6&db=m Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9832493&form=6&db=m Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9842027&form=6&db=m Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9855181&form=6&db=m New treatment options for heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9869162&form=6&db=m Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9871547&form=6&db=m L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9919472&form=6&db=m Pathogenesis of vascular disease in hyperhomocysteinaemia. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9922933&form=6&db=m Therapeutic inhibition of thrombin activities, receptors, and production. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9930220&form=6&db=m [Experimental model of early chronic pelvic vein thrombosis with occlusion spirals and thrombin] ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9930560&form=6&db=m Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10066156&form=6&db=m Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA). diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10070829&form=6&db=m Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073268&form=6&db=m Heparin-induced thrombocytopenia: a ten-year retrospective. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10087043&form=6&db=m Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10087433&form=6&db=m Effects of polysulfonate derivative (GL 522-Y-1) on coagulation in vitro and thrombosis in vivo. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10093889&form=6&db=m A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10096741&form=6&db=m Experimental studies of injection agents for peptic ulcer bleeding endoscopic control. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102460&form=6&db=m Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102564&form=6&db=m Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10194441&form=6&db=m Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10226408&form=6&db=m Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10235427&form=6&db=m Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10323789&form=6&db=m Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10331423&form=6&db=m Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10341841&form=6&db=m Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10357156&form=6&db=m Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10362188&form=6&db=m A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10375391&form=6&db=m Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10393336&form=6&db=m Design and synthesis of para-fluorophenylalanine amide derivatives as thrombin receptor antagonists. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10394164&form=6&db=m A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,2 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10404775&form=6&db=m Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10420478&form=6&db=m [Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10425087&form=6&db=m Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10444030&form=6&db=m Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456621&form=6&db=m Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10457264&form=6&db=m Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10467729&form=6&db=m Fibrinogen. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10468246&form=6&db=m Microvascular responses to cardiopulmonary bypass. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10479672&form=6&db=m Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10494034&form=6&db=m On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10494766&form=6&db=m Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10521382&form=6&db=m Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10544927&form=6&db=m Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10544933&form=6&db=m Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10548424&form=6&db=m Platelet adhesion to human brain microvascular endothelial cells in vitro. Observation with video-enhanced contrast microscopy. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10551684&form=6&db=m Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10552952&form=6&db=m Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10587389&form=6&db=m Thrombin injection versus compression of femoral artery pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10595795&form=6&db=m Synergy between thrombin and serotonin in inducing vascular smooth muscle cell proliferation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604970&form=6&db=m Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10607861&form=6&db=m Strategies and progress towards the ideal orally active thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608000&form=6&db=m Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608001&form=6&db=m Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639214&form=6&db=m Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650852&form=6&db=m Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669659&form=6&db=m Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10684811&form=6&db=m Human endometrial endothelial cells: isolation, characterization, and inflammatory-mediated expression of tissue factor and type 1 plasminogen activator inhibitor. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10685061&form=6&db=m The role of apoptosis in vascular disease. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10688831&form=6&db=m Lepirudin blunts endotoxin-induced coagulation activation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10688985&form=6&db=m Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692450&form=6&db=m Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10695765&form=6&db=m Fibrinogen Bbeta14 Arg-->Cys: further evidence for a role in thrombosis. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10706937&form=6&db=m Heparin cofactor II inhibits thrombus formation in a rat thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10728020&form=6&db=m Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10728396&form=6&db=m Apoptosis in atherosclerosis: beneficial or detrimental? causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10739394&form=6&db=m GPV is a marker of in vivo platelet activation--study in a rat thrombosis model. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751802&form=6&db=m Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10756323&form=6&db=m Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10766244&form=6&db=m PAR3 is a cofactor for PAR4 activation by thrombin. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10767118&form=6&db=m Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10781674&form=6&db=m Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10793011&form=6&db=m Antibodies to topical bovine thrombin correlate with access thrombosis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10796916&form=6&db=m Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10796957&form=6&db=m Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10806208&form=6&db=m Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10806560&form=6&db=m Hypercoagulable states. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10806569&form=6&db=m Statin drugs and dietary isoprenoids as antithrombotic agents. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10810873&form=6&db=m [Antiphospholipid antibodies and thrombosis: the putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10832086&form=6&db=m Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10844408&form=6&db=m Recombinant thrombomodulin inhibits thrombin-induced vascular endothelial growth factor production in neuronal cells. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10847425&form=6&db=m The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10868518&form=6&db=m Antithrombins and the importance of good control. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10907447&form=6&db=m [New medical anticoagulants] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10912644&form=6&db=m Venous thromboembolism in heparin-induced thrombocytopenia. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10925365&form=6&db=m Thrombin induces apoptosis in human tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10936860&form=6&db=m Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10943598&form=6&db=m Activation of coagulation during treatment with haemodialysis. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10952806&form=6&db=m Injection therapy for endoscopic haemostasis. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10956659&form=6&db=m Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10974347&form=6&db=m Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10980906&form=6&db=m Novel inhibitors of factor X for use in cardiovascular diseases. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10990227&form=6&db=m Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10991981&form=6&db=m Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10995591&form=6&db=m Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin fragment 1+2 in mitral stenosis. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11000159&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11005941&form=6&db=m Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11007068&form=6&db=m Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11013045&form=6&db=m Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11020444&form=6&db=m Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11049984&form=6&db=m Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11052874&form=6&db=m Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11053621&form=6&db=m Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11054908&form=6&db=m Pathophysiology of coronary thrombosis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060732&form=6&db=m Bivalirudin: a new generation antithrombotic drug. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11080597&form=6&db=m Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11085063&form=6&db=m [Uremic coagulopathy. Role of thrombin] causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11090049&form=6&db=m Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11121023&form=6&db=m A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11122549&form=6&db=m The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127868&form=6&db=m Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11151655&form=6&db=m [Ultrasound guided percutaneous thrombin injection for treatment of a pseudoaneurysm after inguinal or brachial catheterization; good results in 14 patients] diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11156731&form=6&db=m The mechanism of action of thrombin inhibitors. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11171108&form=6&db=m Preparation of anhydrothrombin and characterization of its interaction with natural thrombin substrates. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11172035&form=6&db=m A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11177336&form=6&db=m Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11212093&form=6&db=m Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11228338&form=6&db=m Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11228341&form=6&db=m Effects of alpha(2)-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11231110&form=6&db=m Computational modelling of inhibitor binding to human thrombin. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11248787&form=6&db=m Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11250982&form=6&db=m Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11263599&form=6&db=m Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11264810&form=6&db=m The Influence of Flow on the Concentration of Platelet Active Substances in the Vicinity of Mural Microthrombi. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11265889&form=6&db=m Effects of intraarterial thrombin in the swine model. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11269422&form=6&db=m Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and thrombosis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11283012&form=6&db=m Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11294800&form=6&db=m Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11331854&form=6&db=m Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11336112&form=6&db=m A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11342132&form=6&db=m Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11357001&form=6&db=m Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395131&form=6&db=m Antithrombin activity of an algal polysaccharide. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11425985&form=6&db=m Prototype percutaneous thrombolytic device: preclinical testing in subacute inferior vena caval thrombosis in a pig model. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11434701&form=6&db=m A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11435305&form=6&db=m Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11438279&form=6&db=m Femoral pseudoaneurysm thrombinjection. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11441979&form=6&db=m Anticoagulation: the present and future. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11470437&form=6&db=m The factor VII zymogen structure reveals reregistration of beta strands during activation. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11485695&form=6&db=m Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary Intervention. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11499974&form=6&db=m Platelet polymorphisms in thrombotic disorders. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11517052&form=6&db=m Low-dose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11529859&form=6&db=m Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11530963&form=6&db=m Heparin-induced thrombocytopenia: natural history, diagnosis, and management. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11544528&form=6&db=m Role of thrombin signalling in platelets in haemostasis and thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11547357&form=6&db=m Measurement of hematological, clinical chemistry, and infection parameters from hirudinized blood collected in universal blood sampling tubes. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11562339&form=6&db=m FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11574979&form=6&db=m Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11575827&form=6&db=m Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11583496&form=6&db=m Activation of coagulation and fibrinolysis in microsurgical reconstructions in the lower extremities. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11604028&form=6&db=m Prediction of enzyme binding: human thrombin inhibition study by quantum chemical and artificial intelligence methods based on X-ray structures. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11604560&form=6&db=m Platelets, leukocytes, and coagulation. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11668424&form=6&db=m Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11686320&form=6&db=m Human thrombi contain an abundance of active thrombin. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11700498&form=6&db=m Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11727307&form=6&db=m Thrombin receptor antagonists as novel therapeutic targets. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11735204&form=6&db=m Ultrasound guided human thrombin injection. A new modality in the management of femoral artery pseudo-aneurysms. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11770864&form=6&db=m Platelet receptor polymorphisms and thrombotic risk. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11770866&form=6&db=m Platelet regulation of thrombin generation in cardiovascular disease. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11772313&form=6&db=m Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11776321&form=6&db=m The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11778006&form=6&db=m The hemolytic-uremic syndrome--toxin, thrombin, and thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11804648&form=6&db=m Novel approaches to the treatment of thrombosis. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11812405&form=6&db=m Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11824003&form=6&db=m Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11830196&form=6&db=m Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11834714&form=6&db=m Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11841339&form=6&db=m The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11855916&form=6&db=m The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877267&form=6&db=m Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877701&form=6&db=m Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11914651&form=6&db=m Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11918917&form=6&db=m Autologous thrombin for treatment of pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11921399&form=6&db=m A novel near-infrared fluorescence sensor for detection of thrombin activation in blood. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11926954&form=6&db=m Ultrasound-guided thrombin injection is the treatment of choice for femoral pseudoaneurysms. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958321&form=6&db=m Percutaneous thrombin injection of carotid artery pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958322&form=6&db=m Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11958802&form=6&db=m Pathological haemostasis and "prothrombotic state" in Behçet's disease. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11964083&form=6&db=m Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11966476&form=6&db=m The levels of five markers of hemostasis and endothelial status at different stages of normotensive pregnancy. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11975790&form=6&db=m Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11986217&form=6&db=m Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11994558&form=6&db=m Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12005203&form=6&db=m Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12008935&form=6&db=m Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12021225&form=6&db=m First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12029263&form=6&db=m Antithrombin III. Key factor in extracorporeal circulation. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12036417&form=6&db=m Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12063808&form=6&db=m Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12064194&form=6&db=m [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis] therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12064570&form=6&db=m The biology of thrombin in acute coronary syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12064571&form=6&db=m The role of thrombin inhibition during percutaneous coronary intervention. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12070133&form=6&db=m The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12075599&form=6&db=m Ipsilateral femoral vein compression: a contraindication to thrombin injection of femoral pseudoaneurysms. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12075943&form=6&db=m Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12091346&form=6&db=m Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12105168&form=6&db=m Antithrombin-heparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161502&form=6&db=m Expression of thrombin receptors in endothelial cells and neutrophils from normal and preeclamptic pregnancies. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12196234&form=6&db=m Treatment of iatrogenic femoral artery false aneurysms with ultrasound-guided thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12211410&form=6&db=m Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12244485&form=6&db=m Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12296618&form=6&db=m Recombinant human activated protein C (Xigris). causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12356489&form=6&db=m Direct thrombin inhibitors. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12368739&form=6&db=m A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12384423&form=6&db=m Protection against thrombosis in mice lacking PAR3. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12406151&form=6&db=m Titania gel reduces thrombin generation. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12426227&form=6&db=m In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431473&form=6&db=m Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431976&form=6&db=m Thrombin rapidly induces protein kinase D phosphorylation, and protein kinase C delta mediates the activation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12441911&form=6&db=m Effect of anticoagulants and antiplatelet agents on platelet-mediated thrombin generation. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12465999&form=6&db=m A guide to drug use during percutaneous coronary intervention. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12468805&form=6&db=m Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12492587&form=6&db=m Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters? causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12493544&form=6&db=m Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12538843&form=6&db=m Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12540960&form=6&db=m Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12544726&form=6&db=m Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12556215&form=6&db=m Therapeutic potential of protease-activated receptor-1 antagonists. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12564089&form=6&db=m [Treatment of pseudoaneurysms with injection of thrombin] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12573700&form=6&db=m A novel class of small functional peptides that bind and inhibit human alpha-thrombin isolated by mRNA display. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12574806&form=6&db=m Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12644344&form=6&db=m The evolving role of direct thrombin inhibitors in acute coronary syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12651253&form=6&db=m Interventional therapy for stenosis and aneurysm in renal graft artery: report of 9 cases. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12652325&form=6&db=m Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12652502&form=6&db=m Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12676802&form=6&db=m Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12689935&form=6&db=m Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12707536&form=6&db=m Alterations in endothelial thrombomodulin expression in zymosan-induced lung injury. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709927&form=6&db=m Neonatal thromboembolism. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12714830&form=6&db=m Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719661&form=6&db=m Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719780&form=6&db=m Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12723936&form=6&db=m LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in rats and dogs. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12725958&form=6&db=m Platelet function assays. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12731676&form=6&db=m In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12738903&form=6&db=m [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12763173&form=6&db=m [Heterozygous prothrombin gene mutation G20210A and associated diseases] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12763496&form=6&db=m Maternal thrombophilia and neonatal thrombosis. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12765335&form=6&db=m Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12774450&form=6&db=m Thrombin contraction of vascular smooth muscle: implications for vasospasm. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12792441&form=6&db=m Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12811009&form=6&db=m Current perspective on antithrombin drugs. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12818630&form=6&db=m A novel approach to thrombin inhibition. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12820494&form=6&db=m [Strategies to improve reperfusion with fibrinolytic therapy in ST-T elevation myocardial infarction] causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12828884&form=6&db=m [Usefulness of sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12829728&form=6&db=m Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12829874&form=6&db=m [Programmed cellular death and atherogenesis: from molecular mechanisms to clinical aspects] ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12831462&form=6&db=m Coagulation and inflammation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12846767&form=6&db=m Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12846829&form=6&db=m Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853709&form=6&db=m Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12855810&form=6&db=m Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871353&form=6&db=m Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871368&form=6&db=m Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871372&form=6&db=m Predicting the pharmacology of thrombin inhibitors. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871419&form=6&db=m Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871465&form=6&db=m Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871470&form=6&db=m The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871538&form=6&db=m A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12876627&form=6&db=m Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12888870&form=6&db=m Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12892834&form=6&db=m Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12893020&form=6&db=m Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12901409&form=6&db=m Percutaneous ultrasonographically guided thrombin injection of iatrogenic pseudoaneurysms in unusual sites. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12902566&form=6&db=m Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12903004&form=6&db=m Treatment of femoral artery pseudoaneurysms using ultrasound-guided thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12904065&form=6&db=m Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12912723&form=6&db=m Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12932163&form=6&db=m Distribution of sac pressure in an experimental aneurysm model after endovascular repair: the effect of endoleak types I and II. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12933533&form=6&db=m Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12947018&form=6&db=m Effects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12970118&form=6&db=m Thrombin formation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12973822&form=6&db=m Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13239730&form=6&db=m Susceptibility to thrombosis in normal young, aging, cortisone-treated, heparinized and x-irradiated hamsters as tested by topical application of thrombin. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14499592&form=6&db=m Structural stability of human alpha-thrombin studied by disulfide reduction and scrambling. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14512012&form=6&db=m Thrombosis of a proximal aortic false aneurysm following AAA repair by endovascular thrombin injection. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14521590&form=6&db=m Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14529396&form=6&db=m Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14556452&form=6&db=m [Platelets and arterial thrombosis] causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14568897&form=6&db=m Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14573423&form=6&db=m Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14593977&form=6&db=m Overview of heparin-induced thrombocytopenia. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14594322&form=6&db=m Deviations in coagulation activation due to treatment with different haemodialysis membranes. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14597584&form=6&db=m Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14604821&form=6&db=m Thrombin interaction with platelet membrane glycoprotein Ib alpha. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14607082&form=6&db=m Targeting thrombin--rational drug design from natural mechanisms. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634048&form=6&db=m Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14651143&form=6&db=m Etiopathophysiology of disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14652070&form=6&db=m Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14698650&form=6&db=m Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14714071&form=6&db=m Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14717971&form=6&db=m Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14727968&form=6&db=m New targets for antithrombotic drugs. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14737006&form=6&db=m Platelets and anti-platelet therapy. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14739624&form=6&db=m Thrombin domains: structure, function and interaction with platelet receptors. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14742760&form=6&db=m Low-molecular-weight heparin-induced thrombocytopenia in a child. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961148&form=6&db=m Thrombin binding to GPIbalpha induces integrin alphaIIbbeta3 dependent platelet adhesion to fibrin in ex vivo flowing whole blood. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14961149&form=6&db=m Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14970041&form=6&db=m Site-specific thromboembolism: a novel animal model for stroke. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14980986&form=6&db=m Treatment of heparin-induced thrombocytopenia: a critical review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017006&form=6&db=m Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15031124&form=6&db=m Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15060420&form=6&db=m The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15072993&form=6&db=m Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15077087&form=6&db=m Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15084542&form=6&db=m Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15104934&form=6&db=m [The hemostatic system in the acute coronary syndromes: physiopathological and therapeutic implications] diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15116259&form=6&db=m The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15140128&form=6&db=m Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15155122&form=6&db=m Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15155790&form=6&db=m Facilitating roles of murine platelet glycoprotein Ib and alphaIIbbeta3 in phosphatidylserine exposure during vWF-collagen-induced thrombus formation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15164605&form=6&db=m [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)] diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15175794&form=6&db=m Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15175809&form=6&db=m Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15194626&form=6&db=m Effects of tirofiban on haemostatic activation in vitro. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15204242&form=6&db=m Inhibition of neointimal hyperplasia by a specific thrombin inhibitor. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15225111&form=6&db=m Anticoagulant drugs: an update. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15227406&form=6&db=m Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15238620&form=6&db=m Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15238823&form=6&db=m Activation of coagulation system in dilated cardiomyopathy: comparison of patients with and without left ventricular thrombus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15247979&form=6&db=m Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15267248&form=6&db=m Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15280200&form=6&db=m Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15304051&form=6&db=m Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15314703&form=6&db=m [Thrombin: antithrombotic properties and pharmacological consequences] causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15317813&form=6&db=m Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15348232&form=6&db=m Surface characterization and platelet adhesion studies on polyethylene surface with hirudin immobilization. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15354313&form=6&db=m Validation and application of an automated 96 -well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of SCH 201781 in human plasma. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15379714&form=6&db=m Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15389730&form=6&db=m Progress in the design of low molecular weight thrombin inhibitors. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15454859&form=6&db=m In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15456496&form=6&db=m The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15480620&form=6&db=m Pseudoaneurysm in children: diagnosis and interventional management. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15482031&form=6&db=m Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15501141&form=6&db=m Comparative aspects of blood coagulation. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15506032&form=6&db=m Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15511384&form=6&db=m Oral Antithrombins and the Future of Antithrombotic Therapy. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15514167&form=6&db=m Chemokines in the pathogenesis of vascular disease. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15522324&form=6&db=m Thrombus-induced endothelial dysfunction: Hemoglobin and fibrin decrease nitric oxide bioactivity without altering eNOS. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569834&form=6&db=m Factor VLeiden inhibits fibrinolysis in vivo. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15572259&form=6&db=m Modes and consequences of thrombin's interaction with fibrin. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613017&form=6&db=m Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15630668&form=6&db=m Current role of antithrombotic agents in the treatment of acute coronary syndromes. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15678443&form=6&db=m Endovascular treatment of a massive retroperitoneal bleeding: successful balloon-catheter delivery of intra-arterial thrombin. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15684708&form=6&db=m Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15692116&form=6&db=m Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15741800&form=6&db=m Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15747263&form=6&db=m Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15781388&form=6&db=m 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15781750&form=6&db=m Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15787345&form=6&db=m Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15823862&form=6&db=m Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15870543&form=6&db=m The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15878322&form=6&db=m Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15893368&form=6&db=m Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15902370&form=6&db=m [Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15903126&form=6&db=m Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15932039&form=6&db=m [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs] therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15934410&form=6&db=m Compression repair versus low-dose thrombin injection for the treatment of iatrogenic femoral pseudoaneurysm: a retrospective case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15969316&form=6&db=m [Besides fibrinogen, are haemostatic, coagulation and/or fibrinolytic parameters predictors or markers of the risk of cardiovascular events?] causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15975616&form=6&db=m Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15978105&form=6&db=m The plasma hemostatic proteome: thrombin generation in healthy individuals. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15978174&form=6&db=m Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15981562&form=6&db=m Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15988269&form=6&db=m The effect of tirofiban on microvascular thrombosis: crush model. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992009&form=6&db=m Synthetic and recombinant antithrombin drugs. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992020&form=6&db=m Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992034&form=6&db=m Low molecular weight heparin in acute stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992155&form=6&db=m Direct thrombin inhibitors: current status and future prospects. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16025990&form=6&db=m [Protein C congenital deficiency. A case report] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16026273&form=6&db=m Maternal fibrinogen is necessary for embryonic development. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16026408&form=6&db=m Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16052301&form=6&db=m Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS). unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16079188&form=6&db=m A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16102110&form=6&db=m Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16123910&form=6&db=m Mechanism of action of the oral direct thrombin inhibitor ximelagatran. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16131539&form=6&db=m Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16144513&form=6&db=m Ximelagatran--recent comparisons with warfarin. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16146463&form=6&db=m The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16146728&form=6&db=m Factor Xa inhibitors: new anti-thrombotic agents and their characteristics. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16181988&form=6&db=m Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16201969&form=6&db=m Crystal structure of wild-type human thrombin in the Na+-free state. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16233053&form=6&db=m Characteristics of a cheese-like food produced by fermentation of the mushroom Schizophyllum commune. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16241948&form=6&db=m Thrombin generation profiles in deep venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16246253&form=6&db=m Chemically modified thrombin and anhydrothrombin that differentiate macromolecular substrates of thrombin. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16275108&form=6&db=m QSAR studies of N(1)-(5-chloro-2-pyridyl)-2-{[4-(alkyl methyl)benzoyl]amino}-5-chlorobenzamide analogs. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305521&form=6&db=m Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305522&form=6&db=m Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16338245&form=6&db=m Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16363230&form=6&db=m Homocysteine and thrombosis: from basic science to clinical evidence. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16371760&form=6&db=m The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16380869&form=6&db=m [Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.] ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387470&form=6&db=m [Activated proteine C] causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16388417&form=6&db=m Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16391010&form=6&db=m Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16394885&form=6&db=m Argatroban anticoagulation in pediatric patients: a literature analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16409475&form=6&db=m Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16427694&form=6&db=m The effect of high-density-lipoprotein on thrombus formation on and endothelial cell attachement to biomaterial surfaces. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16429847&form=6&db=m Vena cava superior syndrome developing in a dialysis patient with antithrombin III deficiency following temporary catheterization. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16437508&form=6&db=m Surgery versus non-surgical treatment for femoral pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16440266&form=6&db=m [Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16455953&form=6&db=m Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16460448&form=6&db=m Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469363&form=6&db=m Aqueous extracts of Ocimum basilicum L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio--venous shunt thrombosis in vivo. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469512&form=6&db=m Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16475045&form=6&db=m New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16479196&form=6&db=m Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505172&form=6&db=m Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16513378&form=6&db=m Tissue factor pathway vs. collagen pathway for in vivo platelet activation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16520730&form=6&db=m Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16525572&form=6&db=m Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16532615&form=6&db=m Flow and thrombosis at orifices simulating mechanical heart valve leakage regions. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16553237&form=6&db=m [Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16634754&form=6&db=m Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16634759&form=6&db=m P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643084&form=6&db=m Percutaneous repair of abdominal aortic pseudoaneurysm by catheter-based delivery of thrombin. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643448&form=6&db=m The effect of red blood cells on thrombin generation. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673270&form=6&db=m Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673612&form=6&db=m [Treatment of iatrogenic femoral pseudoaneurysms by ultrasound-guided percutaneous thrombin injection: effectiveness and complications] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16676066&form=6&db=m Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16728654&form=6&db=m Thrombin-cofactor interactions: structural insights into regulatory mechanisms. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757126&form=6&db=m Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16767070&form=6&db=m Anticoagulation options for intermittent haemodialysis. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16775297&form=6&db=m A dedicated animal model for mechanical thrombectomy in acute stroke. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16775505&form=6&db=m Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16786228&form=6&db=m Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16801109&form=6&db=m Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16824188&form=6&db=m Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16837456&form=6&db=m PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16871082&form=6&db=m Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin? diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890935&form=6&db=m Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16918370&form=6&db=m Links between inflammation and thrombogenicity in atherosclerosis. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16919046&form=6&db=m Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16923021&form=6&db=m Approaches to selective peptidic inhibitors of factor Xa. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952995&form=6&db=m Protease-activated receptors in cardiovascular diseases. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16960880&form=6&db=m Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16990551&form=6&db=m Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17002301&form=6&db=m Evidence for Activation of Tissue Factor by an Allosteric Disulfide Bond. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17003921&form=6&db=m A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17021531&form=6&db=m Anticoagulation of patients with heparin-induced thrombocytopenia in cardiac surgery. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17024597&form=6&db=m Inherited thrombophilia and venous thromboembolism. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17080212&form=6&db=m Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17097558&form=6&db=m Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17103113&form=6&db=m Direct thrombin inhibitors - a survey of recent developments. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17109803&form=6&db=m Bleeding disorders: characterization, dental considerations and management. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17116549&form=6&db=m Arginase activity is increased by thrombin: a mechanism for endothelial dysfunction in arterial thrombosis. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17119458&form=6&db=m Platelet and leukocyte activation in salvaged blood and the effect of its reinfusion on the circulating blood. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17122687&form=6&db=m Treatment of heparin-induced thrombocytopenia: a practical argatroban dosing protocol for nurses. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17124098&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17158345&form=6&db=m Activation of platelet function through G protein-coupled receptors. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17159550&form=6&db=m 99mTc-NC100668, an agent for imaging venous thromboembolism: The effect of anticoagulant or thrombolytic therapy on the uptake and retention of radioactivity in blood clots in vivo. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17166251&form=6&db=m Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17172299&form=6&db=m Forced Unfolding of Coiled-Coils in Fibrinogen by Single-Molecule AFM. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17176266&form=6&db=m Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17185690&form=6&db=m Percutaneous thrombin injection of a pulmonary artery pseudoaneurysm refractory to coil embolization. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17190826&form=6&db=m Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17208341&form=6&db=m Thrombin generation and fibrin clot structure. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17210570&form=6&db=m Dual role of platelet protein kinase C in thrombus formation: stimulation of pro-aggregatory and suppression of procoagulant activity in platelets. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17213677&form=6&db=m Antithrombotic effects of odorless garlic powder both in vitro and in vivo. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17235277&form=6&db=m The pathogenesis and management of disseminated intravascular coagulation. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17243265&form=6&db=m [Platelet--vessel wall interactions] causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17257667&form=6&db=m New acrylic microspheres for arterial embolization: combining radiopacity for precise localization with immobilized thrombin to trigger local blood coagulation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17258798&form=6&db=m The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17293494&form=6&db=m Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17295326&form=6&db=m Management of a spontaneous renal capsule hematoma following cardiac catheterization involving use of a platelet glycoprotein IIb/IIIa inhibitor: a case report. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17357310&form=6&db=m Activity of coagulation and fibrinolytic system components in the vein thrombus. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17454672&form=6&db=m Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17457285&form=6&db=m [Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report] causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461731&form=6&db=m Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17489367&form=6&db=m Anti-hypertensive effect of the Dongchunghacho, Isaria sinclairii, in the spontaneously hypertensive rats. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17490558&form=6&db=m [Research progress in hirudin fusion protein--review] diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17490728&form=6&db=m In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17496204&form=6&db=m Trousseau's syndrome: multiple definitions and multiple mechanisms. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17508246&form=6&db=m Femoral artery thrombosis following percutaneous treatment with thrombin injection of a femoral artery pseudoaneurysm: a case report. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17516031&form=6&db=m alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549253&form=6&db=m Unchecked thrombin is bad news for troubled arteries. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17565235&form=6&db=m Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17566522&form=6&db=m [The numerous properties of the anticoagulant protein C] therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17580217&form=6&db=m Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17580732&form=6&db=m Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17597999&form=6&db=m Update on antithrombin I (fibrin). causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17635703&form=6&db=m In vivo thrombus formation. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17721615&form=6&db=m Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17761939&form=6&db=m Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17885684&form=6&db=m Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17889282&form=6&db=m Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17910639&form=6&db=m Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17911567&form=6&db=m The new anticoagulants. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17916770&form=6&db=m Intrinsic pathway of coagulation and arterial thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17927002&form=6&db=m Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17938815&form=6&db=m Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17955717&form=6&db=m Multivessel coronary thrombosis resulting from heparin induced thrombocytopenia. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17966536&form=6&db=m Spontaneous pseudo-aneurysm of the deep femoral artery treated by a covered stent. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17997091&form=6&db=m Amplified electrochemical aptasensor taking AuNPs based sandwich sensing platform as a model. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18019946&form=6&db=m Tissue factor in thrombosis and hemorrhage. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18021312&form=6&db=m Thrombin bound to a fibrin clot confers angiogenic and hemostatic properties on endothelial progenitor cells. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18030194&form=6&db=m A porcine deep vein thrombosis model for magnetic resonance-guided monitoring of different thrombectomy procedures. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18067490&form=6&db=m Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18081863&form=6&db=m Dual P2Y 12 receptor signaling in thrombin-stimulated platelets--involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18089414&form=6&db=m Heparin-induced thrombocytopenia type II: a serious hazard in preemptive renal transplantation: a case report. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18184032&form=6&db=m Fondaparinux: use in thromboprophylaxis of acute medical patients. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18269690&form=6&db=m Recombinant human activated protein C: current insights into its mechanism of action. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278160&form=6&db=m Thrombin generation and venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278179&form=6&db=m Thrombin and protease-activated receptors (PARs) in atherothrombosis. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18282807&form=6&db=m Thrombin generation, fibrin clot formation and hemostasis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18294856&form=6&db=m Molecular basis of fibrin clot elasticity. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18302088&form=6&db=m The approach to heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18302373&form=6&db=m Effects of shear rate on propagation of blood clotting determined using microfluidics and numerical simulations. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18310501&form=6&db=m Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18315550&form=6&db=m Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18326052&form=6&db=m Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18363818&form=6&db=m Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18367371&form=6&db=m Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18388496&form=6&db=m Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18401270&form=6&db=m Desirudin reduces the rate of microvenous thrombosis in a rat model. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18419749&form=6&db=m Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18420408&form=6&db=m Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18444940&form=6&db=m Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18464157&form=6&db=m Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18464161&form=6&db=m Critical role of FcR gamma-chain, LAT, PLCgamma2 and thrombin in arteriolar thrombus formation upon mild, laser-induced endothelial injury in vivo. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18494938&form=6&db=m Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18498878&form=6&db=m Enoxaparin does not ameliorate limb ischemia-reperfusion injury. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18544303&form=6&db=m Bovine thrombin: history, use, and risk in the surgical patient. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18544310&form=6&db=m Heparin-induced thrombocytopenia: diagnosis and management. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18574711&form=6&db=m Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18590927&form=6&db=m Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18633427&form=6&db=m Association of aortic valve sclerosis with thrombin generation in hypertensive patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18665822&form=6&db=m Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000). causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18665927&form=6&db=m 4-thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growth on subendothelial matrix. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18680535&form=6&db=m High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18685428&form=6&db=m Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18690774&form=6&db=m How Na(+) activates thrombin - a review of the functional and structural data. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18695376&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18772359&form=6&db=m Thrombin mediates the extraintestinal thrombosis associated with experimental colitis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18778188&form=6&db=m New therapeutic option for thromboembolism--dabigatran etexilate. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18819124&form=6&db=m Bivalirudin for anticoagulation in children. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18832913&form=6&db=m A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18945968&form=6&db=m Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18948871&form=6&db=m Transcatheter thrombin embolization of a giant visceral artery aneurysm. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18974382&form=6&db=m Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18979627&form=6&db=m How Na+ activates thrombin--a review of the functional and structural data. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19002042&form=6&db=m Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19054792&form=6&db=m Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19058807&form=6&db=m Compressive mechanical properties of the intraluminal thrombus in abdominal aortic aneurysms and fibrin-based thrombus mimics. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19068790&form=6&db=m [Progression from a routine examination to a study. Having come this far, what should be done from now? A thrombosis risk factor study] causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19085759&form=6&db=m The history of phenotypic testing in thrombosis and hemostasis. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19129243&form=6&db=m Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19152788&form=6&db=m Solidification mechanisms of chitosan-glycerol phosphate/blood implant for articular cartilage repair. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19155517&form=6&db=m Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. causal interaction,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19195685&form=6&db=m Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19204776&form=6&db=m Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19218546&form=6&db=m C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates and protects against carotid artery occlusion and cerebral stroke. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19232683&form=6&db=m Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19238188&form=6&db=m Influence of aromatic and aliphatic moieties on thrombin inhibitors potency. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19256345&form=6&db=m Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19277409&form=6&db=m Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286885&form=6&db=m Platelet receptors and signaling in the dynamics of thrombus formation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19308898&form=6&db=m Assessment of thrombin generation: useful or hype? therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19338378&form=6&db=m Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19350113&form=6&db=m The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19355876&form=6&db=m Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19370614&form=6&db=m Treatment for femoral pseudoaneurysms. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371874&form=6&db=m Thrombin generation by intimal tissue factor contributes to thrombus formation on macrophage-rich neointima but not normal intima of hyperlipidemic rabbits. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19372258&form=6&db=m Dual role of collagen in factor XII-dependent thrombus formation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19372317&form=6&db=m Blood coagulation: hemostasis and thrombin regulation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19422451&form=6&db=m Mechanisms of hydroxyethyl starch induced dilutional coagulopathy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19517216&form=6&db=m Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552570&form=6&db=m Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552847&form=6&db=m [Establishment of rat model of venous thromboembolism] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19561825&form=6&db=m Pseudoaneurysm of the radial artery diagnosed by bedside ultrasound. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19567881&form=6&db=m Generation and phenotypic analysis of protein S-deficient mice. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19572071&form=6&db=m Absence of platelet-dependent fibrin formation in a patient with Scott syndrome. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19581800&form=6&db=m Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19601827&form=6&db=m The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19602496&form=6&db=m Post-sternotomy intercostal artery pseudoaneurysm. Sonographic diagnosis and thrombosis by ultrasound-guided percutaneous thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19625264&form=6&db=m Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630796&form=6&db=m Empirical and theoretical phenotypic discrimination. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19645323&form=6&db=m The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19655821&form=6&db=m Argatroban: a review of its use in the management of heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19657318&form=6&db=m Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19658036&form=6&db=m First trimester maternal concentrations of thrombin-inhibitor complexes and the presence of histologic placental lesions at delivery. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19660789&form=6&db=m Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19661487&form=6&db=m Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19665793&form=6&db=m Development of a new model of transvenous thrombosis in the pig superior sagittal sinus using thrombin injection and balloon occlusion. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19699853&form=6&db=m The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737712&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19795099&form=6&db=m [Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.] causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19804248&form=6&db=m Thrombus formation on apex of arterial stenoses: the need for a fluid high shear stenosis diagnostic device. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19823708&form=6&db=m [Complex supraclavicular false aneurysm. Case report.] diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19846574&form=6&db=m Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19872890&form=6&db=m STUDIES ON BLOOD COAGULATION : IV. THE NATURE OF THE CLOTTING DEFICIENCY IN HEMOPHILIA. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19874458&form=6&db=m Arterial thrombosis: relevance of a model with two levels of severity assessed by histological, ultrastructural and functional characterization. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19882073&form=6&db=m Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19890703&form=6&db=m Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19906551&form=6&db=m Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19918533&form=6&db=m Coil embolization of inferior epigastric artery pseudoaneurysm after percutaneous thrombin injection failure: a case report. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19948715&form=6&db=m Platelet thrombin receptor antagonism and atherothrombosis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19950764&form=6&db=m [Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19954432&form=6&db=m Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19967145&form=6&db=m Platelet response heterogeneity in thrombus formation. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19967151&form=6&db=m A fusion protein with improved thrombolytic effect and low bleeding risk. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20003049&form=6&db=m Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20016849&form=6&db=m The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20032511&form=6&db=m Thrombin induces endothelial arginase through AP-1 activation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20050927&form=6&db=m Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20089298&form=6&db=m Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20096005&form=6&db=m In prothrombin G20210A carriers the genetic mutation and the history of Venous Thrombosis contribute both to thrombin generation independently of factor II plasma levels. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20102150&form=6&db=m Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20102751&form=6&db=m Biomolecular surface engineering of pancreatic islets with thrombomodulin. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20124931&form=6&db=m Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20139363&form=6&db=m Inhibition of factor XIa as a new approach to anticoagulation. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20144050&form=6&db=m Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20174756&form=6&db=m The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20193528&form=6&db=m [Preliminary study on epidemiology of deep venous thrombosis of lower extremity in patients with high risk] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20208970&form=6&db=m Retrieval of "Recovery IVC Filter" after 383 days. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20213258&form=6&db=m Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20218626&form=6&db=m Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300292&form=6&db=m t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20352337&form=6&db=m Transport-Reaction Model of Mural Thrombogenesis: Comparisons of Mathematical Model Predictions and Results from Baboon Models. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20361492&form=6&db=m [Platelet abnormalities in type 2 diabetes mellitus] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20371335&form=6&db=m Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20435232&form=6&db=m Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20441735&form=6&db=m A multiscale model of venous thrombus formation with surface-mediated control of blood coagulation cascade. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20451499&form=6&db=m Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20454680&form=6&db=m Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20469610&form=6&db=m Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20478686&form=6&db=m A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20483158&form=6&db=m The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20519511&form=6&db=m Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20541794&form=6&db=m Evaluation of a post-operative thrombin inhibitor replacement protocol to reduce haemorrhagic and thrombotic complications after paediatric liver transplantation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20546119&form=6&db=m Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20589312&form=6&db=m BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20625277&form=6&db=m Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20657835&form=6&db=m Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20659537&form=6&db=m Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H. Wright. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20659761&form=6&db=m In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20660315&form=6&db=m NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20664889&form=6&db=m Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20664909&form=6&db=m Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20714763&form=6&db=m Thrombin generation in ankylosing spondylitis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20806126&form=6&db=m Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20807656&form=6&db=m Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20807657&form=6&db=m Glycosaminoglycans and activated contact system in cancer patient plasmas. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20859550&form=6&db=m Argatroban in the management of heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20870278&form=6&db=m M-AAA-Thrombin: Potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20930120&form=6&db=m Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20931853&form=6&db=m [Determination of biological activity of extract from hirudo by N-benzoyl-L-arginine ethyl ester] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21042684&form=6&db=m Relationship between thrombin generation and carotid intima-media thickness. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21073394&form=6&db=m A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21078793&form=6&db=m Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21083008&form=6&db=m Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21083469&form=6&db=m Pharmacology of argatroban. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21090833&form=6&db=m Vorapaxar. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21094665&form=6&db=m VAMP3 is associated with endothelial Weibel-Palade bodies and participates in their Ca(2+)-dependent exocytosis. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21113371&form=6&db=m Pseudoaneurysm of ulnar artery after endoscopic carpal tunnel release. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21127733&form=6&db=m Procoagulant Adaptation of a Blood Coagulation Prothrombinase-like Enzyme Complex in Australian Elapid Venom. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21206024&form=6&db=m Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with ?-thrombin. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21225480&form=6&db=m Stroke prevention in atrial fibrillation: atrial appendage closure. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21232250&form=6&db=m Thrombin inhibitors A new generation of antithrombotics. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21239127&form=6&db=m [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21239306&form=6&db=m Hirudin and other thrombin inhibitors experimental results and potential clinical applications. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21281592&form=6&db=m Dilutional control of prothrombin activation at physiologically relevant shear rates. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21286889&form=6&db=m A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21300059&form=6&db=m The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21304105&form=6&db=m Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21314005&form=6&db=m Prothrombotic state in Churg-Strauss syndrome: a case report. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21325994&form=6&db=m The Importance of Tissue Factor Expression by Porcine NICC in Triggering IBMIR in the Xenograft Setting. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21335484&form=6&db=m Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21360607&form=6&db=m Looking at the proteases from a simple perspective. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21364541&form=6&db=m Targeting Tumor Vasculature With an Oncolytic Virus. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21376373&form=6&db=m Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3). diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21401516&form=6&db=m Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21415977&form=6&db=m Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21429567&form=6&db=m Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21436072&form=6&db=m The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21464402&form=6&db=m Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21504721&form=6&db=m A few immobilized thrombins are sufficient for platelet spreading. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21557445&form=6&db=m Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21692994&form=6&db=m Using the laboratory to predict recurrent venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21739425&form=6&db=m Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in haemostasis. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21749674&form=6&db=m Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21772662&form=6&db=m Evaluation of plaque stability of advanced atherosclerotic lesions in apo e-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21781246&form=6&db=m HIT paradigms and paradoxes. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21836071&form=6&db=m Proteomic Signature of Thrombin-Activated Platelets After In Vivo Nitric Oxide-Donor Treatment: Coordinated Inhibition of Signaling (Phosphatidylinositol 3-Kinase-{gamma}, 14-3-3{zeta}, and Growth Factor Receptor-Bound Protein 2) and Cytoskeleton Protein Translocation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21925716&form=6&db=m Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21937274&form=6&db=m Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21944714&form=6&db=m Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21979881&form=6&db=m Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22036808&form=6&db=m Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22053189&form=6&db=m Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22079443&form=6&db=m Thrombin generation in clinical conditions. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22100180&form=6&db=m Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22137742&form=6&db=m Mechanisms of platelet activation by thrombin: A short history. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22152517&form=6&db=m Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22178578&form=6&db=m Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22187047&form=6&db=m The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22198911&form=6&db=m Ultrasonography-guided percutaneous thrombin injection of postcatheterization pseudoaneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22227959&form=6&db=m Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22234363&form=6&db=m The thrombin inhibitors hirudin and Refludan® activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22245244&form=6&db=m Characteristics of Fibrin Formation and Clot Stability in Individuals with Congenital Type IIb Protein C Deficiency. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22309048&form=6&db=m Effects of FEIBA on platelet and leucocyte activation in severe haemophilia patients with inhibitors. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22322136&form=6&db=m Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22370770&form=6&db=m Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22393298&form=6&db=m Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22413715&form=6&db=m Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22428607&form=6&db=m Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22458575&form=6&db=m Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22478907&form=6&db=m Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22482956&form=6&db=m Multiscale model of fibrin accumulation on the blood clot surface and platelet dynamics. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22493296&form=6&db=m Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22497884&form=6&db=m The relationship between aortic aneurysm sac thrombus volume on coagulation, fibrinolysis and platelet activity. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22512557&form=6&db=m Inhibitors of serine proteinases from blood coagulation cascade - view on current developments. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22516070&form=6&db=m Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22520420&form=6&db=m Mechano-rheological properties of the murine thrombus determined via nanoindentation and finite element modeling. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22618708&form=6&db=m Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22632032&form=6&db=m Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22661270&form=6&db=m Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22664295&form=6&db=m Endovascular treatment of an iatrogenic perforation of the internal iliac vein. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22728069&form=6&db=m A novel fibrinogenase from Agkistrodon acutus venom protects against DIC via direct degradation of thrombosis and activation of protein C. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22762893&form=6&db=m Thrombin generation: What have we learned? causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22773837&form=6&db=m Constitutive Dimerization of Glycoprotein VI (GPVI) in Resting Platelets Is Essential for Binding to Collagen and Activation in Flowing Blood. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22781741&form=6&db=m Platelet protease-activated receptor antagonism in cardiovascular medicine. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22782575&form=6&db=m ADAMTS13 exerts a thrombolytic effect in microcirculation. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22809514&form=6&db=m Translational regulation of the serum- and glucocorticoid-inducible kinase-1 (SGK1) in platelets. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22824529&form=6&db=m Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22846590&form=6&db=m Bioengineered surfaces to improve the blood compatibility of biomaterials through direct thrombin inactivation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22851331&form=6&db=m Ultrasound-guided thrombin-gelatin injection is effective for the treatment of iatrogenic femoral artery pseudoaneurysms: Initial results. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22859493&form=6&db=m Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22881838&form=6&db=m The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22905983&form=6&db=m Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22950374&form=6&db=m Long-term estrogen treatment of mice with a prothrombotic phenotype induces sustained increases in thrombin generation without affecting tissue fibrin deposition. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22970706&form=6&db=m Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22972111&form=6&db=m Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22978514&form=6&db=m Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22978548&form=6&db=m By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22984226&form=6&db=m Novel anti-platelet activity of protocatechuic acid through inhibition of high shear stress-induced platelet aggregation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23020632&form=6&db=m Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23080367&form=6&db=m African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23097125&form=6&db=m The Influence of Hindered Transport on the Development of Platelet Thrombi Under Flow. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23105443&form=6&db=m Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23108866&form=6&db=m The effect of cigarette smoke extract on thrombomodulin-thrombin binding: an atomic force microscopy study. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23118275&form=6&db=m Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23118656&form=6&db=m Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23160864&form=6&db=m Treatment of Dabigatran-Associated Bleeding: Case Report and Review of the Literature. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23174566&form=6&db=m Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23235323&form=6&db=m Is thrombin generation at the time of an acute thromboembolic episode a predictor of recurrence? The LInköping Study on Thrombosis (LIST)--a 7-year follow-up. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23236892&form=6&db=m [Morphological results of stromal stem cells of bone marrow origin into the thrombosed vein in experiment]. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23264082&form=6&db=m TAFI gene polymorphisms in patients with cerebral venous thrombosis. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23325480&form=6&db=m Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23347120&form=6&db=m Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23348428&form=6&db=m Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23357535&form=6&db=m Thrombin-induced NF-?B activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23372761&form=6&db=m From principle to practice: bridging the gap in patient profiling. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23402970&form=6&db=m The role of the red cell membrane in thrombin generation. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23406164&form=6&db=m A Critical Role of Thrombin/PAR-1 in ADP-induced Platelet Secretion and the Second Wave of Aggregation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23410540&form=6&db=m Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23423463&form=6&db=m t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23470648&form=6&db=m Obesity and thrombin-generation profiles in women with venous thromboembolism. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23532366&form=6&db=m A biologically active surface enzyme assembly that attenuates thrombus formation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23535565&form=6&db=m Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23546711&form=6&db=m Thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23559635&form=6&db=m Targeting platelet GPIb? reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23570139&form=6&db=m Bivalirudin, thrombin and platelets: clinical implications and future directions. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23570202&form=6&db=m The relationship between thrombin and platelets: linking vessel injury to thrombosis and inflammation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23592808&form=6&db=m Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23612970&form=6&db=m Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23636277&form=6&db=m Elevated plasma factor VIII enhances venous thrombus formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23660876&form=6&db=m Percutaneous thrombin injection in an infant to treat hepatic artery pseudoaneurysm after failed embolization. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23673000&form=6&db=m Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23676348&form=6&db=m Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23680105&form=6&db=m Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23685155&form=6&db=m Thrombin-sensitive expression of the store operated Ca(2+) channel Orai1 in platelets. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23701516&form=6&db=m Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23713461&form=6&db=m Pharmacophore Design, Virtual Screening, Molecular Docking and Optimization Approaches to Discover Potent Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23748731&form=6&db=m Mechanical Thrombectomy of Iliac Vein Thrombosis in a Pig Model Using the Rotarex and Aspirex Catheters. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23785270&form=6&db=m Fibrin networks regulate protein transport during thrombus development. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23800468&form=6&db=m Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23805723&form=6&db=m [Coagulation and fibrinolytic activity of lymph in various pathological conditions (review of own and literature data)]. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23807850&form=6&db=m Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23809129&form=6&db=m Thrombin inhibition by the serpins. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23809131&form=6&db=m Encryption and decryption of tissue factor. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23817201&form=6&db=m Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23818798&form=6&db=m Transitions of care in anticoagulated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23864724&form=6&db=m Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23869089&form=6&db=m Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23955016&form=6&db=m Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23962766&form=6&db=m Modality-Specific Occult Intrarenal Pseudoaneurysm in a Renal Allograft and the Legacy of Catheter Angiography. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23971903&form=6&db=m Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24009132&form=6&db=m Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24015809&form=6&db=m Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24026641&form=6&db=m New insights into modulation of thrombin formation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24034808&form=6&db=m Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24042118&form=6&db=m The trimeric autotransporter DsrA is a major mediator of fibrinogen binding in Haemophilus ducreyi. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24060191&form=6&db=m Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24063304&form=6&db=m Thrombin-Targeted Liposomes Establish A Sustained Localized Anticlotting Barrier Against Acute Thrombosis. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24199765&form=6&db=m Intraprocedural and postprocedural perigraft arterial sac embolization (PASE) for endoleak treatment. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24214371&form=6&db=m Modeling thrombin generation: plasma composition based approach. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24219775&form=6&db=m Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24233488&form=6&db=m Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24236042&form=6&db=m The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24276376&form=6&db=m Targeting platelet thrombin receptor signaling to prevent thrombosis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24319220&form=6&db=m Pros and cons of new oral anticoagulants. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24338998&form=6&db=m Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24343728&form=6&db=m Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24356930&form=6&db=m New insights into the role of erythrocytes in thrombus formation. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24417965&form=6&db=m Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24452853&form=6&db=m Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24468415&form=6&db=m 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24468615&form=6&db=m Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24477356&form=6&db=m Natural inhibitors of thrombin. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24533104&form=6&db=m Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24534482&form=6&db=m Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24604304&form=6&db=m Direct thrombin inhibitors: Patents 2002-2012 (Review). causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24613697&form=6&db=m Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24614354&form=6&db=m Argatroban as novel therapy for suspected thrombosis in patients with continuous flow left ventricle assist device and hemolysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24619100&form=6&db=m [New pharmaceuticals in cardiology : Heart failure, anticoagulation, dyslipidemia]. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24640752&form=6&db=m [Use of thrombin generation assay for the evaluation of coagulation and anticoagulant activity of hemostasis system in patients with abdominal sepsis]. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24650773&form=6&db=m Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24661399&form=6&db=m Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24740120&form=6&db=m Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24759142&form=6&db=m The role of the contact pathway in thrombus propagation. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24844576&form=6&db=m Heparin-induced thrombocytopenia. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24849036&form=6&db=m Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24860049&form=6&db=m [Thrombin generation assays and their clinical application]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24862135&form=6&db=m Insights into platelet-based control of coagulation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24880102&form=6&db=m Reversal of target-specific oral anticoagulants. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24899357&form=6&db=m Clot properties and cardiovascular disease. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24913997&form=6&db=m Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24951425&form=6&db=m A systems approach to hemostasis: 2. Computational analysis of molecular transport in the thrombus microenvironment. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24951426&form=6&db=m A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25030773&form=6&db=m Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25068444&form=6&db=m Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25072553&form=6&db=m Bivalirudin for treatment of LVAD thrombosis: a case series. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25074738&form=6&db=m Two novel mutations in the fibrinogen ? nodule. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25142532&form=6&db=m Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25152637&form=6&db=m Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25153592&form=6&db=m Homology model of human prothrombinase based on the crystal structure of Pseutarin C. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25156858&form=6&db=m Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25163329&form=6&db=m [Discovery and prospects of a novel thrombophilia: antithrombin resistance]. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25163932&form=6&db=m Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25168938&form=6&db=m Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25192011&form=6&db=m Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25212232&form=6&db=m Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25231888&form=6&db=m Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25239831&form=6&db=m How does association process affect fibrinogen hydrolysis by thrombin? therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25242242&form=6&db=m Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25254608&form=6&db=m The association of direct thrombin inhibitor anticoagulants with cardiac thromboses. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25278288&form=6&db=m Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25475476&form=6&db=m Expect the unexpected: acute and subacute coronary stent thrombosis following percutaneous thrombin injection for treatment of femoral pseudoaneurysm. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25481811&form=6&db=m A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25490355&form=6&db=m [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25504546&form=6&db=m Targeted antithrombotic protein micelles. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25523640&form=6&db=m Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25550187&form=6&db=m Spatial aspects of blood coagulation: Two decades of research on the self-sustained traveling wave of thrombin. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25658892&form=6&db=m Practical recommendations on incorporating new oral anticoagulants into routine practice. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25664761&form=6&db=m Purification and Biochemical Characterization of a Novel Fibrinolytic Enzyme from Culture Supernatant of Cordyceps militaris. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25681465&form=6&db=m The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25706367&form=6&db=m Intercostal artery pseudoaneurysm after ultrasound-guided liver biopsy: a case report and review of the literature. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25769543&form=6&db=m Rate-limiting roles of tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25839991&form=6&db=m Usefulness of Platelet Function Tests to Predict Bleeding with Antithrombotic Medications. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25846535&form=6&db=m An addition was made to the abstract: the association of direct thrombin inhibitor anticoagulants with cardiac thromboses. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25848131&form=6&db=m Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25886801&form=6&db=m Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25905776&form=6&db=m Equid herpesvirus type 1 activates platelets. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25923322&form=6&db=m Tripeptide SQL Inhibits Platelet Aggregation and Thrombus Formation by Affecting PI3K/Akt Signaling. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25937820&form=6&db=m A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25966410&form=6&db=m Label-free aptamer biosensor for thrombin detection based on functionalized graphene nanocomposites. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25976012&form=6&db=m Factor XI and contact activation as targets for antithrombotic therapy. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25999588&form=6&db=m The hypercoagulable profile of patients with stent thrombosis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26027127&form=6&db=m [Study on antithrombotic activities and structure-activity relationships of Veratrum nigrum Alkaloids]. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26035696&form=6&db=m Procoagulant platelets and the pathways leading to cell death. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26045608&form=6&db=m Cartilage oligomeric matrix protein is a natural inhibitor of thrombin. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26073152&form=6&db=m Kaempferol inhibits thrombosis and platelet activation. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26081310&form=6&db=m Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26081413&form=6&db=m Left atrial thrombus formation after brief interruption of rivaroxaban. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26123214&form=6&db=m Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26149036&form=6&db=m Acute and persistent platelet and coagulant activities in atherothrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26178257&form=6&db=m The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26239035&form=6&db=m Multifunctional Thrombin-Activatable Polymer Capsules for Specific Targeting to Activated Platelets. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26247237&form=6&db=m Thrombin generation in two families with MYH9-related platelet disorder. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26260610&form=6&db=m The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26369819&form=6&db=m Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26396552&form=6&db=m Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26397418&form=6&db=m Nanostructured bioluminescent sensor for rapidly detecting thrombin. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463037&form=6&db=m Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-?B pathways in human lung epithelial cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26474813&form=6&db=m Necrotic platelets provide a procoagulant surface during thrombosis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26475410&form=6&db=m Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26482989&form=6&db=m Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26514101&form=6&db=m Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26518435&form=6&db=m Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26552309&form=6&db=m [ACTIVATION OF PROTEIN C IN THE IN VITRO THROMBOLYSIS]. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26585954&form=6&db=m Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26594887&form=6&db=m Investigation of the selectivity of thrombin-binding aptamers for thrombin titration in murine plasma. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26633836&form=6&db=m Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26674596&form=6&db=m Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26715178&form=6&db=m Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26731855&form=6&db=m [Novel oral anticoagulants--issues in clinical practice]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26743168&form=6&db=m Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26757013&form=6&db=m Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26769048&form=6&db=m Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26772828&form=6&db=m [Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26782808&form=6&db=m Iron modulates the alpha chain of fibrinogen. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26785615&form=6&db=m Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association? causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26802299&form=6&db=m Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26818901&form=6&db=m The class I phosphoinositide 3-kinases ? and ? control antiphospholipid antibodies-induced platelet activation. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26846610&form=6&db=m Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26848157&form=6&db=m Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26878340&form=6&db=m Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26899841&form=6&db=m Possibility of Using Mesenchymal Stromal Cells to Restore Lymph Flow in Experimental Phlebothrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26917411&form=6&db=m Impact of aerobic exercise on haemostatic indices in pediatric patients with haemophilia. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26929774&form=6&db=m Ultrasound-guided thrombin injection for treatment of superficial traumatic pseudoaneurysms and associated expanding hematomas: experience in five patients. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26948317&form=6&db=m Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26967532&form=6&db=m Standardization of a well-controlled in vivo mouse model of thrombus formation induced by mechanical injury. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26987218&form=6&db=m [MORPHOLOGICAL CHANGES AFTER THE USE OF MULTIPOTENT STROMAL CELLS OF BONE MARROW ORIGIN TO RESTORE THE LYMPH FLOW IN THE REGION OF THROMBOSED VEIN]. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26994821&form=6&db=m Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27015445&form=6&db=m Initial clinical use of a novel mechanical thrombectomy device, XCOILTM, in hemodialysis graft and fistula declot procedures. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27057852&form=6&db=m Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27074440&form=6&db=m Factor XII in Hemostasis and Thrombosis: Active Player or (Innocent) Bystander? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27074907&form=6&db=m Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27119646&form=6&db=m Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27126646&form=6&db=m Systems Analysis of Thrombus Formation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161743&form=6&db=m PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27184031&form=6&db=m Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27207414&form=6&db=m Platelets and coagulation in thrombus formation: aberrations in the Scott syndrome. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27207416&form=6&db=m Flow and delta-P dictate where thrombin, fibrin, and von Willebrand Factor will be found. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27214821&form=6&db=m Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27222580&form=6&db=m Cellular folding pathway of a metastable serpin. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27244105&form=6&db=m Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27297585&form=6&db=m MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27301942&form=6&db=m Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27377013&form=6&db=m The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27380557&form=6&db=m Antithrombotic potential of the contact activation pathway. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27390976&form=6&db=m Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27399131&form=6&db=m The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27421960&form=6&db=m Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27423005&form=6&db=m Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27496751&form=6&db=m Targeting Factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27526540&form=6&db=m [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)]. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27570089&form=6&db=m Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27605669&form=6&db=m Dynamics of thrombin generation and flux from clots during whole human blood flow over collagen/tissue factor surfaces. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27615147&form=6&db=m Prekallikrein deficiency in a 15-year-old boy with Ménière's disease: a case report. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27650017&form=6&db=m [Measuring thrombin formation]. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27666486&form=6&db=m Agkihpin, a novel SVTLE from Gloydius halys Pallas, promotes platelet aggregation in vitro and inhibits thrombus formation in vivo in murine models of thrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27672182&form=6&db=m Multiscale simulation of thrombus growth and vessel occlusion triggered by collagen/tissue factor using a data-driven model of combinatorial platelet signalling. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27704645&form=6&db=m Investigation of the anticoagulant and antithrombotic effects of chlorogenic acid. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27736370&form=6&db=m In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27765812&form=6&db=m Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27780803&form=6&db=m Emerging anticoagulant strategies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27794633&form=6&db=m Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27796581&form=6&db=m Treatment of accidental perianal injection of topical thrombin with intravenous antithrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27903864&form=6&db=m Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27904902&form=6&db=m A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27909693&form=6&db=m Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27936421&form=6&db=m Catheter-directed endovascular application of thrombin: Report of 3 cases and review of the literature. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27936718&form=6&db=m Heparin-Like Chitosan Hydrogels with Tunable Swelling Behavior, Prolonged Clotting Times, and Prevented Contact Activation and Complement Activation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28013226&form=6&db=m Disseminated Intravascular Coagulation. causal interaction,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28083075&form=6&db=m Biorheology of platelet activation in the bloodstream distal to thrombus formation. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28145534&form=6&db=m Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28158181&form=6&db=m Platelet full length TFPI-? in healthy volunteers is not affected by sex or hormonal use. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28164577&form=6&db=m Clinical and Experimental Analysis of Platelet Micro Particles Inducing Thrombosis after Coronary Stenting. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28289017&form=6&db=m Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28403576&form=6&db=m No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28431186&form=6&db=m Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28446364&form=6&db=m Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28571227&form=6&db=m Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28577981&form=6&db=m Thrombin-loaded alginate-calcium microspheres: A novel hemostatic embolic material for transcatheter arterial embolization. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28581331&form=6&db=m Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28594794&form=6&db=m [Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692840&form=6&db=m Normal pregnancy is associated with an increase in thrombin generation from the very early stages of the first trimester. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28704111&form=6&db=m Incomplete dabigatran reversal with idarucizumab. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28707386&form=6&db=m Efficacy and safety of a coagulated thrombus injection for peripheral artery perforation: The coagulated thrombus hemostasis method. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28756877&form=6&db=m Platelet populations and priming in hematological diseases. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28797813&form=6&db=m Sulfated modification and anticoagulant activity of pumpkin (Cucurbita pepo, Lady Godiva) polysaccharide. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28833193&form=6&db=m Coagulation and fibrinolysis in gastric cancer. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28840985&form=6&db=m Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28955812&form=6&db=m Exploring potential anticoagulant drug formulations using thrombin generation test. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29032523&form=6&db=m Thrombin generation test as a marker for high risk venous thrombosis pregnancies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29082360&form=6&db=m Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29100817&form=6&db=m Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29217833&form=6&db=m CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29249166&form=6&db=m Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29286871&form=6&db=m In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29302840&form=6&db=m Introducing the pro-coagulant contact system in the numerical assessment of device-related thrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29309909&form=6&db=m Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29336975&form=6&db=m Mechanical and Biochemical Role of Fibrin Within a Venous Thrombus. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29421655&form=6&db=m Adamts18 deficiency increases arterial thrombus formation associated with vascular defects in mice. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29431737&form=6&db=m A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29461391&form=6&db=m Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29484632&form=6&db=m Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29515707&form=6&db=m Infrarenal Abdominal Aortic Pseudoaneurysm: Is It a Real Emergency? therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29538005&form=6&db=m An evaluation of global coagulation assays in myeloproliferative neoplasm. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29573326&form=6&db=m Platelets loaded with thrombin-encapsulated liposomes have increased coagulability. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29578657&form=6&db=m Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29589187&form=6&db=m Erythrocyte compression index is impaired in patients with residual vein obstruction. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29599453&form=6&db=m Functional cyclophilin D moderates platelet adhesion, but enhances the lytic resistance of fibrin. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29622563&form=6&db=m Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29706854&form=6&db=m Sustained-release synthetic biomarkers for monitoring thrombosis and inflammation using point-of-care compatible readouts. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29724819&form=6&db=m Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29731231&form=6&db=m Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29744232&form=6&db=m Investigation of Interactions between Thrombin and Ten Phenolic Compounds by Affinity Capillary Electrophoresis and Molecular Docking. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29772078&form=6&db=m Evaluating blood clot progression using magnetic particle spectroscopy. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29793324&form=6&db=m Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29794149&form=6&db=m NLRP3 regulates platelet integrin ?IIb?3 outside-in signaling, hemostasis and arterial thrombosis. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29802896&form=6&db=m Cardiac-Specific Overexpression of Oxytocin Receptor Leads to Cardiomyopathy in Mice. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29876713&form=6&db=m Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29884513&form=6&db=m Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29895622&form=6&db=m Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29938976&form=6&db=m Overwiew of the Coagulation System and laboratory tests for its study. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29939163&form=6&db=m Fibrin films: overlooked hemostatic barriers against microbial infiltration. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29952767&form=6&db=m Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30034844&form=6&db=m Argatroban administration as therapy for thrombosis in patients with continuous-flow ventricular assist devices. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30046749&form=6&db=m Integrating platelet and coagulation activation in fibrin clot formation. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30059122&form=6&db=m Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30102257&form=6&db=m The red blood cell death receptor and thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30120650&form=6&db=m Bivalirudin for left ventricular assist device thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30184110&form=6&db=m Thrombin Exosite 1 Inhibition with JNJ-64179375 Inhibits Thrombus Formation in a Human Translational Model of Thrombosis. ongoing research,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30224049&form=6&db=m Quantifying Platelet Margination in Diabetic Blood Flow. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30230231&form=6&db=m Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30232085&form=6&db=m Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30274004&form=6&db=m Thrombin Generation Testing in Patients with Myelofibrosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30326363&form=6&db=m Hemocompatibility and anti-fouling behavior of multilayer biopolymers immobilized on gold-thiolized drug-eluting cardiovascular stents. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30342937&form=6&db=m Hemostasis and anti-necrotic activity of wound-healing dressing containing chitosan nanoparticles. diagnostic usage,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30349889&form=6&db=m Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354195&form=6&db=m Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30459975&form=6&db=m Brachial pseudoaneurysm of the neonate with partial response to thrombin injections and late spontaneous thrombosis and regression during expectant management. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30460085&form=6&db=m Up-regulation of fibrinogen-like protein 2 in porcine endothelial cells by xenogeneic CD40 signal. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30486664&form=6&db=m Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30501722&form=6&db=m [Relation of Thromboelastography with Coagulation Function and Plt Count in Different Coagulation States]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30625393&form=6&db=m Regulation of mitochondrial function as a promising target in platelet activation-related diseases. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30654498&form=6&db=m Thrombin Generation and Cancer: Contributors and Consequences. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30701464&form=6&db=m Thrombin generation profile in non-thrombotic factor V Leiden carriers. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30702990&form=6&db=m Antithrombotic Agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30740983&form=6&db=m Food-derived antithrombotic peptides: Preparation, identification, and interactions with thrombin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30773828&form=6&db=m Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30842734&form=6&db=m Comparison of Effects of Anti-thrombin Aptamers HD1 and HD22 on Aggregation of Human Platelets, Thrombin Generation, Fibrin Formation, and Thrombus Formation Under Flow Conditions. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30855324&form=6&db=m Assessment and management of coagulopathy in critically-ill patients with liver failure. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30870459&form=6&db=m Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30900051&form=6&db=m Kinetics of the coagulation cascade including the contact activation system: sensitivity analysis and model reduction. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30900937&form=6&db=m Thrombin Inhibition: Preliminary Assessment of the Anticoagulant Potential of Turnera subulata (Passifloraceae). causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30907752&form=6&db=m Titration of Bivalirudin Infusion in the Pediatric Cardiac Catheterization Laboratory: A Case Report. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30933373&form=6&db=m Warfarin dose requirement in patients having severe thrombosis or thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31002695&form=6&db=m Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31028852&form=6&db=m Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31032803&form=6&db=m Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31071403&form=6&db=m Purification, compositional analysis, and anticoagulant capacity of chondroitin sulfate/dermatan sulfate from bone of corb (Sciaena umbra). diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31127075&form=6&db=m Independent ischemic stroke risk factors in older Americans: a systematic review. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31129447&form=6&db=m Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31165346&form=6&db=m Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31235258&form=6&db=m Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31249960&form=6&db=m Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31261175&form=6&db=m Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31294514&form=6&db=m Platelet-derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31311294&form=6&db=m Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31339295&form=6&db=m Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31353231&form=6&db=m Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31367094&form=6&db=m Endovascular treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde Angio-Seal deployment. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31381558&form=6&db=m Reduced model to predict thrombin and fibrin during thrombosis on collagen/tissue factor under venous flow: Roles of ?'-fibrin and factor XIa. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31412200&form=6&db=m Leaf-Inspired Authentically Complex Microvascular Networks for Deciphering Biological Transport Process. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31413231&form=6&db=m Genome sequencing, purification, and biochemical characterization of a strongly fibrinolytic enzyme from Bacillus amyloliquefaciens Jxnuwx-1 isolated from Chinese traditional douchi. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31421013&form=6&db=m The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31433171&form=6&db=m Smart Nanotherapeutic Targeting of Tumor Vasculature. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31446241&form=6&db=m Biflavones from Ginkgo biloba as inhibitors of human thrombin. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31451508&form=6&db=m Pharmacological Profile of JNJ-64179375: A Novel, Long Acting Exosite-1 Thrombin Inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31626243&form=6&db=m [Influence of suture material on the development of postoperative complications in vascular surgery and their prevention]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31644402&form=6&db=m The Research Progress of Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31648337&form=6&db=m Role of the coagulation system in the pathogenesis of sickle cell disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31694454&form=6&db=m Early Identification of Argatroban Resistance and the Consideration of Factor VIII. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31710462&form=6&db=m Binding-Induced 3D-Bipedal DNA Walker for Cascade Signal Amplification Detection of Thrombin Combined with Catalytic Hairpin Assembly Strategy. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31726076&form=6&db=m Catalytic microgelators for decoupled control of gelation rate and rigidity of the biological gels. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31743711&form=6&db=m Mechanism and inhibition kinetics of peptide P13 as thrombin inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31756037&form=6&db=m Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31773877&form=6&db=m Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31797863&form=6&db=m Congenital structural and functional fibrinogen disorders: a primer for internists. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31833869&form=6&db=m Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31870256&form=6&db=m DNA Aptamers to Thrombin Exosite I. Structure-Function Relationships and Antithrombotic Effects. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31890070&form=6&db=m Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31935287&form=6&db=m Supramaximal calcium signaling triggers procoagulant platelet formation. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31994911&form=6&db=m Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32016928&form=6&db=m Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery. diagnostic usage,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32057371&form=6&db=m Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32064873&form=6&db=m Novel Anticoagulant Peptide from Lactoferrin Binding Thrombin at the Active Site and Exosite-I. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32107892&form=6&db=m Ultrasound-guided thrombin injections for arterial pseudoaneurysms: a 14-year study conducted at King Khalid University Hospital Vascular Lab. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32152974&form=6&db=m Formulation and Characterization of Antithrombin Perfluorocarbon Nanoparticles. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32153221&form=6&db=m Monitoring Compound-Related Effects on Coagulability in Rats and Cynomolgus and Rhesus Monkeys by Thrombin Generation Kinetic Measurement. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32208214&form=6&db=m Targeting of externalized ?B-crystallin on irradiated endothelial cells with pro-thrombotic vascular targeting agents: Potential applications for brain arteriovenous malformations. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32211132&form=6&db=m Novel single nucleotide mutations in exon-10 of human coagulation Factor V gene in patients with pulmonary thromboembolism. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32276277&form=6&db=m Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32319140&form=6&db=m Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32339947&form=6&db=m VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32351989&form=6&db=m A Preclinical Porcine Model of Portal Vein Thrombosis in Liver Cirrhosis. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32452286&form=6&db=m Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32487767&form=6&db=m Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32505079&form=6&db=m The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32507767&form=6&db=m Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32544100&form=6&db=m Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in precapillary pulmonary arterioles. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32552570&form=6&db=m Ultrasound-Guided Fibrin Glue Injection for Treatment of Iatrogenic Femoral Pseudoaneurysms. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32558620&form=6&db=m COVID-19-associated coagulopathy: An exploration of mechanisms. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32575122&form=6&db=m PAR4 activation involves extracellular loop-3 and transmembrane residue Thr153. therapeutic application,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32586214&form=6&db=m The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32630978&form=6&db=m Interindividual Variability and Normal Ranges of Whole Blood and Plasma Thrombin Generation. diagnostic usage,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32662128&form=6&db=m A novel di-peptide Met-Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq-mediated signaling. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32668058&form=6&db=m Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32692430&form=6&db=m Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32698684&form=6&db=m Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32722805&form=6&db=m Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32764787&form=6&db=m Thrombin generation's role in predicting coronary disease severity. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32773931&form=6&db=m Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32833304&form=6&db=m A simple, cost-effective, and rapid separation process for the isolation of anticoagulant active fraction from the fruit extract of Momordica charantia: Characterization of bioactive components and anticoagulant mechanism of active fraction in a mouse model. ongoing research,unassigned 2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32851720&form=6&db=m NADPH oxidase 1 is a novel pharmacological target for the development of an antiplatelet drug without bleeding side effects. diagnostic usage,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32899083&form=6&db=m Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. causal interaction,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32906155&form=6&db=m Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32918208&form=6&db=m Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32924996&form=6&db=m Contrast-enhanced ultrasound-guided thrombin injection in the management of iatrogenic pseudoaneurysm (PSA): A case report and review of literatures. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32931586&form=6&db=m Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32942315&form=6&db=m Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32960786&form=6&db=m Prothrombotic effects of high uric acid in mice via activation of MEF2C-dependent NF-?B pathway by upregulating let-7c. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32989665&form=6&db=m The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33036973&form=6&db=m Self-regulated hirudin delivery for anticoagulant therapy. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33038586&form=6&db=m Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33126210&form=6&db=m Mechanical thrombectomy and intravascular imaging for cerebral venous sinus thrombosis: a preclinical model. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33134782&form=6&db=m Core and shell platelets of a thrombus: A new microfluidic assay to study mechanics and biochemistry. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33202269&form=6&db=m A Heparin based dual ratiometric sensor for Thrombin. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33227332&form=6&db=m A novel serine protease with anticoagulant and fibrinolytic activities from the fruiting bodies of mushroom Agrocybe aegerita. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33267663&form=6&db=m NADPH Oxidases Are Required for Full Platelet Activation In Vitro and Thrombosis In Vivo but Dispensable for Plasma Coagulation and Hemostasis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33273818&form=6&db=m Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33292285&form=6&db=m Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33294754&form=6&db=m Salvage of autogenous dialysis access with balloon-assisted thrombin injection. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33298665&form=6&db=m Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33321578&form=6&db=m Introduction of a thrombin sensor based on its interaction with dabigatran as an oral direct thrombin inhibitor. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33345438&form=6&db=m Potent Trivalent Inhibitors of Thrombin through Hybridization of Salivary Sulfopeptides from Hematophagous Arthropods. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33353373&form=6&db=m Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33379823&form=6&db=m Near-Patient Thrombin Generation in Patients Undergoing Elective Cardiac Surgery. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33410894&form=6&db=m Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33417801&form=6&db=m Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. ongoing research,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33418199&form=6&db=m Phenolic-amine chemistry mediated synergistic modification with polyphenols and thrombin inhibitor for combating the thrombosis and inflammation of cardiovascular stents. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441565&form=6&db=m A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33472026&form=6&db=m Modeling Thrombus Shell: Linking Adhesion Receptor Properties and Macroscopic Dynamics. ongoing research,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33566465&form=6&db=m Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial. causal interaction,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33657623&form=6&db=m The Art and Science of Building a Computational Model to Understand Hemostasis. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33660669&form=6&db=m Thrombin Generation Following Severe Trauma: Mechanisms, Modulators, and Implications For Hemostasis And Thrombosis. therapeutic application,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33662799&form=6&db=m Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33707842&form=6&db=m Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33725558&form=6&db=m Antithrombin deficiency: A pediatric disorder. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33784534&form=6&db=m Effect of blood loss during caesarean section on coagulation parameters. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33822507&form=6&db=m Fibrinolytic and Thrombolytic Effects of an Enzyme Purified from the Fruiting Bodies of Boletus pseudocalopus (Agaricomycetes) from Korea. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33832398&form=6&db=m Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33968695&form=6&db=m The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33984868&form=6&db=m Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34066261&form=6&db=m Fibrinolysis in Platelet Thrombi. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34083615&form=6&db=m In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIb?. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34091163&form=6&db=m Identification of the functional food ingredients with antithrombotic properties via virtual screen and experimental studies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34095733&form=6&db=m Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34102839&form=6&db=m A Thrombin-Responsive Nanoprobe for In Vivo Visualization of Thrombus Formation through Three-Dimensional Optical/Computed Tomography Hybrid Imaging. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34114997&form=6&db=m Intracardiac thrombus in a patient with mitral bioprosthesis and atrial fibrillation treated with direct oral anticoaugulant: A case report. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34152310&form=6&db=m A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model. therapeutic application,unassigned 1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34160126&form=6&db=m The contribution of TFPI? to the hemostatic response to injury in mice. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34177896&form=6&db=m Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34214595&form=6&db=m Thrombus-targeted nanoparticles for thrombin-triggered thrombolysis and local inflammatory microenvironment regulation. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34215864&form=6&db=m Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34235983&form=6&db=m Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34255420&form=6&db=m Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34276893&form=6&db=m Traumatic Pseudoaneurysm of Anterior Tibial Artery Treated by Thrombin Injection. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34330995&form=6&db=m Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34344416&form=6&db=m Thrombomodulin is associated with increased mortality and organ failure in mechanically ventilated children with acute respiratory failure: biomarker analysis from a multicenter randomized controlled trial. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34380648&form=6&db=m A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34398251&form=6&db=m The role of leukocytes in acute ischemic stroke-related thrombosis: a notable but neglected topic. causal interaction,unassigned 3,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34401468&form=6&db=m Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34436814&form=6&db=m Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy. unassigned - 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34448060&form=6&db=m Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula. therapeutic application,unassigned 4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34491753&form=6&db=m Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34531522&form=6&db=m Venous puncture wound hemostasis results in a vaulted thrombus structured by locally nucleated platelet aggregates. therapeutic application,unassigned 1,0 3.4.21.5 Thrombotic Microangiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7856719&form=6&db=m Constitutive expression and modulation of the functional thrombin receptor in the human kidney. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Thrombotic Microangiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33224575&form=6&db=m Cardiovascular risk in COVID-19 infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6219694&form=6&db=m Activation of coagulation and fibrinolytic systems following stroke. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21817137&form=6&db=m Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.5 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28487393&form=6&db=m Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.5 Torsades de Pointes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17266544&form=6&db=m Computer prediction of cardiovascular and hematological agents by statistical learning methods. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6223963&form=6&db=m [Platelet function during pregnancy, labor, early puerperium, and in preeclampsia] causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.5 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6516813&form=6&db=m Fibrinopeptide A and intravascular coagulation in normotensive and hypertensive pregnancy and parturition. ongoing research,unassigned 2,0 3.4.21.5 Toxic Optic Neuropathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7933697&form=6&db=m Intraocular hemocoagulase in human vitrectomy. ongoing research,unassigned 3,0 3.4.21.5 Trauma, Nervous System http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7692071&form=6&db=m Thrombin may contribute to the pathophysiology of central nervous system injury. causal interaction,unassigned 4,0 3.4.21.5 Trauma, Nervous System http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7976664&form=6&db=m A novel aspect of thrombin in the tissue reaction following central nervous system injury. causal interaction,unassigned 4,0 3.4.21.5 Trauma, Nervous System http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921354&form=6&db=m Role of Thrombin in Central Nervous System Injury and Disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Tricuspid Valve Prolapse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Trypanosomiasis, African http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8644901&form=6&db=m Isolation and characterization of the tsetse thrombin inhibitor: a potent antithrombotic peptide from the saliva of Glossina morsitans morsitans. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2628976&form=6&db=m [Blood coagulation function in pulmonary tuberculosis patients at the stages of surgical treatment] causal interaction,unassigned 1,0 3.4.21.5 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31614900&form=6&db=m Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis. diagnostic usage,unassigned 4,0 3.4.21.5 Tuberculosis, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2396401&form=6&db=m [The use of a concentrate of antithrombin III and disaggregants in the preoperative preparation of patients with pulmonary tuberculosis] diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Tuberous Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719182&form=6&db=m Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection. therapeutic application,unassigned 4,0 3.4.21.5 Univentricular Heart http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1570710&form=6&db=m [Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue] therapeutic application,unassigned 4,0 3.4.21.5 Uremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3131259&form=6&db=m Mechanisms of platelet aggregation disturbances and their relation to treatment in patients with chronic uremia. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.5 Uremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4861946&form=6&db=m [Thrombin formation before and after kidney transplantation in uremia] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Uremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8886550&form=6&db=m Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure. A possible link to increased cardiovascular mortality? diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.5 Uremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18025792&form=6&db=m Modulation of the cationic amino acid transport system y+L by surface potential, ouabain and thrombin in human platelets: effects of uremia. ongoing research,unassigned 2,0 3.4.21.5 Uremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26580207&form=6&db=m Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12621026&form=6&db=m Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Urinary Incontinence http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Urogenital Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28822718&form=6&db=m Role of the Coagulation System in Genitourinary Cancers: Review. diagnostic usage,unassigned 1,0 3.4.21.5 Urolithiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2330704&form=6&db=m [The role of immunologic factors in the pathogenesis of urolithiasis] ongoing research,unassigned 2,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17967729&form=6&db=m Chronic urticaria: A disease at a crossroad between autoimmunity and coagulation. causal interaction,unassigned 1,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20400886&form=6&db=m Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test. causal interaction,unassigned 4,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21083568&form=6&db=m Increase of coagulation potential in chronic spontaneous urticaria. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22272913&form=6&db=m Inflammation and Coagulation in Urticaria and Angioedema. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22439898&form=6&db=m Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria. causal interaction,unassigned 1,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25572563&form=6&db=m Increased thrombin generation potential in patients with chronic spontaneous urticaria. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26554248&form=6&db=m Activation of the Blood Coagulation System in Patients with Chronic Spontaneous Urticaria. diagnostic usage,unassigned 3,0 3.4.21.5 Urticaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28787094&form=6&db=m Mast cells are critical for the limitation of thrombin-induced skin inflammation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Uterine Cervical Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33645436&form=6&db=m Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15001649&form=6&db=m Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding. unassigned - 3.4.21.5 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17253197&form=6&db=m The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. causal interaction,unassigned 4,0 3.4.21.5 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22129041&form=6&db=m Vaginal bleeding in early pregnancy and circulating markers of thrombin generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.5 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25529278&form=6&db=m Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells. ongoing research,unassigned 1,0 3.4.21.5 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28433626&form=6&db=m Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32929773&form=6&db=m Transvaginal ultrasound-guided direct thrombin injection for the treatment of intramyometrial pseudoaneurysm in a young female with uterine hemorrhage after failed uterine artery embolization. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Uterine Prolapse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15735538&form=6&db=m The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Varicocele http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18210055&form=6&db=m [Embolotherapy: principles and indications.] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=786579&form=6&db=m [Sclerosing of bleeding oesophageal varices (author's transl)] ongoing research,unassigned 2,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719808&form=6&db=m Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1920957&form=6&db=m Manifestations of temporary symptoms during endoscopic variceal sclerotherapy using thrombin as a sclerosant. therapeutic application,unassigned 1,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2765808&form=6&db=m Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices: a prospective randomized trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,3 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6978620&form=6&db=m Injection sclerotherapy of esophageal varices using ethanolamine oleate. therapeutic application,unassigned 1,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7942686&form=6&db=m Thrombin injection for bleeding duodenal varices. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8813517&form=6&db=m Thrombin and ethanolamine injection therapy in arresting uncontrolled bleeding from duodenal varices. therapeutic application,unassigned 3,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395749&form=6&db=m Endoscopic treatments for portal hypertension. therapeutic application,unassigned 1,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10394164&form=6&db=m A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,2 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12061687&form=6&db=m Superficial thrombophlebitis of the lower limbs in patients with varicose veins. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23139607&form=6&db=m Human thrombin for the treatment of gastric and ectopic varices. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29868631&form=6&db=m EUS-guided thrombin injection for management of gastric fundal varices. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33669257&form=6&db=m Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,4 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1562762&form=6&db=m Thrombin-antithrombin III complexes in type II diabetes mellitus. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4024054&form=6&db=m Fibrinopeptide A excretion in urine in patients with atherosclerotic artery disease. therapeutic application,unassigned 3,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8562919&form=6&db=m Inflammatory cell participation in coagulation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10527405&form=6&db=m Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11284669&form=6&db=m Shear stress reduces protease activated receptor-1 expression in human endothelial cells. causal interaction,unassigned 3,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11375267&form=6&db=m New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. ongoing research,unassigned 2,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12709053&form=6&db=m A steady-state competition model describes the modulating effects of thrombomodulin on thrombin inhibition by plasminogen activator inhibitor-1 in the absence and presence of vitronectin. unassigned - 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12738160&form=6&db=m Placental insufficiency is characterized by platelet activation in the fetus. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12769638&form=6&db=m Novel and emerging therapies in cardiology and haematology. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14566084&form=6&db=m Role of protease-activated receptors in the vascular system. causal interaction,unassigned 4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14967066&form=6&db=m Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461731&form=6&db=m Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18452714&form=6&db=m PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19652200&form=6&db=m Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. ongoing research,unassigned 1,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20926621&form=6&db=m Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin (PAR1) Receptor Antagonist. therapeutic application,unassigned 4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22458577&form=6&db=m Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24288612&form=6&db=m Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases. unassigned - 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24385341&form=6&db=m Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25465416&form=6&db=m Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34102839&form=6&db=m A Thrombin-Responsive Nanoprobe for In Vivo Visualization of Thrombus Formation through Three-Dimensional Optical/Computed Tomography Hybrid Imaging. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=447860&form=6&db=m Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1328304&form=6&db=m Thrombin receptor expression in normal and atherosclerotic human arteries. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1456880&form=6&db=m The role of the membrane in the expression of the vitamin K-dependent enzymes. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1468495&form=6&db=m Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits. ongoing research,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2016486&form=6&db=m The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. causal interaction,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2046401&form=6&db=m von Willebrand factor and the endothelium. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2375401&form=6&db=m Leukocyte repletion reverses protective effect of neutropenia in thrombin-induced increase in lung vascular permeability. ongoing research,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2793843&form=6&db=m Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3032047&form=6&db=m Thrombin-induced alterations in endothelial permeability. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7004296&form=6&db=m Platelets and their membranes in hemostasis: physiology and pathophysiology. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7477382&form=6&db=m Conversion of thrombin into an anticoagulant by protein engineering. diagnostic usage,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7482429&form=6&db=m Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641321&form=6&db=m Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683662&form=6&db=m Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7762612&form=6&db=m Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7806495&form=6&db=m Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863966&form=6&db=m Activation of blood coagulation by plaque rupture: mechanisms and prevention. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7933264&form=6&db=m Role of thrombin in endothelial cell monolayer repair in vitro. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7952918&form=6&db=m Lipoprotein metabolism and thrombosis. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7955141&form=6&db=m Characterization of thrombin receptor expression during vascular lesion formation. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8132848&form=6&db=m New antithrombotic strategies for resistant thrombotic processes. therapeutic application,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8148468&form=6&db=m Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8163952&form=6&db=m A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8226804&form=6&db=m Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells. ongoing research,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8259551&form=6&db=m Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8291612&form=6&db=m Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8297538&form=6&db=m Cellular mechanisms of atherogenesis. diagnostic usage,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8305417&form=6&db=m Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8495717&form=6&db=m Thrombin promotes aortic endothelial cell spreading and microfilament formation in nonconfluent monolayer cultures. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8555486&form=6&db=m Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8607107&form=6&db=m Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8626514&form=6&db=m Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632823&form=6&db=m Role of the thrombin receptor in development and evidence for a second receptor. causal interaction,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8702860&form=6&db=m Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid. causal interaction,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8702939&form=6&db=m The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8807710&form=6&db=m Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8843797&form=6&db=m Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8853114&form=6&db=m Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor. diagnostic usage,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8925586&form=6&db=m Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinases. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8968361&form=6&db=m Cardiovascular actions of thrombin receptor activation in vivo. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9009139&form=6&db=m Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9012630&form=6&db=m Human brain pericytes differentially regulate expression of procoagulant enzyme complexes comprising the extrinsic pathway of blood coagulation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9057074&form=6&db=m CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9083058&form=6&db=m Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9087410&form=6&db=m Protease-activated receptor 3 is a second thrombin receptor in humans. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9102166&form=6&db=m Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9124369&form=6&db=m Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178727&form=6&db=m Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9182610&form=6&db=m Thrombin regulates nerve growth factor secretion from vascular, but not bladder smooth muscle cells. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9357866&form=6&db=m rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395719&form=6&db=m Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9399073&form=6&db=m The regulation of clotting factors. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9403612&form=6&db=m Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9409233&form=6&db=m Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493599&form=6&db=m Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9561177&form=6&db=m Thromboxane A2 potentiates thrombin-induced proliferation of coronary artery smooth muscle cells. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579635&form=6&db=m The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579636&form=6&db=m Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9674475&form=6&db=m Stimulation of human smooth muscle cell proliferation by thrombin involves increased synthesis of platelet-derived growth factor. diagnostic usage,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9683930&form=6&db=m Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102492&form=6&db=m Antithrombin: facts and new hypotheses. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10204469&form=6&db=m Thrombin activates the growth, cell-cycle kinetics, and clustering of human dental pulp cells. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10212286&form=6&db=m Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations. ongoing research,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10365757&form=6&db=m Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10385784&form=6&db=m Potential non-glycoprotein IIb/IIIa effects of abciximab. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10405207&form=6&db=m Thrombin stimulates synthesis of type IV collagen and tissue inhibitor of metalloproteinases-1 by cultured human mesangial cells. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10467729&form=6&db=m Fibrinogen. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10528826&form=6&db=m Multifunctional roles of thrombin. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10547223&form=6&db=m Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10556229&form=6&db=m Reduction in vascular lesion formation by hirudin secreted from retrovirus-transduced confluent endothelial cells on vascular grafts in baboons. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608012&form=6&db=m Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759008&form=6&db=m Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11013045&form=6&db=m Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11171553&form=6&db=m Gene targeting in hemostasis. tissue factor. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11222273&form=6&db=m Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11284669&form=6&db=m Shear stress reduces protease activated receptor-1 expression in human endothelial cells. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11321530&form=6&db=m Platelet GP Ib/IX/V complex: physiological role. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11418470&form=6&db=m Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11437595&form=6&db=m Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity. diagnostic usage,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11487044&form=6&db=m Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11557687&form=6&db=m Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species. ongoing research,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11604560&form=6&db=m Platelets, leukocytes, and coagulation. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11776315&form=6&db=m Identification of critical residues on thrombin mediating its interaction with fibrin. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11807828&form=6&db=m Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11858476&form=6&db=m The role of alpha(v)beta3 integrins in vascular healing. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11980681&form=6&db=m NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12130670&form=6&db=m Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12774450&form=6&db=m Thrombin contraction of vascular smooth muscle: implications for vasospasm. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12855811&form=6&db=m Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871382&form=6&db=m Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12970120&form=6&db=m Thrombin and platelet activation. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14529396&form=6&db=m Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14573423&form=6&db=m Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15204242&form=6&db=m Inhibition of neointimal hyperplasia by a specific thrombin inhibitor. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15344597&form=6&db=m Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma). causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15388580&form=6&db=m Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15725905&form=6&db=m Coagulation factor V: a plethora of anticoagulant molecules. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15817447&form=6&db=m Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15934860&form=6&db=m The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15964256&form=6&db=m Thrombin mediated migration of osteogenic cells. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15968404&form=6&db=m Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16195337&form=6&db=m A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16363230&form=6&db=m Homocysteine and thrombosis: from basic science to clinical evidence. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16480903&form=6&db=m Structure and interaction modes of thrombin. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16606835&form=6&db=m Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. ongoing research,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673262&form=6&db=m An overview of the structure and function of thrombin. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673263&form=6&db=m The structure of thrombin: a janus-headed proteinase. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16763191&form=6&db=m Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16832569&form=6&db=m Platelets as modifiers of clinical phenotype in hemophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17027650&form=6&db=m Thrombin induces rapid PAR1-mediated non-classical FGF1 release. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17046833&form=6&db=m HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17197526&form=6&db=m Corneal activation of prothrombin to form thrombin, independent of vascular injury. causal interaction,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17490728&form=6&db=m In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17728394&form=6&db=m Lysoplasmenylcholine increases neutrophil adherence to human coronary artery endothelial cells. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17958535&form=6&db=m Impairment of the hemostatic potential of platelets during storage as evaluated by flow cytometry, thrombin generation, and thrombelastography under conditions promoting formation of coated platelets. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18025559&form=6&db=m Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18049308&form=6&db=m Pharmacokinetics and pharmacology of hirulog-like peptide. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18081863&form=6&db=m Dual P2Y 12 receptor signaling in thrombin-stimulated platelets--involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18268094&form=6&db=m Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278179&form=6&db=m Thrombin and protease-activated receptors (PARs) in atherothrombosis. ongoing research,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18292408&form=6&db=m Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18345709&form=6&db=m Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19027114&form=6&db=m Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286885&form=6&db=m Platelet receptors and signaling in the dynamics of thrombus formation. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19433059&form=6&db=m PKCtheta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19527478&form=6&db=m The in vitro effect of recombinant factor VIIa on coated platelet formation and clot dynamics of stored platelet concentrates. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19574550&form=6&db=m Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19618315&form=6&db=m Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630783&form=6&db=m Critical roles for thrombin in acute and chronic inflammation. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19631970&form=6&db=m Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19687358&form=6&db=m Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19691483&form=6&db=m Platelet functions beyond haemostasis. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19739103&form=6&db=m Thrombin induces cyclooxygenase-2 expression and prostaglandin E(2) release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19815553&form=6&db=m Suboptimal activation of protease-activated receptors enhances {alpha}2{beta}1 integrin-mediated platelet adhesion to collagen. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19967145&form=6&db=m Platelet response heterogeneity in thrombus formation. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20941453&form=6&db=m Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21035882&form=6&db=m Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21071698&form=6&db=m Signaling during platelet adhesion and activation. diagnostic usage,unassigned 2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21244899&form=6&db=m Thrombin receptor function and cardiovascular disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21557445&form=6&db=m Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21645004&form=6&db=m Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21848641&form=6&db=m Relative Contribution of STIM1 and CalDAG-GEFI to Calcium-Dependent Platelet Activation and Thrombosis. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22034512&form=6&db=m Inhibition of thrombin receptor signaling on ?-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22516070&form=6&db=m Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23204166&form=6&db=m Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23372929&form=6&db=m Role of caveolin-1 expression in the pathogenesis of pulmonary edema in ventilator-induced lung injury. ongoing research,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23710903&form=6&db=m Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool. diagnostic usage,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24277696&form=6&db=m Thrombin-induced CCAAT/enhancer-binding protein ? activation and IL-8/CXCL8 expression via MEKK1, ERK, and p90 ribosomal S6 kinase 1 in lung epithelial cells. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24357800&form=6&db=m Chloride channels are necessary for full platelet phosphatidylserine exposure and procoagulant activity. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24869936&form=6&db=m New insights into the spatiotemporal localization of prothrombinase in vivo. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24951426&form=6&db=m A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25030773&form=6&db=m Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25480646&form=6&db=m Structure and function of platelet receptors initiating blood clotting. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25800007&form=6&db=m Mechanisms Regulating Acquisition of Platelet-Derived Factor V/Va by Megakaryocytes. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26204458&form=6&db=m Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. ongoing research,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26434726&form=6&db=m Zinc is a transmembrane agonist that induces platelet activation in a tyrosine phosphorylation-dependent manner. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26474813&form=6&db=m Necrotic platelets provide a procoagulant surface during thrombosis. unassigned - 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26728544&form=6&db=m Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis. therapeutic application,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28083075&form=6&db=m Biorheology of platelet activation in the bloodstream distal to thrombus formation. causal interaction,unassigned 3,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29074499&form=6&db=m Endogenous fibrinolysis facilitates clot retraction in vivo. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29296928&form=6&db=m Coordination of platelet agonist signaling during the hemostatic response in vivo. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29326163&form=6&db=m LIM and cysteine-rich domains 1 is required for thrombin-induced smooth muscle cell proliferation and promotes atherogenesis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29704172&form=6&db=m A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31397331&form=6&db=m The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32354154&form=6&db=m Continuous Detection of Increasing Concentrations of Thrombin Employing a Label-Free Photonic Crystal Aptasensor. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32430703&form=6&db=m LPS-induced expression and release of monocyte tissue factor in patients with haemophilia. causal interaction,unassigned 1,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32506822&form=6&db=m Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33537534&form=6&db=m Complement factor C4a does not activate protease-activated receptor 1 (PAR1) or PAR4 on human platelets. causal interaction,unassigned 4,0 3.4.21.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34455908&form=6&db=m Bioinspired artificial platelets: past, present and future. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=238473&form=6&db=m Necrotizing vasculitis. Etiologic aspects of immunology and coagulopathy. causal interaction,unassigned 4,0 3.4.21.5 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853713&form=6&db=m Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.5 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20156770&form=6&db=m Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Vasculitis, Central Nervous System http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1388824&form=6&db=m Does thrombin prevent cerebral vasospasm following aneurysmal subarachnoid haemorrhage? therapeutic application,unassigned 1,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433298&form=6&db=m Comparison of the inhibitory effects of antithrombin III, alpha 2-macroglobulin, and thrombin in human basilar arteries: relevance to cerebral vasospasm. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2579347&form=6&db=m Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6689957&form=6&db=m Comparison of responses elicited by alpha-thrombin in isolated canine basilar, coronary, mesenteric, and renal arteries. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6998061&form=6&db=m Cerebral arterial contractions induced by human and bovine thrombin. causal interaction,unassigned 4,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10069585&form=6&db=m Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11070371&form=6&db=m Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11441217&form=6&db=m Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12764230&form=6&db=m Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19098389&form=6&db=m Basic and translational research on proteinase-activated receptors: the role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage. ongoing research,unassigned 4,0 3.4.21.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20859063&form=6&db=m Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8089219&form=6&db=m Markers of thrombin and plasmin generation in patients with inherited thrombophilia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9922933&form=6&db=m Therapeutic inhibition of thrombin activities, receptors, and production. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669659&form=6&db=m Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11012376&form=6&db=m The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. causal interaction,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11372668&form=6&db=m The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. causal interaction,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11549781&form=6&db=m Treatment of venous thrombosis in the cancer patient. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11575978&form=6&db=m Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11736955&form=6&db=m Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11755953&form=6&db=m The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11778099&form=6&db=m [From heparin to synthetic antithrombotic drugs] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877267&form=6&db=m Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12020054&form=6&db=m Ximelagatran (AstraZeneca). causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12062537&form=6&db=m Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12152677&form=6&db=m Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12215757&form=6&db=m [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement] causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12411922&form=6&db=m Phased-array intracardiac echocardiographic imaging of acute cardiovascular emergencies: Experimental studies in dogs. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12489490&form=6&db=m Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12574809&form=6&db=m Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719781&form=6&db=m The effect of beta-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism. diagnostic usage,unassigned 2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871277&form=6&db=m Management of thrombophilia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12970123&form=6&db=m The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14521593&form=6&db=m Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14585938&form=6&db=m Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14585939&form=6&db=m Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14607082&form=6&db=m Targeting thrombin--rational drug design from natural mechanisms. causal interaction,unassigned 1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14675083&form=6&db=m The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15018589&form=6&db=m Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15018597&form=6&db=m Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15087604&form=6&db=m A review of the clinical uses of ximelagatran in thrombosis syndromes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15304033&form=6&db=m Challenges in the prevention of venous thromboembolism in the elderly. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15320792&form=6&db=m Direct antithrombins: new perspectives in cardiovascular medicine. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333033&form=6&db=m Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15341703&form=6&db=m New anticoagulants and their potential impact on the treatment of thromboembolic disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586623&form=6&db=m Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586625&form=6&db=m Clinical experience with ximelagatran in orthopaedic surgery. causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586626&form=6&db=m Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586627&form=6&db=m Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15624337&form=6&db=m The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15624338&form=6&db=m The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15634273&form=6&db=m A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15639111&form=6&db=m The direct thrombin inhibitors: their role and use for rational anticoagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15701909&form=6&db=m Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711747&form=6&db=m Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,2 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15812200&form=6&db=m The role of ximelagatran in the treatment of venous thromboembolism. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16123915&form=6&db=m Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16144513&form=6&db=m Ximelagatran--recent comparisons with warfarin. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16203879&form=6&db=m Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16268466&form=6&db=m Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16270637&form=6&db=m Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305519&form=6&db=m Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305522&form=6&db=m Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16416154&form=6&db=m Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16475037&form=6&db=m New concepts in heparin-induced thrombocytopenia: diagnosis and management. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16475045&form=6&db=m New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16511607&form=6&db=m Ximelagatran. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16547433&form=6&db=m Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16651602&form=6&db=m Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16717032&form=6&db=m Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16868297&form=6&db=m Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. diagnostic usage,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17003921&form=6&db=m A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17080211&form=6&db=m Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17124098&form=6&db=m New anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17560633&form=6&db=m The endogenous thrombin potential and the risk of venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17565236&form=6&db=m Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17636192&form=6&db=m Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17658944&form=6&db=m Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17729188&form=6&db=m Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17764540&form=6&db=m Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17854314&form=6&db=m Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18217158&form=6&db=m Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278160&form=6&db=m Thrombin generation and venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18302088&form=6&db=m The approach to heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18375602&form=6&db=m Primary prophylaxis of venous thromboembolism in surgical patients. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18399711&form=6&db=m Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18415076&form=6&db=m [Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals] therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18485081&form=6&db=m High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18520714&form=6&db=m Long-term anticoagulation in patients with coronary disease, and future developments. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18534438&form=6&db=m Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18690343&form=6&db=m Thrombin generation in patients after acute deep-vein thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,2 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18778188&form=6&db=m New therapeutic option for thromboembolism--dabigatran etexilate. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18948369&form=6&db=m Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,2 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18950743&form=6&db=m [What's new on antithrombotics in 2007?] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19028773&form=6&db=m Lessons From Ximelagatran : Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19087854&form=6&db=m [New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics] therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19178132&form=6&db=m Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19232683&form=6&db=m Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19320819&form=6&db=m More on: high thrombin generation and the risk of recurrent venous thromboembolism. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19561526&form=6&db=m Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19648146&form=6&db=m Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19656279&form=6&db=m Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19696041&form=6&db=m Dabigatran Etexilate for the Prophylaxis of Venous Thromboembolism After Hip or Knee Replacement: Rationale for Dose Regimen. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19888532&form=6&db=m Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. causal interaction,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19915180&form=6&db=m Desirudin Dosing and Monitoring in Moderate Renal Impairment. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19966341&form=6&db=m Dabigatran versus warfarin in the treatment of acute venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20062924&form=6&db=m Thrombin generation as an intermediate phenotype for venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20352166&form=6&db=m Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20393944&form=6&db=m Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20424539&form=6&db=m Dabigatran: ready for prime time? causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20434759&form=6&db=m Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460350&form=6&db=m Ex Vivo Thrombin Generation in Patients With Venous Thromboembolic Disease or Atrial Fibrillation on Long-Term Oral Anticoagulation. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21047577&form=6&db=m New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct xa inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21069505&form=6&db=m [New oral anticoagulants from the perspective of trauma surgery]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21241354&form=6&db=m Direct Thrombin Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21254900&form=6&db=m Old and new anticoagulant drugs: a minireview. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21359410&form=6&db=m An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21359412&form=6&db=m New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21415977&form=6&db=m Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. causal interaction,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21464402&form=6&db=m Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21487317&form=6&db=m Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21611919&form=6&db=m [New oral anticoagulants for treatment of venous thromboembolism]. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21666370&form=6&db=m Antithrombotic therapy in atrial fibrillation. -Evaluation and positioning of new oral anticoagulant agents-. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21740405&form=6&db=m New Anticoagulants - Promising and Failed Developments. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21838660&form=6&db=m New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21947267&form=6&db=m Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21988948&form=6&db=m Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22077374&form=6&db=m Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22095136&form=6&db=m Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22153026&form=6&db=m Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22252796&form=6&db=m Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22265675&form=6&db=m Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway. causal interaction,unassigned 3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22308803&form=6&db=m [Prevention of venous thromboembolism in surgical patients]. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22314599&form=6&db=m Determination of dabigatran in human plasma samples. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22316436&form=6&db=m Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22322591&form=6&db=m Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,3,4 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22432811&form=6&db=m Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. therapeutic application,unassigned 1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22444784&form=6&db=m Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22542931&form=6&db=m Interference of thrombin in immunological assays for hirudin specific antibodies. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22563715&form=6&db=m Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22928173&form=6&db=m Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22955200&form=6&db=m Vitamin K antagonists. Ready to be replaced? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23043126&form=6&db=m Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23067175&form=6&db=m [Therapeutic approach to the bleeding in association with "old" and "new" anticoagulants]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23114798&form=6&db=m [Dabigatran therapy--perioperative management and interpretation of coagulation tests]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23220847&form=6&db=m Acute management of bleeding in patients on novel oral anticoagulants. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23389892&form=6&db=m Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23846736&form=6&db=m New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23920075&form=6&db=m Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23953903&form=6&db=m New oral anticoagulants for the treatment of venous thromboembolism. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23953905&form=6&db=m Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23962423&form=6&db=m Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24359588&form=6&db=m PK evaluation of fondaparinux sodium for the treatment of thrombosis. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24468415&form=6&db=m 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24861794&form=6&db=m Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24968547&form=6&db=m Dabigatran etexilate in atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25138549&form=6&db=m Dabigatran: patient management in specific clinical settings. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25196808&form=6&db=m Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25431993&form=6&db=m Monitoring and reversal strategies for new oral anticoagulants. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25682084&form=6&db=m Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25762815&form=6&db=m Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26028157&form=6&db=m [Thrombin generation test]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26077323&form=6&db=m Antidotes to non-vitamin K oral anticoagulants: necessary or not? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26259913&form=6&db=m Thrombin Generation Assay in Hospitalized Nonsurgical Patients: A New Tool to Assess Venous Thromboembolism Risk? causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26270886&form=6&db=m Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26425251&form=6&db=m Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26496097&form=6&db=m Thrombin generation and procoagulant microparticle profiles after acute trauma: A prospective cohort study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26546690&form=6&db=m Trousseau's syndrome: cancer-associated thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26629800&form=6&db=m Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. therapeutic application,unassigned 3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161714&form=6&db=m PO-24 - Determinants of thrombin generation in gynaecological malignancies. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27664391&form=6&db=m Early thrombin formation capacity in trauma patients and association with venous thromboembolism. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27797449&form=6&db=m Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28259966&form=6&db=m A genetic risk factor for thrombophilia in a Han Chinese family. unassigned - 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28335612&form=6&db=m Thrombin Generation in Patients With Suspected Venous Thromboembolism. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28362683&form=6&db=m Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,2,3 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28373761&form=6&db=m Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28396988&form=6&db=m The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28412907&form=6&db=m Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28439778&form=6&db=m Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28467656&form=6&db=m Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. therapeutic application,unassigned 3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28662704&form=6&db=m Thrombocytopenia induced by dabigatran: two case reports. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28692314&form=6&db=m Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28730526&form=6&db=m Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. diagnostic usage,unassigned 3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28924530&form=6&db=m Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29563449&form=6&db=m Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30093507&form=6&db=m Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30104289&form=6&db=m Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30175945&form=6&db=m Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30347966&form=6&db=m Dabigatran - the First Approved DTI for SPAF. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30565854&form=6&db=m Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30702990&form=6&db=m Antithrombotic Agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31078120&form=6&db=m A review of global coagulation assays - Is there a role in thrombosis risk prediction? causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31314700&form=6&db=m Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers. causal interaction,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31323706&form=6&db=m Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31694454&form=6&db=m Early Identification of Argatroban Resistance and the Consideration of Factor VIII. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32532481&form=6&db=m Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man. therapeutic application,unassigned 3,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32605001&form=6&db=m Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. causal interaction,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32688432&form=6&db=m Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32726315&form=6&db=m A mathematical model to quantify the effects of platelet count, shear rate, and injury size on the initiation of blood coagulation under venous flow conditions. causal interaction,unassigned 2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32844145&form=6&db=m Diagnostic Accuracy in Acute Venous Thromboembolism: Comparing D-Dimer, Thrombin Generation, Overall Hemostatic Potential, and Fibrin Monomers. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32906769&form=6&db=m Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33239231&form=6&db=m Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33612323&form=6&db=m Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR). causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33636042&form=6&db=m Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33870025&form=6&db=m Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study. diagnostic usage,unassigned 4,0 3.4.21.5 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34027284&form=6&db=m Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=640489&form=6&db=m The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1466485&form=6&db=m Failure of thrombin-antithrombin III complexes in the diagnosis of deep vein thrombosis. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1660013&form=6&db=m Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosis. unassigned - 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2024237&form=6&db=m D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2057920&form=6&db=m Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2678451&form=6&db=m [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?] diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2958657&form=6&db=m [Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin] diagnostic usage,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3380865&form=6&db=m Pharmacological survey of recombinant hirudin. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3581714&form=6&db=m Prophylactic use of antithrombin III concentrate following surgery in congenital antithrombin III deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3814237&form=6&db=m Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6191510&form=6&db=m Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity. causal interaction,unassigned 1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6218846&form=6&db=m Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6241562&form=6&db=m Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6651812&form=6&db=m Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7325396&form=6&db=m [Continuous heparin therapy in deep venous thrombosis and its monitoring with the Howel and thrombin times. Prospective study] therapeutic application,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7495072&form=6&db=m Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7578891&form=6&db=m Challenges in the development of orally bioavailable thrombin active site inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7703589&form=6&db=m Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7919374&form=6&db=m Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7955198&form=6&db=m Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7957610&form=6&db=m Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,4,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8029801&form=6&db=m A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8085239&form=6&db=m Effect of monomethylmethacrylate on procoagulant activities of human monocytes and umbilical vein endothelial cells in vitro. unassigned - 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8154338&form=6&db=m Mechanisms for the anticoagulant effects of synthetic antithrombins. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8263785&form=6&db=m Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578525&form=6&db=m Advances in antithrombotic therapy: novel agents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8596376&form=6&db=m Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8605614&form=6&db=m Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8797131&form=6&db=m Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8839997&form=6&db=m Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883269&form=6&db=m Effect of heparin on the activation of factor XI by fibrin-bound thrombin. therapeutic application,unassigned 1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8899145&form=6&db=m Venous thrombosis revisited. causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8899954&form=6&db=m Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. causal interaction,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9057074&form=6&db=m CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065993&form=6&db=m Blood coagulation and thrombosis in patients with ovarian malignancy. causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9066007&form=6&db=m A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9070519&form=6&db=m Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9128439&form=6&db=m NMR solution structure of a novel hirudin variant HM2, N-terminal 1-47 and N64-->V + G mutant. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9171870&form=6&db=m Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9308743&form=6&db=m An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9382401&form=6&db=m The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493595&form=6&db=m Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493603&form=6&db=m BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531030&form=6&db=m Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531058&form=6&db=m Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579630&form=6&db=m Thrombin and antithrombotics. causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9647415&form=6&db=m Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9736918&form=6&db=m Cardiovascular chemotherapy: anticoagulants. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9914994&form=6&db=m [Morphologic changes in the thrombus and venous wall in experimental phleobothrombosis and thrombophlebitis] diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073268&form=6&db=m Heparin-induced thrombocytopenia: a ten-year retrospective. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102460&form=6&db=m Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102483&form=6&db=m The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10235427&form=6&db=m Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10375391&form=6&db=m Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10404775&form=6&db=m Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456621&form=6&db=m Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10631865&form=6&db=m Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10706936&form=6&db=m Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751802&form=6&db=m Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10781674&form=6&db=m Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,3 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10847425&form=6&db=m The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. diagnostic usage,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10907447&form=6&db=m [New medical anticoagulants] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11108907&form=6&db=m In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11155190&form=6&db=m Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11181274&form=6&db=m [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11441979&form=6&db=m Anticoagulation: the present and future. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11738569&form=6&db=m Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11738570&form=6&db=m Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11772313&form=6&db=m Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11776321&form=6&db=m The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11858483&form=6&db=m Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877267&form=6&db=m Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11921399&form=6&db=m A novel near-infrared fluorescence sensor for detection of thrombin activation in blood. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12152677&form=6&db=m Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12221676&form=6&db=m Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431473&form=6&db=m Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12492587&form=6&db=m Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters? causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12524220&form=6&db=m The dynamics of thrombin formation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12574806&form=6&db=m Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12595918&form=6&db=m The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12723936&form=6&db=m LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in rats and dogs. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871538&form=6&db=m A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12877675&form=6&db=m Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12966603&form=6&db=m Inhibition of annexin V binding to cardiolipin and thrombin generation in an unselected population with venous thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14675088&form=6&db=m Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14714071&form=6&db=m Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats. unassigned - 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15320792&form=6&db=m Direct antithrombins: new perspectives in cardiovascular medicine. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15341703&form=6&db=m New anticoagulants and their potential impact on the treatment of thromboembolic disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586105&form=6&db=m Alternatives to heparin infusion. causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15735792&form=6&db=m Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15870543&form=6&db=m The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15878322&form=6&db=m Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15902370&form=6&db=m [Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15903126&form=6&db=m Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15932039&form=6&db=m [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs] therapeutic application,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15966096&form=6&db=m Laparoscopic ligation of the infrarenal vena cava in combination with transfemoral thrombin infusion: a new animal model of chronic deep venous thrombosis. causal interaction,unassigned 2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15992034&form=6&db=m Low molecular weight heparin in acute stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16026408&form=6&db=m Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16091733&form=6&db=m Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16144513&form=6&db=m Ximelagatran--recent comparisons with warfarin. therapeutic application,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16171603&form=6&db=m Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16234621&form=6&db=m New anticoagulants for venous thromboembolic disease. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16241948&form=6&db=m Thrombin generation profiles in deep venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16305522&form=6&db=m Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16772740&form=6&db=m Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16807647&form=6&db=m Interleukin-10 promoter polymorphism and venous thrombosis: a case-control study. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17073609&form=6&db=m Novel therapeutic agents in the management of hemorrhage and thrombosis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17080212&form=6&db=m Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17116237&form=6&db=m The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17216915&form=6&db=m [Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors] causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17362226&form=6&db=m Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461731&form=6&db=m Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17658944&form=6&db=m Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17760809&form=6&db=m Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18064335&form=6&db=m Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. therapeutic application,unassigned 1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18120518&form=6&db=m Trypsin and thrombin induced venous thrombosis and its prevention with dicumarol, 3,3' methylenebis (4 hydroxycoumarin). causal interaction,unassigned 2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18278160&form=6&db=m Thrombin generation and venous thromboembolism. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18327401&form=6&db=m An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18464157&form=6&db=m Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18590927&form=6&db=m Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18647957&form=6&db=m The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18680535&form=6&db=m High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18690343&form=6&db=m Thrombin generation in patients after acute deep-vein thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,2 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18695356&form=6&db=m Association Analysis of Tissue Factor Pathway Inhibitor Polymorphisms and Haplotypes with Osteonecrosis of the Femoral Head in the Korean Population. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18761717&form=6&db=m Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19068790&form=6&db=m [Progression from a routine examination to a study. Having come this far, what should be done from now? A thrombosis risk factor study] causal interaction,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19232683&form=6&db=m Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19303503&form=6&db=m The role of procoagulants and anticoagulants in the development of venous thromboembolism. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19342662&form=6&db=m Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19379430&form=6&db=m Heparin-induced thrombocytopenia during renal replacement therapy. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19411876&form=6&db=m Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice. causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19500242&form=6&db=m Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552847&form=6&db=m [Establishment of rat model of venous thromboembolism] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19737712&form=6&db=m Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20062924&form=6&db=m Thrombin generation as an intermediate phenotype for venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20096005&form=6&db=m In prothrombin G20210A carriers the genetic mutation and the history of Venous Thrombosis contribute both to thrombin generation independently of factor II plasma levels. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20118812&form=6&db=m Venous thrombosis and procoagulant factors in high-risk neuroblastoma. unassigned - 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20193528&form=6&db=m [Preliminary study on epidemiology of deep venous thrombosis of lower extremity in patients with high risk] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20208970&form=6&db=m Retrieval of "Recovery IVC Filter" after 383 days. unassigned - 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20425533&form=6&db=m Antibodies to serine proteases in the antiphospholipid syndrome. therapeutic application,unassigned 1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20435232&form=6&db=m Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20664909&form=6&db=m Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20809275&form=6&db=m [New oral anticoagulants : Better than vitamin K antagonists?] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21036572&form=6&db=m Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21073394&form=6&db=m A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21262433&form=6&db=m Thrombin generation tests. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21454811&form=6&db=m Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21537160&form=6&db=m Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21538731&form=6&db=m Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21734537&form=6&db=m Abdominal Contouring Procedures Increase Activity of the Coagulation Cascade. unassigned - 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21781246&form=6&db=m HIT paradigms and paradoxes. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22079443&form=6&db=m Thrombin generation in clinical conditions. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22227959&form=6&db=m Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22370770&form=6&db=m Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22459904&form=6&db=m Use of Direct Thrombin Inhibitor for Treatment of Cerebral Venous Thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22551976&form=6&db=m Decreased procoagulant phospholipids in patients treated by vitamin K antagonists. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22565859&form=6&db=m [Pharmacology of the new oral anticoagulants]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22638877&form=6&db=m Anticoagulation-related intracranial hemorrhages. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22762893&form=6&db=m Thrombin generation: What have we learned? causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23019947&form=6&db=m [Clinical research on Sanmiao powder combined fibrinogenase for injection in treatment of acute deep venous thrombosis of lower limbs]. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23080367&form=6&db=m African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23182978&form=6&db=m Oral antithrombotic effects of acylhydrazone derivatives. therapeutic application,unassigned 1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23435652&form=6&db=m The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23470648&form=6&db=m Obesity and thrombin-generation profiles in women with venous thromboembolism. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23629822&form=6&db=m Venous thrombosis associated with HMG-CoA reductase inhibitors. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23680105&form=6&db=m Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification. diagnostic usage,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23818798&form=6&db=m Transitions of care in anticoagulated patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23971903&form=6&db=m Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. therapeutic application,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24083963&form=6&db=m Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24343728&form=6&db=m Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24624626&form=6&db=m [Management of major bleeding complications in patients on long-term treatment with oral anticoagulants]. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25156858&form=6&db=m Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25213262&form=6&db=m Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25708372&form=6&db=m Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25777803&form=6&db=m Treatment Algorithms in Systemic Lupus Erythematosus. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25828970&form=6&db=m Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes. diagnostic usage,unassigned 2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26028157&form=6&db=m [Thrombin generation test]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26123214&form=6&db=m Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26178257&form=6&db=m The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26185485&form=6&db=m Inhibition of thrombin generation in human plasma by phospholipid transfer protein. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26391712&form=6&db=m The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: comment. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26468963&form=6&db=m The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: reply. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26674596&form=6&db=m Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26784699&form=6&db=m Genetic Determinants of Thrombin Generation and Their Relation to Venous Thrombosis: Results from the GAIT-2 Project. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26802299&form=6&db=m Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26846610&form=6&db=m Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26875179&form=6&db=m Direct oral anticoagulants in rare venous thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27077125&form=6&db=m Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27780803&form=6&db=m Emerging anticoagulant strategies. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28594794&form=6&db=m [Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29032523&form=6&db=m Thrombin generation test as a marker for high risk venous thrombosis pregnancies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29082360&form=6&db=m Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29884513&form=6&db=m Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30702990&form=6&db=m Antithrombotic Agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31994911&form=6&db=m Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32211132&form=6&db=m Novel single nucleotide mutations in exon-10 of human coagulation Factor V gene in patients with pulmonary thromboembolism. causal interaction,unassigned 4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32586214&form=6&db=m The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. causal interaction,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32692430&form=6&db=m Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33273818&form=6&db=m Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33372745&form=6&db=m Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33437541&form=6&db=m Association of G20210A Prothrombin Gene Mutation and Cerebral Ischemic Stroke in Young Patients. causal interaction,unassigned 3,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33707842&form=6&db=m Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34110096&form=6&db=m Rapid screening and identification of anticoagulation component from carthami flos by two-dimensional thrombin affinity chromatography combined with HPLC-MS/MS. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34255420&form=6&db=m Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34263100&form=6&db=m D-dimer, thrombin generation, and risk of a first venous thrombosis in the elderly. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.5 Ventilator-Induced Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20004361&form=6&db=m Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling. causal interaction,unassigned 1,0 3.4.21.5 Ventilator-Induced Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21765345&form=6&db=m Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury. ongoing research,unassigned 3,0 3.4.21.5 Ventilator-Induced Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23212101&form=6&db=m Measurement of local permeability at subcellular level in cell models of agonist- and ventilator-induced lung injury. ongoing research,unassigned 1,0 3.4.21.5 Ventricular Dysfunction, Left http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7847939&form=6&db=m Direct effects of thrombin on myocyte contractile function. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.5 Ventricular Dysfunction, Left http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15282454&form=6&db=m Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model. therapeutic application,unassigned 2,0 3.4.21.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9321797&form=6&db=m Ins(1,4,5)P3 and arrhythmogenic responses during myocardial reperfusion: evidence for receptor specificity. unassigned - 3.4.21.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16649726&form=6&db=m Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2160855&form=6&db=m Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9855188&form=6&db=m A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin. diagnostic usage,unassigned 1,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10903034&form=6&db=m Soft tissue adhesive composed of modified gelatin and polysaccharides. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17461934&form=6&db=m Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27182154&form=6&db=m Thrombin activation and liver inflammation in advanced hepatitis C virus infection. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30102144&form=6&db=m Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32870433&form=6&db=m Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.5 Vitamin D Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31614338&form=6&db=m Thrombin generation and fibrin clot structure after vitamin D supplementation. therapeutic application,unassigned 1,0 3.4.21.5 Vitamin K Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6695916&form=6&db=m The multiple coagulopathies of biliary atresia. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Vitamin K Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11846334&form=6&db=m Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.5 Vitamin K Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18716776&form=6&db=m Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.5 Vitamin K Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23482736&form=6&db=m Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April). therapeutic application,unassigned 1,0 3.4.21.5 Vitamin K Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29139025&form=6&db=m Coagulopathy in Zellweger spectrum disorders: a role for vitamin K. causal interaction,unassigned 2,0 3.4.21.5 Vitamin K Deficiency Bleeding http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13176279&form=6&db=m [Prevention of hemorrhagic disease of newborn with oral plasmatic thrombin.] causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2733994&form=6&db=m Intraocular human thrombin infusion in diabetic vitrectomies. unassigned - 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19847806&form=6&db=m Thrombin stimulates RPE cell proliferation by promoting c-Fos-mediated cyclin D1 expression. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20564194&form=6&db=m Thrombin stimulates RPE cell motility by PKC-zeta- and NF-kappaB-dependent gene expression of MCP-1 and CINC-1/GRO chemokines. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20672289&form=6&db=m Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation. diagnostic usage,unassigned 1,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22833386&form=6&db=m Thrombin induces Slug-mediated E-Cadherin transcriptional repression and the parallel up-regulation of N-cadherin by a transcription-independent mechanism in RPE cells. causal interaction,unassigned 2,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25015355&form=6&db=m The role of thrombin in proliferative vitreoretinopathy. ongoing research,unassigned 3,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26247679&form=6&db=m Thrombin promotes the expression of Ccnd1 gene in RPE cells through the activation of converging signaling pathways. ongoing research,unassigned 2,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27496339&form=6&db=m Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment. causal interaction,unassigned 3,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29193875&form=6&db=m Dabigatran inhibits intravitreal thrombin activity. causal interaction,unassigned 3,0 3.4.21.5 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29617690&form=6&db=m Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment. diagnostic usage,unassigned 3,0 3.4.21.5 Vitreous Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2733994&form=6&db=m Intraocular human thrombin infusion in diabetic vitrectomies. unassigned - 3.4.21.5 Vitreous Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3703495&form=6&db=m The use of intravitreal thrombin to control hemorrhage during vitrectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.5 von Willebrand Disease, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21037087&form=6&db=m Key role of glycoprotein Ib-V-IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 von Willebrand Disease, Type 3 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719893&form=6&db=m Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=191950&form=6&db=m Effect of thrombin and ADP on a membrane bound cyclic AMP dependent kinase of human platelets. Studies on normal platelets and those from patients with Von Willebrand's disease. ongoing research,unassigned 4,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11057863&form=6&db=m The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11437595&form=6&db=m Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity. diagnostic usage,unassigned 3,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853710&form=6&db=m Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16684000&form=6&db=m New approaches for measuring coagulation. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19514539&form=6&db=m [Thrombinography: towards a globalization of coagulation tests] diagnostic usage,unassigned 1,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20978999&form=6&db=m Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21037087&form=6&db=m Key role of glycoprotein Ib-V-IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27872729&form=6&db=m Mild Bleeders: Diagnosis is Elusive in Large Number of Patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30504807&form=6&db=m Thrombin generation during a regular menstrual cycle in women with von Willebrand disease. therapeutic application,unassigned 1,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30836803&form=6&db=m Platelets compensate for poor thrombin generation in type 3 von Willebrand disease. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.5 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31829751&form=6&db=m Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1158526&form=6&db=m Evidence of fibrinogen degradation in rat anaphylaxis. diagnostic usage,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1310211&form=6&db=m Thrombin stimulates PDGF production and monocyte adhesion through distinct intracellular pathways in human endothelial cells. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1310589&form=6&db=m Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and -insensitive pathways. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1313426&form=6&db=m Homologous desensitization of HEL cell thrombin receptors. Distinguishable roles for proteolysis and phosphorylation. ongoing research,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1320018&form=6&db=m Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1331412&form=6&db=m Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL. ongoing research,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1333990&form=6&db=m Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. therapeutic application,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1486937&form=6&db=m Thrombin stimulates inositol phosphate formation, intracellular calcium fluxes and DNA synthesis in cultured fetal human non-pigmented ciliary epithelial cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1543755&form=6&db=m Involvement of protein kinase C in thrombin-induced translocation of Gi2 alpha from the membrane to the cytosol in mouse mastocytoma P-815 cells. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1559973&form=6&db=m Thrombin-induced Ca2+ mobilization in vascular smooth muscle utilizes a slowly ribosylating pertussis toxin-sensitive G protein. Evidence for the involvement of a G protein in inositol trisphosphate-dependent Ca2+ release. ongoing research,unassigned 4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1654060&form=6&db=m Sodium fluoride induces phosphoinositide hydrolysis, Ca2+ mobilization, and prostacyclin synthesis in cultured human endothelium: further evidence for regulation by a pertussis toxin-insensitive guanine nucleotide-binding protein. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1708239&form=6&db=m Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1800126&form=6&db=m Thrombin signalling in U937 human monocytic cells is coupled to inositol phosphate formation but not to thromboxane B2 synthesis nor to inhibition of adenylate cyclase: distinct differences in thrombin signalling between U937 cells and platelets. ongoing research,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1845999&form=6&db=m Receptor and G protein-mediated responses to thrombin in HEL cells. causal interaction,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1850329&form=6&db=m Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1850467&form=6&db=m Pertussis toxin reduces endothelium-dependent and independent responses to alpha-2- adrenergic stimulation in systemic canine arteries and veins. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1864960&form=6&db=m Mast cell tryptase is a mitogen for cultured fibroblasts. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1900833&form=6&db=m Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1935970&form=6&db=m Ca2+ ionophore A23187 and thrombin inhibit the pertussis-toxin-induced ADP-ribosylation of the alpha-subunit of the inhibitory guanine-nucleotide-binding protein and other proteins in human platelets. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1953275&form=6&db=m [Activation mechanisms by thrombin and vasopressin of fibroblasts in spontaneously hypertensive rats] unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1991383&form=6&db=m Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries. therapeutic application,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2105325&form=6&db=m Thrombin-induced prostacyclin biosynthesis in human endothelium: role of guanine nucleotide regulatory proteins in stimulus/coupling responses. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2116927&form=6&db=m Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells. causal interaction,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2119237&form=6&db=m Thrombin induces c-fos expression in cultured human endothelial cells by a Ca2(+)-dependent mechanism. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2122922&form=6&db=m G-proteins and endothelial responses. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153536&form=6&db=m Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2155220&form=6&db=m Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets. therapeutic application,unassigned 4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2159022&form=6&db=m Effect of thrombin on calcium homeostasis in chick embryonic heart cells. Receptor-operated calcium entry with inositol trisphosphate and a pertussis toxin-sensitive G protein as second messengers. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2170389&form=6&db=m Agonist stimulation of Na+/K+/Cl- cotransport in rat glomerular mesangial cells. Evidence for protein kinase C-dependent and Ca2+/calmodulin-dependent pathways. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2176213&form=6&db=m Strong and persistent activation of inositol lipid breakdown induces early mitogenic events but not Go to S phase progression in hamster fibroblasts. Comparison of thrombin and carbachol action in cells expressing M1 muscarinic acetylcholine receptors. therapeutic application,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2494171&form=6&db=m Guanosine 5'-O-(3-thiotrisphosphate) potentiates both thrombin- and platelet-derived growth factor-induced inositol phosphate release in permeabilized vascular smooth muscle cells. Signaling mechanisms distinguished by sensitivity to pertussis toxin and phorbol esters. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2504508&form=6&db=m Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2505676&form=6&db=m Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2547835&form=6&db=m Endothelin-induced increases in vascular smooth muscle Ca2+ do not depend on dihydropyridine-sensitive Ca2+ channels. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2552882&form=6&db=m GTP gamma S increases thrombin-mediated inositol trisphosphate accumulation in permeabilized human endothelial cells. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2552999&form=6&db=m Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2820995&form=6&db=m Thrombin activation of the Na+/H+ exchanger in vascular smooth muscle cells. Evidence for a kinase C-independent pathway which is Ca2+-dependent and pertussis toxin-sensitive. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2845929&form=6&db=m Thrombin exerts a dual effect on stimulated adenylate cyclase in hamster fibroblasts, an inhibition via a GTP-binding protein and a potentiation via activation of protein kinase C. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3007118&form=6&db=m Pertussis toxin inhibits thrombin-induced activation of phosphoinositide hydrolysis and Na+/H+ exchange in hamster fibroblasts. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3015684&form=6&db=m Effects of thrombin, phorbol myristate acetate and prostaglandin D2 on 40-41 kDa protein that is ADP ribosylated by pertussis toxin in platelets. diagnostic usage,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3021235&form=6&db=m Effect of pertussis toxin on the phosphodiesteratic cleavage of the polyphosphoinositides by guanosine 5'-O-thiotriphosphate and thrombin in permeabilized human platelets. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3029056&form=6&db=m Further evidence for a phospholipase C-coupled G protein in hamster fibroblasts. Induction of inositol phosphate formation by fluoroaluminate and vanadate and inhibition by pertussis toxin. causal interaction,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3031135&form=6&db=m Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3045568&form=6&db=m Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. therapeutic application,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3099763&form=6&db=m Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3106084&form=6&db=m Stimulus-response coupling in a cell-free platelet membrane system. GTP-dependent release of Ca2+ by thrombin, and inhibition by pertussis toxin and a monoclonal antibody that blocks calcium release by IP3. therapeutic application,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3132162&form=6&db=m No direct correlation between Ca2+ mobilization and dissociation of Gi during platelet phospholipase A2 activation. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3461464&form=6&db=m Treatment of human platelets with trypsin, thrombin, or collagen inhibits the pertussis toxin-induced ADP-ribosylation of a 41-kDa protein. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6437813&form=6&db=m Ni-mediated inhibition of human platelet adenylate cyclase by thrombin. therapeutic application,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7516333&form=6&db=m Differences in intracellular calcium signaling after activation of the thrombin receptor by thrombin and agonist peptide in osteoblast-like cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7533166&form=6&db=m Distinct mechanisms regulate 5-HT2 and thrombin receptor desensitization. ongoing research,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7565635&form=6&db=m Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7593220&form=6&db=m Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679495&form=6&db=m Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7781604&form=6&db=m Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussis toxin-sensitive heterotrimeric G-protein. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7964131&form=6&db=m Changes of cytosolic calcium ion concentrations in human endothelial cells in response to thrombin, platelet-activating factor, and leukotriene B4. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7991631&form=6&db=m Modulation of brain Na+ channels by a G-protein-coupled pathway. therapeutic application,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7994027&form=6&db=m Changes in G protein pattern and in G protein-dependent signaling during erythropoietin- and dimethylsulfoxide-induced differentiation of murine erythroleukemia cells. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8149543&form=6&db=m Involvement of 5-HT2 receptors in chronic endothelial dysfunction after balloon injury of porcine coronary arteries. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8180340&form=6&db=m Regulation of thrombin-induced endothelial cell activation by bacterial toxins. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8209785&form=6&db=m Agonist receptors and G proteins as mediators of platelet activation. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8294438&form=6&db=m Expression of a mutant Gi2 alpha subunit inhibits ATP and thrombin stimulation of cytoplasmic phospholipase A2-mediated arachidonic acid release independent of Ca2+ and mitogen-activated protein kinase regulation. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8314854&form=6&db=m Activation of phospholipase C by heat shock requires GTP analogs and is resistant to pertussis toxin. therapeutic application,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8382482&form=6&db=m Thrombin receptor agonist peptide induction of mitogenesis in CCL39 cells. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8388325&form=6&db=m Dual effect of thrombin on voltage-dependent Ca2+ channels of portal vein smooth muscle cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8458876&form=6&db=m Mediation of growth factor induced DNA synthesis and calcium mobilization by Gq and Gi2. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8566174&form=6&db=m The inositol phosphate response to thrombin in rat right atria differs from the response to noradrenaline. therapeutic application,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8569706&form=6&db=m Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists. therapeutic application,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8605873&form=6&db=m Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8607120&form=6&db=m Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8702939&form=6&db=m The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8750912&form=6&db=m Crosstalk between thrombin and adenylyl cyclase-stimulating agonists in proliferating human erythroid progenitor cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8760037&form=6&db=m Regulation of HSP70 by PTH: a model of gene regulation not mediated by changes in cAMP levels. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8777142&form=6&db=m Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells. ongoing research,unassigned 4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8930892&form=6&db=m Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells. ongoing research,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8947471&form=6&db=m Bombesin and thrombin affect discrete pools of intracellular calcium through different G-proteins. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8982657&form=6&db=m Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9039962&form=6&db=m The G-protein G(i) regulates mitosis but not DNA synthesis in growth factor-activated fibroblasts: a role for the nuclear translocation of G(i). causal interaction,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9061004&form=6&db=m Suppression of the voltage-gated K+ current of human megakaryocytes by thrombin and prostacyclin. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9067639&form=6&db=m Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9083789&form=6&db=m Transfected adenosine A1 receptor-mediated modulation of thrombin-stimulated phospholipase C and phospholipase A2 activity in CHO cells. diagnostic usage,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9111010&form=6&db=m Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. causal interaction,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9167640&form=6&db=m G proteins and phospholipase C mediate thrombin-induced generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9194575&form=6&db=m The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9214627&form=6&db=m Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9247061&form=6&db=m Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses. ongoing research,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9247313&form=6&db=m The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9405282&form=6&db=m Differential routes of Ca2+ influx in Swiss 3T3 fibroblasts in response to receptor stimulation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9453463&form=6&db=m Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579636&form=6&db=m Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9589368&form=6&db=m Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9741823&form=6&db=m Thrombin signal transduction of the fibrinolytic system in human adult venous endothelium in vitro. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9803882&form=6&db=m Endothelial dysfunction and vascular disease. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10340380&form=6&db=m Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10598576&form=6&db=m Pertussis toxin-sensitive and -insensitive thrombin stimulation of Shc phosphorylation and mitogenesis are mediated through distinct pathways. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10844601&form=6&db=m Thrombin is a novel regulator of hexokinase activity in mesangial cells. therapeutic application,unassigned 4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10895075&form=6&db=m Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10993890&form=6&db=m Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. ongoing research,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11306243&form=6&db=m Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11438939&form=6&db=m Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11494060&form=6&db=m Role of the third intracellular loop and of the cytoplasmic tail in the mitogenic signaling of the protease-activated receptor 1. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11752134&form=6&db=m Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11812655&form=6&db=m Thrombin-stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11919159&form=6&db=m RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. causal interaction,unassigned 4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12595282&form=6&db=m Mechanism of thrombin-induced vasodilation in human coronary arterioles. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12642388&form=6&db=m Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle. causal interaction,unassigned 3,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12844349&form=6&db=m Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14521590&form=6&db=m Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15447683&form=6&db=m Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2. ongoing research,unassigned 2,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15683740&form=6&db=m Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of G(q/11), Gi and G(12/13) proteins in signalling by alpha1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15995354&form=6&db=m Phospholipase C-beta3 mediates the thrombin-induced Ca2+ response in glial cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16699171&form=6&db=m Distinct signaling functions for Shc isoforms in the heart. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16725215&form=6&db=m The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. causal interaction,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17111362&form=6&db=m PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells. unassigned - 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21051874&form=6&db=m Inhibition of Rho-Kinase Abrogates Migration of Human Transitional Cell Carcinoma Cells: Results of an in vitro Study. therapeutic application,unassigned 1,0 3.4.21.5 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26557022&form=6&db=m Multiple Signaling Pathways Contribute to the Thrombin-induced Secretory Phenotype in Vascular Smooth Muscle Cells. therapeutic application,unassigned 1,0 3.4.21.5 Wilms Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7518511&form=6&db=m Characterization of platelet activity in neuroblastoma. causal interaction,unassigned 4,0 3.4.21.5 Xanthogranuloma, Juvenile http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12161209&form=6&db=m Management of traumatic hyphema. diagnostic usage,therapeutic application,unassigned 1,3,0